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Summary
Each year, the American Heart Association (AHA), in conjunction with the Centers for 
Disease Control and Prevention, the National Institutes of Health, and other government 
agencies, brings together the most up-to-date statistics on heart disease, stroke, other 
vascular diseases, and their risk factors and presents them in its Heart Disease and Stroke 
Statistical Update. The Statistical Update is a critical resource for researchers, clinicians, 
healthcare policy makers, media professionals, the lay public, and many others who seek the 
best available national data on heart disease, stroke, and other cardiovascular disease–related 
morbidity and mortality and the risks, quality of care, use of medical procedures and 
operations, and costs associated with the management of these diseases in a single 
document. Indeed, since 1999, the Statistical Update has been cited >10 500 times in the 
literature, based on citations of all annual versions. In 2012 alone, the various Statistical 
Updates were cited ≈3500 times (data from Google Scholar). In recent years, the Statistical 
*The findings and conclusions of this report are those of the authors and do not necessarily represent the views of the Centers for 
Disease Control and Prevention.
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Update has undergone some major changes with the addition of new chapters and major 
updates across multiple areas, as well as increasing the number of ways to access and use the 
information assembled.
For this year’s edition, the Statistics Committee, which produces the document for the AHA, 
updated all of the current chapters with the most recent nationally representative data and 
inclusion of relevant articles from the literature over the past year. This year’s edition 
includes a new chapter on peripheral artery disease, as well as new data on the monitoring 
and benefits of cardiovascular health in the population, with additional new focus on 
evidence-based approaches to changing behaviors, implementation strategies, and 
implications of the AHA’s 2020 Impact Goals. Below are a few highlights from this year’s 
Update.
The 2014 Update Expands Data Coverage of the Epidemic of Poor Cardiovascular Health 
Behaviors and Their Antecedents and Consequences
• Adjusted estimated population attributable fractions for cardiovascular disease 
(CVD) mortality were as follows1: 40.6% (95% confidence interval [CI], 24.5%–
54.6%) for high blood pressure; 13.7% (95% CI, 4.8%–22.3%) for smoking; 
13.2% (95% CI, 3.5%–29.2%) for poor diet; 11.9% (95% CI, 1.3%–22.3%) for 
insufficient physical activity; and 8.8% (95% CI, 2.1%–15.4%) for abnormal 
blood glucose levels.
• Although significant progress has been made over the past 4 decades, in 2012, 
among Americans ≥18 years of age, 20.5% of men and 15.9% of women 
continued to be cigarette smokers. In 2011, 18.1% of students in grades 9 
through 12 reported current cigarette use.
• The percentage of the nonsmoking population with exposure to secondhand 
smoke (as measured by serum cotinine levels ≥0.05 ng/mL) declined from 52.5% 
in 1999 to 2000 to 40.1% in 2007 to 2008. More than half of children 3 to 11 
years of age (53.6%) and almost half of those 12 to 19 years of age (46.5%) had 
detectable levels, compared with just over a third of adults 20 years of age and 
older (36.7%).
• The proportion of youth (≤18 years of age) who report engaging in no regular 
physical activity is high, and the proportion increases with age.
• In 2011, among adolescents in grades 9 through 12, 17.7% of girls and 10.0% of 
boys reported that they had not engaged in ≥60 minutes of moderate to vigorous 
physical activity (defined as any activity that increased heart rate or breathing 
rate) at least once in the previous 7 days, despite recommendations that children 
engage in such activity 7 days per week.
• In 2012, 29.9% of adults reported engaging in no aerobic leisure-time physical 
activity.
• In 2009 to 2010, <1% of Americans met at least 4 of 5 healthy dietary goals. 
Among adults aged ≥20 years, only 12.3% met recommended goals for fruits and 
vegetables; 18.3% met goals for fish; 0.6% met goals for sodium; 51.9% met 
et al. Page 2
Circulation. Author manuscript; available in PMC 2017 April 28.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
goals for sugar-sweetened beverages; and 7.3% met goals for whole grains. 
These proportions were even lower in children, with only 29.4% of adolescents 
aged 12 to 19 years meeting goals for low sugar-sweetened beverage intake.
• The estimated prevalence of overweight and obesity in US adults (≥20 years of 
age) is 154.7 million, which represented 68.2% of this group in 2010. Nearly 
35% of US adults are obese (body mass index ≥30 kg/m2). Men and women of 
all race/ethnic groups in the population are affected by the epidemic of 
overweight and obesity.
• Among children 2 to 19 years of age, 31.8% are overweight and obese (which 
represents 23.9 million children) and 16.9% are obese (12.7 million children). 
Mexican American boys and girls and African American girls are 
disproportionately affected. From 1971–1974 to 2007–2010, the prevalence of 
obesity in children 6 to 11 years of age has increased from 4.0% to 18.8%.
• Obesity (body mass index ≥30 kg/m2) is associated with marked excess mortality 
in the US population. Even more notable is the excess morbidity associated with 
overweight and obesity in terms of risk factor development and incidence of 
diabetes mellitus, CVD end points (including coronary heart disease, stroke, and 
heart failure), and numerous other health conditions, including asthma, cancer, 
end-stage renal disease, degenerative joint disease, and many others.
Prevalence and Control of Cardiovascular Health Factors and Risks Remain an Issue for 
Many Americans
• An estimated 31.9 million adults ≥20 years of age have total serum cholesterol 
levels ≥240 mg/dL, with a prevalence of 13.8%.
• Based on 2007 to 2010 data, 33.0% of US adults ≥20 years of age have 
hypertension. This represents ≈78 million US adults with hypertension. The 
prevalence of hypertension is similar for men and women. African American 
adults have among the highest prevalence of hypertension (44%) in the world.
• Among hypertensive Americans, ≈82% are aware of their condition and 75% are 
using antihypertensive medication, but only 53% of those with documented 
hypertension have their condition controlled to target levels.
• In 2010, an estimated 19.7 million Americans had diagnosed diabetes mellitus, 
representing 8.3% of the adult population. An additional 8.2 million had 
undiagnosed diabetes mellitus, and 38.2% had prediabetes, with abnormal fasting 
glucose levels. African Americans, Mexican Americans, Hispanic/Latino 
individuals, and other ethnic minorities bear a strikingly disproportionate burden 
of diabetes mellitus in the United States.
• The prevalence of diabetes mellitus is increasing dramatically over time, in 
parallel with the increases in prevalence of overweight and obesity.
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Rates of Death Attributable to CVD Have Declined, but the Burden of Disease Remains 
High
• The 2010 overall rate of death attributable to CVD was 235.5 per 100 000. The 
rates were 278.4 per 100 000 for white males, 369.2 per 100 000 for black males, 
192.2 per 100 000 for white females, and 260.5 per 100 000 for black females.
• From 2000 to 2010, death rates attributable to CVD declined 31.0%. In the same 
10-year period, the actual number of CVD deaths per year declined by 16.7%. 
Yet in 2010, CVD (I00–I99; Q20–Q28) still accounted for 31.9% (787 650) of all 
2 468 435 deaths, or ≈1 of every 3 deaths in the United States.
• On the basis of 2010 death rate data, >2150 Americans die of CVD each day, an 
average of 1 death every 40 seconds. About 150 000 Americans who died of 
CVD in 2010 were <65 years of age. In 2010, 34% of deaths attributable to CVD 
occurred before the age of 75 years, which is before the current average life 
expectancy of 78.7 years.
• Coronary heart disease alone caused ≈1 of every 6 deaths in the United States in 
2010. In 2010, 379 559 Americans died of CHD. Each year, an estimated ≈620 
000 Americans have a new coronary attack (defined as first hospitalized 
myocardial infarction or coronary heart disease death) and ≈295 000 have a 
recurrent attack. It is estimated that an additional 150 000 silent first myocardial 
infarctions occur each year. Approximately every 34 seconds, 1 American has a 
coronary event, and approximately every 1 minute 23 seconds, an American will 
die of one.
• From 2000 to 2010, the relative rate of stroke death fell by 35.8% and the actual 
number of stroke deaths declined by 22.8%. Yet each year, ≈795 000 people 
continue to experience a new or recurrent stroke (ischemic or hemorrhagic). 
Approximately 610 000 of these are first events and 185 000 are recurrent stroke 
events. In 2010, stroke caused ≈1 of every 19 deaths in the United States. On 
average, every 40 seconds, someone in the United States has a stroke, and 
someone dies of one approximately every 4 minutes.
• The decline in stroke mortality over the past decades, a major improvement in 
population health observed for both sexes and all race and age groups, has 
resulted from reduced stroke incidence and lower case fatality rates. The 
significant improvements in stroke outcomes are concurrent with cardiovascular 
risk factor control interventions. The hypertension control efforts initiated in the 
1970s appear to have had the most substantial influence on the accelerated 
decline in stroke mortality, with lower blood pressure distributions in the 
population. Control of diabetes mellitus and high cholesterol and smoking 
cessation programs, particularly in combination with hypertension treatment, 
also appear to have contributed to the decline in stroke mortality.2
• In 2010, 1 in 9 death certificates (279 098 deaths) in the United States mentioned 
heart failure. Heart failure was the underlying cause in 57 757 of those deaths in 
2010. The number of any-mention deaths attributable to heart failure was 
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approximately as high in 1995 (287 000) as it was in 2010 (279 000). 
Additionally, hospital discharges for heart failure remained stable from 2000 to 
2010, with first-listed discharges of 1 008 000 and 1 023 000, respectively.
The 2014 Update Provides Critical Data About Cardiovascular Quality of Care, Procedure 
Utilization, and Costs
In light of the current national focus on healthcare utilization, costs, and quality, it is critical 
to monitor and understand the magnitude of healthcare delivery and costs, as well as the 
quality of healthcare delivery, related to CVD risk factors and conditions. The Statistical 
Update provides these critical data in several sections.
Quality-of-Care Metrics for CVDs
Quality data are available from the AHA’s Get With The Guidelines programs for coronary 
heart disease, heart failure, and resuscitation and from the American Stroke Association/
AHA’s Get With The Guidelines program for acute stroke. Similar data from the Veterans 
Healthcare Administration, national Medicare and Medicaid data, and Acute Coronary 
Treatment and Intervention Outcomes Network (ACTION)–Get With The Guidelines 
Registry data are also reviewed. These data show impressive adherence to guideline 
recommendations for many, but not all, metrics of quality of care for these hospitalized 
patients. Data are also reviewed on screening for CVD risk factor levels and control.
Cardiovascular Procedure Use and Costs
• The total number of inpatient cardiovascular operations and procedures increased 
28%, from 5 939 000 in 2000 to 7 588 000 in 2010 (National Heart, Lung, and 
Blood Institute computation based on National Center for Health Statistics 
annual data).
• The total direct and indirect cost of CVD and stroke in the United States for 2010 
is estimated to be $315.4 billion. This figure includes health expenditures (direct 
costs, which include the cost of physicians and other professionals, hospital 
services, prescribed medications, home health care, and other medical durables) 
and lost productivity that results from premature mortality (indirect costs).
• By comparison, in 2008, the estimated cost of all cancer and benign neoplasms 
was $201.5 billion ($77.4 billion in direct costs, and $124 billion in mortality 
indirect costs). CVD costs more than any other diagnostic group.
The AHA, through its Statistics Committee, continuously monitors and evaluates sources of 
data on heart disease and stroke in the United States to provide the most current information 
available in the Statistics Update.
This annual Statistical Update is the product of an entire year’s worth of effort by dedicated 
professionals, volunteer physicians and scientists, and outstanding AHA staff members, 
without whom publication of this valuable resource would be impossible. Their 
contributions are gratefully acknowledged.
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Melanie B. Turner, MPH
On behalf of the American Heart Association Statistics
Committee and Stroke Statistics Subcommittee
Note: Population data used in the compilation of National Health and Nutrition Examination 
Survey (NHANES) prevalence estimates are for the latest year of the NHANES survey being 
used. Extrapolations for NHANES prevalence estimates are based on the census resident 
population for 2010 because this is the most recent year of NHANES data used in the 
Statistical Update.
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1. About These Statistics
The AHA works with the CDC’s NCHS, the NHLBI, the NINDS, and other government 
agencies to derive the annual statistics in this Heart Disease and Stroke Statistical Update. 
This chapter describes the most important sources and the types of data we use from them. 
For more details, see Chapter 26 of this document, the Glossary.
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The surveys used are:
• BRFSS—ongoing telephone health survey system
• GCNKSS—stroke incidence rates and outcomes within a biracial population
• MEPS—data on specific health services that Americans use, how frequently they 
use them, the cost of these services, and how the costs are paid
• NHANES—disease and risk factor prevalence and nutrition statistics
• NHIS—disease and risk factor prevalence
• NHDS—hospital inpatient discharges and procedures (discharged alive, dead, or 
status unknown)
• NAMCS—physician office visits
• NHHCS—staff, services, and patients of home health and hospice agencies
• NHAMCS—hospital outpatient and ED visits
• Nationwide Inpatient Sample of the AHRQ—hospital inpatient discharges, 
procedures, and charges
• NNHS—nursing home residents
• National Vital Statistics System—national and state mortality data
• WHO—mortality rates by country
• YRBSS—health-risk behaviors in youth and young adults
Abbreviations Used in Chapter 1
AHA American Heart Association
AHRQ Agency for Healthcare Research and Quality
AP angina pectoris
ARIC Atherosclerosis Risk in Communities Study
BP blood pressure
BRFSS Behavioral Risk Factor Surveillance System
CDC Centers for Disease Control and Prevention
CHS Cardiovascular Health Study
CVD cardiovascular disease
DM diabetes mellitus
ED emergency department
FHS Framingham Heart Study
GCNKSS Greater Cincinnati/Northern Kentucky Stroke Study
HD heart disease
HF heart failure
ICD International Classification of Diseases
ICD-9-CM International Classification of Diseases, Clinical Modification, 9th Revision
ICD-10 International Classification of Diseases, 10th Revision
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MEPS Medical Expenditure Panel Survey
MI myocardial infarction
NAMCS National Ambulatory Medical Care Survey
NCHS National Center for Health Statistics
NHAMCS National Hospital Ambulatory Medical Care Survey
NHANES National Health and Nutrition Examination Survey
NHDS National Hospital Discharge Survey
NHHCS National Home and Hospice Care Survey
NHIS National Health Interview Survey
NHLBI National Heart, Lung, and Blood Institute
NINDS National Institute of Neurological Disorders and Stroke
NNHS National Nursing Home Survey
PAD peripheral artery disease
WHO World Health Organization
YRBSS Youth Risk Behavior Surveillance System
See Glossary (Chapter 26) for explanation of terms.
Disease Prevalence
Prevalence is an estimate of how many people have a disease at a given point or period in 
time. The NCHS conducts health examination and health interview surveys that provide 
estimates of the prevalence of diseases and risk factors. In this Update, the health interview 
part of the NHANES is used for the prevalence of CVDs. NHANES is used more than the 
NHIS because in NHANES, AP is based on the Rose Questionnaire; estimates are made 
regularly for HF; hypertension is based on BP measurements and interviews; and an estimate 
can be made for total CVD, including MI, AP, HF, stroke, and hypertension.
A major emphasis of this Statistical Update is to present the latest estimates of the number 
of people in the United States who have specific conditions to provide a realistic estimate of 
burden. Most estimates based on NHANES prevalence rates are based on data collected 
from 2007 to 2010 (in most cases, these are the latest published figures). These are applied 
to census population estimates for 2010. Differences in population estimates cannot be used 
to evaluate possible trends in prevalence because these estimates are based on extrapolations 
of rates beyond the data collection period by use of more recent census population estimates. 
Trends can only be evaluated by comparing prevalence rates estimated from surveys 
conducted in different years.
Risk Factor Prevalence
The NHANES 2007 to 2010 data are used in this Update to present estimates of the 
percentage of people with high lipid values, DM, overweight, and obesity. The NHIS is used 
for the prevalence of cigarette smoking and physical inactivity. Data for students in grades 9 
through 12 are obtained from the YRBSS.
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Incidence and Recurrent Attacks
An incidence rate refers to the number of new cases of a disease that develop in a population 
per unit of time. The unit of time for incidence is not necessarily 1 year, although we often 
discuss incidence in terms of 1 year. For some statistics, new and recurrent attacks or cases 
are combined. Our national incidence estimates for the various types of CVD are 
extrapolations to the US population from the FHS, the ARIC study, and the CHS, all 
conducted by the NHLBI, as well as the GCNKSS, which is funded by the NINDS. The 
rates change only when new data are available; they are not computed annually. Do not 
compare the incidence or the rates with those in past editions of the Heart Disease and 
Stroke Statistics Update (also known as the Heart and Stroke Statistical Update for editions 
before 2005). Doing so can lead to serious misinterpretation of time trends.
Mortality
Mortality data are generally presented according to the underlying cause of death. “Any-
mention” mortality means that the condition was nominally selected as the underlying cause 
or was otherwise mentioned on the death certificate. For many deaths classified as 
attributable to CVD, selection of the single most likely underlying cause can be difficult 
when several major comorbidities are present, as is often the case in the elderly population. 
It is useful, therefore, to know the extent of mortality attributable to a given cause regardless 
of whether it is the underlying cause or a contributing cause (ie, its “any-mention” status). 
The number of deaths in 2010 with any mention of specific causes of death was tabulated by 
the NHLBI from the NCHS public-use electronic files on mortality.
The first set of statistics for each disease in this Update includes the number of deaths for 
which the disease is the underlying cause. Two exceptions are Chapter 9 (High Blood 
Pressure) and Chapter 19 (Cardiomyopathy and Heart Failure). High BP, or hypertension, 
increases the mortality risks of CVD and other diseases, and HF should be selected as an 
underlying cause only when the true underlying cause is not known. In this Update, 
hypertension and HF death rates are presented in 2 ways: (1) As nominally classified as the 
underlying cause and (2) as anymention mortality.
National and state mortality data presented according to the underlying cause of death were 
computed from the mortality tables of the NCHS World Wide Web site, the Health Data 
Interactive data system of the NCHS, or the CDC compressed mortality file. Any-mention 
numbers of deaths were tabulated from the electronic mortality files of the NCHS World 
Wide Web site and from Health Data Interactive.
Population Estimates
In this publication, we have used national population estimates from the US Census Bureau 
for 2010 in the computation of morbidity data. NCHS population estimates for 2010 were 
used in the computation of death rate data. The Census Bureau World Wide Web site1 
contains these data, as well as information on the file layout.
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Hospital Discharges and Ambulatory Care Visits
Estimates of the numbers of hospital discharges and numbers of procedures performed are 
for inpatients discharged from short-stay hospitals. Discharges include those discharged 
alive, dead, or with unknown status. Unless otherwise specified, discharges are listed 
according to the first-listed (primary) diagnosis, and procedures are listed according to all 
listed procedures (primary plus secondary). These estimates are from the NHDS of the 
NCHS unless otherwise noted. Ambulatory care visit data include patient visits to physician 
offices and hospital outpatient departments and EDs. Ambulatory care visit data reflect the 
first-listed (primary) diagnosis. These estimates are from NAMCS and NHAMCS of the 
NCHS.
International Classification of Diseases
Morbidity (illness) and mortality (death) data in the United States have a standard 
classification system: the ICD. Approximately every 10 to 20 years, the ICD codes are 
revised to reflect changes over time in medical technology, diagnosis, or terminology. Where 
necessary for comparability of mortality trends across the 9th and 10th ICD revisions, 
comparability ratios computed by the NCHS are applied as noted.2 Effective with mortality 
data for 1999, we are using the 10th revision (ICD-10). It will be a few more years before 
the 10th revision is systematically used for hospital discharge data and ambulatory care visit 
data, which are based on ICD-9-CM.3
Age Adjustment
Prevalence and mortality estimates for the United States or individual states comparing 
demographic groups or estimates over time either are age specific or are age adjusted to the 
2000 standard population by the direct method.4 International mortality data are age adjusted 
to the European standard.5 Unless otherwise stated, all death rates in this publication are age 
adjusted and are deaths per 100 000 population.
Data Years for National Estimates
In this Update, we estimate the annual number of new (incidence) and recurrent cases of a 
disease in the United States by extrapolating to the US population in 2010 from rates 
reported in a community- or hospital-based study or multiple studies. Age-adjusted 
incidence rates by sex and race are also given in this report as observed in the study or 
studies. For US mortality, most numbers and rates are for 2010. For disease and risk factor 
prevalence, most rates in this report are calculated from the 2007 to 2010 NHANES. 
Because NHANES is conducted only in the noninstitutionalized population, we extrapolated 
the rates to the total US population in 2010, recognizing that this probably underestimates 
the total prevalence, given the relatively high prevalence in the institutionalized population. 
The numbers and rates of hospital inpatient discharges for the United States are for 2010. 
Numbers of visits to physician offices, hospital EDs, and hospital outpatient departments are 
for 2010. Except as noted, economic cost estimates are for 2010.
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Cardiovascular Disease
For data on hospitalizations, physician office visits, and mortality, CVD is defined according 
to ICD codes given in Chapter 26 of the present document. This definition includes all 
diseases of the circulatory system, as well as congenital CVD. Unless so specified, an 
estimate for total CVD does not include congenital CVD. Prevalence of CVD includes 
people with hypertension, HD, stroke, PAD, and diseases of the veins.
Race
Data published by governmental agencies for some racial groups are considered unreliable 
because of the small sample size in the studies. Because we try to provide data for as many 
racial groups as possible, we show these data for informational and comparative purposes.
Contacts
If you have questions about statistics or any points made in this Update, please contact the 
AHA National Center, Office of Science & Medicine at statistics@heart.org. Direct all 
media inquiries to News Media Relations at inquiries@heart.org or 214-706-1173.
We do our utmost to ensure that this Update is error free. If we discover errors after 
publication, we will provide corrections at our World Wide Web site, http://www.heart.org/
statistics, and in the journal Circulation.
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2. Cardiovascular Health
See Tables 2-1 through 2-8 and Charts 2-1 through 2-13.
After achieving its major Impact Goals for 2010, the AHA created a new set of central 
organizational Impact Goals for the current decade1:
By 2020, to improve the cardiovascular health of all Americans by 20%, while 
reducing deaths from CVDs and stroke by 20%.1
These goals introduce a new concept, cardiovascular health, which is characterized by 7 
health metrics. Ideal cardiovascular health is defined by the absence of clinically manifest 
CVD together with the simultaneous presence of optimal levels of all 7 metrics, including 4 
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health behaviors (not smoking and having sufficient PA, a healthy diet pattern, and 
appropriate energy balance as represented by normal body weight) and 3 health factors 
(optimal total cholesterol, BP, and fasting blood glucose, in the absence of drug treatment; 
Table 2-1). Because a spectrum of cardiovascular health can also be envisioned and the ideal 
cardiovascular health profile is known to be rare in the US population, a broader spectrum of 
cardiovascular health can also be represented as being “ideal,” “intermediate,” or “poor” for 
each of the health behaviors and health factors.1 Table 2-1 provides the specific definitions 
for ideal, intermediate, and poor cardiovascular health for each of the 7 metrics, both for 
adults (≥20 years of age) and children (age ranges for each metric depending on data 
availability).
Abbreviations Used in Chapter 2
AHA American Heart Association
ARIC Atherosclerosis Risk in Communities Study
BMI body mass index
BP blood pressure
BRFSS Behavioral Risk Factor Surveillance System
CDC Centers for Disease Control and Prevention
CHD coronary heart disease
CHF congestive heart failure
CI confidence interval
CVD cardiovascular disease
DASH Dietary Approaches to Stop Hypertension
DBP diastolic blood pressure
DM diabetes mellitus
FDA Food and Drug Administration
HbA1c hemoglobin A1c
HBP high blood pressure
HD heart disease
HF heart failure
HR hazard ratio
ICD International Classification of Diseases
ICD-10 International Classification of Diseases, 10th Revision
MI myocardial infarction
NHANES National Health and Nutrition Examination Survey
NOMAS Northern Manhattan Study
PA physical activity
PE physical education
REGARDS Reasons for Geographic and Racial Differences in Stroke
SBP systolic blood pressure
SE standard error
UN United Nations
WHO World Health Organization
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This concept of cardiovascular health represents a new focus for the AHA, with 3 central 
and novel emphases:
• An expanded focus on CVD prevention and promotion of positive 
“cardiovascular health,” in addition to the treatment of established CVD.
• Efforts to promote both healthy behaviors (healthy diet pattern, appropriate 
energy intake, PA, and nonsmoking) and healthy biomarker levels (optimal blood 
lipids, BP, glucose levels) throughout the lifespan.
• Population-level health promotion strategies to shift the majority of the public 
towards greater cardiovascular health, in addition to targeting those individuals at 
greatest CVD risk, since healthy lifestyles in all domains are uncommon 
throughout the US population.
Beginning in 2011, and recognizing the time lag in the nationally representative US data 
sets, this chapter in the annual Statistical Update evaluates and publishes metrics and 
information to provide insights into both progress toward meeting the 2020 AHA goals and 
areas that require greater attention to meet these goals.
Cardiovascular Health: Current Prevalence
• The most up-to-date data on national prevalence of ideal, intermediate, and poor 
levels of each of the 7 cardiovascular health metrics are shown for adolescents 
and teens 12 to 19 years of age (Chart 2-1) and for adults ≥20 years of age (Chart 
2-2).
• For most metrics, the prevalence of ideal levels of health behaviors and health 
factors is higher in US children than in US adults. Major exceptions are diet and 
PA, for which prevalence of ideal levels in children is similar to (for PA) or 
worse (for diet) than in adults.
• Among children (Chart 2-1), the prevalence (unadjusted) of ideal levels of 
cardiovascular health behaviors and factors currently varies from <1% for the 
healthy diet pattern (ie, <1 in 100 US children meets at least 4 of the 5 dietary 
components) to >80% for the smoking, BP, and fasting glucose metrics.
• Among US adults (Chart 2-2), the age-standardized prevalence of ideal levels of 
cardiovascular health behaviors and factors currently varies from 0.5% for 
having at least 4 of 5 components of the healthy diet pattern to up to 76% for 
never having smoked or being a former smoker who has quit for >12 months.
• Age-standardized and age-specific prevalence estimates for ideal cardiovascular 
health and for ideal levels of each of its components are shown for 2007 to 2008 
(baseline) and 2009 to 2010 in Table 2-2.
– In 2009 to 2010, the prevalence of ideal levels across 7 health factors 
and health behaviors decreased dramatically from younger to older age 
groups. The same trend was seen in 2007 to 2008.
– The prevalence of both children and adults meeting the dietary goals 
appeared to improve between 2007 to 2008 and 2009 to 2010, although 
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this improvement should be viewed with caution given the challenges 
of accurately determining time trends across only 2 cycles of NHANES 
data collection. The improvement was attributable to the greater 
numbers of children and adults who met the whole grains goal, greater 
numbers of middle-aged and older adults who met the fruits and 
vegetables goal, and greater numbers of adults who met the fish goal.
• Chart 2-3 displays the prevalence estimates for the population of US children 
(12–19 years of age) meeting different numbers of criteria for ideal 
cardiovascular health (out of 7 possible) in 2009 to 2010.
– Few US children (<7%) meet only 0, 1, or 2 criteria for ideal 
cardiovascular health.
– Nearly half of US children (45%) meet 3 or 4 criteria for ideal 
cardiovascular health, and about half meet 5 or 6 criteria (mostly 5 
criteria).
– Virtually no children meet all 7 criteria for ideal cardiovascular health.
– Overall distributions are similar in boys and girls.
• Charts 2-4 and 2-5 display the age-standardized prevalence estimates of US 
adults meeting different numbers of criteria for ideal cardiovascular health (out 
of 7 possible) in 2009 to 2010, overall and stratified by age, sex, and race.
– Approximately 2% of US adults have 0 of the 7 criteria at ideal levels, 
and another 12% meet only 1 of 7 criteria. This is much worse than 
among children.
– Most US adults (≥65%) have 2, 3, or 4 criteria at ideal cardiovascular 
health, with ≈1 in 5 adults within each of these categories.
– Approximately 13% of US adults meet 5 criteria, 4% meet 6 criteria, 
and 0.1% meet 7 criteria at ideal levels.
– Presence of ideal cardiovascular health is both age and sex related 
(Chart 2-4). Younger adults are more likely to meet greater numbers of 
ideal metrics than are older adults. More than 60% of Americans >60 
years of age have ≤2 metrics at ideal levels. At any age, women tend to 
have more metrics at ideal levels than do men.
– Race is also related to presence of ideal cardiovascular health (Chart 
2-5). Blacks and Mexican Americans tend to have fewer metrics at ideal 
levels than whites or other races. Approximately 6 in 10 white adults 
and 7 in 10 black or Mexican American adults have no more than 3 of 7 
metrics at ideal levels.
• Chart 2-6 displays the age-standardized percentages of US adults and 
percentages of children who have ≥5 of the metrics (out of 7 possible) at ideal 
levels.
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– Approximately 50% of US children 12 to 19 years of age have ≥5 
metrics at ideal levels, with lower prevalence in girls (46%) than in boys 
(51%).
– In comparison, only 17% of US adults have ≥5 metrics with ideal 
levels, with lower prevalence in men (11%) than in women (24%).
– Among adults, whites are more likely to have ≥5 metrics at ideal levels 
(19%) than are Mexican Americans (12%) or blacks (10%).
• Chart 2-7 displays the age-standardized percentages of US adults meeting 
different numbers of criteria for both poor and ideal cardiovascular health. 
Meeting the AHA 2020 Strategic Impact Goals is predicated on reducing the 
relative percentage of those with poor levels while increasing the relative 
percentage of those with ideal levels for each of the 7 metrics.
– Approximately 92% of US adults have ≥1 metric at poor levels.
– Approximately 35% of US adults have ≥3 metrics at poor levels.
– Few US adults (<3%) have ≥5 metrics at poor levels.
– More US adults have 4 to 6 ideal metrics than 4 to 6 poor metrics.
• Using data from the BRFSS, Fang and colleagues2 estimated the prevalence of 
ideal cardiovascular health by state, which ranged from 1.2% (Oklahoma) to 
6.9% (District of Columbia). Southern states tended to have higher rates of poor 
cardiovascular health, lower rates of ideal cardiovascular health, and lower mean 
cardiovascular health scores than New England and Western states (Chart 2-8).
• The prevalence of poor health behaviors and health factors and their awareness, 
treatment, and control are displayed in Table 2-3 separately for those with and 
without self-reported CVD.
– Americans with CVD are much more likely to be current or former 
smokers than Americans without CVD.
– Approximately 20% of US adults are current smokers or have quit 
recently (<12 months ago).
– As measured by self-reported data, Americans with CVD are very 
likely to have intermediate or poor levels of PA (74.1%), whereas 
Americans without CVD still commonly have such levels (58.4%). 
Furthermore, 64.5% of those with CVD and 47.3% of those without 
CVD report engaging in no moderate or vigorous activity at all.
– Seventy percent of US adults with CVD and 79% of those without 
CVD meet 0 or only 1 of the 5 healthy diet metrics.
– Two thirds of US adults are overweight, with little difference by 
prevalent CVD. Half of all US adults with CVD and one third without 
CVD are obese.
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– Hypertension is present in 28.5% of US adults without CVD and 51.0% 
of US adults with CVD. Of these, nearly all with CVD are aware of 
their hypertension (98.6%) and are receiving treatment (97.4%), but a 
much smaller proportion of those without CVD are aware (70.6%) or 
receiving treatment (61.4%).
– Both presence of hypercholesterolemia (total cholesterol ≥240 mg/dL 
or receiving medication) and DM (fasting glucose ≥126 mg/dL or 
receiving medications) and awareness and treatment of these conditions 
are similarly higher among those with CVD than among those without 
CVD.
Cardiovascular Health: Trends Over Time
• The trends over the past decade in each of the 7 cardiovascular health metrics 
(for diet, trends from 2005–2006 to 2009–2010) are shown in Chart 2-9 (for 
children 12–19 years of age) and Chart 2-10 (for adults ≥20 years of age).
– Fewer children over time are meeting the BMI metric, whereas more 
are meeting the smoking and total cholesterol metrics. Other metrics do 
not show consistent trends over time in children.
– More adults over time are meeting the smoking metric, whereas fewer 
are meeting the BMI and glucose metrics. Trends for other metrics are 
not evident over time in adults.
• On the basis of NHANES data from 1988 to 2008, if current trends continue, 
estimated cardiovascular health is projected to improve by 6% between 2010 and 
2020, short of the AHA’s goal of 20% improvement (Chart 2-11).3 On the basis 
of current trends among individual metrics, anticipated declines in prevalence of 
smoking, high cholesterol, and high BP (in men) would be offset by substantial 
increases in the prevalence of obesity and DM and small changes in ideal dietary 
patterns or PA.3
• On the basis of these projections in cardiovascular health factors and behaviors, 
CHD deaths are projected to decrease by 30% between 2010 and 2020 because 
of projected improvements in total cholesterol, SBP, smoking and PA (≈167 000 
fewer deaths), offset by increases in DM and BMI (≈24 000 more deaths).4
Cardiovascular Diseases
• In 2010, the age-standardized death rate attributable to all CVD was 236.6 per 
100 000 (includes congenital CVD [ICD-10 I00-I99, Q20-Q28]; Chart 2-12), 
down 8.8% from 259.4 per 100 000 in 2007 (baseline data for the 2020 Impact 
Goals on CVD and stroke mortality).5
– Death rates in 2010 attributable to stroke, CHD, and other CVDs were 
39.1, 113.6, and 82.7 per 100 000, respectively.5
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• Data from NHANES 2009 to 2010 reveal that overall, 7.2% of Americans self-
reported having some type of CVD (Table 2-3), including 3.2% with CHD, 2.7% 
with stroke, and 2.0% with CHF (some individuals reported >1 condition).
Relevance of Ideal Cardiovascular Health
Since the AHA announced its 2020 Impact Goals, multiple investigations have confirmed 
the importance of these metrics of cardiovascular health. Overall, these data demonstrate the 
relevance of the concept of cardiovascular health to the risk of future risk factors, disease, 
and mortality, including a strong inverse, stepwise association with all-cause, CVD, and 
ischemic HD mortality.
• Bambs et al,6 Folsom et al,7 and Dong et al8 have all described the low 
prevalence (<1%) of ideal cardiovascular health, defined as being in the ideal 
category of all 7 AHA metrics in the Heart Strategies Concentrating on Risk 
Evaluation, ARIC, and NOMAS cohorts, respectively.
• In ARIC and NOMAS, a stepwise inverse association was present between the 
number of ideal health metrics and incident CVD events (including CHD death, 
nonfatal MI, stroke, and HF) during 20 and 11 years of follow-up, 
respectively.7,8 For ARIC participants with 0, 1, 2, 3, 4, 5, 6, and 7 metrics at 
ideal levels, the age-, sex-, and race-adjusted rates of incident CVD incidence 
were 3.21, 2.19, 1.60, 1.20, 0.86, 0.64, 0.39, and 0 per 100 person-years, 
respectively.7 Findings were similar in the Aerobics Center Longitudinal Study, 
in which individuals with 6 to 7 ideal metrics had a 63% lower risk of CVD 
death (HR [95% CI], 0.37 [0.15, 0.95]) compared with individuals with 0 to 2 
ideal metrics.9
• A similar stepwise association was present between the number of ideal 
cardiovascular health metrics and risk of all-cause mortality, CVD mortality, and 
ischemic HD mortality after 14.5 years of follow-up based on NHANES 1988 to 
2006 data.10 The HRs for individuals with 6 or 7 ideal health metrics compared 
with individuals with 0 ideal health metrics were 0.49 (95% CI, 0.33–0.74) for 
all-cause mortality, 0.24 (95% CI, 0.13–0.47) for CVD mortality, and 0.30 (95% 
CI, 0.13–0.68) for ischemic HD mortality.10 Ford et al11 demonstrated similar 
relationships.
• The adjusted population attributable fractions for CVD mortality were as 
follows10:
– 40.6% (95% CI, 24.5%–54.6%) for HBP
– 13.7% (95% CI, 4.8%–22.3%) for smoking
– 13.2% (95% CI, 3.5%–29.2%) for poor diet
– 11.9% (95% CI, 1.3%–22.3%) for insufficient PA
– 8.8% (95% CI, 2.1%–15.4%) for abnormal glucose levels
• The adjusted population attributable fractions for ischemic HD mortality were as 
follows10:
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– 34.7% (95% CI, 6.6%–57.7%) for HBP
– 16.7% (95% CI, 6.4%–26.6%) for smoking
– 20.6% (95% CI, 1.2%–38.6%) for poor diet
– 7.8% (95% CI, 0%–22.2%) for insufficient PA
– 7.5% (95% CI, 3.0%–14.7%) for abnormal glucose levels
• Data from the Cardiovascular Lifetime Risk Pooling Project indicate that adults 
with all-optimal risk factor levels (similar to having ideal cardiovascular health 
factor levels of cholesterol, blood sugar, and BP, as well as nonsmoking status) 
have substantially longer overall and CVD-free survival than those who have 
poor levels of ≥1 of these cardiovascular health factor metrics. For example, at an 
index age of 45 years, men with optimal risk factor profiles lived on average 14 
years longer free of all CVD events, and ≈12 years longer overall, than 
individuals with ≥2 risk factors.12
• Importantly, in many of these analyses, ideal health behaviors and ideal health 
factors were each independently associated with lower CVD risk in a stepwise 
fashion (Chart 2-13). Thus, across any levels of health behaviors, health factors 
were still associated with incident CVD, and across any levels of health factors, 
health behaviors were still associated with incident CVD.
• Interestingly, based on NHANES 1999 to 2002, only modest intercorrelations are 
present between different cardiovascular health metrics. For example, these 
ranged from a correlation of −0.12 between PA and HbA1c to a correlation of 
0.29 between BMI and HbA1c. Thus, although the 7 AHA cardiovascular health 
metrics appear modestly interrelated, substantial independent variation in each 
exists, and each is independently related to cardiovascular outcomes.11
• The AHA metrics may also be related to risk of noncardiovascular conditions. 
Rasmussen-Torvik et al13 demonstrated a graded, inverse association between 
ideal cardiovascular health and cancer incidence, with 51% lower risk among 
individuals with 6 or 7 ideal cardiovascular health metrics than among those with 
0 ideal metrics. These results were only partially attenuated (25% lower risk) 
when smoking was removed from the sum of metrics. In contrast, Artero et al9 
did not find a significant association between ideal cardiovascular health and 
death attributable to cancer in the Aerobics Center Longitudinal Study. The AHA 
cardiovascular health metrics have also been cross-sectionally associated with 
lower prevalence of depressive symptoms in the REGARDS cohort.14
• Recent analyses from the US Burden of Disease Collaborators demonstrated that 
each of the 7 health factors and behaviors causes substantial mortality and 
morbidity in the United States. The top risk factor related to overall disease 
burden was suboptimal diet, followed by tobacco smoking, high BMI, HBP, high 
fasting plasma glucose, and physical inactivity.14a
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Achieving the 2020 Impact Goals
• Taken together, these data continue to demonstrate both the tremendous 
relevance of the AHA 2020 Impact Goals for cardiovascular health and the 
substantial progress that will be needed to achieve these goals over the next 
decade.
• A range of complementary strategies and approaches can lead to improvements 
in cardiovascular health. These include each of the following:
– Individual-focused approaches, which target lifestyle and treatments at 
the individual level (Table 2-4)
– Healthcare systems approaches, which encourage, facilitate, and reward 
efforts by providers to improve health behaviors and health factors 
(Table 2-5)
– Population approaches, which target lifestyle and treatments in schools 
or workplaces, local communities, and states, as well as throughout the 
nation (Table 2-6)
• Such approaches can focus on both (1) improving cardiovascular health among 
those who currently have less than optimal levels and (2) preserving 
cardiovascular health among those who currently have ideal levels (in particular, 
children, adolescents, and young adults) as they age.
• The metrics with the greatest potential for improvement are health behaviors, 
including diet quality, PA, and body weight. However, each of the cardiovascular 
health metrics can be improved and deserves major focus.
• Continued emphasis is also needed on the treatment of acute CVD events and 
secondary prevention through treatment and control of health behaviors and risk 
factors.
• For each cardiovascular health metric, modest shifts in the population 
distribution toward improved health would produce relatively large increases in 
the proportion of Americans in both ideal and intermediate categories. For 
example, on the basis of NHANES 2009 to 2010, the current prevalence of ideal 
levels of BP among US adults is 44.3%. To achieve the 2020 goals, a 20% 
relative improvement would require an increase in this proportion to 53.1% by 
2020 (44.3% × 1.20). On the basis of NHANES data, a reduction in population 
mean BP of just 2 mm Hg would result in 56.1% of US adults having ideal levels 
of BP, which represents a 26.8% relative improvement in this metric (Table 2-7). 
Larger population reductions in BP would lead to even larger numbers of people 
with ideal levels. Such small reductions in population BP could result from small 
health behavior changes at a population level, such as increased PA, increased 
fruit and vegetable consumption, decreased sodium intake, decreased adiposity, 
or some combination of these and other lifestyle changes, with resulting 
substantial projected decreases in CVD rates in US adults.15
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• The AHA has a broad range of policy initiatives to improve cardiovascular health 
and meet the 2020 Strategic Impact Goals (Table 2-8). Future Statistical Updates 
will update these initiatives and track progress toward the 2020 Impact Goals.
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3. Smoking/Tobacco Use
See Table 3-1 and Charts 3-1 and 3-2.
Smoking is a major risk factor for CVD and stroke.1 The AHA has identified never tried or 
never smoked a whole cigarette (for children) and never smoking or quitting >12 months ago 
(for adults) as 1 of the 7 components of ideal cardiovascular health.2 According to NHANES 
2009 to 2010 data, 85.2% of children and 76.2% of adults met these criteria.
et al. Page 24
Circulation. Author manuscript; available in PMC 2017 April 28.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Prevalence
Youth—(See Chart 3-1.)
• In 2011, in grades 9 through 12:
– 18.1% of students reported current cigarette use (on ≥1 day during the 
30 days before the survey), 13.1% of students reported current cigar 
use, and 7.7% of students reported current smokeless tobacco use. 
Overall, 23.4% of students reported any current tobacco use (YRBS; 
Chart 3-1).3
– Male students were more likely than female students to report current 
cigarette use (19.9% compared with 16.1%). Male students were also 
more likely than female students to report current cigar use (17.8% 
compared with 8.0%) and current smokeless tobacco use (12.8% 
compared with 2.2%; YRBS).3
– Non-Hispanic white students were more likely than Hispanic or non-
Hispanic black students to report any current tobacco use, which 
includes cigarettes, cigars, or smokeless tobacco (26.5% compared with 
20.5% for Hispanic students and 15.4% for non-Hispanic black 
students; YRBS).3
• Among youths 12 to 17 years of age in 2011, 2.4 million (10.0%) used a tobacco 
product (cigarettes, cigars, or smokeless tobacco) in the past month, and 1.9 
million (7.8%) used cigarettes. Cigarette use in the past month in this age group 
declined significantly from 13.0% in 2002 to 7.8% in 2011 (NSDUH).4
• Data from the YRBS5 for students in grades 9 to 12 indicated the following:
– The percentage of students who reported ever trying cigarettes 
remained stable from 1991 to 1999 and then declined from 70.4% in 
1999 to 44.7% in 2011.
– The percentage who reported current cigarette use (on at least 1 day in 
the 30 days before the survey) increased between 1991 and 1997 and 
then declined from 36.4% in 1997 to 18.1% in 2011.
– The percentage who reported current frequent cigarette use (smoked on 
≥20 of the 30 days before the survey) increased from 1991 to 1999 and 
then declined from 16.8% in 1999 to 6.4% in 2011.
• In 2011, 49.9% of students in grades 9 to 12 who currently smoked cigarettes 
had tried to quit smoking cigarettes during the previous 12 months. The 
prevalence of trying to quit smoking was higher among female student smokers 
(53.9%) than among male student smokers (47.0%) and among white females 
(54.0%) and Hispanic females (55.9%) than among white males (46.3%) and 
Hispanic males (44.7%; YRBS).3
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Abbreviations Used in Chapter 3
AHA American Heart Association
AIAN American Indian or Alaska Native
AMI acute myocardial infarction
BRFSS Behavioral Risk Factor Surveillance System
CHD coronary heart disease
CI confidence interval
CVD cardiovascular disease
NH non-Hispanic
NHANES National Health and Nutrition Examination Survey
NHIS National Health Interview Survey
NSDUH National Survey on Drug Use and Health
RR relative risk
WHO World Health Organization
YRBS Youth Risk Behavior Survey
Adults—(See Table 3-1 and Chart 3-2.)
• In 2012, among adults ≥18 years of age:
– 20.5% of men and 15.9% of women were current cigarette smokers 
(NHIS).6
– The percentage of current cigarette smokers (18.1%) declined 25% 
since 1998 (24.1%).6,7
– The states with the highest percentage of current cigarette smokers were 
Kentucky (28.3%), West Virginia (28.2%), and Arkansas (25.0%). Utah 
had the lowest percentage of smokers (10.6%) (BRFSS).8
• In 2011, an estimated 68.2 million Americans ≥12 years of age were current 
(past month) users of a tobacco product (cigarettes, cigars, smokeless tobacco, or 
tobacco in pipes). The rate of current use of any tobacco product in this age 
range declined from 2007 to 2011 (from 28.6% to 26.5%; NSDUH).4
• From 1998 to 2007, cigarette smoking prevalence among adults ≥18 years of age 
decreased in 44 states and the District of Columbia. Six states had no substantial 
changes in prevalence after controlling for age, sex, and race/ethnicity (BRFSS).9
• In 2009 to 2011, among people ≥65 years of age, 8.9% of men and 8.7% of 
women were current smokers. In this age group, men were more likely than 
women to be former smokers (53.0% compared with 30.6%) on the basis of age-
adjusted estimates (NHIS).10
• In 2009 to 2011, among adults ≥18 years of age, Asian men (15.1%) and 
Hispanic men (16.3%) were less likely to be current cigarette smokers than non-
Hispanic black men (23.2%), non-Hispanic white men (23.6%), and American 
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Indian or Alaska Native men (23.7%) on the basis of ageadjusted estimates 
(NHIS). Similarly, in 2009 to 2011, Asian women (5.7%) and Hispanic women 
(8.9%) were less likely to be current cigarette smokers than non-Hispanic black 
women (16.9%), non-Hispanic white women (20.3%), and American Indian or 
Alaska Native women (23.6%; NHIS).10
• In 2010 to 2011, among women 15 to 44 years of age, past-month cigarette use 
was lower for those who were pregnant (17.6%) than among those who were not 
pregnant (25.4%). This pattern was found for women 18 to 25 years of age 
(22.4% versus 29.9% for pregnant and nonpregnant women, respectively) and for 
women 26 to 44 years of age (14.3% versus 25.7%, respectively; NSDUH).4
Incidence
• In 2011:
– Approximately 2.4 million people ≥12 years of age smoked cigarettes 
for the first time within the past 12 months, which was similar to the 
estimate in 2010. The 2011 estimate averages out to ≈6500 new 
cigarette smokers every day. Most new smokers (55.7%) in 2011 were 
<18 years of age when they first smoked cigarettes (NSDUH).4
– The number of new smokers <18 years of age (1.3 million) was similar 
to that in 2002 (1.3 million); however, new smokers ≥18 years of age 
increased from ≈600 000 in 2002 to 1.1 million in 2011 (NSDUH).4
– Among people 12 to 49 years of age who had started smoking within 
the past 12 months, the average age of first cigarette use was 17.2 years, 
similar to the average in 2010 (17.3 years).4
• Data from 2002 to 2004 suggest that ≈1 in 5 nonsmokers 12 to 17 years of age is 
likely to start smoking. Youths in the Mexican subpopulations were significantly 
more susceptible (28.8%) to start smoking than those in non-Hispanic white 
(20.8%), non-Hispanic black (23.0%), Cuban (16.4%), Asian Indian (15.4%), 
Chinese (15.3%), and Vietnamese (13.8%) subpopulations. There was no 
significant difference in susceptibility to start smoking between boys and girls in 
any of the major populations or subpopulations (NSDUH).11
Morbidity
A 2010 report of the US Surgeon General on how tobacco causes disease summarizes an 
extensive body of literature on smoking and CVD and the mechanisms through which 
smoking is thought to cause CVD.12 Among its conclusions are the following:
• There is a sharp increase in CVD risk with low levels of exposure to cigarette 
smoke, including secondhand smoke, and a less rapid further increase in risk as 
the number of cigarettes per day increases.
• A meta-analysis comparing pooled data of ≈2.4 million smokers and nonsmokers 
found the RR ratio of smokers to nonsmokers for developing CHD was 25% 
higher in women than in men (95% CI, 1.12–1.39).13
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• Current smokers have a 2 to 4 times increased risk of stroke compared with 
nonsmokers or those who have quit for >10 years.14,15
• Recent analysis has found that tobacco exposure is a top risk factor for disability 
in the United States, second only to dietary risks.16
• Worldwide, tobacco smoking (including secondhand smoke) was 1 of the top 3 
leading risk factors for disease in 2010.17
Mortality
• In 2005, tobacco smoking was the cause of ≈467 000 adult deaths (19.1%) in the 
United States. Approximately one third of these deaths were related to CVD.18
• During 2000 to 2004, ≈49 000 (11.1%) of cigarette smoking–related deaths were 
attributable to secondhand smoke.19
• Each year from 2000 to 2004, smoking caused 3.1 million years of potential life 
lost for males and 2.0 million years for females, excluding deaths attributable to 
smoking-attributable residential fires and adult deaths attributable to secondhand 
smoke.19
• From 2000 to 2004, smoking during pregnancy resulted in an estimated 776 
infant deaths annually.17
• During 2000 to 2004, cigarette smoking resulted in an estimated 269 655 deaths 
annually among males and 173 940 deaths annually among females.19
• On average, male smokers die 13.2 years earlier than male nonsmokers, and 
female smokers die 14.5 years earlier than female nonsmokers.1
• In 2010, tobacco smoking was the second-leading risk factor for deaths in the 
United States, after dietary risks.16
• Overall mortality among US smokers is 3 times higher than that for never-
smokers.20
• Worldwide, tobacco smoking (including secondhand smoke) was estimated to 
contribute to 6.2 million deaths in 2010.17
Smoking Cessation
• Smoking cessation reduces the risk of cardiovascular morbidity and mortality for 
smokers with and without CHD.
– There is no evidence to date that reducing the amount smoked by 
smoking fewer cigarettes per day reduces the risk of CVD.12
• Smokers who quit smoking at 25 to 34 years of age gained 10 years of life 
compared with those who continued to smoke. Those aged 35 to 44 years gained 
9 years and those aged 45 to 54 years gained 6 years of life, on average, 
compared with those who continued to smoke.20
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• In 2010, 48.3% of adult current smokers ≥18 years of age who had a health 
checkup during the preceding year reported that they had been advised to quit. 
Smokers between 18 and 24 (31%) and 24 to 44 (44%) years of age were less 
likely to be advised to quit than those at older ages (57%; NHIS).21
• Cessation medications (including sustained-release bupropion, varenicline, and 
nicotine gum, lozenge, nasal spray, and patch) are effective for helping smokers 
quit.22
• In addition to medications, smoke-free policies, increases in tobacco prices, 
cessation advice from healthcare professionals, and quitlines and other 
counseling have contributed to smoking cessation.21
• In 2010, 52.4% of adult smokers reported trying to quit smoking in the past year; 
6.2% reported they recently quit smoking. Of those who tried to quit smoking, 
30.0% used cessation medications.21
• To help combat the global problem of tobacco exposure, in 2003 the WHO 
adopted the Framework Convention on Tobacco Control treaty. The WHO 
Framework Convention on Tobacco Control contains a set of universal standards 
to limit tobacco supply and demand worldwide. These standards include the use 
of tax policies to reduce tobacco consumption, a ban on the indoor use of 
tobacco products, implementation of educational programs about the dangers of 
tobacco use, and restrictions of the sale of tobacco products to international 
travelers. Since it came into force in 2005, >175 countries have ratified the WHO 
Framework Convention on Tobacco Control.23
Secondhand Smoke
• Data from a 2006 report of the US Surgeon General on the consequences of 
involuntary exposure to tobacco smoke12 indicate the following:
– Nonsmokers who are exposed to secondhand smoke at home or at work 
increase their risk of developing CHD by 25% to 30%.
– Short exposures to secondhand smoke can cause blood platelets to 
become stickier, damage the lining of blood vessels, and decrease 
coronary flow velocity reserves, potentially increasing the risk of an 
AMI.
• In 2008, data from 11 states showed that the majority of people surveyed in each 
state reported having smoke-free home rules, ranging from 68.8% in West 
Virginia to 85.6% in Arizona (BRFSS).24
• As of December 31, 2010, 25 states and the District of Columbia had laws that 
prohibited smoking in indoor areas of worksites, restaurants, and bars; no states 
had such laws in 2000. As of December 31, 2010, an additional 10 states had 
laws that prohibited smoking in 1 or 2 but not all 3 venues.25
• In 2012, 30 of the 50 largest US cities prohibited indoor smoking in private 
workplaces, either through state or local ordinances.26
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• Pooled data from 17 studies in North America, Europe, and Australasia suggest 
that smoke-free legislation can reduce the incidence of acute coronary events by 
10%.27
• The percentage of the US nonsmoking population with serum cotinine ≥0.05 
ng/mL declined from 52.5% in 1999 to 2000 to 40.1% in 2007 to 2008, with 
declines occurring for both children and adults. During 2007 to 2008, the 
percentage of nonsmokers with detectable serum cotinine was 53.6% for those 3 
to 11 years of age, 46.5% for those 12 to 19 years of age, and 36.7% for those 
≥20 years of age. The percentage was also higher for non-Hispanic blacks 
(55.9%) than for non-Hispanic whites (40.1%) and Mexican Americans (28.5%; 
NHANES).28
Cost
• Direct medical costs ($96 billion) and lost productivity costs ($97 billion) 
associated with smoking totaled an estimated $193 billion per year between 2000 
and 2004.18
• In 2008, $9.94 billion was spent on marketing cigarettes in the United States.29
• Cigarette prices have increased 283% between the early 1980s and 2011, which 
contributed to decreased sales from ≈30 million packs sold in 1982 to ≈14 
million packs sold in 2011.29
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4. Physical Inactivity
See Table 4-1 and Charts 4-1 through 4-5.
Physical inactivity is a major risk factor for CVD and stroke.1 The AHA has identified ≥60 
minutes of moderate- or vigorous-intensity activity every day (for children) and ≥150 
min/wk of moderate-intensity activity or ≥75 min/wk of vigorous-intensity activity or a 
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combination thereof (for adults) as 1 of the 7 components of ideal cardiovascular health.2 In 
2009 to 2010, 36.5% of children and 41.1% of adults met these criteria.
Prevalence
Youth
Inactivity: (See Chart 4-1.)
In 20113:
• Nationwide, 13.8% of adolescents were inactive during the previous 7 days, as 
indicated by their response that they did not participate in ≥60 minutes of any 
kind of PA that increased their heart rate and made them breathe hard on any 1 of 
the previous 7 days.
• Girls were more likely than boys to report inactivity (17.7% versus 10.0%).
• The prevalence of inactivity was highest among black (26.7%) and Hispanic 
(21.3%) girls, followed by white girls (13.7%), black boys (12.3%), Hispanic 
boys (10.7%), and white boys (8.5%).
Abbreviations Used in Chapter 4
AHA American Heart Association
CARDIA Coronary Artery Risk Development in Young Adults
CHD coronary heart disease
CI confidence interval
CRP C-reactive protein
CVD cardiovascular disease
DBP diastolic blood pressure
DM diabetes mellitus
EF ejection fraction
FMD flow-mediated dilation
HbA1c hemoglobin AIc
HDL high-density lipoprotein
HF heart failure
HR hazard ratio
MI myocardial infarction
NH non-Hispanic
NHANES National Health and Nutrition Examination Survey
NHIS National Health Interview Survey
PA physical activity
PAD peripheral artery disease
RR relative risk
SBP systolic blood pressure
WHO World Health Organization
Television/Video/Computers: (See Chart 4-2.)
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In 20113:
• Nationwide, 31.1% of adolescents used a computer for activities other than 
school work (eg, videogames or other computer games) for ≥3 hours per day on 
an average school day.
• The prevalence of using computers or watching television ≥3 hours per day was 
highest among black (41.1%) and Hispanic (36.3%) boys, followed by white 
boys (33.3%), black girls (35.2%), Hispanic girls (28.3%), and white girls 
(22.6%).
• 32.4% of adolescents watched television for ≥3 hours per day.
• The prevalence of watching television ≥3 hours per day was highest among black 
girls (54.9%) and boys (54.4%), followed by Hispanic boys (38.4%) and girls 
(37.2%) and white boys (27.3%) and girls (23.9%).
• Increased television time has significant nutritional associations with weight gain 
(refer to Chapter 5, Nutrition).
Activity Recommendations: (See Charts 4-3 and 4-4.)
• In 2011, the proportion of students who met activity recommendations of ≥60 
minutes of PA on 7 days of the week was 28.7% nationwide and declined from 
9th (30.7%) to 12th (25.1%) grades. At each grade level, the proportion was 
higher in boys than in girls.3
• In 2011, more high school boys (38.3%) than girls (18.5%) self-reported having 
been physically active ≥60 minutes per day on all 7 days; self-reported rates of 
activity were higher in white (30.4%) than in black (26.0%) or Hispanic (26.5%) 
adolescents.3
• The 2010 National Youth Physical Activity and Nutrition Study showed that a 
total of 15.3% of high school students met the recommendations for aerobic 
activity, 51.0% met the recommendations for muscle-strengthening activity, and 
12.2% met the recommendations for both aerobic and muscle-strengthening 
activities.4
• There was a marked discrepancy between the proportion of youth (ages 6–11 
years) who reported engaging in ≥60 minutes of moderate-to-vigorous PA on 
most days of the week and those who actually engaged in moderate-to-vigorous 
PA for ≥60 minutes when activity was measured objectively with accelerometers 
(ie, portable motion sensors that record and quantify the duration and intensity of 
movements) in the NHANES 2003 to 2004 survey.5
• On the basis of accelerometer counts per minute >2020, 42% of 6- to 11-year-
olds accumulated ≥260 minutes of moderate-to-vigorous PA on ≥5 days per 
week, whereas only 8% of 12-to 15-year-olds and 7.6% of 16- to 19-year-olds 
achieved similar counts.5
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• More boys than girls met PA recommendations (≥60 minutes of moderate to 
vigorous activity on most days of the week) as measured by accelerometry.5
Structured Activity Participation
• Despite recommendations from the National Association for Sport and Physical 
Education that schools should require daily physical education for students in 
kindergarten through 12th grade,6 only 51.8% of students attended physical 
education classes in school daily (56.7% of boys and 46.7% of girls).3
• Physical education class participation declined from the 9th through the 12th 
grades among boys and girls.3
• Little more than half (58.4%) of high school students played on at least 1 school 
or community sports team in the previous year; however, the prevalence declined 
with increasing grade level, from 61.4% in the 9th grade to 52.5% in the 12th 
grade.3
Adults
Inactivity: According to 2012 data from the NHIS, in adults ≥18 years of age:
• 29.9% do not engage in leisure-time PA (“no leisure-time PA/inactivity” refers to 
no sessions of light/moderate or vigorous PA of ≥10 minutes’ duration).7
• Inactivity was higher among women than men (31.0% versus 28.6%, age 
adjusted) and increased with age from 24.5% to 31.8%, 35.7%, and 51.4% 
among adults 18 to 44, 45 to 64, 65 to 74, and ≥75 years of age, respectively.7
• Non-Hispanic black and Hispanic adults were more likely to be inactive (39.4% 
and 39.8%, respectively) than were non-Hispanic white adults (26.2%) on the 
basis of age-adjusted estimates.7
Activity Recommendations: (See Table 4-1 and Chart 4-5.)
According to 2012 data from the NHIS, in adults ≥18 years of age:
• 20.7% met the 2008 federal PA guidelines for both aerobic and strengthening 
activity, an important component of overall physical fitness.7
• The age-adjusted proportion who reported engaging in moderate or vigorous PA 
that met the 2008 aerobic PA guidelines for Americans (≥150 minutes of 
moderate PA or 75 minutes of vigorous PA or an equivalent combination each 
week) was 50.1%; 53.9% of men and 46.5% of women met the 
recommendations. Age-adjusted prevalence was 53.6% for non-Hispanic whites, 
40.9% for non-Hispanic blacks, and 42.5% for Hispanics.7
• The proportion of respondents who did not meet the federal aerobic PA 
guidelines increased with age from 43.8% of 18- to 44-year-olds to 71.9% of 
adults ≥75 years of age.7
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• Non-Hispanic black adults (59.1%) and Hispanic/Latino adults (57.4%) were 
more likely not to meet the federal aerobic PA guidelines than non-Hispanic 
white (46.4%) adults, according to age-adjusted estimates.7
• The percentage of adults ≥25 years of age not meeting the full (aerobic and 
muscle-strengthening) federal PA guidelines was inversely associated with 
education; 66.4% of participants with no high school diploma, 57.6% of those 
with a high school diploma or a high school equivalency credential, 46.8% of 
those with some college, and 33.2% of those with a bachelor’s degree or higher 
did not meet the full federal PA guidelines.7
• The proportion of adults ≥25 years of age who met the 2008 federal PA 
guidelines for aerobic activity was positively associated with education level: 
62.9% of those with a college degree or higher met the PA guidelines compared 
with 31.5% of adults with less than a high school diploma.7
• The proportion of adults reporting levels of PA consistent with the 2008 Physical 
Activity Guidelines for Americans remains low and decreases with age.8,9 
Thirty-three percent of respondents in a study examining awareness of current 
US PA guidelines had direct knowledge of the recommended dosage of PA (ie, 
frequency/duration).10
• The percentage of adults reporting ≥150 minutes of moderate PA or 75 minutes 
of vigorous PA or an equivalent combination weekly decreased with age from 
55.8% for adults 18 to 44 years of age to 27.4% for those ≥75 years of age, on 
the basis of the 2011 NHIS.9
• The percentage of men who engaged in both leisure-time aerobic and 
strengthening activities decreased with age, from 39.8% at age 18 to 24 years to 
11.1% at ≥75 years of age. The percentage of women who engaged in both 
leisure-time aerobic and strengthening activities also decreased with age, from 
20.7% at age 18 to 24 years to 5.3% at ≥75 years of age, on the basis of the 2011 
NHIS.9
• Using PA recommendations that existed at the time of the survey, adherence to 
PA recommendations was much lower when based on PA measured by 
accelerometer in NHANES 2003 to 20045:
– Among adults 20 to 59 years of age, 3.8% of men and 3.2% of women 
met recommendations to engage in moderate-to-vigorous PA 
(accelerometer counts >2020/min) for 30 minutes (in sessions of ≥10 
minutes) on ≥5 of 7 days.
– Among those ≥60 years of age, adherence was 2.5% in men and 2.3% 
in women.
• Accelerometry data from NHANES 2003 to 2006 showed that men engaged in 
35 minutes of moderate activity per day, whereas for women, it was 21 minutes. 
More than 75% of moderate activity was accumulated in 1-minute bouts. Levels 
of activity declined sharply after the age of 50 years in all groups.11
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• In a review examining self-reported versus actual measured PA (eg, 
accelerometers, pedometers, indirect calorimetry, doubly labeled water, heart rate 
monitor), 60% of respondents self-reported higher values of activity than what 
was measured by use of direct methods.12
• Among men, self-reported PA was 44% greater than actual measured values; 
among women, self-reported activity was 138% greater than actual measured 
PA.12
Trends
Youth—In 20113:
• Among adolescents, there was a significant decrease in the prevalence of 
watching television ≥3 hours per day, from 42.8% in 1999 to 32.4%, although 
there was no significant decrease from the 2009 prevalence of 32.8%.
• Among students nationwide, there was a significant increase in the prevalence of 
having participated in muscle-strengthening activities on ≥3 days per week, from 
47.8% in 1991 to 55.6%.
• Nationwide, the prevalence of adolescents using computers ≥3 hours per day 
increased from 21.1% in 2005 to 24.9% in 2009 and 31.1% in 2011.
• Among adolescents nationwide, the prevalence of attending physical education 
classes at least once per week did not increase significantly, from 48.9% in 1991 
to 51.8%.
• The prevalence of adolescents playing ≥1 team sport in the past year increased 
from 55.1% in 1999 to 58.4%.
Adults
• Between NHANES III (1988–1994) and NHANES 2001 to 2006, the non–age-
adjusted proportion of adults who engaged in >12 bouts of PA per month 
declined from 57.0% to 43.3% in men and from 49.0% to 43.3% in women.13
• The proportion of US adults who meet criteria for muscle strength has improved 
between 1998 and 2011. Annual estimates of the percentage of US adults who 
met the muscle-strengthening criteria increased from 17.7% in 1998 to 24.5% in 
2011, and estimates of the percentage who met both the muscle-strengthening 
and aerobic criteria increased from 14.4% in 1998 to 21.0% in 2011.8,14
• A 2.3% decline in physical inactivity between 1980 and 2000 was estimated to 
have prevented or postponed ≈17 445 deaths (≈5%) attributable to CHD in the 
United States.15
CVD and Metabolic Risk Factors
Youth
• More girls (67.9%) than boys (55.7%) reported having exercised to lose weight 
or to keep from gaining weight.3
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• White girls (72.2%) were more likely than black (54.2%) and Hispanic (66.3%) 
girls to report exercising to lose weight or to keep from gaining weight.3
• Total and vigorous PA are inversely correlated with body fat and the prevalence 
of obesity.16
• Among children 4 to 18 years of age, increased time in moderate to vigorous PA 
was associated with improvements in waist circumference, SBP, fasting 
triglycerides, HDL cholesterol, and insulin. These findings were significant 
regardless of the amount of the children’s sedentary time.17
• Among children aged 4 to 18 years, both higher activity levels and lower 
sedentary time measured by accelerometry were associated with more favorable 
metabolic risk factor profiles.17
Adults
• Participants in the Diabetes Prevention Project randomized trial who met the PA 
goal of 150 minutes of PA per week were 44% less likely to develop DM after 
3.2 years of follow-up, even if they did not meet the weight-loss target.18
• Exercise for weight loss, without dietary interventions, was associated with 
significant reductions in DBP (−2 mm Hg; 95% CI, −4 to −1 mm Hg), 
triglycerides (−0.2 mmol/L; 95% CI, −0.3 to −0.1 mmol/L), and fasting glucose 
(−0.2 mmol/L; 95% CI, −0.3 to −0.1 mmol/L).19
• A total of 120 to 150 minutes per week of moderate-intensity activity, compared 
with none, can reduce the risk of developing metabolic syndrome.20
• In CARDIA, women who maintained high activity through young adulthood 
gained 6.1 fewer kilograms of weight and 3.8 fewer centimeters in waist 
circumference in middle age than those with lower activity. Highly active men 
gained 2.6 fewer kilograms and 3.1 fewer centimeters than their lower-activity 
counterparts.21
• Self-reported low lifetime recreational activity has been associated with 
increased PAD.22
• In 3 US cohort studies, men and women who increased their PA over time gained 
less weight in the long term, whereas those who decreased their PA over time 
gained more weight and those who maintained their current PA had intermediate 
weight gain.23
• Among US men and women, every hour per day of increased television watching 
was associated with 0.3 lb of greater weight gain every 4 years, whereas every 
hour per day of decreased television watching was associated with a similar 
amount of relative weight loss.23
Morbidity and Mortality
• Physical inactivity is responsible for 12.2% of the global burden of MI after 
accounting for other CVD risk factors such as cigarette smoking, DM, 
et al. Page 38
Circulation. Author manuscript; available in PMC 2017 April 28.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
hypertension, abdominal obesity, lipid profile, no alcohol intake, and 
psychosocial factors.24
• In a meta-analysis of longitudinal studies among women, RRs of incident CHD 
were 0.83 (95% CI, 0.69–0.99), 0.77 (95% CI, 0.64–0.92), 0.72 (95% CI, 0.59–
0.87), and 0.57 (95% CI, 0.41–0.79) across increasing quintiles of PA compared 
with the lowest quintile.25
• A 2003 meta-analysis of 23 studies on the association of PA with stroke 
indicated that compared with low levels of activity, high (RR, 0.79; 95% CI, 
0.69–0.91) and moderate (RR, 0.91; 95% CI, 0.80–1.05) levels of activity were 
inversely associated with the likelihood of developing total stroke (ischemic and 
hemorrhagic).26
• With television watching as a sedentary activity, 2 hours of television per day is 
associated with an RR for type 2 DM of 1.20 (95% CI, 1.14–1.27), an RR for 
fatal or nonfatal CVD of 1.15 (95% CI, 1.06–1.23), and an RR for all-cause 
mortality of 1.13 (95% CI, 1.07–1.18). The risk for all-cause mortality further 
increases with >3 hours of television daily.27
• Longitudinal studies commonly report a graded, inverse association of PA 
amount and duration (ie, dose) with incident CHD and stroke.28
• The PA guidelines for adults cite evidence that ≈150 minutes per week of 
moderate-intensity aerobic activity, compared with none, can reduce the risk of 
CVD.29
• Adherence to PA guidelines for both aerobic and muscle-strengthening activities 
is associated with 27% lower all-cause mortality among adults without existing 
chronic conditions such as DM, cancer, MI, angina, CVD, stroke, or respiratory 
diseases and with 46% lower mortality among people with chronic 
comorbidities.29
• In the Health Professionals Follow-Up Study, for every 3-hour-per-week increase 
in vigorous-intensity activity, the multivariate RR of MI was 0.78 (95% CI, 0.61–
0.98) for men. This 22% reduction of risk can be explained in part by beneficial 
effects of PA on HDL cholesterol, vitamin D, apolipoprotein B, and HbA1c.30
• In a 20-year study of older male veterans, an inverse, graded, and independent 
association between impaired exercise capacity and all-cause mortality risk was 
found. For each increase of 1 metabolic equivalent tasks in exercise capacity, 
mortality risk was 12% lower (HR, 0.88; 95% CI, 0.86–0.90). Unfit individuals 
who improved their fitness status had a 35% lower mortality risk (HR, 0.65; 95% 
CI, 0.46–0.93) than those who remained unfit.31
Secondary Prevention
• PA improves inflammatory markers in people with existing stable CHD. After a 
6-week training session, CRP levels declined by 23.7% (P<0.001), and plasma 
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vascular cell adhesion molecule-1 levels declined by 10.23% (P<0.05); there was 
no difference in leukocyte count or levels of intercellular adhesion molecule-1.32
• In a randomized trial of patients with PAD, supervised treadmill exercise training 
and lower-extremity resistance training were each associated with significant 
improvements in functional performance and quality of life compared with a 
usual-care control group. Exercise training was additionally associated with 
improved brachial artery FMD, whereas resistance training was associated with 
better stair-climbing ability versus control.33
• On the basis of a meta-analysis of 34 randomized controlled trials, exercise-
based cardiac rehabilitation after MI was associated with lower rates of 
reinfarction, cardiac mortality, and overall mortality.34
• The benefit of intense exercise training for cardiac rehabilitation in people with 
HF was tested in a trial of 27 patients with stable, medically treated HF. Intense 
activity (an aerobic interval-training program 3 times per week for 12 weeks) 
was associated with a significant 35% improvement in left ventricular EF and 
decreases in pro-brain natriuretic peptide (40%), left ventricular end-diastolic 
volume (18%), and left ventricular end-systolic volume (25%) compared with 
control and endurance-training groups.35
• Exercise training in patients with HF with preserved EF was associated with 
improved exercise capacity and favorable changes in diastolic function.36
Costs
• The economic consequences of physical inactivity are substantial. In a summary 
of WHO data sources, the economic costs of physical inactivity were estimated 
to account for 1.5% to 3.0% of total direct healthcare expenditures in developed 
countries such as the United States.37
• Interventions and community strategies to increase physical activity have been 
shown to be cost-effective in terms of reducing medical costs38:
– Nearly $3 in medical cost savings is realized for every $1 invested in 
building bike and walking trails.
– Incremental cost and incremental effectiveness ratios range from $14 
000 to $69 000 per quality-adjusted life-year gained from interventions 
such as pedometer or walking programs compared with no intervention, 
especially in high-risk groups.
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5. Nutrition
See Tables 5-1 and 5-2 and Charts 5-1 through 5-3.
This chapter of the Update highlights national dietary consumption data, focusing on key 
foods, nutrients, dietary patterns, and other dietary factors related to cardiometabolic health. 
It is intended to examine current intakes, trends and changes in intakes, and estimated effects 
on disease to support and further stimulate efforts to monitor and improve dietary habits in 
relation to cardiovascular health.
Abbreviations Used in Chapter 5
ALA α-linoleic acid
ARIC Atherosclerosis Risk in Communities Study
BMI body mass index
BP blood pressure
BRFSS Behavioral Risk Factor Surveillance System
CHD coronary heart disease
CHF congestive heart failure
CI confidence interval
CVD cardiovascular disease
DASH Dietary Approaches to Stop Hypertension
DBP diastolic blood pressure
DHA docosahexaenoic acid
DM diabetes mellitus
EPA eicosapentaenoic acid
GFR glomerular filtration rate
GISSI Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto miocardico
HD heart disease
HDL high-density lipoprotein
HEI Healthy Eating Index
HF heart failure
LDL low-density lipoprotein
MI myocardial infarction
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n-6-PUFA ω-6-polyunsaturated fatty acid
NA not available
NH non-Hispanic
NHANES National Health and Nutrition Examination Survey
OR odds ratio
PA physical activity
RR relative risk
SBP systolic blood pressure
SD standard deviation
WHI Women’s Health Initiative
Prevalence
Foods and Nutrients: Adults—(See Table 5-1; NHANES 2009–2010.)
The dietary consumption by US adults of selected foods and nutrients related to 
cardiometabolic health is detailed in Table 5-1 according to sex and race or ethnic 
subgroups:
• Average consumption of whole grains was 1.1 servings per day by white men 
and women and 0.8 servings per day by black men and women, with only 
between 7% and 10% of white and black adults meeting guidelines of ≥3 
servings per day. Average whole grain consumption by Mexican Americans was 
≈2 servings per day, with 27% to 29% consuming ≥3 servings per day.
• Average fruit consumption ranged from 1.2 to 1.9 servings per day in these sex 
and race or ethnic subgroups: 11% to 13% of whites, 7% to 8% of blacks, and 
14% of Mexican Americans met guidelines of ≥2 cups per day. When 100% fruit 
juices were included, the number of servings increased, and the proportions of 
adults consuming ≥2 cups per day approximately doubled in whites and Mexican 
Americans and nearly quadrupled in blacks.
• Average vegetable consumption ranged from 1.3 to 2.2 servings per day; 6% to 
8% of whites, 2% to 5% of blacks, and 2 to 4% of Mexican Americans 
consumed ≥2.5 cups per day. The inclusion of vegetable juices and sauces 
generally produced little change in these consumption patterns.
• Average consumption of fish and shellfish was lowest among Mexican American 
and white women (1.2 and 1.4 servings per week, respectively) and highest 
among black women (2.1 servings per week); ≈72% to 78% of all adults in each 
sex and race or ethnic subgroup consumed <2 servings per week. Approximately 
9% to 10% of whites, 10% to 12% of blacks, and 7% to 13% of Mexican 
Americans consumed ≥250 mg of eicosapentaenoic acid and docosahexaenoic 
acid per day.
• Average consumption of nuts, legumes, and seeds was ≈2.5 servings per week 
among whites and blacks and 5 to 8 servings per week among Mexican 
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Americans. Approximately 22% of whites, 18% of blacks, and 40% of Mexican 
Americans met guidelines of ≥4 servings per week.
• Average consumption of processed meats was lowest among Mexican American 
women (1.2 servings per week) and highest among black men (3.3 servings per 
week). Between 49% (black men) and 75% (Mexican American women) of 
adults consumed 2 or fewer servings per week.
• Average consumption of sugar-sweetened beverages ranged from ≈6 servings per 
week among white women to 12 servings per week among Mexican American 
men. Women generally consumed less than men. From 29% (Mexican American 
men) to 68% (white women) of adults consumed no more than 36 oz (4.5 8-oz 
servings) per week.
• Average consumption of sweets and bakery desserts ranged from ≈4.5 servings 
per day (Mexican Americans) to 7 servings per day (white women). 
Approximately two thirds of white women and more than half of all other sex 
and race groups consumed >2.5 servings per week.
• Between 35% and 58% of adults in each sex and race or ethnic subgroup 
consumed <10% of total calories from saturated fat, and between 56% and 72% 
consumed <300 mg of dietary cholesterol per day.
• Only 6% to 12% of whites, 2% to 5% of blacks, and 13% of Mexican Americans 
consumed ≥28 g of dietary fiber per day.
• Only 5% to 7% of whites, 6% to 12% of blacks, and 10% of Mexican Americans 
consumed <2.3 g of sodium per day.
Foods and Nutrients: Children and Teenagers—(See Table 5-2; NHANES 2009–
2010.)
The dietary consumption by US children and teenagers of selected foods and nutrients 
related to cardiometabolic health is detailed in Table 5-2:
• Average whole grain consumption was low, <1 serving per day in all age and sex 
groups, with <7% of all children in different age and sex subgroups meeting 
guidelines of ≥3 servings per day.
• Average fruit consumption was low and decreased with age: 1.6 to 1.7 servings 
per day in younger boys and girls (5–9 years of age), 1.3 servings per day in 
adolescent boys and girls (10–14 years of age), and 0.9 to 1.2 servings per day in 
teenage boys and girls (15–19 years of age). The proportion meeting guidelines 
of ≥2 cups per day was also low and decreased with age: ≈10% in those 5 to 9 
years of age, 8% in those 10 to 14 years of age, and 5% in those 15 to 19 years of 
age. When 100% fruit juices were included, the number of servings consumed 
approximately doubled, and proportions consuming ≥2 cups per day increased to 
approximately one third of those 5 to 9 years of age and one fourth of those 10 to 
14 years and 15 to 19 years of age.
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• Average vegetable consumption was low, ranging from 0.8 to 1.3 servings per 
day, with at most 3% of children in different age and sex subgroups meeting 
guidelines of ≥2.5 cups per day.
• Average consumption of fish and shellfish was low, ranging between 0.3 and 0.9 
servings per week in all age and sex groups. Among all ages, only 5% to 11% of 
youth consumed ≥2 servings per week.
• Average consumption of nuts, legumes, and seeds ranged from 1.4 to 1.9 
servings per week among different age and sex groups. Only between 11% and 
14% of children in different age and sex subgroups consumed ≥4 servings per 
week.
• Average consumption of processed meats ranged from ≈2 to 3 servings per 
week; was generally higher than the average consumption of nuts, legumes, and 
seeds; and was up to 8 times higher than the average consumption of fish and 
shellfish. Approximately 40% and 50% of children consumed >2 servings per 
week.
• Average consumption of sugar-sweetened beverages was higher in boys than in 
girls and increased with age, from ≈7 to 8 servings per week in 5- to 9-year-olds, 
9 to 10 servings per week in 10- to 14-year-olds, and 13 to 16 servings per week 
in 15- to 19-year-olds (each energy adjusted to 2000 kcal/d). This was generally 
considerably higher than the average consumption of whole grains, fruits, 
vegetables, fish and shellfish, or nuts, legumes, and seeds. Less than half of 
children 5 to 9 years of age and less than one quarter of boys 15 to 19 years of 
age consumed <4.5 servings per week.
• Average consumption of sweets and bakery desserts was ≈9 to 10 servings per 
week in 5- to 9-year-olds, 7 to 8 servings per week in 10- to 14-year-olds, and 5 
to 8 servings per week in 15- to 19-year-olds. From 61% (boys 15–19 years of 
age) to 79% (girls 5–9 years of age) of youths consumed >2.5 servings per week.
• Average consumption of eicosapentaenoic acid and docosahexaenoic acid was 
low, ranging from 39 to 63 mg/d in boys and girls at all ages. Fewer than 6% of 
children and teenagers at any age consumed ≥250 mg/d.
• Average consumption of saturated fat was ≈11% of calories, and average 
consumption of dietary cholesterol ranged from 225 to 250 mg/d. Approximately 
30% to 40% of youth consumed <10% energy from saturated fat, and >75% 
consumed <300 mg of dietary cholesterol per day.
• Average consumption of dietary fiber ranged from 14 to 15 g/d. Less than 2% of 
children in all age and sex subgroups consumed ≥28 g/d.
• Average consumption of sodium ranged from 3.3 to 3.5 g/d. Only between 2% 
and 9% of children in different age and sex subgroups consumed <2.3 g/d.
Energy Balance—Energy balance, or consumption of total calories appropriate for needs, 
is determined by the balance of average calories consumed versus expended, with this 
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balance depending on multiple factors, including calories consumed, PA, body size, age, sex, 
and underlying basal metabolic rate. Thus, one individual may consume relatively high 
calories but have negative energy balance (as a result of even greater calories expended), 
whereas another individual may consume relatively few calories but have positive energy 
balance (because of low calories expended). Given such variation, the most practical and 
reasonable method to assess energy balance in populations is to assess changes in weight 
over time (Trends section).
• Average daily caloric intake in the United States is ≈2500 calories in adult men 
and 1800 calories in adult women (Table 5-1). In children and teenagers, average 
caloric intake is higher in boys than in girls and increases with age in boys (Table 
5-2). Trends in energy balance are described below. The average US adult gains 
≈1 lb per year. In an analysis of >120 000 US men and women in 3 separate US 
cohorts followed up for up to 20 years, changes in intakes of different foods and 
beverages were linked to long-term weight gain in different ways.1 Foods and 
beverages most positively linked to weight gain included refined grains, starches, 
and sugars, including potatoes, white bread, white rice, low-fiber breakfast 
cereals, sweets/desserts, and sugar-sweetened beverages, as well as red and 
processed meats. In contrast, increased consumption of several other foods, 
including nuts, whole grains, fruits, vegetables, and yogurt, was linked to relative 
weight loss over time. These findings indicate that attention to dietary quality, 
not simply counting total calories, is crucial for energy balance.1
• Diet quality also appears to influence energy expenditure. After intentional 
weight loss, isocaloric diets higher in fat and lower in rapidly digestible 
carbohydrates produced significantly smaller declines in total energy expenditure 
than low-fat, high-carbohydrate diets.2 Similarly, isocaloric meals richer in 
rapidly digestible carbohydrate increased hunger and stimulated brain regions 
associated with reward and craving compared with isocaloric meals lower in 
rapidly digestible carbohydrate.3
• Other nutritional determinants of positive energy balance (more calories 
consumed than expended), as determined by adiposity or weight gain, include 
larger portion sizes4,5 and greater consumption of fast food and commercially 
prepared meals.6–10
• Preferences for portion size are associated with BMI, socioeconomic status, 
eating in fast food restaurants, and television watching.11,12 Portion sizes are 
larger at fast food restaurants than at home or at other restaurants.13
• Between 1999 and 2004, 53% of Americans consumed an average of 1 to 3 
restaurant meals per week, and 23% consumed ≥4 restaurant meals per week.14 
Spending on food away from home, including restaurant meals, catered foods, 
and food eaten during out-of-town trips, increased from 26% of average annual 
food expenditures in 1970 to 42% in 2004.14
• Macronutrient composition of the overall diet or of specific foods, such as 
percentage of calories from total fat, does not appear to be strongly associated 
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with energy balance as ascertained by weight gain or loss.1,15–17 In contrast, 
dietary quality as characterized by higher or lower intakes of specific foods and 
beverages is strongly linked to weight gain (see above).1
• Emerging evidence suggests that consumption of trans fat may be associated 
with energy imbalance as assessed by changes in adiposity or weight, as well as 
more specific adverse effects on visceral adiposity.18–20
• Other individual factors associated with positive energy balance (weight gain) 
include greater television watching (with evidence that effects are mediated by 
diet, rather than physical inactivity, including greater snacking in front of the 
television and the influence of advertising on poor food choices)1,21–25 and lower 
average sleep duration.1,26
• Randomized controlled trials of weight loss in obese individuals generally show 
modestly greater weight loss with low-carbohydrate (high-fat) diets than with 
low-fat diets at 6 months, but at 1 year, such differences diminish, and a diet that 
focuses on dietary quality and whole foods may be most successful in the long 
term.27–30
• A comparison of BRFSS data in 1996 and 2003 suggested a shift in self-reported 
dietary strategies to lose weight, with the proportion focusing on calorie 
restriction increasing from 11.3% to 24.9% and the proportion focusing on 
restricting fat consumption decreasing from 41.6% to 29.1%.31
• On the basis of BRFSS data from 2003, among all American adults who were 
overweight or obese, a higher proportion was trying to lose weight if also 
diagnosed with hypertension (58% trying to lose weight), DM (60%), or both 
diseases (72%) than adults with neither condition (50%).32
• A 2007 to 2008 national survey of 1082 retail stores in 19 US cities found that 
energy-dense snack foods/beverages were present in 96% of pharmacies, 94% of 
gas stations, 22% of furniture stores, 16% of apparel stores, and 29% to 65% of 
other types of stores.33
• Societal and environmental factors independently associated with energy 
imbalance (weight gain), via either increased caloric consumption or decreased 
expenditure, include education, income, race/ethnicity, and local conditions such 
as availability of grocery stores, types of restaurants, safety, parks and open 
spaces, and walking or biking paths.34–36 PA is covered in Chapter 4 of this 
update.
Dietary Patterns
In addition to individual foods and nutrients, overall dietary patterns can be used to assess 
more global dietary quality. Different dietary patterns have been defined, including the HEI, 
Alternative HEI, Western versus prudent dietary patterns, Mediterranean dietary pattern, and 
DASH-type diet. The higher-monounsaturated-fat DASH-type diet is generally similar to a 
traditional Mediterranean dietary pattern.37
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• In 1999 to 2004, only 19.4% of hypertensive US adults were following a DASH-
type diet (based on intake of fiber, magnesium, calcium, sodium, potassium, 
protein, total fat, saturated fat, and cholesterol). This represented a decrease from 
26.7% of hypertensive US adults in 1988 to 1994.38
• Among older US adults (≥60 years of age) in 1999 to 2002, 72% met guidelines 
for dietary cholesterol intake, but only between 18% and 32% met guidelines for 
the HEI food groups (meats, dairy, fruits, vegetables, and grains). On the basis of 
the HEI score, only 17% of older US adults consumed a good-quality diet. 
Higher HEI scores were seen in white adults and individuals with greater 
education; lower HEI scores were seen in black adults and smokers.39
Dietary Supplements
Use of dietary supplements is common in the United States among both adults and children:
• Approximately half of US adults in 2007 to 2010 used ≥1 dietary supplement, 
with the most common supplement being multivitamin-multimineral products 
(32% of men and women reporting use).40 It has been shown that most 
supplements are taken daily and for ≥2 years.41 Supplement use is associated 
with older age, higher education, greater PA, moderate alcohol consumption, 
lower BMI, abstinence from smoking, having health insurance, and white 
race.40,41 Previous research also suggests that supplement users have higher 
intakes of most vitamins and minerals from their food choices alone than 
nonusers.42,43 The primary reasons US adults in 2007 to 2010 reported for using 
dietary supplements were to “improve overall health” (45%) and to “maintain 
health” (33%).40
• One third (32%) of US children (birth to 18 years of age) used dietary 
supplements in 1999 to 2002, with the highest use (48.5%) occurring among 4- 
to 8-year-olds. The most common supplements were multivitamins and 
multiminerals (58% of supplement users). The primary nutrients supplemented 
(either by multivitamins or individual vitamins) included vitamin C (29% of US 
children), vitamin A (26%), vitamin D (26%), calcium (21%), and iron (19%). 
Supplement use was associated with higher family income, a smoke-free home 
environment, lower child BMI, and less screen time (television, video games, or 
computers).44
• In a 2005 to 2006 telephone survey of US adults, 41.3% were making or had 
made in the past a serious weight-loss attempt. Of these, one third (33.9%) had 
used a dietary supplement for weight loss, with such use being more common in 
women (44.9%) than in men (19.8%) and in blacks (48.7%) or Hispanics 
(41.6%) than in whites (31.2%); in those with high school education or less 
(38.4%) than in those with some college or more (31.1%); and in those with 
household income <$40 000 per year (41.8%) than in those with higher incomes 
(30.3%).45
• Multiple trials of most dietary supplements, including folate, vitamin C, and 
vitamin E, have generally shown no significant benefits for CVD risk, and even 
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potential for harm.36 For example, a multicenter randomized trial in patients with 
diabetic nephropathy found that B vitamin supplementation (folic acid 2.5 mg/d, 
vitamin B6 25 mg/d, and vitamin B12 1 mg/d) decreased GFR and increased risk 
of MI and stroke compared with placebo.46
• Fish oil supplements at doses of 1 to 2 g/d have shown CVD benefits in 2 large 
randomized, open-label trials and 1 large randomized, placebo-controlled trial 
(GISSI-Prevenzione, Japan Eicosapentaenoic Acid Lipid Intervention Study, and 
GISSI-HF),47–49 but several other trials of fish oil have not shown significant 
effects on CVD risk.50 A meta-analysis of all randomized controlled clinical 
trials demonstrated a significant reduction for cardiac mortality but no 
statistically significant effects on other CVD end points.51
Trends
Energy Balance—(See Chart 5-1.)
Energy balance, or consumption of total calories appropriate for needs, has been steadily 
worsening in the United States over the past several decades, as evidenced by the dramatic 
increases over the past 30 years in overweight and obesity among both children and adults 
across broad cross sections of sex, race/ethnicity, geographic residence, and socioeconomic 
status. However, in more recent years, rates of obesity and overweight among both adults 
and children have begun to level off.52–54
• The US obesity epidemic began in approximately 1980, accelerated from 1990 to 
2005, and may be slowing in more recent years. Examining trends in diet, 
activity, and other factors from 1980 to present is important to elucidate the 
drivers of this remarkably recent epidemic.
• Although trends in total calories consumed are difficult to quantify exactly 
because of differing methods of serial national dietary surveys over time, 
multiple lines of evidence indicate that average total energy consumption has 
increased by ≥200 kcal/d per person in the past 3 decades.
• Data from NHANES indicate that between 1971 and 2004, average total energy 
consumption among US adults increased by 22% in women (from 1542 to 1886 
kcal/d) and by 10% in men (from 2450 to 2693 kcal/d).14 These increases are 
supported by data from 2 older surveys, the Nationwide Food Consumption 
Survey (1977–1978) and the Continuing Surveys of Food Intake (1989–1998).13 
However, recent data show that energy intake appeared relatively stable among 
US adults during 1999 to 2008.55
• The increases in calories consumed between 1971 and 2004 are attributable 
primarily to greater average carbohydrate intake, particularly of starches, refined 
grains, and sugars (Foods and Nutrients section). Other specific changes related 
to increased caloric intake in the United States include larger portion sizes, 
greater food quantity and calories per meal, and increased consumption of sugar-
sweetened beverages, snacks, commercially prepared (especially fast-food) 
meals, and higher-energy-density foods.7,13,56–60
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• Between 1977 and 1996, the average portion sizes for nearly all foods increased 
at fast-food outlets, other restaurants, and home. These included a 33% increase 
in the average portion of Mexican food (from 408 to 541 calories), a 34% 
increase in the average portion of cheeseburgers (from 397 to 533 calories), a 
36% increase in the average portion of French fries (from 188 to 256 calories), 
and a 70% increase in the average portion of salty snacks such as crackers, potato 
chips, pretzels, puffed rice cakes, and popcorn (from 132 to 225 calories).13
• Among US children 2 to 7 years of age, an estimated energy imbalance of only 
110 to 165 kcal/d (the equivalent of one 12- to 16-oz bottle of soda/cola) was 
sufficient to account for the excess weight gain between 1988 and 1994 and 1999 
and 2002.61
• In a quantitative analysis using various US surveys between 1977 and 2006, the 
relations of changes in energy density, portion sizes, and number of daily eating/
drinking occasions to changes in total energy intake were assessed.62 Decreases 
in energy density were actually linked to lower total energy intake over time, 
whereas increases in both portion size and number of eating occasions were 
linked to greater energy intake.
• Among US children 2 to 18 years of age, increases in energy intake between 
1977 and 2006 (179 kcal/d) were entirely attributable to substantial increases in 
energy eaten away from home (255 kcal/d).63 The percentage of energy eaten 
away from home increased from 23.4% to 33.9% during this time, with a shift 
toward energy from fast food as the largest contributor to foods away from home 
for all age groups.
• A county-level investigation based on BRFSS and NHANES data found that 
prevalence of sufficient PA in the United States increased from 2001 to 2009 but 
that this was matched by increases in obesity in almost all counties during the 
same time period, with low correlation between level of PA and obesity in US 
counties.64
Foods and Nutrients—Several changes in foods and nutrients have occurred over time. 
Selected changes are highlighted below.
Macronutrients: (See Chart 5-1.)
• Starting in 1977 and continuing until the most recent dietary guidelines revision 
in 2010, a major focus of US dietary guidelines was reduction of dietary fats.65 
During this time, average total fat consumption declined as a percent of calories 
from 36.9% to 33.4% in men and from 36.1% to 33.8% in women.14 However, 
more recent analyses show that there were no significant trends in total fat intake 
among US adults from 1999 to 2008.55
• Dietary guidelines during this time also emphasized carbohydrate consumption 
as the base of one’s dietary pattern66 and more recently specified the importance 
of complex rather than refined carbohydrates (eg, as the base of the Food Guide 
Pyramid).65 From 1971 to 2004, total carbohydrate intake increased from 42.4% 
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to 48.2% of calories in men and from 45.4% to 50.6% of calories in women.14 
Evaluated as absolute intakes, the increase in total calories consumed during this 
period was attributable primarily to the greater consumption of carbohydrates, 
both as foods (starches and grains) and as beverages.67,68 However, more recent 
analyses show that there has been a decrease in carbohydrate intake (expressed 
as percentage of energy) among US adults from 1999 to 2008.55
Sugar-Sweetened Beverages: (See Chart 5-2.)
• Between 1965 and 2002, the average percentage of total calories consumed from 
beverages in the United States increased from 11.8% to 21.0% of energy, which 
represents an overall absolute increase of 222 kcal/d per person.59 This increase 
was largely caused by increased consumption of sugar-sweetened beverages and 
alcohol: Average consumption of fruit juices went from 20 to 39 kcal/d; of milk, 
from 125 to 94 kcal/d; of alcohol, from 26 to 99 kcal/d; of sweetened fruit 
drinks, from 13 to 38 kcal/d; and of soda/cola, from 35 to 143 kcal/d.62
• In contrast, between 1999 and 2010, sugar-sweetened beverage intake decreased 
among both youth and adults in the United States, consistent with increased 
attention to their importance as a cause of obesity. In 2009 to 2010, youth and 
adults consumed a daily average of 155 and 151 kcal/d from sugar-sweetened 
beverages, respectively, a decrease from 1999 to 2000 of 68 and 45 kcal/d, 
respectively.69
• In addition to increased overall consumption, the average portion size of a single 
sugar-sweetened beverage increased by >50% between 1977 and 1996, from 
13.1 to 19.9 fl oz.13
• Among children and teenagers (2–19 years of age), the largest increases in 
consumption of sugar-sweetened beverages between 1988 to 1994 and 1999 to 
2004 were seen among black and Mexican American youths compared with 
white youths.60
Fruits and Vegetables
• Between 1994 and 2005, the average consumption of fruits and vegetables 
declined slightly, from a total of 3.4 to 3.2 servings per day. The proportions of 
men and women consuming combined fruits and vegetables ≥5 times per day 
were low (≈20% and 29%, respectively) and did not change during this period.70
Morbidity and Mortality
Effects on Cardiovascular Risk Factors—Dietary habits affect multiple 
cardiovascular risk factors, including both established risk factors (SBP, DBP, LDL 
cholesterol levels, HDL cholesterol levels, glucose levels, and obesity/weight gain) and 
novel risk factors (eg, inflammation, cardiac arrhythmias, endothelial cell function, 
triglyceride levels, lipoprotein[a] levels, and heart rate):
• A DASH dietary pattern with low sodium reduced SBP by 7.1 mm Hg in adults 
without hypertension and by 11.5 mm Hg in adults with hypertension.71
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• Compared with the low-fat DASH diet, DASH-type diets that increased 
consumption of either protein or unsaturated fat had similar or greater beneficial 
effects on CVD risk factors. Compared with a baseline usual diet, each of the 
DASH-type diets, which included various percentages (27%–37%) of total fat 
and focused on whole foods such as fruits, vegetables, whole grains, and fish, as 
well as potassium and other minerals and low sodium, reduced SBP by 8 to 10 
mm Hg, DBP by 4 to 5 mm Hg, and LDL cholesterol by 12 to 14 mg/dL. The 
diets that had higher levels of protein and unsaturated fat also lowered 
triglyceride levels by 16 and 9 mg/dL, respectively.72 The DASH-type diet 
higher in unsaturated fat also improved glucose-insulin homeostasis compared 
with the low-fat/high-carbohydrate DASH diet.73
• In a meta-analysis of randomized controlled trials, consumption of 1% of 
calories from trans fat in place of saturated fat, monounsaturated fat, or 
polyunsaturated fat, respectively, increased the ratio of total to HDL cholesterol 
by 0.031, 0.054, and 0.67; increased apolipoprotein B levels by 3, 10, and 11 
mg/L; decreased apolipoprotein A-1 levels by 7, 5, and 3 mg/L; and increased 
lipoprotein(a) levels by 3.8, 1.4, and 1.1 mg/L.74
• In meta-analyses of randomized controlled trials, consumption of 
eicosapentaenoic acid and docosahexaenoic acid for 212 weeks lowered SBP by 
2.1 mm Hg75 and lowered resting heart rate by 2.5 beats per minute.76
• In a pooled analysis of 25 randomized trials totaling 583 men and women both 
with and without hypercholesterolemia, nut consumption significantly improved 
blood lipid levels.77 For a mean consumption of 67 g of nuts per day, total 
cholesterol was reduced by 10.9 mg/dL (5.1%), LDL cholesterol by 10.2 mg/dL 
(7.4%), and the ratio of total cholesterol to HDL cholesterol by 0.24 (5.6% 
change; P<0.001 for each). Triglyceride levels were also reduced by 20.6 mg/dL 
(10.2%) in subjects with high triglycerides (2150 mg/dL). Different types of nuts 
had similar effects.77
• A review of cross-sectional and prospective cohort studies suggests that higher 
intake of sugar-sweetened beverages is associated with greater visceral fat and 
higher risk of type 2 DM.78 Two randomized trials have confirmed that reducing 
intake of sugar-sweetened beverages reduces weight gain in children.79,80
• In a randomized controlled trial, compared with a low-fat diet, 2 Mediterranean 
dietary patterns that included either virgin olive oil or mixed nuts lowered SBP 
by 5.9 and 7.1 mm Hg, plasma glucose by 7.0 and 5.4 mg/dL, fasting insulin by 
16.7 and 20.4 pmol/L, the homeostasis model assessment index by 0.9 and 1.1, 
and the ratio of total to HDL cholesterol by 0.38 and 0.26 and raised HDL 
cholesterol by 2.9 and 1.6 mg/dL, respectively. The Mediterranean dietary 
patterns also lowered levels of C-reactive protein, interleukin-6, intercellular 
adhesion molecule-1, and vascular cell adhesion molecule-1.81
Effects on Cardiovascular Outcomes—Because dietary habits affect a broad range of 
established and novel risk factors, estimation of the impact of nutritional factors on 
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cardiovascular health by considering only a limited number of pathways (eg, only effects on 
lipids, BP, and obesity) will systematically underestimate or even misconstrue the actual 
total impact on cardiovascular health. Randomized controlled trials and prospective 
observational studies have been used to quantify the total effects of dietary habits on clinical 
outcomes.
Fats and Carbohydrates
• In the WHI randomized clinical trial (n=48 835), reduction of total fat 
consumption from 37.8% energy (baseline) to 24.3% energy (at 1 year) and 
28.8% energy (at 6 years) had no effect on incidence of CHD (RR, 0.98; 95% CI, 
0.88–1.09), stroke (RR, 1.02; 95% CI, 0.90–1.15), or total CVD (RR, 0.98; 95% 
CI, 0.92–1.05) over a mean of 8.1 years.82 This was consistent with null results 
of 4 prior randomized clinical trials and multiple large prospective cohort studies 
that indicated little effect of total fat consumption on CVD risk.83
• In 3 separate meta-analyses of prospective cohort studies, the largest of which 
included 21 studies with up to 2 decades of follow-up, saturated fat consumption 
overall had no significant association with incidence of CHD, stroke, or total 
CVD.84–86 In comparison, in a pooled individual-level analysis of 11 prospective 
cohort studies, the specific exchange of polyunsaturated fat consumption in place 
of saturated fat was associated with lower CHD risk, with 13% lower risk for 
each 5% energy exchange (RR, 0.87; 95% CI, 0.70–0.97).87 These findings are 
consistent with a meta-analysis of randomized controlled trials in which 
increased polyunsaturated fat consumption in place of saturated fat reduced CHD 
events, with 10% lower risk for each 5% energy exchange (RR, 0.90; 95% CI, 
0.83–0.97).88
• In a pooled analysis of individual-level data from 11 prospective cohort studies 
in the United States, Europe, and Israel that included 344 696 participants, each 
5% higher energy consumption of carbohydrate in place of saturated fat was 
associated with a 7% higher risk of CHD (RR, 1.07; 95% CI, 1.01–1.14).87 Each 
5% higher energy consumption of monounsaturated fat in place of saturated fat 
was not significantly associated with CHD risk.87
• Together these findings suggest that reducing saturated fat without specifying the 
replacement may have minimal effects on CHD risk, whereas increasing 
polyunsaturated fats from vegetable oils will reduce CHD.37
• In a meta-analysis of prospective cohort studies, each 2% of calories from trans 
fat was associated with a 23% higher risk of CHD (RR, 1.23; 95% CI, 1.11–
1.37).89
• In meta-analyses of prospective cohort studies, greater consumption of refined 
complex carbohydrates, starches, and sugars, as assessed by glycemic index or 
load, was associated with significantly higher risk of CHD and DM. When the 
highest category was compared with the lowest category, risk of CHD was 36% 
greater (glycemic load: RR, 1.36; 95% CI, 1.13–1.63), and risk of DM was 40% 
greater (glycemic index: RR, 1.40; 95% CI, 1.23–1.59).90,91
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Foods and Beverages
• In meta-analyses of prospective cohort studies, each daily serving of fruits or 
vegetables was associated with a 4% lower risk of CHD (RR, 0.96; 95% CI, 
0.93–0.99) and a 5% lower risk of stroke (RR, 0.95; 95% CI, 0.92–0.97).92,93
• In a meta-analysis of prospective cohort studies, greater whole grain intake (2.5 
compared with 0.2 servings per day) was associated with a 21% lower risk of 
CVD events (RR, 0.79; 95% CI, 0.73–0.85), with similar estimates in men and 
women and for various outcomes (CHD, stroke, and fatal CVD). In contrast, 
refined grain intake was not associated with lower risk of CVD (RR, 1.07; 95% 
CI, 0.94–1.22).94
• In a meta-analysis of 16 prospective cohort studies that included 326 572 
generally healthy individuals in Europe, the United States, China, and Japan, fish 
consumption was associated with significantly lower risk of CHD mortality.95 
Compared with no consumption, an estimated 250 mg of long-chain omega-3 
fatty acids per day was associated with 35% lower risk of CHD death (P<0.001).
• In a meta-analysis of prospective cohort and case-control studies from multiple 
countries, consumption of unprocessed red meat was not significantly associated 
with incidence of CHD. In contrast, each 50-g serving per day of processed 
meats (eg, sausage, bacon, hot dogs, deli meats) was associated with a higher 
incidence of CHD (RR, 1.42; 95% CI, 1.07–1.89).96
• In a meta-analysis of prospective cohort studies that included 442 101 
participants and 28 228 DM cases, unprocessed red meat consumption was 
associated with a higher risk of DM (RR, 1.19; 95% CI, 1.04–1.37, per 100 g/d). 
On a per g/d basis, risk of DM was nearly 7-fold higher for processed meat 
consumption (RR, 1.51; 95% CI, 1.25–1.83, per 50 g/d).97
• In a meta-analysis of 6 prospective observational studies, nut consumption was 
associated with significantly lower incidence of CHD (comparing higher to low 
intake: RR, 0.70; 95% CI, 0.57–0.82).85
• Higher consumption of dairy or milk products is associated with lower incidence 
of DM and trends toward lower risk of stroke.77,90,91 Some limited evidence 
suggests that these associations are stronger for low-fat dairy or milk than for 
other dairy products. Dairy consumption is not significantly associated with 
higher or lower risk of CHD.85,98
• Among 88 520 generally healthy women in the Nurses’ Health Study who were 
34 to 59 years of age in 1980 and were followed up from 1980 to 2004, regular 
consumption of sugar-sweetened beverages was independently associated with 
higher incidence of CHD, with 23% and 35% higher risk with 1 and ≥2 servings 
per day, respectively, compared with <1 per month.99 Among the 15 745 
participants in the ARIC study, the OR for developing CHD was 2.59 for 
participants who had a serum uric acid level >9.0 mg/dL and who drank >1 
sugar-sweetened soda per day.100
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Sodium and Potassium
• Lower estimated consumption of dietary sodium was not associated with lower 
CVD mortality in NHANES,101 although such findings may be limited by 
changes in behaviors that result from underlying risk (reverse causation). In a 
post hoc analysis of the Trials of Hypertension Prevention, participants 
randomized to low-sodium interventions had a 25% lower risk of CVD (RR, 
0.75; 95% CI, 0.57–0.99) after 10 to 15 years of follow-up after the original 
trials.102
• In a meta-analysis of small randomized trials of sodium reduction of ≥6 months’ 
duration, nonsignificant trends were seen toward fewer CVD events in subjects 
with normal BP (RR, 0.71; 95% CI, 0.42–1.20; n=200 events) or hypertension 
(RR, 0.84; 95% CI, 0.57–1.23; n=93 events), but findings were not statistically 
significant, with relatively low statistical power because of the small numbers of 
events. Sodium restriction increased total mortality in trials of patients with CHF 
(RR, 2.59; 95% CI, 1.04–6.44), but these data were based on very few events 
(n=21 deaths).103
• In a meta-analysis of 13 prospective cohorts that included 177 025 participants 
and >11 000 vascular events, higher sodium consumption was associated with 
greater risk of stroke (pooled RR, 1.23; 95% CI, 1.06–1.43; P=0.007) and a trend 
toward higher risk of CVD (1.14; 95% CI, 0.99–1.32; P=0.07). These 
associations were greater with larger differences in sodium intake and longer 
follow-up.104
• In a meta-analysis of 15 prospective cohort samples that included 247 510 
participants and 7066 strokes, 3058 CHD events, and 2497 total CVD events, 
each 1.64-g/d (42 mmol/d) higher potassium intake was associated with a 21% 
lower risk of stroke (RR, 0.79; 95% CI, 0.68–0.90) and trends toward lower risk 
of CHD and total CVD.105
Dietary Patterns
• In a cohort of 380 296 US men and women, greater versus lower adherence to a 
Mediterranean dietary pattern, characterized by higher intakes of vegetables, 
legumes, nuts, fruits, whole grains, fish, and unsaturated fat and lower intakes of 
red and processed meat, was associated with a 22% lower cardiovascular 
mortality (RR, 0.78; 95% CI, 0.69–0.87).106 Similar findings have been seen for 
the Mediterranean dietary pattern and risk of incident CHD and stroke107 and for 
the DASH-type dietary pattern.108
• In a cohort of 72 113 US female nurses, a dietary pattern characterized by higher 
intakes of vegetables, fruits, legumes, fish, poultry, and whole grains was 
associated with a 28% lower cardiovascular mortality (RR, 0.72; 95% CI, 0.60–
0.87), whereas a dietary pattern characterized by higher intakes of processed 
meat, red meat, refined grains, French fries, and sweets/desserts was associated 
with a 22% higher cardiovascular mortality (RR, 1.22; 95% CI, 1.01–1.48).109 
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Similar findings have been seen in other cohorts and for other outcomes, 
including development of DM and metabolic syndrome.110–116
• The observational findings for benefits of a healthy food–based dietary pattern 
have been confirmed in 2 randomized clinical trials, including a small secondary 
prevention trial in France among patients with recent MI117 and a large primary 
prevention trial in Spain among patients with CVD risk factors.118 The latter trial 
demonstrated a 30% reduction in the risk of stroke, MI, and death attributable to 
cardiovascular causes in those patients randomized to Mediterranean-style diets.
Impact on US Mortality
• One report used consistent and comparable risk assessment methods and 
nationally representative data to estimate the impact of all major modifiable risk 
factors on mortality and morbidity in the United States in 1990 and 2010.119 
Suboptimal dietary habits were the leading cause of both mortality and 
disability-adjusted life-years lost, exceeding even tobacco. In 2010, a total of 678 
000 deaths of all causes were attributable to suboptimal diet.
• A previous investigation reported the estimated mortality effects of several 
specific dietary risk factors in 2005 in the United States. High dietary salt 
consumption was estimated to be responsible for 102 000 annual deaths, low 
dietary omega-3 fatty acids for 84 000 annual deaths, high dietary trans fatty 
acids for 82 000 annual deaths, and low consumption of fruits and vegetables for 
55 000 annual deaths.120
Cost
(See Chart 5-3.)
The US Department of Agriculture forecast that the Consumer Price Index for all food 
would increase 3.0% to 4.0% in 2013 as retailers continued to pass on higher commodity 
and energy costs to consumers in the form of higher retail prices. The Consumer Price Index 
for food increased 3.7% in 2011. Prices for foods eaten at home increased 4.8% in 2011, 
whereas prices for foods eaten away from home increased by 1.9%.121
• The proportion of total US food expenditures for meals outside the home, as a 
share of total food dollars, increased from 27% in 1961 to 40% in 1981 to 49% 
in 2011.66
• The proportion of sales of meals and snacks from fast-food restaurants compared 
with total meals and snacks away from home increased from 5% in 1958 to 29% 
in 1982 to 36% in 2011.121
• As a proportion of income, food has become less expensive over time in the 
United States. As a share of personal disposable income, average (mean) total 
food expenditures by families and individuals have decreased from 22.3% (1949) 
to 18.1% (1961) to 14.9% (1981) to 11.3% (2011). For any given year, the share 
of disposable income spent on food is inversely proportional to absolute income. 
The share increases as absolute income levels decline.121
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• Among 153 forms of fruits and vegetables priced with 2008 Nielsen Homescan 
data, price and calorie per portion of 20 fruits and vegetables were compared 
with 20 common snack foods such as cookies, chips, pastries, and crackers. 
Average price per portion of fruits and vegetables was 31 cents with an average 
of 57 calories per portion, compared with 33 cents and 183 calories per portion 
for snack foods.121
• An overview of the costs of various strategies for primary prevention of CVD 
determined that the estimated costs per year of life gained were between $9800 
and $18 000 for statin therapy, ≈$1500 for nurse screening and lifestyle advice, 
$500 to $1250 for smoking cessation, and $20 to $900 for population-based 
healthy eating.122
• Each year, >$33 billion in medical costs and $9 billion in lost productivity 
resulting from HD, cancer, stroke, and DM are attributed to poor nutrition.123–126
• Two separate cost-effectiveness analyses estimated that population reductions in 
dietary salt would not only be cost-effective but actually cost-saving.127,128 In 1 
analysis, a 1.2-g/d reduction in dietary sodium was projected to reduce US 
annual cases of incident CHD by 60 000 to 120 000, stroke by 32 000 to 66 000, 
and total mortality by 44 000 to 92 000.128 If accomplished through a regulatory 
intervention, estimated savings in healthcare costs would be $10 to $24 billion 
annually.128 Such an intervention would be more cost-effective than using 
medications to lower BP in all people with hypertension.
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6. Overweight and Obesity
See Table 6-1 and Charts 6-1 through 6-3.
Overweight and obesity are major risk factors for CVD and stroke.1,2 The AHA has 
identified BMI <85th percentile (for children) and <25 kg/m2 (for adults aged ≥20 years) as 
1 of the 7 components of ideal cardiovascular health.3 In 2009 to 2010, 64.2% of children 
and 31.1% of adults met these criteria (see Chapter 2, Cardiovascular Health).
Abbreviations Used in Chapter 6
AF atrial fibrillation
AFFIRM Atrial Fibrillation Follow-up Investigation of Rhythm Management
AHA American Heart Association
BMI body mass index
BP blood pressure
BRFSS Behavioral Risk Factor Surveillance System
CAD coronary artery disease
CARDIA Coronary Artery Risk Development in Young Adults
CDC Centers for Disease Control and Prevention
CHD coronary heart disease
CHF congestive heart failure
CI confidence interval
CVD cardiovascular disease
DM diabetes mellitus
FHS Framingham Heart Study
HbA1c hemoglobin A1c
HDL high-density lipoprotein
HR hazard ratio
HUNT 2 Nord-Trøndelag Health Study
MEPS Medical Expenditure Panel Survey
MESA Multi-Ethnic Study of Atherosclerosis
MI myocardial infarction
NCDR National Cardiovascular Data Registry
NCHS National Center for Health Statistics
NH non-Hispanic
NHANES National Health and Nutrition Examination Survey
NHDS National Hospital Discharge Survey
NHIS National Health Interview Survey
NHLBI National Heart, Lung, and Blood Institute
OR odds ratio
PA physical activity
RR relative risk
SBP systolic blood pressure
SD standard deviation
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STEMI ST-segment–elevation myocardial infarction
Prevalence
Youth—(See Table 6-1 and Chart 6-1.)
• The prevalence of overweight and obesity in children 2 to 5 years of age, based 
on a BMI-for-age value ≥85th percentile of the 2000 CDC growth charts, was 
26% for non-Hispanic white boys and 21% for non-Hispanic white girls, 31% for 
non-Hispanic black boys and 27% for non-Hispanic black girls, and 34% for 
Mexican American boys and 33% for Mexican American girls according to 2009 
to 2010 data from NHANES (NCHS). In children 6 to 11 years of age, the 
prevalence was 30% for non-Hispanic white boys and 25% for non-Hispanic 
white girls, 41% for non-Hispanic black boys and 44% for non-Hispanic black 
girls, and 39% for Mexican American boys and 40% for Mexican American 
girls. In children 12 to 19 years of age, the prevalence was 32% for non-Hispanic 
white boys and 28% for non-Hispanic white girls, 37% for non-Hispanic black 
boys and 45% for non-Hispanic black girls, and 46% for Mexican American 
boys and 41% for Mexican American girls.4
• The national prevalence of obesity in children 2 to 5 years of age, based on BMI-
for-age values ≥95th percentile of the 2000 CDC growth charts, was 12% for 
non-Hispanic white boys and 6% for non-Hispanic white girls, 21% for non-
Hispanic black boys and 17% for non-Hispanic black girls, and 19% for Mexican 
American boys and 12% for Mexican American girls according to 2009 to 2010 
data from NHANES (NCHS). In children 6 to 11 years of age, the prevalence 
was 17% for non-Hispanic white boys and 11% for non-Hispanic white girls, 
30% for non-Hispanic black boys and 28% for non-Hispanic black girls, and 
22% for Mexican American boys and 22% for Mexican American girls. In 
children 12 to 19 years of age, the prevalence was 18% for non-Hispanic white 
boys and 15% for non-Hispanic white girls, 23% for non-Hispanic black boys 
and 25% for non-Hispanic black girls, and 29% for Mexican American boys and 
19% for Mexican American girls.4 Regional variation exists in these prevalences.
• Overall, 18% of US children and adolescents 6 to 19 years of age have BMI-for-
age values ≥95th percentile of the 2000 CDC growth charts for the United States 
(NHANES 2009–2010, NCHS).4
• NHANES 2009 to 2010 found that 16.9% (95% CI, 15.4%–18.4%) of youth 
aged 2 to 19 years were obese, which was unchanged from NHANES 2007 to 
2008. Rates of overweight and obesity (≥85th BMI percentile) were 39.1% for 
Hispanics, 39.4% for Mexican Americans, 27.9% for non-Hispanic whites, and 
39.1% for non-Hispanic blacks.4
• A study of >8500 4-year-olds in the Early Childhood Longitudinal Study, Birth 
Cohort (National Center for Education Statistics) found that 1 in 5 were obese. 
Almost 13% of Asian children, 16% of white children, nearly 21% of black 
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children, 22% of Hispanic children, and 31% of American Indian children were 
obese. Children were considered obese if their BMI was ≥95th percentile on the 
basis of CDC BMI growth charts.5
• Childhood sociodemographic factors may contribute to sex disparities in obesity 
prevalence. A study of data from the National Longitudinal Study of Adolescent 
Health (Add Health) found that parental education consistently modified sex 
disparity in blacks. The sex gap was largest in those with low parental education 
(16.7% of men compared with 45.4% of women were obese) and smallest in 
those with high parental education (28.5% of men compared with 31.4% of 
women were obese). In whites, there was little overall sex difference in obesity 
prevalence.6
• The obesity epidemic is disproportionally more rampant among children living in 
low-income, low-education, and higher-unemployment households, according to 
data from the National Survey of Children’s Health.7
• Data from 2011 show that among low-income preschool children, American 
Indians/Alaskan Natives have an obesity rate of 17.7%, whereas rates are 14.7% 
for Hispanics, 10.6% for non-Hispanic blacks, 10.3% for non-Hispanic whites, 
and 9.3% for Asian/Pacific Islanders.8
• According to 1999 to 2008 NHANES survey data, lowest-income girls had an 
obesity prevalence of 17.9% compared with 13.1% among those with higher 
income; similar observations were observed for boys (20.6% versus 15.6%, 
respectively).9
• According to the National Longitudinal Study of Adolescent Health, 1.0% of 
adolescents were severely obese in 1996 (defined as age <20 years and BMI 
≥95th sex-specific BMI-for-age growth chart or BMI ≥30 kg/m2); the majority 
(70.5%) maintained this weight status into adulthood. Obese adolescents had a 
16-fold increased risk of becoming severely obese adults compared with those 
with normal weight or those who were overweight.10
• NHANES 2003 to 2004 and 2005 to 2006 data were used to determine 
overweight and obesity prevalence in rural versus urban youth; the results 
showed that 39% of rural versus 32% of urban children had BMI >85th 
percentile.11
Adults—(See Table 6-1 and Chart 6-2.)
• According to NHANES 2007 to 2010 (unpublished NHLBI tabulations):
– Overall, 68% of US adults were overweight or obese (73% of men and 
64% of women).
– Among men, Mexican-Americans (81%) and non-Hispanic whites 
(73%) were more likely to be overweight or obese than non-Hispanic 
blacks (69%).
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– Among women, non-Hispanic blacks (80%) and Mexican-Americans 
(78%) were more likely to be overweight or obese than non-Hispanic 
whites (60%).
– Among US adults, 35% were obese (35% of men and 36% of women).
– Among men, non-Hispanic blacks (38%) and Mexican-Americans 
(36%) were more likely to be obese than non-Hispanic whites (34%).
– Among women, non-Hispanic blacks (54%) and Mexican-Americans 
(45%) were more likely to be obese than non-Hispanic whites (33%).
• When estimates were based on self-reported height and weight in the 
BRFSS/CDC survey in 2011, the prevalence of obesity ranged from 20.7% in 
Colorado to 34.9% in Mississippi. The median percentage by state was 27.8%.12 
Additionally, no state met the Healthy People 2010 goal of reducing obesity to 
15% of adults.13
• On the basis of self-reported weights and heights from the 2012 NHIS14:
– Blacks ≥18 years of age (27.9%), American Indians or Alaska Natives 
(26.6%), and whites (35.7%) were less likely than Asians (57.6%) to be 
at a healthy weight.
– Blacks ≥18 years of age (36.2%) and American Indians or Alaska 
Natives (41.2%) were more likely to be obese than were whites (28.0%) 
and Asians (9.9%).
• Most adults in Asian subgroups were in the healthy weight range, with rates 
ranging from 51% for Filipino adults to 68% for Chinese adults. Although the 
prevalence of obesity is low within the Asian adult population, Filipino adults 
(14%) were more than twice as likely to be obese (BMI ≥30 kg/m2) as Asian 
Indian (6%), Vietnamese (5%), or Chinese (4%) adults.15
• According to the 2008 National Healthcare Disparities Report (based on 
NHANES 2003–2006)16:
– Approximately 64.8% of obese adults were told by a doctor or health 
professional that they were overweight.
– The proportion of obese adults told that they were overweight was 
significantly lower for non-Hispanic blacks (60.5%) and Mexican 
Americans (57.1%) than for non-Hispanic whites (66.4%), for middle-
income people than for high-income people (62.4% versus 70.6%), and 
for adults with less than a high school education than for those with any 
college education (59.2% versus 70.3%).
• As judged by an analysis of data from MESA, a large proportion of white, black, 
and Hispanic participants were overweight (60%–85%) or obese (30%–50%), 
whereas fewer Chinese American participants were overweight (33%) or obese 
(5%).17
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• According to NHANES 2007 to 2010 data, 35% of US adults >65 years of age 
were obese, which represents 13 million individuals.18
Trends
Youth—(See Chart 6-3.)
• Among infants and children between 6 and 23 months of age, the prevalence of 
high weight for recumbent length was 7% in 1976 to 1980 and 12% in 2003 to 
2006 (NHANES, NCHS).19
• The obesity epidemic in children continues to grow on the basis of recent data 
from the Bogalusa Heart Study. Compared with 1973 to 1974, the proportion of 
children 5 to 17 years of age who were obese was 5 times higher in 2008 to 
2009.20
• A comparison of NHANES 2009 to 2010 data with 1999 to 2000 data 
demonstrates an increase in obesity prevalence in male youth of 5% (OR, 1.05; 
95% CI, 1.01–1.10) but not in female youth (OR, 1.02; 95% CI, 0.98–1.07).4
Adults
• On the basis of 2009 self-reported BRFSS data, overall obesity prevalence was 
26.7% in the United States, with rates of 27.4% in men and 26.0% in women. By 
race/ethnicity, the prevalence of obesity among non-Hispanic whites was 25.2%, 
whereas it was 36.8% among non-Hispanic blacks and 30.7% among Hispanics. 
There was an inverse association by education level: College graduates had a 
20.8% rate of obesity, whereas those who attained less than a high school 
education had an obesity prevalence of 32.9%.21
• According to NHANES data, between 2009 and 2010, the prevalence of obesity 
remained steady among US adult men and women, with no significant change 
compared with 2003 to 2008.22 Among adults aged ≥65 years, the prevalence of 
obesity increased linearly for men between 1999 and 2010, but the increase 
among women was not statistically significant.18
• Forecasts through 2030 using the BRFSS 1990 to 2008 data set suggest that by 
2030, 51% of the population will be obese, with 11% with severe obesity, an 
increase of 33% for obesity and 130% for severe obesity.23
Morbidity
• Overweight children and adolescents are at increased risk for future adverse 
health effects, including the following24:
– Increased prevalence of traditional cardiovascular risk factors such as 
hypertension, hyperlipidemia, and DM.
– Poor school performance, tobacco use, alcohol use, premature sexual 
behavior, and poor diet.
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– Other associated health conditions, such as asthma, hepatic steatosis, 
sleep apnea, stroke, some cancers (breast, colon, and kidney), renal 
insufficiency, musculoskeletal disorders, and gallbladder disease.
• Data from 4 Finnish cohort studies examining childhood and adult BMI with a 
mean follow-up of 23 years found that overweight or obese children who 
remained obese in adulthood had increased risks of type 2 DM, hypertension, 
dyslipidemia, and carotid atherosclerosis. However, those who became normal 
weight by adulthood had risks comparable to individuals who were never 
obese.25
• The CARDIA study showed that young adults who were overweight or obese 
had lower health-related quality of life than normal-weight participants 20 years 
later. On the basis of data from the Medical Outcomes Study 12-item short-form 
health survey, overweight and obese participants had lower multivariable-
adjusted scores on the physical component summary score but not on the mental 
component summary score.25a
• The increasing prevalence of obesity is driving an increased incidence of type 2 
DM. Data from the FHS indicate a doubling in the incidence of DM over the past 
30 years, most dramatically during the 1990s and primarily among individuals 
with a BMI >30 kg/m2.26
• Among 68 070 participants across multiple NHANES surveys, the decline in BP 
in recent birth cohorts is slowing, mediated by BMI.27
• In a meta-analysis from 58 cohorts, representing 221 934 people in 17 developed 
countries with 14 297 incident CVD outcomes, BMI, waist circumference, and 
waist-to-hip ratio were only minimally associated with cardiovascular outcomes 
after controlling for baseline SBP, DM, and total and HDL cholesterol in 
addition to age, sex, and smoking status. Measures of adiposity also did not 
improve risk discrimination or reclassification when risk factor data were 
included.28
• The population attributable fraction for CHD associated with reducing current 
population mean BMI to 21 kg/m2 in the Asia-Pacific region ranged from 2% in 
India to 58% in American Samoa; the population attributable fraction for 
ischemic stroke ranged from 3% in India to 64% in American Samoa. These data 
from 15 countries show the proportion of CVD that would be prevented if the 
population mean BMI were reduced below the current overweight cut point.29
• Obesity is also a strong predictor of sleep-disordered breathing, itself strongly 
associated with the development of CVD, as well as with myriad other health 
conditions, including numerous cancers, nonalcoholic fatty liver disease, 
gallbladder disease, musculoskeletal disorders, and reproductive abnormalities.30
• A systematic review of prospective studies examining overweight and obesity as 
predictors of major stroke subtypes in >2 million participants over ≥4 years 
found an adjusted RR for ischemic stroke of 1.22 (95% CI, 1.05–1.41) in 
overweight individuals and an RR of 1.64 (95% CI, 1.36–1.99) for obese 
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individuals relative to normal-weight individuals. RRs for hemorrhagic stroke 
were 1.01 (95% CI, 0.88–1.17) and 1.24 (95% CI, 0.99–1.54) for overweight and 
obese individuals, respectively. These risks were graded with increasing BMI and 
were independent of age, lifestyle, and other cardiovascular risk factors.31
• A recent meta-analysis of 15 prospective studies demonstrated the increased risk 
for Alzheimer disease or vascular dementia and any dementia was 1.35 and 1.26 
for overweight, respectively, and 2.04 and 1.64 for obesity, respectively.32 The 
inclusion of obesity in dementia forecast models increases the estimated 
prevalence of dementia through 2050 by 9% in the United States and 19% in 
China.33
• Ten-year follow-up data from the Swedish Obese Subjects intervention study 
indicated that to maintain a favorable effect on cardiovascular risk factors, more 
than the short-term goal of 5% weight loss is needed to overcome secular trends 
and aging effects.34
• A randomized clinical trial of 130 severely obese adult individuals randomized to 
either 12 months of diet and PA or only 6 months of PA resulted in 12.1 and 9.9 
kg, respectively, of weight loss at 1 year, with improvements in waist 
circumference, visceral fat, BP, and insulin resistance.35
Mortality
• Elevated childhood BMIs in the highest quartile were associated with premature 
death as an adult in a cohort of 4857 American Indian children during a median 
follow-up of 23.9 years.36
• According to NHIS data, among young adults aged 18 to 39 years, the HR for 
all-cause mortality was 1.07 (95% CI, 0.91–1.26) for overweight individuals, 
1.41 (95% CI, 1.16–1.73) for obese individuals, and 2.46 for extremely obese 
individuals (95% CI, 1.91–3.16).37
• Among adults, obesity was associated with nearly 112 000 excess deaths (95% 
CI, 53 754–170 064) relative to normal weight in 2000. Grade 1 obesity (BMI 30 
to <35 kg/m2) was associated with almost 30 000 of these excess deaths (95% 
CI, 8534–68 220) and grade 2 to 3 obesity (BMI ≥35 kg/m2) with >82 000 (95% 
CI, 44 843–119 289). Underweight was associated with nearly 34 000 excess 
deaths (95% CI, 15 726–51 766). As other studies have found,38 overweight 
(BMI 25 to <30 kg/m2) was not associated with excess deaths.39
• A recent systematic review (2.88 million individuals and >270 000 deaths) 
showed that relative to normal BMI (18.5 to <25 kg/m2), all-cause mortality was 
lower for overweight (HR, 0.94; 95% CI, 0.91–0.96) but was not elevated for 
grade 1 obesity (HR, 0.95; 95% CI, 0.88–1.01). All-cause mortality was higher 
for obesity (all grades; HR, 1.18; 95% CI, 1.12–1.25) and grades 2 and 3 obesity 
(HR, 1.29; 95% CI, 1.18–1.41).40
• In a collaborative analysis of data from almost 900 000 adults in 57 prospective 
studies, mostly in western Europe and North America, overall mortality was 
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lowest at a BMI of ≈22.5 to 25 kg/m2 in both sexes and at all ages, after 
exclusion of early follow-up and adjustment for smoking status. Above this 
range, each 5-kg/m2-higher BMI was associated with ≈30% higher all-cause 
mortality, and no specific cause of death was inversely associated with BMI. 
Below 22.5 to 25 kg/m2, the overall inverse association with BMI was 
predominantly related to strong inverse associations for smoking-related 
respiratory disease, and the only clearly positive association was for ischemic 
heart disease.41
• In a meta-analysis of 1.46 million white adults, over a mean follow-up period of 
10 years, all-cause mortality was lowest at BMI levels of 20.0 to 24.9 kg/m2. 
Among women, compared with a BMI of 22.5 to 24.9 kg/m2, the HRs for death 
were as follows: BMI 15.0 to 18.4 kg/m2, 1.47; 18.5 to 19.9 kg/m2, 1.14; 20.0 to 
22.4 kg/m2, 1.0; 25.0 to 29.9 kg/m2, 1.13; 30.0 to 34.9 kg/m2, 1.44; 35.0 to 39.9 
kg/m2, 1.88; and 40.0 to 49.9 kg/m2, 2.51. Similar estimates were observed in 
men.42
• Overweight was associated with significantly increased mortality resulting from 
DM or kidney disease and was not associated with increased mortality resulting 
from cancer or CVD in an analysis of 2004 data from NHANES. Obesity was 
associated with significantly increased mortality caused by CVD, some cancers, 
and DM or kidney disease. Obesity was associated with 13% of CVD deaths in 
2004.43
• A BMI paradox has been reported, with higher-BMI patients demonstrating 
favorable outcomes in CHF, hypertension, peripheral vascular disease, and CAD; 
similar findings have been seen for percent body fat. In AFFIRM, a multicenter 
trial of AF, obese patients had lower all-cause mortality (HR, 0.77; P=0.01) than 
normal-weight patients after multivariable adjustment over a 3-year follow-up 
period.44
• Interestingly, among 2625 participants with new-onset DM, rates of total, CVD, 
and non-CVD mortality were higher among normal-weight people compared 
with overweight/obese participants, with adjusted HRs of 2.08 (95% CI, 1.52–
2.85), 1.52 (95% CI, 0.89–2.58), and 2.32 (95% CI, 1.55–3.48), respectively.45
• Calculations based on NHANES data from 1978 to 2006 suggest that the gains in 
life expectancy from smoking cessation are beginning to be outweighed by the 
loss of life expectancy related to obesity.46
• Because of the increasing prevalence of obesity, the number of quality-adjusted 
life-years lost as a result of obesity is similar to or greater than that lost as a 
result of smoking, according to data from the BRFSS.47
• Recent estimates suggest that reductions in smoking, cholesterol, BP, and 
physical inactivity levels resulted in a gain of 2 770 500 life-years; however, 
these gains were reduced by a loss of 715 000 life-years caused by the increased 
prevalence of obesity and DM.48
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• In a comparison of 5 different anthropometric variables (BMI, waist 
circumference, hip circumference, waist-to-hip ratio, and waist-to-height ratio) in 
62 223 individuals from Norway with 12 years of follow-up from the HUNT 2 
study, the risk of death per SD increase in each measure was 1.02 (95% CI, 0.99–
1.06) for BMI, 1.10 (95% CI, 1.06–1.14) for waist circumference, 1.01 (95% CI, 
0.97–1.05) for hip circumference, 1.15 (95% CI, 1.11–1.19) for waist-to-hip 
ratio, and 1.12 (95% CI, 1.08–1.16) for waist-to-height ratio. For CVD mortality, 
the risk of death per SD increase was 1.12 (95% CI, 1.06–1.20) for BMI, 1.19 
(95% CI, 1.12–1.26) for waist circumference, 1.06 (95% CI, 1.00–1.13) for hip 
circumference, 1.23 (95% CI, 1.16–1.30) for waist-to-hip ratio, and 1.24 (95% 
CI, 1.16–1.31) for waist-to-height ratio.49
• According to data from the NCDR, among patients presenting with STEMI and a 
BMI ≥40 kg/m2, in-hospital mortality rates were higher for patients with class III 
obesity (OR, 1.64; 95% CI, 1.32–2.03) when class I obesity was used as the 
referent.50
• In a study of 22 203 women and men from England and Scotland, metabolically 
unhealthy obese individuals were at an increased risk of all-cause mortality 
compared with metabolically healthy obese individuals (HR, 1.72; 95% CI, 
1.23–2.41).51
Cost
• If current trends in the growth of obesity continue, total healthcare costs 
attributable to obesity could reach $861 to $957 billion by 2030, which would 
account for 16% to 18% of US health expenditures.52
• According to NHANES I data linked to Medicare and mortality records, obese 
45-year-olds had lifetime Medicare costs of $163 000 compared with $117 000 
among those with normal weight by the time they reached 65 years of age.53
• The total excess cost related to the current prevalence of adolescent overweight 
and obesity is estimated to be $254 billion ($208 billion in lost productivity 
secondary to premature morbidity and mortality and $46 billion in direct medical 
costs).54
• According to 2006 MEPS and 2006 BRFSS data, annual medical expenditures 
would be 6.7% to 10.7% lower in the absence of obesity.55
• According to data from the Medicare Current Beneficiary Survey from 1997 to 
2006, in 1997, expenditures for a Part A and Part B services beneficiary were 
$6832 for a normal-weight individual, which was more than for overweight 
($5473) or obese ($5790) individuals. However, over time, expenses increased 
more rapidly for overweight and obese individuals.56
• The costs of obesity are high: Obese people pay on average $1429 (42%) more 
for healthcare costs than normal-weight individuals. For obese beneficiaries, 
Medicare pays $1723 more, Medicaid pays $1021 more, and private insurers pay 
$1140 more than for beneficiaries who are at normal weight. Similarly, obese 
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people have 46% higher inpatient costs and 27% more outpatient visits and 
spend 80% more on prescription drugs.57
Bariatric Surgery
• Patients with BMI >40 kg/m2 or >35 kg/m2 with an obesity-related comorbidity 
are eligible for gastric bypass surgery, which is typically performed as either a 
Roux-en-Y gastric bypass or a biliopancreatic diversion.
• According to the 2006 NHDS, the incidence of bariatric surgery was estimated at 
113 000 cases per year, with costs of nearly $1.5 billion annually.58
• In a large bariatric surgery cohort, the prevalence of high 10-year predicted CVD 
risk was 36.5%,59 but 76% of those with low 10-year risk had high lifetime 
predicted CVD risk. The corresponding prevalence in US adults is 18% and 
56%, respectively.60
• Among obese Swedish patients undergoing bariatric surgery and followed up for 
up to 15 years, maximum weight loss was 32%. The risk of death was 0.76 
among those who underwent bariatric surgery compared with matched control 
subjects.57 More recent data examining MI and stroke showed that bariatric 
surgery was associated with fewer CVD deaths (HR, 0.47; 95% CI, 0.29–0.76) 
and fewer strokes (HR, 0.67; 95% CI, 0.54–0.83) than in the control group. 
However, CVD risk was related to baseline CVD risk factors rather than to 
baseline BMI or 2-year weight change.61
• Among 641 patients followed up for 10 years compared with 627 matched 
control subjects, after 2 years of follow-up, 72% of the surgically treated patients 
versus 21% of the control patients had remission of their DM; at 10 years of 
follow-up, results were 36% and 13%, respectively. Similar results have been 
observed for hypertension, elevated triglycerides, and low HDL cholesterol.62
• According to retrospective data from the United States, among 9949 patients 
who underwent gastric bypass surgery, after a mean of 7 years, long-term 
mortality was 40% lower among the surgically treated patients than among obese 
control subjects. Specifically, cancer mortality was reduced by 60%, DM 
mortality by 92%, and CAD mortality by 56%. Nondisease death rates (eg, 
accidents, suicide) were 58% higher in the surgery group.63
• A recent retrospective cohort from the Veterans Affairs medical system showed 
that in a propensity-matched analysis, bariatric surgery was not associated with 
reduced mortality compared with obese control subjects (time-adjusted HR, 0.94; 
95% CI, 0.64–1.39).64
• Two recent randomized controlled trials were performed that randomized 
bariatric surgery compared with intensive medical treatment among patients with 
type 2 DM. The first study randomized 150 patients and conducted 12-month 
follow-up; this study showed that glycemic control improved (6.4%) and weight 
loss was greater (29.4 versus 5.4 kg) in the surgical arm.65 The second trial 
randomized 60 patients to bariatric surgery versus medical therapy and 
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conducted follow-up for 24 months. The results showed that DM remission 
occurred in 75% of the group that underwent gastric bypass surgery compared 
with 0% of those in the medical treatment arm, with HbA1c values of 6.35% in 
the surgical arm compared with 7.69% in the medical treatment arm.66
• Of 120 patients with type 2 DM and a BMI between 30 and 39.9 kg/m2, 60 who 
were randomized to Roux-en-Y gastric bypass were almost 5-fold (OR, 4.8; 95% 
CI, 1.9–11.7) more likely to achieve an HbA1c <7.0% at 12-month follow-up. 
However, there were 22 serious adverse events in the intervention arm, including 
early and late perioperative complications and nutritional deficiencies.67
• A recent cost-effectiveness study of laparoscopic adjustable gastric banding 
showed that after 5 years, $4970 was saved in medical expenses; if indirect costs 
were included (absenteeism and presenteeism), savings increased to $6180 and 
$10 960, respectively.68 However, when expressed per quality-adjusted life 
expectancy, only $6600 was gained for laparoscopic gastric bypass, $6200 for 
laparoscopic adjustable gastric band, and $17 300 for open Roux-en-Y gastric 
bypass, none of which exceeded the standard $50 000 per quality-adjusted life 
expectancy gained.69
• Adolescents (aged 10–19 years old) underwent bariatric surgery at a rate of 
0.8/100 000 procedures, which increased to 2.3/100 000 in 2003 and remained 
constant by 2009 at 2.4/100 000.70
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7. Family History and Genetics
See Tables 7-1 through 7-3.
Biologically related first-degree relatives (siblings, offspring and parents) share roughly 50% 
of their genetic variation with one another. This constitutes much greater sharing of genetic 
variation than with a randomly selected person from the population, and thus, when a trait 
aggregates within a family, this lends evidence for a genetic risk factor for the trait. 
Similarly, racial/ethnic minorities are more likely to share their genetic variation within their 
demographic than with other demographics. Familial aggregation of CVD may be related to 
aggregation of specific behaviors (eg, smoking, alcohol use) or risk factors (eg, 
hypertension, DM, obesity) that may themselves have environmental and genetic 
contributors. Unlike classic mendelian genetic risk factors, whereby usually 1 mutation 
directly causes 1 disease, a complex trait’s genetic contributors may increase risk without 
necessarily always causing the condition. The effect size of any specific contributor to risk 
may be small but widespread throughout a population, or may be large but affect only a 
small population, or may have an enhanced risk when an environmental contributor is 
present. Although the breadth of all genetic research into CVD is beyond the scope of this 
chapter, we present a summary of evidence that a genetic risk for CVD is likely, as well as a 
summary of evidence on the most consistently replicated genetic markers for HD and stroke 
identified to date.
Abbreviations Used in Chapter 7
AAA abdominal aortic aneurysm
ABI ankle-brachial index
AF atrial fibrillation
BMI body mass index
CAC coronary artery calcification
CAD coronary artery disease
CARDIoGRAMplusC4D Coronary Artery Disease Genome-wide Replication and Meta-Analysis (CARDIOGRAM) 
plus the Coronary Artery Disease (C4D) Genetics Consortium
CHD coronary heart disease
CI confidence interval
CVD cardiovascular disease
DBP diastolic blood pressure
DM diabetes mellitus
FHS Framingham Heart Study
GFR glomerular filtration rate
HbA1c hemoglobin A1c (glycosylated hemoglobin)
HD heart disease
HDL high-density lipoprotein
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HF heart failure
LDL low-density lipoprotein
MI myocardial infarction
NHANES National Health and Nutrition Examination Survey
NHLBI National Heart, Lung, and Blood Institute
OR odds ratio
SBP systolic blood pressure
SE standard error
SNP single-nucleotide polymorphism
Family History
Prevalence
• Among adults ≥20 years of age, 12.6% (SE 0.5%) reported having a parent or 
sibling with a heart attack or angina before the age of 50 years. The racial/ethnic 
breakdown is as follows (NHANES 2007–2010, unpublished NHLBI tabulation):
– For non-Hispanic whites, 12.4% (SE 0.7%) for men, 14.9% (SE 0.9%) 
for women
– For non-Hispanic blacks, 8.1% (SE 0.8%) for men, 13.0% (SE 0.9%) 
for women
– For Mexican Americans, 8.1% (SE 0.9%) for men, 10.0% (SE 1.1%) 
for women
– For other Hispanics, 8.8% (SE 1.5%) for men, 12.0% (SE 1.2%) for 
women
– For other races, 8.7% (SE 2.1%) for men, 10.7% (SE 2.6%) for women
• HD occurs as people age, and those without a family history of HD may survive 
longer, so the prevalence of family history will vary depending on the age at 
which it is assessed. The breakdown of reported family history of heart attack by 
age in the US population as measured by NHANES is as follows (NHANES 
2007–2010, unpublished NHLBI tabulation):
– Age 20 to 39 years, 8.4% (SE 0.9%) for men, 10.3% (SE 0.7%) for 
women
– Age 40 to 59 years, 12.8% (SE 0.9%) for men, 15.3% (SE 1.1%) for 
women
– Age 60 to 79 years, 13.7% (SE 0.9%) for men, 17.5% (SE 1.2%) for 
women
– Age ≥80 years, 9.8% (SE 1.5%) for men, 13.7% (SE 0.6%) for women
et al. Page 82
Circulation. Author manuscript; available in PMC 2017 April 28.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
• In the multigenerational FHS, only 75% of participants with a documented 
parental history of a heart attack before age 55 years reported that history when 
asked.1
Impact of Family History
• Premature paternal history of a heart attack has been shown to approximately 
double the risk of a heart attack in men and increase the risk in women by 
≈70%.2,3
• History of a heart attack in both parents increases the risk of heart attack, 
especially when 1 parent had a premature heart attack4 (Table 7-1).
• Sibling history of HD has been shown to increase the odds of HD in men and 
women by ≈50%.5
• Premature family history of angina, MI, angioplasty, or bypass surgery increased 
the lifetime risk by ≈50% for both HD (from 8.9% to 13.7%) and CVD mortality 
(from 14.1% to 21%).6
• Similarly, parental history of AF is associated with ≈80% increased odds of AF 
in men and women,7 and a history of stroke in a first-degree relative increases 
the odds of stroke in men and women by ≈50%.8
Genetics
Heart Disease
• Genome-wide association is a robust technique to identify associations between 
genotypes and phenotypes. Table 7-2 presents results from the 
CARDIoGRAMplusC4D Consortium, which represents the largest genetic study 
of CAD to date. Although the ORs are modest, ranging from 1.06 to 1.51 per 
copy of the risk allele (individuals may harbor up to 2 copies of a risk allele), 
these are common alleles, which suggests that the attributable risk may be 
substantial. Additional analysis suggested that loci associated with CAD were 
involved in lipid metabolism and inflammation pathways.9
• The relationship between genetic variants associated with CHD and measured 
CHD risk factors is complex, with some genetic markers associated with 
multiple risk factors and other markers showing no association with risk 
factors.10
• Genetic markers discovered thus far have not been shown to add to 
cardiovascular risk prediction tools beyond current models that incorporate 
family history.11 Genetic markers have also not been shown to improve 
prediction of subclinical atherosclerosis beyond traditional risk factors.12 
However, an association between genetic markers and coronary calcification has 
been seen.13
• The most consistently replicated genetic marker for HD in European-derived 
populations is located at 9p21.3. At this single-nucleotide polymorphism, ≈27% 
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of the white population is estimated to have 0 risk alleles, 50% is estimated to 
have 1 risk allele, and the remaining 23% is estimated to have 2 risk alleles.14
• The 10-year HD risk for a 65-year-old man with 2 risk alleles at 9p21.3 and no 
other traditional risk factors is ≈13.2%, whereas a similar man with 0 alleles 
would have a 10-year risk of ≈9.2%. The 10-year HD risk for a 40-year-old 
woman with 2 alleles and no other traditional risk factors is ≈2.4%, whereas a 
similar woman with 0 alleles would have a 10-year risk of ≈1.7%.14
• Variation at the 9p21.3 region also increases the risk of HF15 and sudden death.16 
Associations have also been observed between the 9p21.3 region and CAC.17,18 
Additionally, stronger associations have been found between variation at 9p21.3 
and earlier17,18 and more severe19 heart attacks. The biological mechanism 
underpinning the association of genetic variation in the 9p21 region with disease 
outcomes is still under investigation.
Stroke
• The same 9p21.3 region has also been associated with intracranial aneurysm,20 
AAA,21 and ischemic stroke.22
• For large-vessel ischemic stroke, an association for large-vessel stroke with 
histone deacetylase 9 on chromosome 7p21.1 has been identified (>9000 
subjects) and replicated (>12 000 subjects).22,23
CVD Risk Factors
• Heritability is the ratio of genetically caused variation to the total variation of a 
trait or measure. Table 7-3 presents heritability estimates for standard CVD risk 
factors using data generated from the FHS. These data suggest that most CVD 
risk factors have at least moderate heritability.
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8. High Blood Cholesterol and Other Lipids
See Table 8-1 and Charts 8-1 through 8-3.
High cholesterol is a major risk factor for CVD and stroke.1 The AHA has identified 
untreated total cholesterol <170 mg/dL (for children) and <200 mg/dL (for adults) as 1 of 
the 7 components of ideal cardiovascular health.2 In 2009 to 2010, 61.9% of children and 
47.3% of adults met these criteria.
Prevalence
For information on dietary cholesterol, total fat, saturated fat, and other factors that affect 
blood cholesterol levels, see Chapter 5 (Nutrition).
Youth—(See Chart 8-1.)
• Among children 6 to 11 years of age, the mean total cholesterol level is 161.9 
mg/dL. For boys, it is 162.3 mg/dL; for girls, it is 161.5 mg/dL. The racial/ethnic 
breakdown is as follows (NHANES 2007–2010, unpublished NHLBI tabulation):
– For non-Hispanic whites, 160.9 mg/dL for boys and 161.6 mg/dL for 
girls
– For non-Hispanic blacks, 165.2 mg/dL for boys and 157.9 mg/dL for 
girls
– For Mexican Americans, 159.6 mg/dL for boys and 160.7 mg/dL for 
girls
• Among adolescents 12 to 19 years of age, the mean total cholesterol level is 
158.2 mg/dL. For boys, it is 156.1 mg/dL; for girls, it is 160.3 mg/dL. The racial/
ethnic breakdown is as follows (NHANES 2007–2010, unpublished NHLBI 
tabulation):
– For non-Hispanic whites, 156.8 mg/dL for boys and 161.1 mg/dL for 
girls
– For non-Hispanic blacks, 154.1 mg/dL for boys and 160.6 mg/dL for 
girls
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– For Mexican Americans, 157.8 mg/dL for boys and 158.0 mg/dL for 
girls
• The prevalence of abnormal lipid levels among youths 12 to 19 years of age is 
20.3%; 14.2% of normal-weight youths, 22.3% of overweight youths, and 42.9% 
of obese youths have ≥1 abnormal lipid level (NHANES 1999–2006, NCHS).3
• Approximately 7.8% of adolescents 12 to 19 years of age have total cholesterol 
levels ≥200 mg/dL (NHANES 2007–2010, unpublished NHLBI tabulation).
• Fewer than 1% of adolescents are potentially eligible for pharmacological 
treatment on the basis of guidelines from the American Academy of 
Pediatrics.3,4
Abbreviations Used in Chapter 7
AHA American Heart Association
BRFSS Behavioral Risk Factor Surveillance System
CDC Centers for Disease Control and Prevention
CHD coronary heart disease
CVD cardiovascular diseases
DM diabetes mellitus
HD heart disease
HDL high-density lipoprotein
LDL low-density lipoprotein
Mex. Am. Mexican American
NCHS National Center for Health Statistics
NH non-Hispanic
NHANES National Health and Nutrition Examination Survey
NHLBI National Heart, Lung, and Blood Institute
Adults—(See Table 8-1 and Charts 8-2 and 8-3.)
• An estimated 31.9 million adults ≥20 years of age have serum total cholesterol 
levels ≥240 mg/dL (extrapolated to 2010 by use of NCHS/NHANES 2007–2010 
data), with a prevalence of 13.8% (Table 8-1; unpublished NHLBI tabulation).
• Approximately 5.6% of adults ≥20 years of age have undiagnosed 
hypercholesterolemia, defined as a total cholesterol level ≥240 mg/dL and the 
participant having responded “no” to ever having been told by a doctor or other 
healthcare professional that the participant’s blood cholesterol level was high 
(NHANES 2007–2010, unpublished NHLBI tabulation).
• Between the periods 1988 to 1994 and 1999 to 2002 (NHANES/NCHS), the age-
adjusted mean serum total cholesterol level of adults ≥20 years of age decreased 
from 206 to 203 mg/dL, and LDL cholesterol levels decreased from 129 to 123 
mg/dL.5
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• Data from NHANES 2003 to 2008 (NCHS) showed the serum total crude mean 
cholesterol level in adults ≥20 years of age was 195 mg/dL for men and 201 
mg/dL for women.6
• Data from the Minnesota Heart Survey (1980–1982 to 2000–2002) showed a 
decline in age-adjusted mean total cholesterol concentrations from 5.49 and 5.38 
mmol/L (98.8 and 96.8 mg/dL) for men and women, respectively, in 1980 to 
1982 to 5.16 and 5.09 mmol/L (92.8 and 91.6 mg/dL), respectively, in 2000 to 
2002; however, the decline was not uniform across all age groups. Middle-aged 
to older people have shown substantial decreases, but younger people have 
shown little overall change and recently had increased total cholesterol values. 
Lipid-lowering drug use rose significantly for both sexes among those 35 to 74 
years of age. Awareness, treatment, and control of hypercholesterolemia have 
increased; however, more than half of those at borderline-high risk remain 
unaware of their condition.7
• According to data from NHANES 2005 to 2006, between the periods 1999 to 
2000 and 2005 to 2006, mean serum total cholesterol levels in adults ≥20 years 
of age declined from 204 to 199 mg/dL. This decline was observed for men ≥40 
years of age and for women ≥60 years of age. There was little change over this 
time period for other sex/age groups. In 2005 to 2006, ≈65% of men and 70% of 
women had been screened for high cholesterol in the past 5 years, and 16% of 
adults had serum total cholesterol levels ≥240 mg/dL.8
• According to data from NHANES 2007 to 2008, mean serum total cholesterol 
levels in adults aged 20 to 74 years declined further to 197 mg/dL. Overall, the 
decline in cholesterol levels in recent years appears to reflect greater uptake of 
cholesterol-lowering medications rather than changes in dietary patterns.9
• According to data from NHANES, from 1999 to 2006, the prevalence of elevated 
LDL cholesterol levels (as defined by levels higher than the specified Adult 
Treatment Panel III risk category) in adults ≥20 years of age has decreased by 
≈33%.10
• During the period from 1999 to 2006, 26.0% of adults had hypercholesterolemia, 
9% of adults had both hypercholesterolemia and hypertension, 1.5% of adults 
had DM and hypercholesterolemia, and 3% of adults had all 3 conditions.11
Screening
• Data from the BRFSS study of the CDC in 2011 showed that the percentage of 
adults who had been screened for high cholesterol in the preceding 5 years 
ranged from 66.3% in Utah to 83.7% in Massachusetts. The median percentage 
among all 50 states was 75.5%.12
• The percentage of adults who reported having had a cholesterol check increased 
from 68.6% during 1999 to 2000 to 74.8% during 2005 to 2006.13
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Awareness
• Data from the BRFSS (CDC) survey in 2011 showed that among adults screened 
for high cholesterol, the percentage who had been told that they had high 
cholesterol ranged from 33.5% in Colorado to 42.3% in Mississippi. The median 
percentage among states was 38.4%.12
• Among adults with hypercholesterolemia, the percentage who had been told that 
they had high cholesterol increased from 42.0% during 1999 to 2000 to 50.4% 
during 2005 to 2006.13
Treatment
• NHANES data on the treatment of high LDL cholesterol showed an increase 
from 28.4% of individuals during 1999 to 2002 to 48.1% during 2005 to 2008.14
• Self-reported use of cholesterol-lowering medications increased from 8.2% 
during 1999 to 2000 to 14.0% during 2005 to 2006.13
Adherence
Youth—The American Academy of Pediatrics recommends screening for dyslipidemia in 
children and adolescents who have a family history of dyslipidemia or premature CVD, 
those whose family history is unknown, and those youths with risk factors for CVD, such as 
being overweight or obese, having hypertension or DM, or being a smoker.3
Analysis of data from NHANES 1999 to 2006 showed that the overall prevalence of 
abnormal lipid levels among youths 12 to 19 years of age was 20.3%.3
Adults
• On the basis of data from the Third Report of the Expert Panel on Detection, 
Evaluation, and Treatment of High Blood Cholesterol in Adults1:
– Fewer than half of all people who qualify for any kind of lipid-
modifying treatment for CHD risk reduction are receiving it.
– Fewer than half of even the highest-risk people (those with 
symptomatic CHD) are receiving lipid-lowering treatment.
– Only approximately one third of treated patients are achieving their 
LDL goal; <20% of patients with CHD are at their LDL goal.
• Data from NHANES 2005 to 2006 indicate that among those with elevated LDL 
cholesterol levels, 35.5% had not been screened previously, 24.9% were screened 
but not told they had elevated cholesterol, and 39.6% were treated 
inadequately.10
• There were 33.2% of adults overall during 2005 to 2008 in NHANES who 
achieved LDL cholesterol goals. Among adults without health insurance, only 
22.6% achieved LDL cholesterol goals; however, 82.8% of those adults with 
uncontrolled LDL cholesterol did have some form of health insurance.14
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Lipid Levels
LDL (Bad) Cholesterol
Youth
• There are limited data available on LDL cholesterol for children 6 to 11 years of 
age.
• Among adolescents 12 to 19 years of age, the mean LDL cholesterol level is 89.5 
mg/dL. For boys, it is 88.6 mg/dL, and for girls, it is 90.5 mg/dL. The racial/
ethnic breakdown is as follows (NHANES 2007–2010, unpublished NHLBI 
tabulation):
– Among non-Hispanic whites, 90.4 mg/dL for boys and 90.9 mg/dL for 
girls
– Among non-Hispanic blacks, 85.8 mg/dL for boys and 91.8 mg/dL for 
girls
– Among Mexican Americans, 90.6 mg/dL for boys and 87.1 mg/dL for 
girls
• High levels of LDL cholesterol occurred in 7.3% of male adolescents and 7.6% 
of female adolescents during 2007 to 2010.3
Adults
• The mean level of LDL cholesterol for American adults ≥20 years of age was 
115.8 mg/dL in 2007 to 2010.8 Levels of 130 to 159 mg/dL are considered 
borderline high, levels of 160 to 189 mg/dL are classified as high, and levels of 
≥190 mg/dL are considered very high according to Adult Treatment Panel III.
• According to NHANES 2007 to 2010 (unpublished NHLBI tabulation):
– Among non-Hispanic whites, mean LDL cholesterol levels were 115.1 
mg/dL for men and 115.7 mg/dL for women.
– Among non-Hispanic blacks, mean LDL cholesterol levels were 115.9 
mg/dL for men and 114.2 mg/dL for women.
– Among Mexican Americans, mean LDL cholesterol levels were 119.7 
mg/dL for men and 115.0 mg/dL for women.
• The age-adjusted prevalence of high LDL cholesterol in US adults was 26.6% in 
1988 to 1994 and 25.3% in 1999 to 2004 (NHANES/NCHS). Between 1988 to 
1994 and 1999 to 2004, awareness increased from 39.2% to 63.0%, and use of 
pharmacological lipid-lowering treatment increased from 11.7% to 40.8%. LDL 
cholesterol control increased from 4.0% to 25.1% among those with high LDL 
cholesterol. In 1999 to 2004, rates of LDL cholesterol control were lower among 
adults 20 to 49 years of age than among those ≥65 years of age (13.9% versus 
30.3%, respectively), among non-Hispanic blacks and Mexican Americans than 
among non-Hispanic whites (17.2% and 16.5% versus 26.9%, respectively), and 
among men than among women (22.6% versus 26.9%, respectively).15
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• Mean levels of LDL cholesterol decreased from 126.1 mg/dL during 1999 to 
2000 to 116.1 mg/dL during 2009 to 2010. The prevalence of high LDL 
cholesterol decreased from 31.5% during 1999 to 2000 to 28.2% during 2009 to 
2010 (unpublished NHLBI tabulation).
HDL (Good) Cholesterol
Youth
• Among children 6 to 11 years of age, the mean HDL cholesterol level is 53.6 
mg/dL. For boys, it is 55.1 mg/dL, and for girls, it is 51.9 mg/dL. The racial/
ethnic breakdown is as follows (NHANES 2007–2010, unpublished NHLBI 
tabulation):
– Among non-Hispanic whites, 53.9 mg/dL for boys and 51.4 mg/dL for 
girls
– Among non-Hispanic blacks, 59.9 mg/dL for boys and 55.3 mg/dL for 
girls
– Among Mexican Americans, 53.5 mg/dL for boys and 50.5 mg/dL for 
girls
• Among adolescents 12 to 19 years of age, the mean HDL cholesterol level is 
51.4 mg/dL. For boys, it is 49.2 mg/dL, and for girls, it is 53.6 mg/dL. The 
racial/ethnic breakdown is as follows (NHANES 2007–2010, unpublished 
NHLBI tabulation):
– Among non-Hispanic whites, 48.4 mg/dL for boys and 53.0 mg/dL for 
girls
– Among non-Hispanic blacks, 53.9 mg/dL for boys and 55.4 mg/dL for 
girls
– Among Mexican Americans, 47.5 mg/dL for boys and 53.3 mg/dL for 
girls
• Low levels of HDL cholesterol occurred in 21.7% of male adolescents and 
10.7% of female adolescents during 2007 to 2010 (NHANES 2007–2010, 
unpublished NHLBI tabulation).
Adults
• An HDL cholesterol level <40 mg/dL in adult males and <50 mg/dL in adult 
females is considered low and is a risk factor for HD and stroke.1 The mean level 
of HDL cholesterol for American adults ≥20 years of age is 52.5 mg/dL 
(NHANES 2007–2010, unpublished NHLBI tabulation).
• According to NHANES 2007 to 2010 (unpublished NHLBI tabulation):
– Among non-Hispanic whites, mean HDL cholesterol levels were 46.7 
mg/dL for men and 58.1 mg/dL for women
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– Among non-Hispanic blacks, mean HDL cholesterol levels were 52.6 
mg/dL for men and 58.7 mg/dL for women
– Among Mexican Americans, mean HDL cholesterol levels were 45.4 
mg/dL for men and 53.7 mg/dL for women
Triglycerides
Youth
• There are limited data available on triglycerides for children 6 to 11 years of age.
• Among adolescents 12 to 19 years of age, the geometric mean triglyceride level 
is 82.9 mg/dL. For boys, it is 85.6 mg/dL, and for girls, it is 80.1 mg/dL. The 
racial/ethnic breakdown is as follows (NHANES 2007–2010, unpublished 
NHLBI tabulation):
– Among non-Hispanic whites, 89.6 mg/dL for boys and 83.5 mg/dL for 
girls
– Among non-Hispanic blacks, 66.7 mg/dL for boys and 58.6 mg/dL for 
girls
– Among Mexican Americans, 97.1 mg/dL for boys and 83.5 mg/dL for 
girls
• High levels of triglycerides occurred in 9.4% of male adolescents and 6.7% of 
female adolescents during 2007 to 2010.3
Adults
• A fasting triglyceride level ≥150 mg/dL in adults is considered elevated and is a 
risk factor for HD and stroke. The geometric mean level of triglycerides for 
American adults ≥20 years of age is 130.3 mg/dL (NHANES 2007–2010, 
unpublished NHLBI tabulation).
– Among men, the geometric mean triglyceride level is 141.7 mg/dL 
(NHANES 2007–2010, unpublished NHLBI tabulation). The racial/
ethnic breakdown is as follows:
♦ 140.0 mg/dL for non-Hispanic white men
♦ 111.3 mg/dL for non-Hispanic black men
♦ 161.4 mg/dL for Mexican American men
– Among women, the geometric mean triglyceride level is 119.1 mg/dL, 
with the following racial/ethnic breakdown:
♦ 121.5 mg/dL for non-Hispanic white women
♦ 94.4 mg/dL for non-Hispanic black women
♦ 134.1 mg/dL for Mexican American women
et al. Page 93
Circulation. Author manuscript; available in PMC 2017 April 28.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
• Approximately 27% of adults ≥20 years of age had a triglyceride level ≥150 
mg/dL during 2007 to 2010 (NHANES 2007–2010, unpublished NHLBI 
tabulation).
• Fewer than 3% of adults with a triglyceride level ≥150 mg/dL received 
pharmacological treatment during 1999 to 2004.16
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9. High Blood Pressure
ICD-9 401 to 404, ICD-10 I10 to I15. See Tables 9-1 and 9-2 and Charts 9-1 through 9-5.
High blood pressure is a major risk factor for CVD and stroke.1 The AHA has identified 
untreated BP <90th percentile (for children) and <120/<80 mm Hg (for adults aged ≥20 
years) as 1 of the 7 components of ideal cardiovascular health.2 In 2009 to 2010, 85.8% of 
children and 44.3% of adults met these criteria (Chapter 2, Cardiovascular Health).
Abbreviations Used in Chapter 9
AHA American Heart Association
ARIC Atherosclerosis Risk in Communities Study
BP blood pressure
BRFSS Behavioral Risk Factor Surveillance System
CDC Centers for Disease Control and Prevention
CHD coronary heart disease
CHF congestive heart failure
CHS Cardiovascular Health Study
CRP C-reactive protein
CVD cardiovascular disease
DBP diastolic blood pressure
DM diabetes mellitus
ED emergency department
FHS Framingham Heart Study
HBP high blood pressure
HD heart disease
ICD-9 International Classification of Diseases, 9th Revision
ICD-9-CM International Classification of Diseases, Clinical Modification, 9th Revision
ICD-10 International Classification of Diseases, 10th Revision
LDL low-density lipoprotein
MEPS Medical Expenditure Panel Survey
MESA Multi-Ethnic Study of Atherosclerosis
NAMCS National Ambulatory Medical Care Survey
NCHS National Center for Health Statistics
NH non-Hispanic
NHAMCS National Hospital Ambulatory Medical Care Survey
NHANES National Health and Nutrition Examination Survey
NHDS National Hospital Discharge Survey
NHES National Health Examination Survey
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NHIS National Health Interview Survey
NHLBI National Heart, Lung, and Blood Institute
NINDS National Institute of Neurological Disorders and Stroke
NNHS National Nursing Home Survey
PA physical activity
REGARDS Reasons for Geographic and Racial Differences in Stroke
SBP systolic blood pressure
SEARCH Search for Diabetes in Youth Study
WHI Women’s Health Initiative
Prevalence
(See Table 9-1 and Chart 9-1.)
• HBP is defined as:
– SBP ≥140 mm Hg or DBP ≥90 mm Hg or taking antihypertensive 
medicine, or
– Having been told at least twice by a physician or other health 
professional that one has HBP.
• One in 3 US adults has HBP (unpublished NHLBI tabulation).
• Data from NHANES 2007 to 2010 found that ≈6% of US adults have 
undiagnosed hypertension. Data from the 2007 to 2008 BRFSS, NHIS, and 
NHANES surveys found 27.8%, 28.5%, and 30.7% US adults were told they had 
hypertension, respectively.3
• Prevalence of hypertension (age adjusted) among US adults ≥18 years of age was 
estimated to be 28.6% in NHANES 2009 to 2010.
– Among those 18 to 39 years of age, prevalence was 6.8%; among those 
40 to 59 years of age, prevalence was 30.4%; and among those ≥60 
years of age, prevalence was 66.7%. Furthermore, prevalence of 
hypertension among non-Hispanic blacks, non-Hispanic whites, and 
Hispanics was 40.4%, 27.4%, and 26.1%, respectively.4
• An estimated 77.9 million adults ≥20 years of age have HBP, extrapolated to 
2010 with NHANES 2007 to 2010 data (Table 9-1).
• NHANES data show that a higher percentage of men than women have 
hypertension until 45 years of age. From 45 to 54 and from 55 to 64 years of age, 
the percentages of men and women with hypertension are similar. After that, a 
higher percentage of women have hypertension than men (Chart 9-1).
• HBP is 2 to 3 times more common in women taking oral contraceptives than in 
women not taking them.1
• Data from NHANES 1999 to 2008 and BRFSS 1997 to 2009 estimated the 
prevalence of hypertension in men and women ≥30 years of age to be 37.6% and 
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40.1%, respectively. Awareness, treatment, and control of hypertension varied 
across the country and were highest in the southeastern United States. Between 
2001 and 2009, control of hypertension increased, as did prevalence of 
hypertension.5
• Data from the 2011 BRFSS/CDC indicate that the percentage of adults ≥18 years 
of age who had been told that they had HBP ranged from 22.9% in Utah to 
40.1% in Alabama. The median percentage was 30.8%.6
• According to 2003 to 2008 NHANES data, among US adults with hypertension, 
8.9% met the criteria for resistant hypertension (BP was ≥140/90 mm Hg, and 
they reported using antihypertensive medications from 3 different drug classes or 
drugs from ≥4 antihypertensive drug classes regardless of BP). This represents 
12.8% of the population taking antihypertensive medication.7
• According to data from NHANES 1988 to 1994 and 2007 to 2008, HBP control 
rates improved from 27.3% to 50.1%, treatment improved from 54.0% to 73.5%, 
and the control/treated rates improved from 50.6% to 72.3%.8
• Projections show that by 2030, ≈41.4% of US adults will have hypertension, an 
increase of 8.4% from 2012 estimates (unpublished AHA computation, based on 
methodology described by Heidenreich et al9).
Older Adults
• In 2009 to 2010, hypertension was among the diagnosed chronic conditions that 
were more prevalent among older (≥65 years of age) women than older men 
(57% for women, 54% for men). Ever-diagnosed conditions that were more 
prevalent among older men than older women included HD (37% for men, 26% 
for women) and DM (24% for men, 18% for women), on the basis of data from 
NHIS/NCHS.10
• The age-adjusted prevalence of hypertension (both diagnosed and undiagnosed) 
in 2003 to 2006 was 75% for older women and 65% for older men on the basis 
of data from NHANES/NCHS.11
• Data from the 2004 NNHS revealed the most frequent chronic medical condition 
among this nationally representative sample of long-term stay residents aged ≥65 
years was hypertension (53% of men and 56% of women). In men, prevalence of 
hypertension decreased with increasing age.12
• Among US adults ≥65 years of age (NHANES 1999–2004), prevalence of 
hypertension was 70.8%, awareness of hypertension was 75.9%, treatment for 
hypertension was 69.3%, and control of hypertension was 48.8%. Women had a 
slightly higher prevalence than men and a significantly lower rate of 
hypertension control.13
Children and Adolescents
• Data from participants aged 12 to 19 years in the 2005 to 2010 NHANES found 
ideal blood pressure (<95th percentile) to be present in 78% of males and 90% of 
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females; poor blood pressure (>95th percentile) was found in 2.9% of male and 
3.7% of female participants.14
• Analysis of data from participants aged 12 to 19 years in NHANES 1999 to 2008 
found the prevalence of prehypertension/hypertension was 14%. Furthermore, 
there was no significant change in the prevalence of prehypertension/
hypertension between 1999 to 2000 and 2007 to 2008 among this age group.15
• Analysis of the NHES, the Hispanic Health and Nutrition Examination Survey, 
and the NHANES/NCHS surveys of the NCHS (1963–2002) found that the BP, 
pre-HBP, and HBP trends in children and adolescents 8 to 17 years of age moved 
downward from 1963 to 1988 and upward thereafter. Pre-HBP and HBP 
increased 2.3% and 1%, respectively, between 1988 and 1999. Increased obesity 
(abdominal obesity more so than general obesity) partially explained the HBP 
and pre-HBP rise from 1988 to 1999. BP and HBP reversed their downward 
trends 10 years after the increase in the prevalence of obesity. In addition, an 
ethnic and sex gap appeared in 1988 for pre-HBP and in 1999 for HBP: Non-
Hispanic blacks and Mexican Americans had a greater prevalence of HBP and 
pre-HBP than non-Hispanic whites, and the prevalence was greater in boys than 
in girls. In that study, HBP in children and adolescents was defined as SBP or 
DBP that was, on repeated measurement, ≥95th percentile.16
• A study in Ohio of >14 000 children and adolescents 3 to 18 years of age who 
were observed at least 3 times between 1999 and 2006 found that 507 children 
(3.6%) had hypertension. Of these, 131 (26%) had been diagnosed and 376 
(74%) were undiagnosed. In addition, 3% of those with hypertension had stage 2 
hypertension, and 41% of those with stage 2 hypertension were undiagnosed. 
Criteria for prehypertension were met by 485 children. Of these, 11% were 
diagnosed. In this study, HBP in children and adolescents was defined as SBP or 
DBP that was, on repeated measurement, ≥95th percentile.17
• Analysis of data from the SEARCH study, which included children 3 to 17 years 
of age with type 1 and type 2 DM, found the prevalence of elevated BP to be 
5.9% among those with type 1 DM and 23.7% among those with type 2 DM.18
• A study of high school students in Houston, TX (mean age 15.4 years; 45.2% 
male, 49.3% Hispanic, 25.2% Caucasian, and 16.1% African American) found 
≈30% of the students had ≥1 elevated BP measurement; elevated BP was 
significantly influenced by obesity.19
• Longitudinal BP outcomes from the National Childhood Blood Pressure database 
(ages 13–15 years) were examined after a single BP measurement. Among those 
determined to have prehypertension, 14% of boys and 12% of girls had 
hypertension 2 years later; the overall rate of progression from prehypertension 
to hypertension was ≈7%.20
Race/Ethnicity and HBP
(See Table 9-1 and Chart 9-2.)
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• The prevalence of hypertension in blacks in the United States is among the 
highest in the world, and it is increasing. From 1988 to 1994 through 1999 to 
2002, the prevalence of HBP in adults increased from 35.8% to 41.4% among 
blacks, and it was particularly high among black women at 44.0%. Prevalence 
among whites also increased, from 24.3% to 28.1%.21
• Compared with whites, blacks develop HBP earlier in life, and their average BPs 
are much higher. As a result, compared with whites, blacks have a 1.3-times 
greater rate of nonfatal stroke, a 1.8-times greater rate of fatal stroke, a 1.5-times 
greater rate of death attributable to HD, and a 4.2-times greater rate of end-stage 
kidney disease (fifth and sixth reports of the Joint National Committee on 
Prevention, Detection, Evaluation, and Treatment of High Blood Pressure).
• Data from the 2012 NHIS showed that black adults 18 years of age were more 
likely (32.9%) to have been told on ≥2 occasions that they had hypertension than 
white adults (22.9%), American Indian/Alaska Native adults (24.8%), or Asian 
adults (21.2%).22
• Trend analyses that used NHANES 1988 to 1994 and 1999 to 2004 data among 
non-Hispanic black and non-Hispanic white men and women found that non-
Hispanic blacks had the highest prevalence of hypertension among both men and 
women during both time periods. The largest increase in prevalence of 
hypertension occurred among women (both non-Hispanic black and non-
Hispanic white) compared with men. Racial/ethnic disparities did not change 
over time periods.23
• Analysis from the REGARDS study of the NINDS suggests that efforts to raise 
awareness of prevalent hypertension among blacks apparently have been 
successful (31% greater odds in blacks relative to whites), and efforts to 
communicate the importance of receiving treatment for hypertension have been 
successful (69% greater odds among blacks relative to whites); however, 
substantial racial disparities remain with regard to the control of BP (SBP <140 
mm Hg, DBP <90 mm Hg), with the odds of control being 27% lower in blacks 
than in whites. In contrast, geographic disparities in hypertension awareness, 
treatment, and control were minimal.24
• The CDC analyzed death certificate data from 1995 to 2002 (any-mention 
mortality; ICD-9 codes 401–404 and ICD-10 codes I10–I13). The results 
indicated that Puerto Rican Americans had a consistently higher hypertension-
related death rate than all other Hispanic subpopulations and non-Hispanic 
whites. The age-standardized hypertension-related mortality rate was 127.2 per 
100 000 population for all Hispanics, similar to that of non-Hispanic whites 
(135.9). The age-standardized rate for Hispanic females (118.3) was substantially 
lower than that observed for Hispanic males (135.9). Hypertension-related 
mortality rates for males were higher than rates for females for all Hispanic 
subpopulations. Puerto Rican Americans had the highest hypertension-related 
death rate among all Hispanic subpopulations (154.0); Cuban Americans had the 
lowest (82.5).25
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• Some studies suggest that Hispanic Americans have rates of HBP similar to or 
lower than those of non-Hispanic white Americans. Findings from a new 
analysis of combined data from the NHIS of 2000 to 2002 point to a health 
disparity between black and white adults of Hispanic descent. Black Hispanics 
were at slightly greater risk than white Hispanics, although non-Hispanic black 
adults had by far the highest rate of HBP. The racial disparity among Hispanics 
also was evident in the fact that higher-income, better-educated black Hispanics 
still had a higher rate of HBP than lower-income, less-educated white 
Hispanics.26 Data from the NHLBI’s ARIC study found that hypertension was a 
particularly powerful risk factor for CHD in black people, especially black 
women.27
• Data from MESA found that being born outside the United States, speaking a 
language other than English at home, and living fewer years in the United States 
were each associated with a decreased prevalence of hypertension.28
• Filipino (27%) and Japanese (25%) adults were more likely than Chinese (17%) 
or Korean (17%) adults to have ever been told that they had hypertension.29
Mortality
(See Table 9-1.)
• HBP mortality in 2010 was 63 119. Any-mention mortality in 2010 was 362 895. 
The 2010 death rate was 18.8.30
• The 2010 overall death rate resulting from HBP was 18.8. Death rates were 17.2 
for white males, 50.2 for black males, 15.0 for white females, and 37.1 for black 
females. When any-mention mortality for 2010 was used, the overall death rate 
was 108.9. Death rates were 112.5 for white males, 216.8 for black males, 90.6 
for white females, and 161.9 for black females.30
• From 2000 to 2010, the death rate attributable to HBP increased 16.0%, and the 
actual number of deaths rose 41.5% (AHA tabulation).31
• A mathematical model was developed to estimate the number of deaths that 
potentially could be prevented annually by increasing the use of 9 clinical 
preventive services. The model predicted that a 10% increase in hypertension 
treatment would result in ≈14 000 deaths prevented.32
• Analysis of NHANES I and II comparing hypertensive and nonhypertensive 
individuals found a reduction in age-adjusted mortality rate of 4.6 per 1000 
person-years among people with hypertension compared with a reduction of 4.2 
per 1000 person-years among those without hypertension.33
• Assessment of 30-year follow-up of the Hypertension Detection and Follow-up 
Program identified the long-term benefit of stepped care, as well as the increased 
survival for hypertensive African Americans.34
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• Assessment of the Charleston Heart Study and Evans County Heart Study 
identified the excess burden of elevated BP for African Americans and its effect 
on long-term health outcomes.35
• Data from the Harvard Alumni Health Study found that higher BP in early 
adulthood was associated several decades later with higher risk for all-cause 
mortality, CVD mortality, and CHD mortality but not stroke mortality.36
Risk Factors
• Numerous risk factors and markers for development of hypertension have been 
identified, including age, ethnicity, family history of hypertension and genetic 
factors, lower education and socioeconomic status, greater weight, lower PA, 
tobacco use, psychosocial stressors, sleep apnea, and dietary factors (including 
dietary fats, higher sodium intake, lower potassium intake, and excessive alcohol 
intake).
• A study of related individuals in the NHLBI’s FHS suggested that different sets 
of genes regulate BP at different ages.37
• Recent data from the Nurses’ Health Study suggest that a large proportion of 
incident hypertension in women can be prevented by controlling dietary and 
lifestyle risk factors.38
• A meta-analysis identified the benefit of a goal BP of 130/80 mm Hg for 
individuals with hypertension and type 2 DM but less evidence for treatment 
below this value.39
Aftermath
• Approximately 69% of people who have a first heart attack, 77% of those who 
have a first stroke, and 74% of those who have CHF have BP >140/90 mm Hg 
(NHLBI unpublished estimates from ARIC, CHS, and FHS Cohort and 
Offspring studies).
• Data from FHS/NHLBI indicate that recent (within the past 10 years) and remote 
antecedent BP levels may be an important determinant of risk over and above the 
current BP level.40
• Data from the FHS/NHLBI indicate that hypertension is associated with shorter 
overall life expectancy, shorter life expectancy free of CVD, and more years 
lived with CVD.41
– Total life expectancy was 5.1 years longer for normotensive men and 
4.9 years longer for normotensive women than for hypertensive people 
of the same sex at 50 years of age.
– Compared with hypertensive men at 50 years of age, men with 
untreated BP <140/90 mm Hg survived on average 7.2 years longer 
without CVD and spent 2.1 fewer years of life with CVD. Similar 
results were observed for women.
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Hospital Discharges/Ambulatory Care Visits
(See Table 9-1.)
• From 2000 to 2010, the number of inpatient discharges from short-stay hospitals 
with HBP as the first-listed diagnosis increased from 457 000 to 488 000 (no 
significant difference; NCHS, NHDS). The number of all-listed discharges 
increased from 8 034 000 to 11 282 000 (NHLBI, unpublished data from the 
NHDS, 2010; diagnoses in 2010 were truncated at 7 diagnoses for comparability 
with earlier year).
• Data from the Nationwide Inpatient Sample from the years 2000 to 2007 found 
the frequency of hospitalizations for adults aged ≥18 years of age with a 
hypertensive emergency increased from 101 to 111 per 100 000 in 2007 (average 
increase of 1.11%). In contrast to the increased number of hospitalizations, the 
all-cause in-hospital mortality rate decreased during the same period from 2.8% 
to 2.6%.42
• Data from ambulatory medical care use estimates for 2010 showed that the 
number of visits for essential hypertension was 43 436 000. Of these, 38 916 000 
were physician office visits, 940 000 were ED visits, and 3 580 000 were 
outpatient department visits (NAMCS and NHAMCS, NHLBI tabulation).
• In 2010, there were 280 000 hospitalizations with a first-listed diagnosis of 
essential hypertension (ICD-9-CM code 401), but essential hypertension was 
listed as either a primary or a secondary diagnosis on 11 048 000 hospitalized 
inpatient visits (unpublished data from the NHDS, NHLBI tabulation).
Awareness, Treatment, and Control
(See Table 9-2 and Charts 9-3 through 9-5.)
• Data from NHANES 2007 to 2010 showed that of those with hypertension who 
were ≥20 years of age, 81.5% were aware of their condition, 74.9% were under 
current treatment, 52.5% had their hypertension under control, and 47.5% did not 
have it controlled (NHLBI tabulation).
• Data from NHANES 2009 to 2010 showed that 81.9% of adults were aware of 
their hypertension. Furthermore, 76.4% self-reported that they were currently 
taking prescribed medication to control hypertension. Awareness of hypertension 
was lower among those aged 18 to 39 years than among aged 40 to 59 years and 
those aged ≥60 years of age. Non-Hispanic black adults were more aware of their 
hypertension than Hispanics (87.0% and 77.7%, respectively).4
• Analysis of NHANES 2007 to 2008 and 2009 to 2010 found the proportion of 
adults with controlled hypertension increased from 48.4% to 53.3%, respectively. 
Medication use to lower hypertension was lowest for those aged 18 to 39 years 
(46.0%) compared with those aged 40 to 59 years (77.1%) and those aged ≥60 
years (80.7%). Non-Hispanic black adults were more likely to take 
antihypertensive medication than non-Hispanic whites or Hispanic adults 
(79.7%, 76.6%, and 69.6%, respectively).4
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• Data from the FHS of the NHLBI show that among those ≥80 years of age, only 
38% of men and 23% of women had BPs that met targets set forth in the 
National High Blood Pressure Education Program’s clinical guidelines. Control 
rates in men <60, 60 to 79, and ≥80 years of age were 38%, 36%, and 38%, 
respectively; for women in the same age groups, they were 38%, 28%, and 23%, 
respectively.43
• Data from the WHI observational study of nearly 100 000 postmenopausal 
women across the country enrolled between 1994 and 1998 indicate that 
although prevalence rates ranged from 27% of women 50 to 59 years of age to 
41% of women 60 to 69 years of age to 53% of women 70 to 79 years of age, 
treatment rates were similar across age groups: 64%, 65%, and 63%, 
respectively. Despite similar treatment rates, hypertension control is especially 
poor in older women, with only 29% of hypertensive women 70 to 79 years of 
age having clinic BPs <140/90 mm Hg compared with 41% and 37% of those 50 
to 59 and 60 to 69 years of age, respectively.44
• Among a cohort of postmenopausal women taking hormone replacement, 
hypertension was the most common comorbidity, with a prevalence of 34%.45
• A study of >300 women in Wisconsin showed a need for significant 
improvement in BP and LDL levels. Of the screened participants, 35% were not 
at BP goal, 32.4% were not at LDL goal, and 53.5% were not at both goals.46
• In 2005, a survey of people in 20 states conducted by the BRFSS of the CDC 
found that 19.4% of respondents had been told on ≥2 visits to a health 
professional that they had HBP. Of these, 70.9% reported changing their eating 
habits; 79.5% reduced the use of or were not using salt; 79.2% reduced the use of 
or eliminated alcohol; 68.8% were exercising; and 73.4% were taking 
antihypertensive medication.47
• Among 1509 NHANES 2005 to 2006 participants aged ≥30 years with 
hypertension, 24% were categorized as low risk, 21% as intermediate risk, and 
23% as high risk according to Framingham global risk. Furthermore, an 
additional 32% had CVD. Treatment for hypertension varied by risk category 
and ranged from 58% to 75%; hypertension control was 80% for those in the 
low-risk category and <50% for those in the high-risk category.48
• According to data from NHANES 2001 to 2006, non-Hispanic blacks had 90% 
higher odds of poorly controlled BP than non-Hispanic whites. Among those 
who were hypertensive, non-Hispanic blacks and Mexican Americans had 40% 
higher odds of uncontrolled BP than non-Hispanic whites.49
• According to data from NHANES 1998 to 2008 for adults with DM, prevalence 
of hypertension increased, whereas awareness, treatment, and control improved 
during these time periods; however, for adults 20 to 44 years of age, there was no 
evidence of improvement.50
• “Resistant hypertension” is a treatment and control issue for nearly 1 in 10 
hypertensive adults. This category of HBP represents individuals with 
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uncontrolled HBP despite the use of ≥3 antihypertensive medications or with BP 
controlled with the use of ≥4 medications.51,52
Cost
(See Table 9-1.)
• The estimated direct and indirect cost of HBP for 2010 is $46.4 billion (MEPS, 
NHLBI tabulation).
• Projections show that by 2030, the total cost of HBP could increase to an 
estimated $274 billion (unpublished AHA computation, based on methodology 
described in Heidenreich et al9).
Prehypertension
• Prehypertension is untreated SBP of 120 to 139 mm Hg or untreated DBP of 80 
to 89 mm Hg and not having been told on 2 occasions by a physician or other 
health professional that one has hypertension.
• Among disease-free participants in NHANES 1999 to 2006, the prevalence of 
prehypertension was 36.3%. Prevalence was higher in men than in women. 
Furthermore, prehypertension was correlated with an adverse cardiometabolic 
risk profile.53
• Follow-up of 9845 men and women in the FHS/NHLBI who attended 
examinations from 1978 to 1994 revealed that at 35 to 64 years of age, the 4-year 
incidence of hypertension was 5.3% for those with baseline BP <120/80 mm Hg, 
17.6% for those with SBP of 120 to 129 mm Hg or DBP of 80 to 84 mm Hg, and 
37.3% for those with SBP of 130 to 139 mm Hg or DBP of 85 to 89 mm Hg. At 
65 to 94 years of age, the 4-year incidences of hypertension were 16.0%, 25.5%, 
and 49.5% for these BP categories, respectively.54
• Data from FHS/NHLBI also reveal that prehypertension is associated with 
elevated relative and absolute risks for CVD outcomes across the age spectrum. 
Compared with normal BP (<120/80 mm Hg), prehypertension was associated 
with a 1.5- to 2-fold increased risk for major CVD events in those <60, 60 to 79, 
and ≥80 years of age. Absolute risks for major CVD associated with 
prehypertension increased markedly with age: 6-year event rates for major CVD 
were 1.5% in prehypertensive people <60 years of age, 4.9% in those 60 to 79 
years of age, and 19.8% in those ≥80 years of age.43
• In a study of NHANES 1999 to 2000 (NCHS), people with prehypertension were 
more likely than those with normal BP levels to have above-normal cholesterol 
levels (≥200 mg/dL) and to be overweight or obese, whereas the probability of 
current smoking was lower. People with prehypertension were 1.65 times more 
likely to have ≥1 of these adverse risk factors than were those with normal BP.55
• Assessment of the REGARDS data identified high risk of prehypertension to be 
associated with increased age and black race.56
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• A meta-analysis of 12 prospective cohort studies (including 518 520 participants) 
found prehypertension was associated with incident stroke. The risk was 
particularly noted in nonelderly people and for those with BP values in the 
higher prehypertension range.57
• Prehypertension was found to be significantly associated with stroke.57
• Prehypertension was highest in blacks with other risk factors, including DM and 
elevated CRP.56
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10. Diabetes Mellitus
ICD-9 250; ICD-10 E10 to E14. See Table 10-1 and Charts 10-1 through 10-4.
DM is a major risk factor for CVD and stroke.1 The AHA has identified untreated fasting 
blood glucose levels of <100 mg/dL for children and adults as 1 of the 7 components of 
ideal cardiovascular health.2 In 2009 to 2010, 88.2% of children and 57.4% of adults met 
these criteria.2
Prevalence
• The prevalence of DM for all age groups worldwide was estimated to be 2.8% in 
2000 and is projected to be 4.4% in 2030. The total number of people with DM 
is projected to rise from 171 million in 2000 to 366 million in 2030.3
Youths
• Approximately 186 000 people <20 years of age have DM. Each year, ≈15 000 
people <20 years of age are diagnosed with type 1 DM. Healthcare providers are 
finding more and more children with type 2 DM, a disease usually diagnosed in 
adults ≥40 years of age. Children who develop type 2 DM are typically 
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overweight or obese and have a family history of the disease. Most are American 
Indian, black, Asian, or Hispanic/Latino.4
• During the period from 2002 to 2005, 3600 youth (age <20 years) were 
diagnosed with type 2 DM annually.5
• Among adolescents 10 to 19 years of age diagnosed with DM, 57.8% of blacks 
were diagnosed with type 2 versus type 1 DM compared with 46.1% of Hispanic 
youths and 14.9% of white youths.6
• According to the Bogalusa Heart Study, a long-term follow-up study of youths 
aging into adulthood, youths who were prediabetic or who had DM were more 
likely to have a constellation of metabolic disorders in young adulthood (19–44 
years of age), including obesity, hypertension, dyslipidemia, and metabolic 
syndrome, all of which predispose to CHD.7
• Among youths with type 2 DM, 10.4% are overweight and 79.4% are obese.8
• According to NHANES data from 1999 to 2007, among US adolescents aged 12 
to 19 years, the prevalence of prediabetes and DM increased from 9% to 23%.9
• The TODAY cohort comprised youths aged 10 to 17 years (41.1% Hispanic and 
31.5% non-Hispanic black) participating in a randomized controlled study of 
new-onset type 2 DM; 41.5% of participants had household income <$25 000.10 
The results of the clinical trial demonstrated that only half of the children 
maintained durable glycemic control with monotherapy,11 a higher rate of 
treatment failure than observed in adult cohorts.
• In the TODAY cohort, youths who had type 2 DM were sedentary >56 minutes 
longer per day (via accelerometry) than obese youth from NHANES.12
• Of 1514 SEARCH participants, 95% reported having undergone BP checks and 
88% reported having had lipid-level checks, whereas slightly more than two 
thirds (68%) reported having had HbA1c testing or eye examinations (66%).13
Abbreviations Used in Chapter 10
ACC American College of Cardiology
ACCORD Action to Control Cardiovascular Risk in Diabetes
ACS acute coronary syndrome
ADVANCE Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled 
Evaluation
AF atrial fibrillation
AHA American Heart Association
AHRQ Agency for Healthcare Research and Quality
AMI acute myocardial infarction
ARIC Atherosclerosis Risk in Communities study
BMI body mass index
BP blood pressure
BRFSS Behavioral Risk Factor Surveillance System
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CDC Centers for Disease Control and Prevention
CHD coronary heart disease
CHS Cardiovascular Health Study
CI confidence interval
CVD cardiovascular disease
DM diabetes mellitus
ED emergency department
ESRD end-stage renal disease
EVEREST Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study With Tolvaptan
FHS Framingham Heart Study
HbA1c hemoglobin A1c
HD heart disease
HDL high-density lipoprotein
HF heart failure
HR hazard ratio
ICD-9 International Classification of Diseases, 9th Revision
ICD-10 International Classification of Diseases, 10th Revision
IDDM insulin-dependent diabetes mellitus
LDL low-density lipoprotein
MESA Multi-Ethnic Study of Atherosclerosis
MI myocardial infarction
NCHS National Center for Health Statistics
NH non-Hispanic
NHANES National Health and Nutrition Examination Survey
NHDS National Hospital Discharge Survey
NHIS National Health Interview Survey
NHLBI National Heart, Lung, and Blood Institute
NSTEMI non–ST-segment–elevation myocardial infarction
OR odds ratio
PA physical activity
PAR population-attributable risk
RR relative risk
SBP systolic blood pressure
SEARCH Search for Diabetes in Youth Study
STEMI ST-segment–elevation myocardial infarction
TODAY Treatment Options for Type 2 Diabetes in Adolescents and Youth
UA unstable angina
Adults—(See Table 10-1 and Charts 10-1 through 10-3.)
• On the basis of data from NHANES 2007 to 2010 (unpublished NHLBI 
tabulation), an estimated 19.7 million Americans ≥20 years of age have 
physician-diagnosed DM. An additional 8.2 million adults have undiagnosed 
DM, and 87.3 million adults have prediabetes (eg, fasting blood glucose of 100 
et al. Page 110
Circulation. Author manuscript; available in PMC 2017 April 28.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
to <126 mg/dL). The prevalence of prediabetes in the US adult population is 
38%.
• The prevalence of diagnosed DM in adults ≥65 years of age was 26.9% in 2010, 
and an additional 50% (>20 million) had prediabetes based on fasting glucose, 
oral glucose tolerance testing, or HbA1c. In addition, data from NHANES 2005 
to 2006 show that 46% of DM cases remain undiagnosed in this group aged ≥65 
years.14
• According to the Bogalusa Heart Study, men >20 years of age have a slightly 
higher prevalence of DM (11.8%) than women (10.8%).6
• After adjustment for population age differences, 2007 to 2009 national survey 
data for people >20 years of age indicate that 7.1% of non-Hispanic whites, 8.4% 
of Asian Americans, 11.8% of Hispanics, and 12.6% of non-Hispanic blacks had 
diagnosed DM.5
• Compared with non-Hispanic white adults, the risk of diagnosed DM was 18% 
higher among Asian Americans, 66% higher among Hispanics/Latinos, and 77% 
higher among non-Hispanic blacks.5
• In 2004 to 2006, the prevalence of diagnosed DM was more than twice as high 
for Asian Indian adults (14%) as for Chinese (6%) or Japanese (5%) adults.15
• Type 2 DM accounts for 90% to 95% of all diagnosed cases of DM in adults.5
• On the basis of 2012 BRFSS (CDC) data, the prevalence of adults in the United 
States who reported ever having been told by a physician that they had DM 
ranged from 6.9% in Alaska to 13.0% in West Virginia. The mean percentage 
among all states was 10.1%.16
• The CDC analyzed data from 1994 to 2004 collected by the Indian Health 
Service that indicated that the age-adjusted prevalence of DM per 1000 
population increased 101.2% among American Indian/Alaska Native adults <35 
years of age (from 8.5% to 17.1%). During this time period, the prevalence of 
diagnosed DM was greater among females than males in all age groups.17
• On the basis of projections from NHANES studies between 1984 and 2004, the 
total prevalence of DM in the United States is expected to more than double from 
2005 to 2050 (from 5.6% to 12.0%) in all age, sex, and race/ethnicity groups. 
Increases are projected to be largest for the oldest age groups (for instance, 
projected to increase by 220% among those 65–74 years of age and by 449% 
among those ≥75 years of age). DM prevalence is projected to increase by 99% 
among non-Hispanic whites, by 107% among non-Hispanic blacks, and by 127% 
among Hispanics. The age/race/ethnicity group with the largest increase is 
expected to be blacks ≥75 years of age (projected increase of 606%).18
• According to NHIS data from 1997 to 2008, the prevalence of DM was higher at 
both time points among Asian Americans (4.3%–8.2%) than among whites 
(3.8%–6.0%), with the Asian American group also having a greater proportional 
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increase (1.9- versus 1.5-fold increase). This was observed despite lower BMI 
levels (23.6 versus 26.1 kg/m2 in the earliest time period) among Asians.19
• According to international survey and epidemiologic data from 2.7 million 
participants, the prevalence of DM in adults increased from 8.3% in men and 
7.5% in women in 1980 to 9.8% in men and 9.2% in women in 2008. The 
number of individuals affected with DM increased from 153 million in 1980 to 
347 million in 2008.20
Incidence
Youths
• In the SEARCH study, the incidence of DM in youths overall was 24.3 per 100 
000 person-years. Among children <10 years of age, most had type 1 DM, 
regardless of race/ethnicity. The highest rates of incident type 1 DM were 
observed in non-Hispanic white youths (18.6, 28.1, and 32.9 per 100 000 person-
years for age groups of 0–4, 5–9, and 10–14 years, respectively). Overall, type 2 
DM was relatively infrequent, with the highest rates (17.0–49.4 per 100 000 
person-years) seen among 15- to 19-year-old minority groups.6
• Of 2291 individuals <20 years of age with newly diagnosed DM, slightly more 
than half (54.5%) had autoimmune, insulin-sensitive DM, and 15.9% had 
nonautoimmune, insulin-resistant DM.21
• Projecting disease burden by 2050, the number of youths with type 1 DM will 
conservatively increase from 166 018 to 203 382, and the number with type 2 
DM will increase from 20 203 to 30 111. Less conservative modeling projects 
the number of type 1 DM patients at 587 488 and of those with type 2 DM at 84 
131 by 2050.22
Adults—(See Table 10-1.)
• A total of 1.9 million new cases of DM (type 1 or type 2) were diagnosed in US 
adults ≥20 years of age in 2010.5
• Data from the FHS indicate a doubling in the incidence of DM over the past 30 
years, most dramatically during the 1990s. Among adults 40 to 55 years of age in 
each decade of the 1970s, 1980s, and 1990s, the age-adjusted 8-year incidence 
rates of DM were 2.0%, 3.0%, and 3.7% among women and 2.7%, 3.6%, and 
5.8% among men, respectively. Compared with the 1970s, the age- and sex-
adjusted OR for DM was 1.40 in the 1980s and 2.05 in the 1990s (P for 
trend=0.0006). Most of the increase in absolute incidence of DM occurred in 
individuals with a BMI ≥30 kg/m2 (P for trend=0.03).23
• DM incidence in adults also varies markedly by race. Over 5 years of follow-up 
in 45- to 84-year-olds in MESA, 8.2% of the cohort developed DM. The 
cumulative incidence was highest in Hispanics (11.3%), followed by black 
(9.5%), Chinese (7.7%), and white (6.3%) participants.24
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• On the basis of meta-analyses of 4 longitudinal cohort studies comprising 175 
938 individuals and 1.1 million person-years of follow-up, a statistically 
significant adjusted association was observed between net duration of television 
viewing and risk for incident type 2 DM, with a 20% increased risk per each 2-
hour daily increment of exposure (adjusted RR, 1.20; 95% CI, 1.14–1.27).25
• According to NHANES data from 1988 to 1994 compared with 2005 to 2010, 
the prevalence of DM increased from 8.4% to 12.1%. This increase was most 
pronounced among those ≥65 years of age (increase in prevalence from 18.6% to 
28.5%).26
• According to data from NHANES and BRFSS, up to 48.7% of individuals with 
self-reported DM did not meet glycemic, BP, and lipid targets, and only 14.3% 
met all 3 targets and did not smoke.27
• Gestational DM complicates 2% to 10% of pregnancies and increases the risk of 
developing type 2 DM by 35% to 60%.5
Mortality
(See Table 10-1.)
DM mortality in 2010 was 69 071. Any-mention mortality in 2010 was 234 051.28
• The 2010 overall underlying-cause death rate attributable to DM was 20.8. Death 
rates per 100 000 people were 23.1 for white males, 43.6 for black males, 15.6 
for white females, and 35.1 for black females.28
• According to data from the National Diabetes Information Clearinghouse, the 
National Institute of Diabetes and Digestive and Kidney Diseases, and the 
National Institutes of Health:
– At least 68% of people >65 years of age with DM die of some form of 
HD; 16% die of stroke.
– HD death rates among adults with DM are 2 to 4 times higher than the 
rates for adults without DM.5
• In a collaborative meta-analysis of 820 900 individuals from 97 prospective 
studies, DM was associated with the following risks: all-cause mortality, HR 
1.80 (95% CI, 1.71–1.90); cancer death, HR 1.25 (95% CI, 1.19–1.31); and 
vascular death, HR 2.32 (95% CI, 2.11–2.56). In particular, DM was associated 
with death attributable to the following cancers: liver, pancreas, ovary, colorectal, 
lung, bladder, and breast. A 50-year-old with DM died on average 6 years earlier 
than an individual without DM.29
• FHS/NHLBI data show that having DM significantly increased the risk of 
developing CVD (HR 2.5 for women and 2.4 for men) and of dying when CVD 
was present (HR 2.2 for women and 1.7 for men). Diabetic men and women ≥50 
years of age lived an average of 7.5 and 8.2 years less than their nondiabetic 
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counterparts. The differences in life expectancy free of CVD were 7.8 and 8.4 
years, respectively.30
• Analysis of data from NHANES 1971 to 2000 found that men with DM 
experienced a 43% relative reduction in the age-adjusted mortality rate, which 
was similar to that of nondiabetic men. Among women with DM, however, 
mortality rates did not decrease, and the difference in mortality rates between 
diabetic and nondiabetic women doubled.31
• During 1979 to 2004, DM death rates for black youths 1 to 19 years of age were 
approximately twice those for white youths. During 2003 to 2004, the annual 
average DM death rate per 1 million youths was 2.46 for black youths and 0.91 
for white youths.32
• Among individuals ≥65 years of age participating in the CHS, during follow-up 
for up to 16 years, adjusted CHD mortality risk was similar for those with 
prevalent CHD free of DM at study entry compared with participants with DM 
but free of CHD (HR, 1.04; 95% CI, 0.83–1.30).33
• Analysis of data from the FHS from 1950 to 2005 found reductions in all-cause 
and CVD mortality among men and women with and without DM; however, all-
cause and CVD mortality rates among individuals with DM remain ≈2-fold 
higher than for individuals without DM.34
• According to NHIS data from 1997 to 2006, the rate of CVD death among adults 
with DM decreased by 40% (95% CI, 23%–54%). Similarly, all-cause mortality 
decreased by 23% (95% CI, 10%–35%). In contrast, over this same period 
among adults without DM, the CVD mortality rate decreased by 60%, and the 
all-cause mortality rate decreased by 44%.35
Awareness
(See Chart 10-4.)
• Analysis of NHANES/NCHS data from 1988 to 1994 and from 2005 to 2006 in 
adults ≥20 years of age showed that 40% of those with DM did not know they 
had it.14 Although the prevalence of diagnosed DM has increased significantly 
over the past decade, the prevalence of undiagnosed DM and impaired fasting 
glucose has remained relatively stable. Minority groups remain 
disproportionately affected.36
• Analysis of NHANES data collected during 2007 to 2010 indicated that the 
prevalence of DM was 8.3% among people ≥20 years of age. Prevalence of DM 
was defined as people who were told by a physician or other health professional 
that they had DM (NHANES 2007–2010, NHLBI tabulation).
• Of the estimated 27.9 million adults with DM, 70.6% were told they had DM or 
were undergoing treatment, and 29.4% (8.2 million) were unaware of the 
diagnosis. Of 12.9 million people being treated (65.5% of the diagnosed diabetic 
population), 5.1 million (39.5%) had their hyperglycemia under control (ie, they 
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were undergoing treatment and had fasting plasma glucose <126 mg/dL), and 7.8 
million (60.5%) were being treated but did not have their hyperglycemia under 
control (fasting plasma glucose ≥126 mg/dL). An estimated 6.8 million 
individuals with diagnosed DM are not treated with glucose-lowering therapy 
(NHANES 2007–2010, NHLBI tabulation).
Aftermath
• Although the exact date of DM onset can be difficult to determine, increasing 
duration of DM diagnosis is associated with increasing CVD risk. Longitudinal 
data from FHS suggest that the risk factor–adjusted RR of CHD is 1.38 (95% CI, 
0.99–1.92) times higher and the risk for CHD death is 1.86 (95% CI, 1.17–2.93) 
times higher for each 10-year increase in duration of DM.37
• On the basis of data from the NCHS/NHIS, 1997 to 200538
– The estimated number of people ≥35 years of age with DM with a self-
reported cardiovascular condition increased 36%, from 4.2 million in 
1997 to 5.7 million in 2005; however, the respective age-adjusted 
prevalence decreased 11.2%, from 36.6% in 1997 to 32.5% in 2005, 
reflecting an increase in the number of patients diagnosed with DM that 
exceeded the increase in CVD prevalence.
– Age-adjusted CVD prevalence was higher among men than women, 
among whites than blacks, and among non-Hispanics than Hispanics. 
Among women, the age-adjusted prevalence decreased by 11.2%; 
among men, it did not decrease significantly. Among blacks, the age-
adjusted prevalence of self-reported CVD decreased by 25.3%; among 
whites, no significant decrease occurred; among non-Hispanics, the rate 
decreased by 12%. No clear trends were detected among Hispanics.
– Because the total number of people with DM and self-reported CVD 
increased over this period but proportions with self-reported CVD 
declined, the data suggest that the mean age at which people are 
diagnosed with DM is decreasing, or the higher CVD mortality rate 
among older diabetic individuals is removing them from ability to self-
report CVD. These and other data show a consistent increase over time 
in the United States of the number of people with DM and CVD.
• Data from the FHS show that despite improvements in CVD morbidity and 
mortality over >4 decades of observation, DM continues to be associated with 
incremental CVD risk. Participants 45 to 64 years of age from the FHS original 
and offspring cohorts who attended examinations in 1950 to 1966 (“earlier” time 
period) and 1977 to 1995 (“later” time period) were followed up for incident MI, 
CHD death, and stroke. Among participants with DM, the age- and sex-adjusted 
CVD incidence rate was 286.4 per 10 000 person-years in the earlier period and 
146.9 per 10 000 person-years in the later period, a 35.4% decline. HRs for DM 
as a predictor of incident CVD were not significantly different in the earlier (risk 
factor–adjusted HR, 2.68; 95% CI, 1.88–3.82) versus later (HR, 1.96; 95% CI, 
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1.44–2.66) period.39 Thus, although there was a 50% reduction in the rate of 
incident CVD events among adults with DM, the absolute risk of CVD remained 
2-fold greater than among people without DM.39
– Data from these earlier and later time periods in FHS also suggest that 
the increasing prevalence of DM is leading to an increasing rate of 
CVD, resulting in part from CVD risk factors that commonly 
accompany DM. The age- and sex-adjusted HR for DM as a CVD risk 
factor was 3.0 in the earlier time period and 2.5 in the later time period. 
Because the prevalence of DM has increased over time, the PAR for 
DM as a CVD risk factor increased from 5.4% in the earlier time period 
to 8.7% in the later time period (attributable risk ratio, 1.62; P=0.04). 
Adjustment for CVD risk factors (age, sex, hypertension, current 
smoking, high cholesterol, and obesity) weakened this attributable risk 
ratio to 1.5 (P=0.12).40
– Other data from FHS show that over a 30-year period, CVD among 
women with DM was 54.8% among normal-weight women but 78.8% 
among obese women. Among normal-weight men with DM, the 
lifetime risk of CVD was 78.6%, whereas it was 86.9% among obese 
men.41
• Other studies show that the increased prevalence of DM is being followed by an 
increasing prevalence of CVD morbidity and mortality. New York City death 
certificate data for 1989 to 1991 and 1999 to 2001 and hospital discharge data for 
1988 to 2002 show increases in all-cause and cause-specific mortality between 
1990 and 2000, as well as in annual hospitalization rates for DM and its 
complications among patients hospitalized with AMI and/or DM. During this 
decade, all-cause and cause-specific mortality rates declined, although not for 
patients with DM; rates increased 61% and 52% for diabetic men and women, 
respectively, as did hospitalization rates for DM and its complications. The 
percentage of all AMIs occurring in patients with DM increased from 21% to 
36%, and the absolute number more than doubled, from 2951 to 6048. Although 
hospital days for AMI fell overall, for those with DM, they increased 51% (from 
34 188 to 51 566). These data suggest that increases in DM rates threaten the 
long-established nationwide trend toward reduced coronary artery events.42
• Data from the ARIC study of the NHLBI found that the magnitude of 
incremental CHD risk associated with DM was smaller in blacks than in 
whites.43
• A subgroup analysis was conducted of patients with DM enrolled in randomized 
clinical trials that evaluated ACS therapies. The data included 62 036 patients 
from Thrombolysis in Myocardial Infarction studies (46 577 with STEMI and 15 
459 with UA/NSTEMI). Of these, 17.1% had DM. Modeling showed that 
mortality at 30 days was significantly higher among patients with DM than 
among those without DM who presented with UA/NSTEMI (2.1% versus 1.1%; 
P≤0.001) and STEMI (8.5% versus 5.4%; P=0.001), with adjusted risks for 30-
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day mortality in DM versus no DM of 1.78 for UA/NSTEMI (95% CI, 1.24–
2.56) and 1.40 (95% CI, 1.24–1.57) for STEMI. DM was also associated with 
significantly higher mortality 1 year after UA/NSTEMI or STEMI. By 1 year 
after ACS, patients with DM who presented with UA/NSTEMI had a risk of 
death that approached that of patients without DM who presented with STEMI 
(7.2% versus 8.1%).44
• In analyses from the National Registry of Myocardial Infarction comprising data 
registered on 1 734 431 patients admitted with AMI to 1964 participating US 
hospitals, the incremental adjusted OR for hospital mortality associated with DM 
declined from 1.24 (95% CI, 1.16–1.32) in 1994 to 1.08 (95% CI, 0.99–1.19) in 
2006, which demonstrates a closing of the acute hospital mortality gap 
associated with DM.45
• In an analysis of provincial health claims data for adults living in Ontario, 
Canada, between 1992 and 2000, the rate of patients admitted for AMI and 
stroke decreased to a greater extent in the diabetic than the nondiabetic 
population (AMI, −15.1% versus −9.1%, P=0.0001; stroke, −24.2% versus 
−19.4%, P=0.0001). Patients with DM experienced reductions in case fatality 
rates related to AMI and stroke similar to those without DM (−44.1% versus 
−33.2%, P=0.1, and −17.1% versus −16.6%, P=0.9, respectively) and similarly 
comparable decreases in all-cause mortality. Over the same period, the number 
of DM cases increased by 165%, which translates to a marked increase in the 
proportion of CVD events occurring among patients with DM: AMI, 44.6%; 
stroke, 26.1%; AMI deaths, 17.2%; and stroke deaths, 13.2%.46
• In the same data set, the transition to a high-risk category (an event rate 
equivalent to a 10-year risk of 20% or an event rate equivalent to that associated 
with previous MI) occurred at a younger age for men and women with DM than 
for those without DM (mean difference, 14.6 years). For the outcome of AMI, 
stroke, or death resulting from any cause, men and women with DM entered the 
high-risk category at 47.9 and 54.3 years of age, respectively. The data suggest 
that DM confers a risk equivalent to aging 15 years. In North America, diverse 
data show lower rates of CVD among people with DM, but as the prevalence of 
DM has increased, so has the absolute burden of CVD, especially among middle-
aged and older individuals.47
• DM increases the risk of HF and adversely affects outcomes among patients with 
HF.
– DM alone qualifies for the most recent ACC Foundation/AHA 
diagnostic criteria for stages A and B HF, a classification of patients 
without HF but at notably high risk for its development.48
– In MESA, DM was associated with a 2-fold increased adjusted risk of 
incident HF among 6814 individuals free of CVD at baseline over a 
mean follow-up of 4 years (HR, 1.99; 95% CI, 1.08–3.68).49
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– Post hoc analysis of data from the EVEREST randomized trial of 
patients hospitalized with decompensated systolic HF stratified by DM 
status, which evaluated cardiovascular outcomes over a follow-up 
period of 9.9 months, demonstrated an increased adjusted HR for the 
composite of cardiovascular mortality and HF rehospitalization 
associated with DM (HR, 1.17; 95% CI, 1.04–1.31).50
• DM increases the risk of AF. On the basis of meta-analysis of published 
observational data comprising 11 studies and >1.6 million participants, DM was 
crudely associated with a 40% increased risk for AF (RR, 1.39; 95% CI, 1.10–
1.75) with the association remaining significant after multivariable adjustment 
(adjusted RR, 1.24; 95% CI, 1.06–1.44), yielding an estimate of the population 
attributable fraction of AF attributable to DM of 2.5%.51
• DM increases the risk of stroke, with the RR ranging from 1.8- to 6-fold 
increased risk.37,52
– DM is associated with increased ischemic stroke incidence at all ages, 
with the incremental risk associated with DM being most prominent 
before 55 years of age in blacks and before 65 years of age in whites.52
– Ischemic stroke patients with DM are younger, more likely to be black, 
and more likely to have hypertension, prior MI, and high cholesterol 
than nondiabetic patients.52
• DM accounted for 44% of the new cases of ESRD in 2007.53
• In 2011, the incidence rate of ESRD attributed to DM in adults ≥20 years 
increased with age from 5.02 per 100 000 in those aged 20 to 29 years to 109.81 
per 100 000 in those ≥70 years, compared with rates of 2.41 and 83.19, 
respectively, in those without DM.54
• According to NHANES data, the prevalence of diabetic kidney disease has 
increased from 2.2% in NHANES III to 3.3% in NHANES 2005 to 2008. These 
increases were observed in direct proportion to increases in DM.55
• HbA1c levels ≥6.5% can be used to diagnose DM.55a In the population-based 
ARIC study, over a 14-year follow-up period that preceded the endorsement of 
HbA1c as a diagnostic criterion, HbA1c levels ≥6.5% at study entry were 
associated with a multivariable-adjusted HR of 16.5 (95% CI, 14.2–19.1) for 
diagnosed DM based on contemporaneous diagnostic criteria and 1.95 (95% CI, 
1.53–2.48) for CHD relative to those with HbA1c <5.0%.56
• According to data from the ARIC study and NHANES III, the sensitivity and 
specificity for diagnosing DM with HbA1c criteria (compared with a single 
fasting glucose measurement of ≥126 mg/dL) were 47% and 98%, respectively.
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Risk Factors
• DM, especially type 2 DM, is associated with clustered risk factors for CHD, 
with a prevalence of 75% to 85% for hypertension among adults with DM, 70% 
to 80% for elevated LDL, and 60% to 70% for obesity.57
• Aggressive treatment of hypertension is recommended for adults with DM to 
prevent cardiovascular complications. Between NHANES III (1984–1992) and 
NHANES 1999 to 2004, the proportion of patients with DM whose BP was 
treated increased from 76.5% to 87.8%, and the proportion whose BP was 
controlled nearly doubled (from 15.9% to 29.6%).58
• Aggressive treatment of hypercholesterolemia is recommended for adults with 
DM, with the cornerstone of treatment being statin therapy, which is 
recommended for all patients with DM >40 years of age independent of baseline 
cholesterol, with targeted LDL cholesterol <100 mg/dL and optimally <70 
mg/dL.59
• CHD risk factors among patients with DM remain suboptimally treated, although 
improvements have been observed over the past decade. Between 1999 and 2008, 
in up to 2623 adult participants with DM, data from NHANES showed that 
improvements were observed for the achieved targets for control of HbA1c (from 
37.0% to 55.2%), BP (from 35.2% to 51.0%), and LDL cholesterol (from 32.5% 
to 52.9%).60
• Data from the 2012 National Healthcare Disparities Report (AHRQ, US 
Department of Health and Human Services) found that only about 23% of adults 
over age 40 years with DM received all 4 interventions to reduce risk factors 
recommended for comprehensive DM care in 2009. The proportion receiving all 
4 interventions was lower among blacks and Hispanics than whites.61
– In multivariable models, among those aged 40 to 64 years, only about 
65% had their blood pressure <140/80 mm Hg, with blacks less likely 
than whites to achieve this blood pressure level.61
• In 1 large academic medical center, outpatients with type 2 DM were observed 
during an 18-month period for proportions of patients who had HbA1c levels, BP, 
or total cholesterol levels measured; who had been prescribed any drug therapy if 
HbA1c levels, SBP, or LDL cholesterol levels exceeded recommended treatment 
goals; and who had been prescribed greater-than-starting-dose therapy if these 
values were above treatment goals. Patients were less likely to have cholesterol 
levels measured (76%) than HbA1c levels (92%) or BP (99%; P<0.0001 for 
either comparison). The proportion of patients who received any drug therapy 
was greater for above-goal HbA1c (92%) than for above-goal SBP (78%) or LDL 
cholesterol (38%; P<0.0001 for each comparison). Similarly, patients whose 
HbA1c levels were above the treatment goal (80%) were more likely to receive 
greater-than-starting-dose therapy than were those who had above-goal SBP 
(62%) and LDL cholesterol levels (13%; P<0.0001).62
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– Data from the same academic medical center also showed that CVD 
risk factors among women with DM were managed less aggressively 
than among men with DM. Women were less likely than men to have 
HbA1c <7% (without CHD: adjusted OR for women versus men 0.84, 
P=0.005; with CHD: 0.63, P<0.0001). Women without CHD were less 
likely than men to be treated with lipid-lowering medication (0.82; 
P=0.01) or, when treated, to have LDL cholesterol levels <100 mg/dL 
(0.75; P=0.004) and were less likely than men to be prescribed aspirin 
(0.63; P<0.0001). Women with DM and CHD were less likely than men 
to be prescribed aspirin (0.70, P<0.0001) and, when treated for 
hypertension or hyperlipidemia, were less likely to have BP levels 
<130/80 mm Hg (0.75; P<0.0001) or LDL cholesterol levels <100 
mg/dL (0.80; P=0.006).63
• Analysis of data from the CHS of the NHLBI found that lifestyle risk factors, 
including PA level, dietary habits, smoking habits, alcohol use, and adiposity 
measures, assessed late in life, were each independently associated with risk of 
new-onset DM. Participants whose PA level and dietary, smoking, and alcohol 
habits were all in the low-risk group had an 82% lower incidence of DM than all 
other participants. When absence of adiposity was added to the other 4 low-risk 
lifestyle factors, incidence of DM was 89% lower.64
• According to 2007 data from the BRFSS, only 25% of adults with DM achieved 
recommended levels of total PA based on the 2007 American Diabetes 
Association guidelines.65
Hospitalizations
(See Table 10-1.)
Youths
• Nationwide Inpatient Sample data from 1993 to 2004 were analyzed for 
individuals 0 to 29 years of age with a diagnosis of DM. Rates of hospitalizations 
increased by 38%. Hospitalization rates were higher for females (42%) than for 
males (29%). Inflation-adjusted total charges for DM hospitalizations increased 
130%, from $1.05 billion in 1993 to $2.42 billion in 2004.66
Adults
• According to NHDS data reported by the CDC in an analysis of data from 2010, 
DM was a listed diagnosis in 16% of US adult hospital discharges. Of the 5.1 
million discharges with DM listed, circulatory diseases was the most common 
first-listed diagnosis (24.1%; 1.3 million discharges) and DM the second most 
common (11.5%; 610 000 discharges).67
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Hypoglycemia
• Hypoglycemia is a common side effect of DM treatment, typically defined as a 
blood glucose level <50 mg/dL; severe hypoglycemia is additionally defined as 
patients needing assistance to treat themselves.
• In the ADVANCE trial, 2.1% of patients had an episode of severe hypoglycemia.
• Severe hypoglycemia was associated with an increased risk of major 
macrovascular events (HR, 2.88; 95% CI, 2.01–4.12), cardiovascular death (HR, 
2.68; 95% CI, 1.72–4.19), and all-cause death (HR, 2.69; 95% CI, 1.97–3.67), 
including nonvascular outcomes. The lack of specificity of hypoglycemia with 
vascular outcomes suggests that it might be a marker for susceptibility. Risk 
factors for hypoglycemia included older age, DM duration, worse renal function, 
lower BMI, lower cognitive function, use of multiple glucose-lowering 
medications, and randomization to the intensive glucose control arm.68
• According to data from the 2004 to 2008 MarketScan database of type 2 DM, 
which consisted of 536 581 individuals, the incidence rate of hypoglycemia was 
153.8 per 10 000 person-years and was highest in adults aged 18 to 34 years 
(218.8 per 10 000 person-years).69
• According to data from 2956 adults >55 years of age from the ACCORD trial, 
poor cognitive function, defined as a 5-point poorer baseline score on the Digit 
Symbol Substitution Test, was associated with a 13% increased risk of severe 
hypoglycemia that required medical assistance.70
• In a sample of 813 adults with type 2 DM enrolled in commercial health plans, 
71% reported experiencing symptoms of hypoglycemia.71
Cost
(See Table10-1.)
• In 2012, the cost of DM was estimated at $245 billion, up from $174 billion in 
2007, accounting for 1 in 5 healthcare dollars. Of these costs, $176 billion were 
direct medical costs and $69 billion resulted from reduced productivity. Inpatient 
care accounted for 43% of these costs, 18% were attributable to prescription 
costs to treat DM complications, and 12% were related to antidiabetes agents and 
supplies.72
• After adjustment for age and sex, medical costs for patients with DM were 2.3 
times higher than for people without DM.5
• According to the insurance claims and MarketScan data from 7556 youths <19 
years of age with insulin-treated DM, costs for youths with hypoglycemia were 
$12 850 compared with $8970 for youths without hypoglycemia. For diabetic 
ketoacidosis, costs were $14 236 for youths with versus $8398 for youths 
without diabetic ketoacidosis.73
• The cost of hypoglycemia, according to data from 536 581 individuals with type 
2 DM from the 2004 to 2008 MarketScan database, was $52 223 675, which 
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accounted for 1.0% of inpatient costs, 2.7% of ED costs, and 0.3% of out-patient 
costs. This resulted in a mean cost of $17 564 for an inpatient admission, $1387 
for an ED visit, and $394 for an outpatient visit.69
Type 1 DM
• Type 1 DM constitutes 5% to 10% of DM in the United States.74
• The Colorado IDDM Study Registry and SEARCH for Diabetes in Youth 
registry demonstrated an increasing incidence of type 1 DM among Colorado 
youths ≤17 years of age, with an increase in the incidence of 2.3% (95% CI, 
1.6%–3.1%) per year over the past 26 years.75
• Between 1996 and 2010, the number of youths with type 1 DM increased by 
5.7% per year.76
• Among youths with type 1 DM, the prevalence of overweight is 22.1% and the 
prevalence of obesity is 12.6%.8
• A long-term study of patients with type 1 DM that began in 1966 showed that 
over 30 years of follow-up, overall risk of mortality associated with type 1 DM 
was 7 times greater than that of the general population. Females had a 13.2-fold 
incremental mortality risk compared with a 5.0-fold increased risk in males. 
During the course of study, the incremental mortality risk associated with type 1 
DM declined from 9.3 to 5.6 times that of nondiabetic control subjects.77
• According to 30-year mortality data from Allegheny County, PA, those with type 
1 DM have a mortality rate 5.6 times higher than the general population.78
• The leading cause of death among patients with type 1 DM is CVD, which 
accounted for 22% of deaths among those in the Allegheny County, PA, type 1 
DM registry, followed by renal (20%) and infectious (18%) causes.79
• Long-term follow-up data from the Diabetes Control and Complications Trial/
Epidemiology of Diabetes Interventions and Complications Study Research 
Group showed that intensive versus conventional treatment in the Diabetes 
Control and Complications Trial was associated with a 42% reduced risk of CVD 
(P=0.02) and a 57% reduced risk of the composite end point (P=0.02; included 
nonfatal MI, stroke, and CVD death).80
• Observational data from the Swedish National Diabetes Register showed that 
most CVD risk factors were more adverse among patients with HbA1c between 
8.0% and 11.9% than among those with HbA1c between 5.0% and 7.9%. Per 1% 
unit increase in HbA1c, the HR of fatal and nonfatal CHD was 1.30 in 
multivariable-adjusted models and 1.27 for fatal and nonfatal CVD. Among 
patients with HbA1c 8.0% to 11.9% compared with those with HbA1c 5.0% to 
7.9%, the HR of fatal/nonfatal CHD was 1.71 and the risk of fatal/nonfatal CVD 
was 1.59.81
• Among 2787 patients from the EURODIAB Prospective Complications Study, 
age, waist-hip ratio, pulse pressure, non-HDL cholesterol, microalbuminuria, and 
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peripheral and autonomic neuropathy were risk factors for all-cause, CVD, and 
non-CVD mortality.81a
• Among 3610 older patients (>60 years of age) with type 1 DM, the risk of severe 
hypoglycemia was twice as high as for those <60 years of age (40.1 versus 24.3 
per 100 patient-years).82
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11. Metabolic Syndrome
• Metabolic syndrome is a multicomponent risk factor for CVD and type 2 DM 
that reflects the clustering of individual cardiometabolic risk factors related to 
abdominal obesity and insulin resistance. Although several different clinical 
definitions for metabolic syndrome have been proposed, the International 
Diabetes Federation, NHLBI, AHA, and others recently proposed a harmonized 
definition for metabolic syndrome.1 By this definition, metabolic syndrome is 
diagnosed when any 3 of the following 5 risk factors are present (most but not all 
people with DM will be classified as having metabolic syndrome by this 
definition because they will have ≥2 other factors besides the glucose criterion; 
many will prefer to separate those with DM into a separate group for risk 
stratification or treatment purposes):
– Fasting plasma glucose ≥100 mg/dL or undergoing drug treatment for 
elevated glucose
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– HDL cholesterol <40 mg/dL in men or <50 mg/dL in women or 
undergoing drug treatment for reduced HDL cholesterol
– Triglycerides ≥150 mg/dL or undergoing drug treatment for elevated 
triglycerides
– Waist circumference >102 cm in men or >88 cm in women for people 
of most ancestries living in the United States. Ethnicity and country-
specific thresholds can be used for diagnosis in other groups, 
particularly Asians and individuals of non-European ancestry who have 
predominantly resided outside the United States.
– BP ≥130 mm Hg systolic or ≥85 mm Hg diastolic or undergoing drug 
treatment for hypertension or antihypertensive drug treatment in a 
patient with a history of hypertension.
• Those with a fasting glucose level ≥126 mg/dL or a casual glucose value ≥200 
mg/dL or taking hypoglycemic medication can normally be classified separately 
as having DM; many of these people will also have metabolic syndrome from the 
presence of additional risk factors noted above.
• The new harmonized metabolic syndrome definition identifies a similar risk 
group and predicts CVD risk similarly to the prior metabolic syndrome 
definitions.2
• There are many adverse health conditions that are related to metabolic syndrome 
but are not part of its clinical definition. These include nonalcoholic fatty liver 
disease, sexual dysfunction (erectile dysfunction in men and polycystic ovarian 
syndrome in women), and obstructive sleep apnea, as well as a general 
proinflammatory and pro-thrombotic state.3
• Identification and treatment of metabolic syndrome fits closely with the current 
AHA 2020 Impact Goals, including emphasis on PA, healthy diet, and healthy 
weight for attainment of ideal BP, serum cholesterol, and fasting blood glucose. 
Metabolic syndrome should be considered largely a disease of unhealthy 
lifestyle. Prevalence of metabolic syndrome is a secondary metric in the 2020 
Impact Goals. Identification of metabolic syndrome represents a call to action for 
the healthcare provider and patient to address the underlying lifestyle-related risk 
factors. A multidisciplinary team of healthcare professionals is desirable to 
adequately address these multiple issues in patients with metabolic syndrome.4
Abbreviations Used in Chapter 11
AF atrial fibrillation
AHA American Heart Association
ARIC Atherosclerosis Risk in Communities
BMI body mass index
BP blood pressure
CAC coronary artery calcification
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CAD coronary artery disease
CHD coronary heart disease
CI confidence interval
COURAGE Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation
CRP C-reactive protein
CT computed tomography
CVD cardiovascular disease
DM diabetes mellitus
ECG electrocardiogram
FRS Framingham Risk Score
HDL high-density lipoprotein
HF heart failure
HIV human immunodeficiency virus
HR hazard ratio
IMT intima-media thickness
LDL low-density lipoprotein
MESA Multi-Ethnic Study of Atherosclerosis
MI myocardial infarction
NCHS National Center for Health Statistics
NHANES National Health and Nutrition Examination Survey
NHLBI National Heart, Lung, and Blood Institute
OR odds ratio
PA physical activity
PAR population attributable risk
PCI percutaneous coronary intervention
RR relative risk
WHO World Health Organization
Prevalence
Adults—The following estimates include many of those who have DM, in addition to those 
with metabolic syndrome without DM:
• Prevalence of metabolic syndrome varies by the definition used, with definitions 
such as that from the International Diabetes Federation and the harmonized 
definition suggesting lower thresholds for defining central obesity in European 
whites, Asians (in particular, South Asians), Middle Easterners, Sub-Saharan 
Africans, and Hispanics, which results in higher prevalence estimates.5
• On the basis of NHANES 2003 to 2006 data and National Cholesterol Education 
Program/Adult Treatment Panel III guidelines, ≈34% of adults ≥20 years of age 
met the criteria for metabolic syndrome.6
• Also based on NHANES 2003 to 2006 data6
– The age-adjusted prevalence was 35.1% for men and 32.6% for women.
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– Among men, the age-specific prevalence ranged from 20.3% among 
people 20 to 39 years of age to 40.8% for people 40 to 59 years of age 
and 51.5% for people ≥60 years of age. Among women, the age-
specific prevalence ranged from 15.6% among people 20 to 39 years of 
age to 37.2% for people 40 to 59 years of age and 54.4% for those ≥60 
years of age.
– The age-adjusted prevalences of people with metabolic syndrome were 
37.2%, 25.3%, and 33.2% for non-Hispanic white, non-Hispanic black, 
and Mexican American men, respectively. Among women, the 
percentages were 31.5%, 38.8%, and 40.6%, respectively.
– The age-adjusted prevalence was ≈53% higher among non-Hispanic 
black women than among non-Hispanic black men and ≈22% higher 
among Mexican American women than among Mexican American 
men.
• The prevalence of metabolic syndrome is also high among immigrant Asian 
Indians, ranging between 26.8% and 38.2% depending on the definition used.7
• Among American Indian and Alaska Native people living in the southwestern 
United States, the prevalence of metabolic syndrome was reported to be 43.2% in 
men and 47.3% in women; among Alaska Native people, prevalences were 
26.5% and 31.2%, respectively.8
• The prevalence of metabolic syndrome among pregnant women increased to 
26.5% during 1999 to 2004 from 17.8% during 1988 to 1994.9
• The prevalence of metabolic syndrome has been noted to be high among select 
special populations, including those taking atypical antipsychotic drugs,10 those 
receiving prior organ transplants,11 HIV-infected individuals,12 and individuals 
in select professions, including law enforcement13 and firefighters.14
• There is a bidirectional relationship between metabolic syndrome and 
depression. In prospective studies, the presence of depression increases the risk 
of metabolic syndrome (OR, 1.49; 95% CI, 1.19–1.87), whereas metabolic 
syndrome increases the risk of depression (OR, 1.52; 95% CI, 1.20–1.91).15
• Metabolic syndrome is becoming hyperendemic around the world. Recent 
evidence has described the prevalence of metabolic syndrome in Canada,16 Latin 
America,17 India,18 and China,19 as well as many other countries.
• In the INTER-HEART case-control study of MI in 26 903 subjects from 52 
countries, metabolic syndrome was present in 29.1% of case subjects and just 
16.8% of control subjects. The age- and obesity-adjusted prevalence of metabolic 
syndrome was highest in cases among women (32.1%), South Asians (29.8%), 
and other Asians (28.7%).20
• Despite its prevalence, the public’s recognition of metabolic syndrome is 
limited.21 A diagnosis of metabolic syndrome may increase risk perception and 
motivation toward a healthier behavior.22
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Children/Adolescents
• According to the 2009 AHA scientific statement about metabolic syndrome in 
children and adolescents, metabolic syndrome should be diagnosed with caution 
in this age group because metabolic syndrome categorization in adolescents is 
not stable.23 Approximately half of the 1098 adolescent participants in the 
Princeton School District Study diagnosed with pediatric Adult Treatment Panel 
III metabolic syndrome lost the diagnosis over 3 years of follow-up.24
• Additional evidence of the instability of the diagnosis of metabolic syndrome in 
children exists. In children 6 to 17 years of age participating in research studies 
in a single clinical research hospital, the diagnosis of metabolic syndrome was 
unstable in 46% of cases after a mean of 5.6 years of follow-up.25
• On the basis of NHANES 1999 to 2002 data, the prevalence of metabolic 
syndrome in adolescents 12 to 19 years of age was 9.4%, which represents ≈2.9 
million people. It was 13.2% in boys, 5.3% in girls, 10.7% in whites, 5.2% in 
blacks, and 11.1% in Mexican Americans.26
• In 1999 to 2004, ≈4.5% of US adolescents 12 to 17 years of age had metabolic 
syndrome according to the definition developed by the International Diabetes 
Federation.27 In 2006, this prevalence would have represented ≈1.1 million 
adolescents 12 to 17 years of age with metabolic syndrome. It increased from 
1.2% among those 12 to 13 years of age to 7.1% among those 14 to 15 years of 
age and was higher among boys (6.7%) than girls (2.1%). Furthermore, 4.5% of 
white adolescents, 3.0% of black adolescents, and 7.1% of Mexican American 
adolescents had metabolic syndrome. The prevalence of metabolic syndrome 
remained relatively stable during successive 2-year periods: 4.5% for 1999 to 
2000, 4.4% to 4.5% for 2001 to 2002, and 3.7% to 3.9% for 2003 to 2004.
• Recent NHANES data among those aged 10 to 18 years in 2007 to 2008 showed 
an overall prevalence of metabolic syndrome of 3.9% in boys and 3.6% in girls, 
with the highest prevalence among Mexican Americans (7.6%) compared with 
African-Americans (2.1%) and whites (3.1%).28
• In 1999 to 2002, among overweight or obese adolescents, 44% had metabolic 
syndrome.26 In 1988 to 1994, two thirds of all adolescents had ≥1 metabolic 
abnormality.29
• Of 31 participants in the NHLBI Lipid Research Clinics Princeton Prevalence 
Study and the Princeton Follow-up Study who had metabolic syndrome at 
baseline, 21 (68%) had metabolic syndrome 25 years later.30 After adjustment 
for age, sex, and race, the baseline status of metabolic syndrome was 
significantly associated with an increased risk of having metabolic syndrome 
during adulthood (OR, 6.2; 95% CI, 2.8–13.8).
• In the Bogalusa Heart Study, 4 variables (BMI, homeostasis model assessment of 
insulin resistance, ratio of triglycerides to HDL cholesterol, and mean arterial 
pressure) considered to be part of metabolic syndrome clustered together in 
blacks and whites and in children and adults.31 The degree of clustering was 
et al. Page 132
Circulation. Author manuscript; available in PMC 2017 April 28.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
stronger among adults than among children. The clustering of rates of change in 
the components of metabolic syndrome in blacks exceeded that in whites. 
Cardiovascular abnormalities are associated with metabolic syndrome in children 
and adolescents.32,33
Risk
Adults
• Consistent with 2 earlier meta-analyses, a recent meta-analysis of prospective 
studies concluded that metabolic syndrome increased the risk of developing 
CVD (summary RR, 1.78; 95% CI, 1.58–2.00).34 The risk of CVD tended to be 
higher in women (summary RR, 2.63) than in men (summary RR, 1.98; P=0.09). 
On the basis of results from 3 studies, metabolic syndrome remained a predictor 
of cardiovascular events after adjustment for the individual components of the 
syndrome (summary RR, 1.54; 95% CI, 1.32–1.79). A more recent meta-analysis 
among 87 studies comprising 951 083 subjects showed an even higher risk of 
CVD associated with metabolic syndrome (summary RR, 2.35; 95% CI, 2.02–
2.73), with significant increased risks (RRs ranging from 1.6 to 2.9) for all-cause 
mortality, CVD mortality, MI, and stroke, as well as for those with metabolic 
syndrome without DM.35
• In one of the earlier studies among US adults, mortality follow-up of the second 
NHANES showed a stepwise increase in risk of CHD, CVD, and total mortality 
across the spectrum of no disease, metabolic syndrome (without DM), DM, prior 
CVD, and those with CVD and DM, with an HR for CHD mortality of 2.02 
(95% CI, 1.42–2.89) associated with metabolic syndrome. Increased risk was 
seen with increased numbers of metabolic syndrome risk factors.36
• Several studies suggest that the FRS is a better predictor of incident CVD than 
metabolic syndrome.37–39 In the San Antonio Heart Study, the area under the 
receiver-operating characteristic curve was 0.816 for the FRS and 0.811 for the 
FRS plus metabolic syndrome.37 Furthermore, the sensitivity for CVD at a fixed 
specificity was significantly higher for the FRS than for metabolic syndrome. In 
ARIC, inclusion of metabolic syndrome did not improve the risk prediction 
achieved by the FRS.38 In the British Regional Heart Study, the area under the 
receiver-operating characteristic curve for the FRS was 0.73 for incident CHD 
during 10 years of follow-up, and the area under the receiver-operating 
characteristic curve for the number of metabolic syndrome components was 
0.63.39 For CHD events during 20 years of follow-up, the areas under the 
receiver-operating characteristic curves were 0.68 for the FRS and 0.59 for the 
number of metabolic syndrome components.
• Estimates of RR for CVD generally increase as the number of components of 
metabolic syndrome increases.39 Compared with men without an abnormal 
component in the Framingham Offspring Study, the HRs for CVD were 1.48 
(95% CI, 0.69–3.16) for men with 1 or 2 components and 3.99 (95% CI, 1.89–
8.41) for men with ≥3 components.40 Among women, the HRs were 3.39 (95% 
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CI, 1.31–8.81) for 1 or 2 components and 5.95 (95% CI, 2.20–16.11) for ≥3 
components. Compared with men without a metabolic abnormality in the British 
Regional Heart Study, the HRs were 1.74 (95% CI, 1.22–2.39) for 1 component, 
2.34 (95% CI, 1.65–3.32) for 2 components, 2.88 (95% CI, 2.02–4.11) for 3 
components, and 3.44 (95% CI, 2.35–5.03) for 4 or 5 components.39
• The cardiovascular risk associated with metabolic syndrome varies on the basis 
of the combination of metabolic syndrome components present. Of all possible 
ways to have 3 metabolic syndrome components, the combination of central 
obesity, elevated BP, and hyperglycemia conferred the greatest risk for CVD 
(HR, 2.36; 95% CI, 1.54–3.61) and mortality (HR, 3.09; 95% CI, 1.93–4.94) in 
the Framingham Offspring Study.41
• Data from the Aerobics Center Longitudinal Study indicate that risk for CVD 
mortality is increased in men without DM who have metabolic syndrome (HR, 
1.8; 95% CI, 1.5–2.0); however, among those with metabolic syndrome, the 
presence of DM is associated with even greater risk for CVD mortality (HR, 2.1; 
95% CI, 1.7–2.6).42 Analysis of data from NCHS was used to determine the 
number of disease-specific deaths attributable to all nonoptimal levels of each 
risk factor exposure by age and sex. The results of the analysis of dietary, 
lifestyle, and metabolic risk factors show that targeting a handful of risk factors 
has large potential to reduce mortality in the United States.43
• Among stable CAD patients in the COURAGE trial, the presence of metabolic 
syndrome was associated with an increased risk of death or MI (unadjusted HR, 
1.41; 95% CI, 1.15–1.73; P=0.001); however, after adjustment for its individual 
components, metabolic syndrome was no longer significantly associated with 
outcome (HR, 1.15; 95% CI, 0.79–1.68; P=0.46). Early PCI in addition to 
medical therapy did not significantly reduce the risk of death or MI regardless of 
metabolic syndrome or DM status.44
• In the INTER-HEART case-control study of 26 903 subjects from 52 countries, 
metabolic syndrome was associated with an increased risk of MI, both according 
to the WHO (OR, 2.69; 95% CI, 2.45–2.95) and the International Diabetes 
Federation (OR, 2.20; 95% CI, 2.03–2.38) definitions, with a PAR of 14.5% 
(95% CI, 12.7%–16.3%) and 16.8% (95% CI, 14.8%–18.8%), respectively, and 
associations that were similar across all regions and ethnic groups. In addition, 
the presence of ≥3 risk factors with subthresh-old values was associated with 
increased risk of MI (OR, 1.50; 95% CI, 1.24–1.81) compared with having 
“normal” values. Similar results were observed when the International Diabetes 
Federation definition was used.20
• In the Three-City Study, among 7612 participants aged ≥65 years who were 
followed up for 5.2 years, metabolic syndrome was associated with increased 
total CHD (HR, 1.78; 95% CI, 1.39–2.28) and fatal CHD (HR, 2.40; 95% CI, 
1.41–4.09); however, metabolic syndrome was not associated with CHD beyond 
its individual risk components.45
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• In MESA, among 6603 people aged 45 to 84 years (1686 [25%] with metabolic 
syndrome without DM and 881 [13%] with DM), subclinical atherosclerosis 
assessed by CAC was more severe in people with metabolic syndrome and DM 
than in those without these conditions, and the extent of CAC was a strong 
predictor of CHD and CVD events in these groups.46 Furthermore, the 
progression of CAC was greater in people with metabolic syndrome and DM 
than in those without, and progression of CAC predicted future CVD event risk 
both in those with metabolic syndrome and in those with DM.47,48
• In addition to CVD, metabolic syndrome has been associated with incident AF49 
and HF.50
• So-called metabolically benign obesity without metabolic syndrome is associated 
with similar all-cause mortality to lean individuals.51
• Metabolic syndrome is associated with increased healthcare use and healthcare-
related costs among individuals with and without DM. Overall, healthcare costs 
increase by ≈24% for each additional metabolic syndrome component present.52
Children
• Few prospective pediatric studies have examined the future risk for CVD or DM 
according to baseline metabolic syndrome status. Data from 771 participants 6 to 
19 years of age from the NHLBI’s Lipid Research Clinics Princeton Prevalence 
Study and the Princeton Follow-up Study showed that the risk of developing 
CVD was substantially higher among those with metabolic syndrome than 
among those without this syndrome (OR, 14.6; 95% CI, 4.8–45.3) who were 
followed up for 25 years.30
• Another analysis of 814 participants in this cohort showed that those 5 to 19 
years of age who had metabolic syndrome at baseline had an increased risk of 
having DM 25 to 30 years later compared with those who did not have the 
syndrome at baseline (OR, 11.5; 95% CI, 2.1–63.7).53
• Additional data from the Princeton Follow-up Study, the Fels Longitudinal 
Study, and the Muscatine Study suggest that the absence of components of 
metabolic syndrome in childhood has a high negative predictive value for the 
development of metabolic syndrome or DM in adulthood.54
• In a study of 6328 subjects from 4 prospective studies, compared with people 
with normal BMI as children and as adults, those with consistently high 
adiposity from childhood to adulthood had an increased risk of the following 
metabolic syndrome components: hypertension (RR, 2.7; 95% CI, 2.2–3.3), low 
HDL (RR, 2.1; 95% CI, 1.8–2.5), elevated triglycerides (RR, 3.0; 95% CI, 2.4–
3.8), type 2 DM (RR, 5.4; 95% CI, 3.4–8.5), and increased carotid IMT (RR, 1.7; 
95% CI, 1.4–2.2). Those who were overweight or obese during childhood but 
were not obese as adults had no increased risk compared with those with 
consistently normal BMI.55
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• In 1757 youths from the Bogalusa Heart Study and the Cardiovascular Risk in 
Young Finns Study, those with metabolic syndrome in youth and adulthood were 
at 3.4 times increased risk of high carotid IMT and 12.2 times increased risk of 
type 2 DM in adulthood as those without metabolic syndrome at either time. 
Adults whose metabolic syndrome had resolved after their youth were at no 
increased risk of having high IMT or type 2 DM.56
Risk Factors
• Risk of metabolic syndrome probably begins before birth. The Prediction of 
Metabolic Syndrome in Adolescence Study showed that the coexistence of low 
birth weight, small head circumference, and parental history of overweight or 
obesity places children at the highest risk for metabolic syndrome in 
adolescence. Other risk factors identified included parental history of DM, 
gestational hypertension in the mother, and lack of breastfeeding.57
• In prospective or retrospective cohort studies, the following factors have been 
reported as being directly associated with incident metabolic syndrome, defined 
by one of the major definitions: age,35,37–39 low educational attainment,58,59 low 
socioeconomic status,60 smoking,59–62 parental smoking,63 low levels of 
PA,59–62, 64–66 low levels of physical fitness,64,67–70 intake of soft drinks,71 
intake of diet soda,72 magnesium intake,73 energy intake,66 carbohydrate 
intake,58,61,74 total fat intake,37,53 Western dietary pattern,72 meat intake,72 
intake of fried foods,72 skipping breakfast,70 heavy alcohol consumption,75 
abstention from alcohol use,58 parental history of DM,53 long-term stress at 
work,76 pediatric metabolic syndrome,53 obesity or BMI,37,38,42,46,56 childhood 
obesity,77 waist circumference,74,78–82 intra-abdominal fat,83 gain in weight or 
BMI,37,63 change in weight or BMI,61,78,84 weight fluctuation,85 BP,74,78,81,86 
heart rate,87 homeostasis model assessment,79,88 fasting insulin,79 2-hour 
insulin,79 proinsulin,79 fasting glucose or hyperglycemia,39,58,60 2-hour 
glucose,79 impaired glucose tolerance,79 triglycerides,74,78–81,89 low HDL 
cholesterol,74,77–79,81 oxidized LDL,88 uric acid,84,90 γ-
glutamyltransferase,84,91,92 alanine transaminase,84,91,93,94 plasminogen 
activator inhibitor-1,95 aldosterone,95 leptin,96 CRP,97,98 adipocyte–fatty acid 
binding protein,99 free testosterone index,100 active periodontitis,101 and urinary 
bisphenol A levels.102
• The following factors have been reported as being inversely associated with 
incident metabolic syndrome, defined by one of the major definitions, in 
prospective or retrospective cohort studies: muscular strength,103 change in PA 
or physical fitness,61,67 aerobic training,104 alcohol intake,40,46 Mediterranean 
diet,105 dairy consumption,72 vitamin D intake,106 intake of tree nuts,107 insulin 
sensitivity,79 ratio of aspartate aminotransferase to alanine transaminase,93 total 
testosterone,79,82,83 serum 25-hydroxyvitamin D,108 sex hormone–binding 
globulin,79,82,83 and Δ5-desaturase activity.109
• In the Data From the Epidemiological Study on the Insulin Resistance Syndrome 
cohort, metabolic syndrome was associated with an unfavorable hemodynamic 
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profile, including increased brachial central pulse pressure and increase pulse 
pressure amplification, compared with similar individuals with isolated 
hypertension but without metabolic syndrome.110 In MESA, metabolic syndrome 
was associated with major and minor ECG abnormalities, although this varied by 
sex.111
• Individuals with metabolic syndrome have a higher degree of endothelial 
dysfunction than individuals with a similar burden of traditional cardiovascular 
risk factors.112 Metabolic syndrome is associated with increased thrombosis, 
including increased resistance to aspirin.113
• In modern imaging studies using echocardiography, magnetic resonance 
imaging, cardiac CT, and positron emission tomography, metabolic syndrome 
has been shown to be closely related to increased epicardial adipose tissues,114 
increased visceral fat in other locations,115 high-risk coronary plaque features 
including increased necrotic core,116 impaired coronary flow reserve,117 and left 
ventricular diastolic dysfunction.118
• Men are more likely than women to develop metabolic syndrome,58,78 and 
blacks have been shown to be less likely to develop metabolic syndrome than 
whites.58
• In >6 years of follow-up in the ARIC Study, 1970 individuals (25%) developed 
metabolic syndrome, and compared with the normal-weight group (BMI <25 
kg/m2), the ORs of developing metabolic syndrome were 2.81 (95% CI, 2.50–
3.17) and 5.24 (95% CI, 4.50–6.12) for the overweight (BMI 25–30 kg/m2) and 
obese (BMI ≥30 kg/m2) groups, respectively. Compared with the lowest quartile 
of leisure-time PA, the ORs of developing metabolic syndrome were 0.80 (95% 
CI, 0.71–0.91) and 0.92 (95% CI, 0.81–1.04) for people in the highest and 
middle quartiles, respectively.119
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12. Chronic Kidney Disease
ICD-10 N18.0. See Tables 12-1 through 12-3.
End-stage Renal Disease
Prevalence, Incidence, and Risk—(See Tables 12-1 and 12-2.)
ESRD is a condition that is most commonly associated with DM or HBP, occurs when the 
kidneys are functioning at a very low level, and is currently defined as the receipt of chronic 
renal replacement treatment such as hemodialysis, peritoneal dialysis, or kidney 
transplantation. The ESRD population is increasing in size and cost as those with CKD 
transition to ESRD and as a result of changing practice patterns in the United States.
• Data from the 2010 annual report of the United States Renal Data System 
showed that in 2008, the prevalence of ESRD was 547 982, with 70% of these 
prevalent cases being treated with hemodialysis.1
• In 2008, 112 476 new cases of ESRD were reported.1
• In 2008, 17 413 kidney transplants were performed.1
• Data from a large cohort of insured patients showed that in addition to 
established risk factors for ESRD, lower hemoglobin levels, higher serum uric 
acid levels, self-reported history of nocturia, and family history of kidney disease 
are independent risk factors for ESRD.2
• Data from a large insured population revealed that among adults with a GFR >60 
mL·min−1·1.73 m−2 and no evidence of proteinuria or hematuria at baseline, risks 
for ESRD increased dramatically with higher baseline BP level, and in this same 
patient population, BP-associated risks were greater in men than in women and 
in blacks than in whites.3
• Compared with white patients with similar levels of kidney function, black 
patients are much more likely to progress to ESRD and are on average 10 years 
younger when they reach ESRD.4,5
• Results from a large community-based population showed that higher BMI also 
independently increased the risk of ESRD. The higher risk of ESRD with 
overweight and obesity was consistent across age, sex, and race and in the 
presence or absence of DM, hypertension, or known baseline kidney disease.6
Abbreviations Used in Chapter 12
ACTION Acute Coronary Treatment and Intervention Outcomes Network
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AF atrial fibrillation
AMI acute myocardial infarction
BMI body mass index
BP blood pressure
CHD coronary heart disease
CHF congestive heart failure
CI confidence interval
CKD chronic kidney disease
CVD cardiovascular disease
DM diabetes mellitus
eGFR estimated glomerular filtration rate
ESRD end-stage renal disease
GFR glomerular filtration rate
HBP high blood pressure
HF heart failure
HR hazard ratio
ICD-10 International Classification of Diseases, 10th Revision
JNC V fifth report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High 
Blood Pressure
MI myocardial infarction
NCHS National Center for Health Statistics
NHANES National Health and Nutrition Examination Survey
PAD peripheral arterial disease
RR relative risk
Age, Sex, Race, and Ethnicity
• The median age of the population with ESRD in 2008 varied across different 
racial/ethnic groups: 57.4 years for blacks, 58.0 years for Native Americans, 59.3 
years for Asians, and 60.6 years for whites.1
• Treatment of ESRD is more common in men than in women.1
• Blacks, Hispanics, Asian Americans, and Native Americans have significantly 
higher rates of ESRD than do whites/Europeans. Blacks represent nearly 32% of 
treated patients with ESRD.1
Chronic Kidney Disease
Prevalence
• CKD, defined as reduced GFR, excess urinary protein excretion, or both, is a 
serious health condition and a worldwide public health problem. The incidence 
and prevalence of CKD are increasing in the United States and are associated 
with poor outcomes and a high cost to the US healthcare system. Controversy 
exists about whether CKD itself independently causes incident CVD, but it is 
clear that people with CKD, as well as those with ESRD, represent a population 
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at very high risk for CVD events. In fact, individuals with CKD are more likely 
to die of CVD than to transition to ESRD. The United States Renal Data System 
estimates that by 2020, >700 000 Americans will have ESRD, with >500 000 
requiring dialysis and >250 000 receiving a transplant.
• The National Kidney Foundation Kidney Disease Outcome Quality Initiative 
developed guidelines in 2002 that provided a standardized definition for CKD. 
Prevalence estimates may differ depending on assumptions used in obtaining 
estimates, including which equation is used to estimate GFR and methods for 
measuring proteinuria.7
• The most recent US prevalence estimates of CKD come from NHANES 1988 to 
1994 and 1999 to 2004 (NCHS) in adults ≥20 years of age.8
– The prevalence of CKD in 1999 to 2004 (stages 1 to 5)9 was 13.1%. 
This represents an increase from the 10.0% prevalence estimate from 
NHANES 1988 to 1994 (NCHS).
– The prevalence of stage 1 CKD (eGFR ≥90 mL·min−1· 1.73 m−2 with 
kidney damage, ie, presence of albuminuria) is 1.8%.
– The prevalence of stage 2 CKD (eGFR 60–89 mL·min−1·1.73 m−2 with 
kidney damage) is 3.2%.
– The prevalence of stage 3 CKD (eGFR 30–59 mL·min−1·1.73 m−2) is 
7.7%.
– The prevalence of stages 4 and 5 CKD (eGFR <29 mL·min−1·1.73 m−2) 
is 0.4%.
• More than 26 million people (13%) in the United States have CKD, and most are 
undiagnosed.8 Another 20 million are at increased risk for CKD.10
Demographics
• According to current definitions, the prevalence of CKD was higher with older 
age,1 as follows:
– 6.0% for those 20 to 39 years of age
– 11.6% for those 40 to 59 years of age
– 38.8% for those ≥60 years of age
• CKD prevalence was greater among those with DM (43.8%) and hypertension 
(29.4%) than among those without these chronic conditions.1
• The prevalence of CKD was slightly higher among Mexican Americans (18.7%) 
and non-Hispanic blacks (19.9%) than among non-Hispanic whites (16.1%). 
This disparity was most evident for those with stage 1 CKD; non-Hispanic 
whites had a CKD prevalence of 4.2% compared with prevalences among 
Mexican Americans and non-Hispanic blacks of 10.2% and 9.4%, respectively.11
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Risk Factors
• Many traditional CVD risk factors are also risk factors for CKD, including older 
age, male sex, hypertension, DM, smoking, and family history of CVD.
• Recent evidence suggests that BMI is associated with worsening CKD.
– In a cohort of 652 African American individuals with hypertensive 
nephrosclerosis, BMI was independently associated with urine total 
protein and albumin excretion.12
• In addition, both the degree of CKD (ie, eGFR) and urine albumin are strongly 
associated with the progression from CKD to ESRD. Furthermore, urine albumin 
level is associated with progression to CKD across all levels of reduced eGFR.13
• Other risk factors include systemic conditions such as auto-immune diseases, 
systemic infections, and drug exposure, as well as anatomically local conditions 
such as urinary tract infections, urinary stones, lower urinary tract obstruction, 
and neoplasia. Even after adjustment for these risk factors, excess CVD risk 
remains.14
ESRD/CKD and CVD
(See Table 12-3.)
• CVD is the leading cause of death among those with ESRD, although the 
specific cardiovascular cause of death may be more likely to be arrhythmic than 
an AMI, end-stage HF, or stroke. CVD mortality is 5 to 30 times higher in 
dialysis patients than in subjects from the general population of the same age, 
sex, and race.15,16
– Individuals with less severe forms of kidney disease are also at 
significantly increased CVD risk independent of typical CVD risk 
factors.17
– CKD is a risk factor for recurrent CVD events.18
– CKD is also a risk factor for AF.19
• Studies from a broad range of cohorts demonstrate an association between 
reduced eGFR and elevated risk of CVD, CVD outcomes, and all-cause 
death17,20–25 that appears to be largely independent of other known major CVD 
risk factors.
• Although clinical practice guidelines recommend management of mineral and 
bone disorders secondary to CKD, a recent meta-analysis suggests that there is 
no consistent association between calcium and parathyroid hormone and the risk 
of death or cardiovascular events.26
• Any degree of albuminuria, starting below the micro-albuminuria cut point, has 
been shown to be an independent risk factor for cardiovascular events, CHF 
hospitalization, PAD, and all-cause death in a wide variety of cohorts.27–32
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• A recent meta-analysis of 21 published studies of albuminuria involving 105 872 
participants (730 577 person-years) from 14 studies with urine albumin/
creatinine ratio measurements and 1 128 310 participants (4 732 110 person-
years) from 7 studies with urine dipstick measurements showed that excess 
albuminuria or proteinuria is independently associated with a higher risk of CVD 
and all-cause mortality.33
– People with both albuminuria/proteinuria and reduced eGFR are at 
particularly high risk for CVD, CVD outcomes, and death.34
– The exact reasons why CKD and ESRD increase the risk of CVD have 
not been completely delineated but are clearly multifactorial and likely 
involve pathological alterations in multiple organ systems and 
pathways.
• One potential explanation for the higher CVD event rate in patients with CKD is 
the low uptake of standard therapies for patients presenting with MI. In a recent 
analysis from the ACTION registry, patients presenting with CKD had a 
substantially higher mortality rate. In addition, patients with CKD were less 
likely to receive standard therapies for the treatment of MI.35
Cost: ESRD
• The total annual cost of treating ESRD in the United States was $26.8 billion in 
2008, which represents nearly 6% of the total Medicare budget.1
• The total annual cost associated with CKD has not been determined accurately to 
date.
Cystatin C: Kidney Function and CVD
Serum cystatin C, another marker of kidney function, has been proposed to be a more 
sensitive indicator of kidney function than serum creatinine and creatinine-based estimating 
formulas at higher levels of GFR. It is a low-molecular-weight protein produced at a 
constant rate by all nucleated cells and appears not to be affected significantly across age, 
sex, and levels of muscle mass. Cystatin C is excreted by the kidneys, filtered through the 
glomerulus, and nearly completely reabsorbed by proximal tubular cells.36 Several equations 
have been proposed using cystatin C alone and in combination with serum creatinine to 
estimate kidney function.37,38
All-Cause Mortality—Elevated levels of cystatin C have been shown to be associated with 
increased risk for all-cause mortality in studies from a broad range of cohorts.39–41
• In addition to GFR and urine albumin-to-creatinine ratio, cystatin C provides 
incremental information for the prediction of ESRD and mortality.
– In a recent analysis of 26 643 US adults, the addition of cystatin C to 
the combination of creatinine and albumin-to-creatinine ratio resulted in 
a significant improvement in the prediction of both all-cause mortality 
and the development of ESRD.42
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Cardiovascular Disease
• Data from a large national cohort found higher values of cystatin C to be 
associated with prevalent stroke, angina, and MI,43 as well as higher BMI.44
• Elevated cystatin C was an independent risk factor for HF,45,46 PAD events,47 
clinical atherosclerosis, and subclinical measures of CVD in older adults,48 as 
well as for cardiovascular events among those with CHD.39,49
• In several diverse cohorts, elevated cystatin C has been found to be associated 
with CVD-related mortality,41,50,51 including sudden cardiac death.52
• In a recent clinical trial of 9270 patients with CKD, the effect of lipid-lowering 
therapy with simvastatin plus ezetimibe was associated with a lower risk for 
major atherosclerotic events compared with placebo.53
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13. Total Cardiovascular Diseases
ICD-9 390 to 459, 745 to 747, ICD-10 I00 to I99, Q20 to Q28; see Glossary (Chapter 26) for 
details and definitions.
See Tables 13-1 through 13-4 and Charts 13-1 through 13-21.
Prevalence
(See Table 13-1 and Chart 13-1.)
An estimated 83.6 million American adults (>1 in 3) have ≥ 1 types of CVD. Of these, 42.2 
million are estimated to be ≥60 years of age. Total CVD includes diseases listed in the bullet 
points below, with the exception of congenital CVD. Because of overlap across conditions, it 
is not possible to add these conditions to arrive at a total.
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• HBP—77.9 million (defined as systolic pressure ≥140 mm Hg and/or diastolic 
pressure ≥90 mm Hg, use of anti-hypertensive medication, or being told at least 
twice by a physician or other health professional that one has HBP).
• CHD—15.4 million
– MI (heart attack)—7.6 million
– AP (chest pain)—7.8 million
– HF—5.1 million
– Stroke (all types)—6.8 million
– Congenital cardiovascular defects— 650 000 to 1.3 million
• The following age-adjusted prevalence estimates from the NHIS, NCHS are for 
diagnosed conditions for people ≥18 years of age in 20121:
– Among whites only, 10.9% have HD, 6.1% have CHD, 22.9% have 
hypertension, and 2.5% have had a stroke.
– Among blacks or African Americans, 10.8% have HD, 6.5% have 
CHD, 32.9% have hypertension, and 3.9% have had a stroke.
– Among Hispanics or Latinos, 7.8% have HD, 5.3% have CHD, 20.9% 
have hypertension, and 2.7% have had a stroke.
– Among Asians, 6.8% have HD, 4.5% have CHD, 21.2% have 
hypertension, and 1.8% have had a stroke.
– Among American Indians or Alaska Natives, 12.5% have HD, 8.1% 
have CHD, and 24.8% have hypertension. The statistic for stroke for 
this group is not shown because of unreliability.*
– Among Native Hawaiians or other Pacific Islanders 12.5% have HD, 
10.3% have CHD, and 36.5% have hypertension. The statistics for 
stroke for this group are not shown because of unreliability.*
• Asian Indian adults (9%) are ≈2-fold more likely than Korean adults (4%) to 
have ever been told they have HD, based on data for 2004 to 2006.2
1. By 2030, 43.9% of the US population is projected to have some form of 
CVD (unpublished AHA tabulation, based on methodology described 
by Heidenreich et al).3
Abbreviations Used in Chapter 13
AHA American Heart Association
AMI acute myocardial infarction
AP angina pectoris
*Statistics 12.5% and 10.3% are statistically unreliable (relative standard error >30% and <50%). The statistic not shown has a relative 
standard error >50%.
et al. Page 154
Circulation. Author manuscript; available in PMC 2017 April 28.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
ARIC Atherosclerosis Risk in Communities study
BMI body mass index
BP blood pressure
BRFSS Behavioral Risk Factor Surveillance System
CABG cardiac revascularization (coronary artery bypass graft)
CAD coronary artery disease
CARDIA Coronary Artery Risk Development in Young Adults
CDC Centers for Disease Control and Prevention
CHD coronary heart disease
CHF congestive heart failure
CLRD chronic lower respiratory disease
CPR cardiopulmonary resuscitation
CVD cardiovascular disease
DM diabetes mellitus
ED emergency department
FHS Framingham Heart Study
HBP high blood pressure
HCM hypertrophic cardiomyopathy
HD heart disease
HF heart failure
HIV human immunodeficiency virus
ICD-9 International Classification of Diseases, 9th Revision
ICD-10 International Classification of Diseases, 10th Revision
LDL low-density lipoprotein
MEPS Medical Expenditure Panel Survey
MESA Multi-Ethnic Study of Atherosclerosis
MI myocardial infarction
NAMCS National Ambulatory Medical Care Survey
NCHS National Center for Health Statistics
NH non-Hispanic
NHAMCS National Hospital Ambulatory Medical Care Survey
NHANES National Health and Nutrition Examination Survey
NHDS National Hospital Discharge Survey
NHIS National Health Interview Survey
NHHCS National Home and Hospice Care Survey
NHLBI National Heart, Lung, and Blood Institute
NNHS National Nursing Home Survey
PA physical activity
PCI percutaneous coronary intervention
RR relative risk
SBP systolic blood pressure
UA unstable angina
WONDER Wide-ranging Online Data for Epidemiologic Research
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Incidence
(See Chart 13-2.)
• On the basis of the NHLBI’s FHS original and offspring cohort data from 1980 
to 20034
– The average annual rate of first cardiovascular events rises from 3 per 
1000 men at 35 to 44 years of age to 74 per 1000 men at 85 to 94 years 
of age. For women, comparable rates occur 10 years later in life. The 
gap narrows with advancing age.
– Before 75 years of age, a higher proportion of CVD events attributable 
to CHD occur in men than in women, and a higher proportion of events 
attributable to stroke occur in women than in men.
• Among American Indian men 45 to 74 years of age, the incidence of CVD 
ranges from 20 to 28 per 1000 population. Among women, it ranges from 9 to 15 
per 1000.5
• Data from the FHS indicate that the subsequent lifetime risk for all CVD in 
recipients starting free of known disease is almost 2 in 3 for men and >1 in 2 for 
women at 45 years of age (Table 13-4).5a
• Analysis of FHS data among participants free of CVD at 50 years of age showed 
the lifetime risk for developing CVD was 51.7% for men and 39.2% for women. 
Median overall survival was 30 years for men and 36 years for women.6
Mortality
(See Table 13-1 through 13-3 and Charts 13-3 through 13-18.)
ICD-10 I00 to I99, Q20 to Q28 for CVD; C00 to C97 for cancer; C33 to C34 for lung 
cancer; C50 for breast cancer; J40 to J47 for CLRD; G30 for Alzheimer disease; E10 to E14 
for DM; and V01 to X59 and Y85 to Y86 for accidents.
• Mortality data show that CVD as the listed underlying cause of death (including 
congenital cardiovascular defects) accounted for 31.9% (787 650) of all 2 468 
435 deaths in 2010, or 1 of every 3 deaths in the United States. CVD any-
mentions (1 344 185 deaths in 2010) constituted 54.5% of all deaths that year 
(NHLBI; NCHS public use data files).7
• In every year since 1900 except 1918, CVD accounted for more deaths than any 
other major cause of death in the United States.8,9
• On average, >2150 Americans die of CVD each day, an average of 1 death every 
40 seconds. CVD currently claims more lives each year than cancer and CLRD 
combined.7
• The 2010 death rate attributable to CVD was 235.5 (excluding congenital 
cardiovascular defects; NCHS). The death rates were 283.4 for males and 197.3 
for females. The rates were 278.4 for white males, 369.2 for black males, 192.2 
for white females, and 260.5 for black females. From 2000 to 2010, death rates 
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attributable to CVD declined 31.0%. In the same 10-year period, the actual 
number of CVD deaths per year declined by 16.7% (AHA tabulation).7
• Among other causes of death in 2010, cancer caused 574 743 deaths; CLRD, 138 
080; accidents, 120 859; and Alzheimer disease, 83 494.7
• On the basis of 2010 mortality data, CVD (including congenital cardiovascular 
defects) caused ≈1 death per minute among females, or 400 322 deaths. That 
represents approximately the same number of female lives as were claimed by 
cancer, CLRD, and Alzheimer disease combined (unpublished AHA tabulation). 
There were 40 996 deaths attributable to breast cancer in females in 2010; lung 
cancer claimed 70 550 females. Death rates for females were 22.1 for breast 
cancer and 38.1 for lung cancer. One in 30 deaths of females was attributable to 
breast cancer, whereas 1 in 7.2 was attributable to CHD. For comparison, 1 in 4.5 
females died of cancer, whereas 1 in 3.1 died of CVD.7
• Approximately 150 000 Americans died of CVD in 2010 who were <65 years of 
age, and 34% of deaths attributed to CVD occurred before the age of 75 years,7 
which is well below the average life expectancy of 78.7 years.9
• If all forms of major CVD were eliminated, life expectancy could rise by almost 
7 years. If all forms of cancer were eliminated, the estimated gain could be 3 
years. According to the same study, the probability at birth of eventually dying of 
major CVD (I00–I78) is 47%, and the chance of dying of cancer is 22%. 
Additional probabilities are 3% for accidents, 2% for DM (unrelated to CVD), 
and 0.7% for HIV.10
• In 2010, the leading causes of death in women ≥65 years of age were diseases of 
the heart (No. 1), cancer (No. 2), stroke (No. 3), and CLRD (No. 4). In older 
men, they were diseases of the heart (No. 1), cancer (No. 2), CLRD (No. 3), and 
stroke (No. 4).7
• A study of the decrease in US deaths attributable to CHD from 1980 to 2000 
suggests that ≈47% of the decrease was attributable to increased use of evidence-
based medical therapies and 44% to changes in risk factors in the population 
attributable to lifestyle and environmental changes.8
• Analysis of data from NCHS was used to determine the number of disease-
specific deaths attributable to all non-optimal levels of each risk factor exposure, 
by age and sex. In 2005, tobacco smoking and HBP were estimated to be 
responsible for 467 000 deaths, accounting for ≈1 in 5 or 6 deaths among US 
adults. Overweight/obesity and physical inactivity were each estimated to be 
responsible for nearly 1 in 10 deaths. High dietary salt, low dietary omega-3 fatty 
acids, and high dietary trans fatty acids were the dietary risks with the largest 
estimated excess mortality effects.10
Aftermath
• Among an estimated 45 million people with functional disabilities in the United 
States, HD, stroke, and hypertension are among the 15 leading conditions that 
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caused those disabilities. Disabilities were defined as difficulty with activities of 
daily living or instrumental activities of daily living, specific functional 
limitations (except vision, hearing, or speech), and limitation in ability to do 
housework or work at a job or business.11
Awareness of Warning Signs and Risk Factors for CVD
• Surveys conducted every 3 years since 1997 by the AHA to evaluate trends in 
women’s awareness, knowledge, and perceptions related to CVD found most 
recently (in 2012) that awareness of HD as the leading cause of death among 
women was 56%, 30% higher than in 1997 (P<0.001). Awareness among black 
and Hispanic women in 2012 was similar to that of white women in 1997; 
however, awareness rates in 2012 among black and Hispanic women remained 
well below that of white women in 2012. Awareness of heart attack signs 
remained low for all racial/ethnic and age groups surveyed.12
• A total of 875 students in 4 Michigan high schools were given a survey to obtain 
data on the perception of risk factors and other knowledge-based assessment 
questions about CVD. Accidents were rated as the greatest perceived lifetime 
health risk (39%). Nearly 17% selected CVD as the greatest lifetime risk, which 
made it the third most popular choice after accidents and cancer. When asked to 
identify the greatest cause of death for each sex, 42% correctly recognized CVD 
for men, and 14% correctly recognized CVD for women; 40% incorrectly chose 
abuse/use behavior with a substance other than cigarettes as the most important 
CVD risk behavior.13
Awareness of CPR
• Seventy-nine percent of the lay public are confident that they know what actions 
to take in a medical emergency; 98% recognize an automated external 
defibrillator as something that administers an electric shock to restore a normal 
heart beat among victims of sudden cardiac arrest; and 60% are familiar with 
CPR (Harris Interactive survey conducted on behalf of the AHA among 1132 US 
residents >18 years of age, January 8, 2008–January 21, 2008).
Disparities in CVD Risk Factors
(See Chart 13-19.)
• Data from the 2003 CDC BRFSS survey of adults ≥18 years of age showed the 
prevalence of respondents who reported having ≥2 risk factors for HD and stroke 
was successively higher at higher age groups. The prevalence of having ≥2 risk 
factors was highest among blacks (48.7%) and American Indian/Alaska Natives 
(46.7%) and lowest among Asians (25.9%); prevalence was similar in women 
(36.4%) and men (37.8%). The prevalence of multiple risk factors ranged from 
25.9% among college graduates to 52.5% among those with less than a high 
school diploma (or its equivalent). People reporting household income of ≥$50 
000 had the lowest prevalence (28.8%), and those reporting household income of 
<$10 000 had the highest prevalence (52.5%). Adults who reported being unable 
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to work had the highest prevalence (69.3%) of ≥2 risk factors, followed by 
retired people (45.1%), unemployed adults (43.4%), homemakers (34.3%), and 
employed people (34.0%). Prevalence of ≥2 risk factors varied by state/ territory 
and ranged from 27.0% (Hawaii) to 46.2% (Kentucky). Twelve states and 2 
territories had a multiple risk factor prevalence of ≥40%: Alabama, Arkansas, 
Georgia, Indiana, Kentucky, Louisiana, Mississippi, North Carolina, Ohio, 
Oklahoma, Tennessee, West Virginia, Guam, and Puerto Rico.14
• Analysis of several data sets by the CDC showed that in adults ≥18 years of age, 
disparities were common in all risk factors examined. In men, the highest 
prevalence of obesity (29.7%) was found in Mexican Americans who had 
completed a high school education. Black women with or without a high school 
education had a high prevalence of obesity (48.4%). Hypertension prevalence 
was high among blacks (41.2%) regardless of sex or educational status. 
Hypercholesterolemia was high among white and Mexican American men and 
white women regardless of educational status. CHD and stroke were inversely 
related to education, income, and poverty status. Hospitalization for total HD and 
AMI was greater among men, but hospitalization for CHF and stroke was greater 
among women. Among Medicare enrollees, CHF hospitalization was higher 
among blacks, Hispanics, and American Indian/Alaska Natives than among 
whites, and stroke hospitalization was highest among blacks. Hospitalizations for 
CHF and stroke were highest in the southeastern United States. Life expectancy 
remains higher in women than in men and in whites than in blacks by ≈5 years. 
CVD mortality at all ages tended to be highest in blacks.15
• Analysis of >14 000 middle-aged subjects in the ARIC study sponsored by the 
NHLBI showed that >90% of CVD events in black subjects, compared with 
≈70% in white subjects, appeared to be explained by elevated or borderline risk 
factors. Furthermore, the prevalence of participants with elevated risk factors was 
higher in black subjects; after accounting for education and known CVD risk 
factors, the incidence of CVD was identical in black and white subjects. Thus, 
the observed higher CVD incidence rate in black subjects appears to be largely 
attributable to a greater prevalence of elevated risk factors. These results suggest 
that the primary prevention of elevated risk factors might substantially impact the 
future incidence of CVD, and these beneficial effects would likely be applicable 
not only for white but also for black subjects.16
• Data from the MEPS 2004 Full-Year Data File showed that nearly 26 million US 
adults ≥18 years of age were told by a doctor that they had HD, stroke, or any 
other heart-related disease17:
– 38.6% maintained a healthy weight. Among those told that they had 
HD, 33.9% had a healthy weight compared with 39.3% who had never 
been told they had HD.
– 78.8% did not currently smoke. Among those ever told that they had 
indicators of HD, 18.3% continued to smoke.
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– More than 93% engaged in at least 1 recommended behavior for 
prevention of HD: 75.5% engaged in 1 or 2; 18% engaged in all 3; and 
6.5% did not engage in any of the recommended behaviors.
– Age-based variations:
♦ Moderate to vigorous PA ≥3 times per week varied according 
to age. Younger people (18–44 years of age) were more likely 
(59.9%) than those who were older (45–64 and ≥65 years of 
age, 55.3% and 48.5%, respectively) to engage in regular PA.
♦ A greater percentage of those 18 to 44 years of age had a 
healthy weight (43.7%) than did those 45 to 64 years of age 
and ≥65 years of age (31.4% and 37.3%, respectively).
♦ People ≥65 years of age were more likely to be current 
nonsmokers (89.7%) than were people 18 to 44 years of age 
and 45 to 64 years of age (76.1% and 77.7%, respectively).
– Race/ethnicity-based variations:
♦ Non-Hispanic whites were more likely than Hispanics or non-
Hispanic blacks to engage in moderate to vigorous PA (58.5% 
versus 51.4% and 52.5%, respectively).
♦ Non-Hispanic whites were more likely to have maintained a 
healthy weight than were Hispanics or non-Hispanic blacks 
(39.8% versus 32.1% and 29.7%, respectively).
♦ Hispanics were more likely to be nonsmokers (84.2%) than 
were non-Hispanic whites and non-Hispanic blacks (77.8% 
and 76.3%, respectively).
– Sex-based variations:
♦ Men were more likely to have engaged in moderate to 
vigorous PA ≥3 times per week than women (60.3% versus 
53.1%, respectively).
♦ Women were more likely than men to have maintained a 
healthy weight (45.1% versus 31.7%, respectively).
♦ 81.7% of women did not currently smoke, compared with 
75.7% of men.
– Variations based on education level:
♦ A greater percentage of adults with at least some college 
education engaged in moderate to vigorous PA ≥3 times per 
week (60.8%) than did those with a high school education or 
less than a high school education (55.3% and 48.3%, 
respectively).
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♦ A greater percentage of adults with at least some college 
education had a healthy weight (41.2%) than did those with a 
high school or less than high school education (36.2% and 
36.1%, respectively).
♦ There was a greater percentage of nonsmokers among those 
with a college education (85.5%) than among those with a 
high school or less than high school education (73.8% and 
69.9%, respectively).
• A study of nearly 1500 participants in MESA found that Hispanics with 
hypertension, hypercholesterolemia, or DM who spoke Spanish at home or had 
spent less than half a year in the United States had higher SBP, LDL cholesterol, 
and fasting blood glucose, respectively, than Hispanics who spoke English and 
who had lived a longer period of time in the United States.18
• Recent findings from >15 000 Hispanics of diverse background demonstrated 
that a sizeable proportion of both men and women had major CVD risk factors, 
with higher prevalence among Puerto Rican subgroups and those with lower 
socioeconomic status and a higher level of acculturation.19
Family History of CVD
• A family history of CVD increases risk of CVD, with the largest increase in risk 
if the family member’s CVD was premature.20
• There is consistent evidence from multiple large-scale prospective epidemiology 
studies for a strong and significant association of a reported family history of 
premature parental CHD with incident MI or CHD in offspring. In the FHS, the 
occurrence of a validated premature atherosclerotic CVD event in either a 
parent21 or a sibling22 was associated with an ≈2-fold elevated risk for CVD, 
independent of other traditional risk factors.
• Addition of family history of premature CVD to a model that contained 
traditional risk factors provided modestly improved prognostic value in the 
FHS.21 Family history of premature MI is also an independent risk factor in 
other multivariable risk models that contain traditional risk factors in large 
cohorts of women23 and men.24
• Parental history of premature CHD is associated with increased burden of 
subclinical atherosclerosis in the coronary arteries and the abdominal aorta.25,26
• In the FHS, a parental history of validated HF is associated with a 1.7-fold higher 
risk of HF in offspring, after multivariable adjustment.27
• A family history of early-onset sudden cardiac death in a first-degree relative is 
associated with a >2-fold higher risk for sudden cardiac death in offspring on the 
basis of available case-control studies.28
• The 2004 HealthStyles survey of 4345 people in the United States indicated that 
most respondents believe that knowing their family history is important for their 
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own health, but few are aware of the specific health information from relatives 
necessary to develop a family history.29
• A family history of premature CVD was associated with a significant increase in 
lifetime risk for CVD mortality in men. The effect of a premature family history 
on lifetime risk was similar to that observed for other major CVD risk factors.30
• An accurate and complete family history may identify rare mendelian conditions 
such as HCM, long-QT syndrome, or familial hypercholesterolemia. However, in 
the majority of people with a family history of a CVD event, a known rare 
mendelian condition is not identified.
• Studies are under way to determine genetic variants that may help identify 
individuals at increased risk of CVD.
Impact of Healthy Lifestyle and Low Risk Factor Levels
Much of the literature on CVD has focused on factors associated with increasing risk for 
CVD and on factors associated with poorer outcomes in the presence of CVD; however, in 
recent years, a number of studies have defined the potential beneficial effects of healthy 
lifestyle factors and lower CVD risk factor burden on CVD outcomes and longevity. These 
studies suggest that prevention of risk factor development at younger ages may be the key to 
“successful aging,” and they highlight the need for evaluation of the potential benefits of 
intensive prevention efforts at younger and middle ages once risk factors develop to increase 
the likelihood of healthy longevity.
• Data from the Cardiovascular Lifetime Risk Pooling Project, which involved 18 
cohort studies and combined data on 257 384 black men and women and white 
men and women, indicate that at 45 years of age, participants with optimal risk 
factor profile had a substantially lower lifetime risk of CVD events than those 
with 1 major risk factor (1.4% versus 39.6% among men; 4.1% versus 20.2% 
among women). Having ≥2 major risk factors further increased lifetime risk to 
49.5% in men and 30.7% in women.31
• A recent study examined the association between low lifetime predicted risk for 
CVD (ie, having all optimal or near-optimal risk factor levels) and burden of 
subclinical atherosclerosis in younger adults in the CARDIA and MESA studies 
of the NHLBI. Among participants <50 years of age, nearly half had low and 
half had high predicted lifetime risk for CVD. Those with low predicted lifetime 
risk had lower prevalence and less severe amounts of coronary calcification and 
less carotid intima-media thickening, even at these younger ages, than those with 
high predicted lifetime risk. During follow-up, those with low predicted lifetime 
risk also had less progression of coronary calcium.32
• Among >7900 men and women from the FHS followed up for 111 000 person-
years, median survival was highly associated with risk factor presence and 
burden at 50 years of age. Men and women with optimal risk factors had a 
median life expectancy ≥10 years longer than those with ≥2 major risk factors at 
age 50 years.6
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• In another study, FHS investigators followed up 2531 men and women who were 
examined between the ages of 40 and 50 years and observed their overall rates of 
survival and survival free of CVD to 85 years of age and beyond. Low levels of 
the major risk factors in middle age were associated with overall survival and 
morbidity-free survival to ≥85 years of age.33
– Overall, 35.7% survived to the age of 85 years, and 22% survived to 
that age free of major morbidities.
– Factors associated with survival to the age of 85 years included female 
sex, lower SBP, lower total cholesterol, better glucose tolerance, 
absence of current smoking, and higher level of education attained. 
Factors associated with survival to the age of 85 years free of MI, UA, 
HF, stroke, dementia, and cancer were nearly identical.
– When adverse levels of 4 of these factors were present in middle age, 
<5% of men and ≈15% of women survived to 85 years of age.
• Data from the Chicago Heart Association Detection Project (1967–1973, with an 
average follow-up of 31 years) showed the following:
– In younger women (18–39 years of age) with favorable levels for all 5 
major risk factors (BP, serum cholesterol, BMI, DM, and smoking), 
future incidence of CHD and CVD is rare, and long-term and all-cause 
mortality are much lower than for those who have unfavorable or 
elevated risk factor levels at young ages. Similar findings applied to 
men in this study.34
– Participants (18–64 years of age at baseline) without a history of MI 
were investigated to determine whether traditional CVD risk factors 
were similarly associated with CVD mortality in black and white men 
and women. In general, the magnitude and direction of associations 
were similar by race. Most traditional risk factors demonstrated similar 
associations with mortality in black and white adults of the same sex. 
Small differences were primarily in the strength and not the direction of 
the association.35
– Remaining lifetime risks for CVD death were noted to increase 
substantially and in a graded fashion according to the number of risk 
factors present in middle age (40–59 years of age). However, remaining 
lifetime risks for non-CVD death also increased dramatically with 
increasing CVD risk factor burden. These data help to explain the 
markedly greater longevity experienced by those who reach middle age 
free of major CVD risk factors.36
– Presence of a greater number of risk factors in middle age is associated 
with lower scores at older ages on assessment of social functioning, 
mental health, walking, and health perception in women, with similar 
findings in men.37
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– Risk factor burden in middle age is associated with better quality of life 
at follow-up in older age (≈25 years later) and lower average annual 
Medicare costs at older ages.37,38 Similarly, the existence of a greater 
number of risk factors in middle age is associated with higher average 
annual CVD-related and total Medicare costs (once Medicare eligibility 
is attained).38
• A study of 84 129 women enrolled in the Nurses’ Health Study identified 5 
healthy lifestyle factors, including absence of current smoking, drinking half a 
glass or more of wine per day (or equivalent alcohol consumption), ≥30 minutes 
of moderate or vigorous PA per day, BMI <25 kg/ m2, and dietary score in the 
top 40% (which included diets with lower amounts of trans fats, lower glycemic 
load, higher cereal fiber, higher marine omega-3 fatty acids, higher folate, and 
higher polyunsaturated to saturated fat ratio). When 3 of the 5 healthy lifestyle 
factors were present, the RR for CHD over a 14-year period was 57% lower; 
when 4 were present, the RR was 66% lower; and when all 5 factors were 
present, the RR was 83% lower.39 However, data from NHANES 1999 to 2002 
showed that only approximately one third of adults complied with ≥6 of the 
recommended heart-healthy behaviors. Dietary recommendations in general and 
daily fruit intake recommendations in particular were least likely to be 
followed.40
• Among individuals 70 to 90 years of age, adherence to a Mediterranean-style 
diet and greater PA are associated with 65% to 73% relatively lower rates of all-
cause mortality, as well as lower mortality rates attributable to CHD, CVD, and 
cancer.41
• Seventeen-year mortality data from the NHANES II Mortality Follow-Up Study 
indicated that the RR for fatal CHD was 51% lower for men and 71% lower for 
women with none of 3 major risk factors (hypertension, current smoking, and 
elevated total cholesterol [≥240 mg/dL]) than for those with ≥1 risk factor. Had 
all 3 major risk factors not occurred, it is hypothesized that 64% of all CHD 
deaths among women and 45% of CHD deaths in men could have been 
avoided.42
Hospital Discharges, Ambulatory Care Visits, Home Healthcare Patients, Nursing Home 
Residents, and Hospice Care Discharges
(See Table 13-1 and Charts 13-20 and 13-21.)
• From 2000 to 2010, the number of inpatient discharges from short-stay hospitals 
with CVD as the first-listed diagnosis decreased from 6 294 000 to 5 802 000 
(NHDS, NCHS, and NHLBI). In 2010, CVD ranked highest among all disease 
categories in hospital discharges (NHDS, NCHS, and NHLBI).
• In 2010, there were 75 432 000 physician office visits with a primary diagnosis 
of CVD (NCHS, NAMCS, NHLBI tabulation). In 2010, there were 4 640 000 
ED visits and 7 829 000 hospital outpatient department visits with a primary 
diagnosis of CVD (NHAMCS, NHLBI tabulation).
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• In 2009, ≈1 of every 6 hospital stays, or 6 million, resulted from CVD (AHRQ, 
Nationwide Inpatient Sample). The total inpatient hospital cost for CVD was 
$71.2 billion, approximately one fourth of the total cost of inpatient hospital care 
in the United States. The average cost per hospitalization was ≈41% higher than 
the average cost for all stays. Hospital admissions that originated in the ED 
accounted for 60.7% of all hospital stays for CVD. This was 41% higher than the 
rate of 43.1% for all types of hospital stays; 3.3% of patients admitted to the 
hospital for CVD died in the hospital, which was significantly higher than the 
average in-hospital death rate of 2.1% for all hospitalized patients.43
• In 2004, CAD was estimated to be responsible for 1.2 million hospital stays and 
was the most expensive condition treated. This condition resulted in >$44 billion 
in expenses. More than half of the hospital stays for CAD were among patients 
who also received PCI or CABG during their stay. AMI resulted in $31 billion in 
inpatient hospital charges for 695 000 hospital stays. The 1.1 million 
hospitalizations for CHF amounted to nearly $29 billion in hospital charges.44
• In 2003, ≈48.3% of inpatient hospital stays for CVD were for women, who 
accounted for 42.8% of the national cost ($187 billion) associated with these 
conditions. Although only 40% of hospital stays for AMI and CAD were for 
women, more than half of all stays for nonspecific chest pain, CHF, and stroke 
were for women. There was no difference between men and women in 
hospitalizations for cardiac dysrhythmias.45
• Circulatory disorders were the most frequent reason for admission to the hospital 
through the ED, accounting for 26.3% of all admissions through the ED. After 
pneumonia, the most common heart-related conditions (in descending order) 
were CHF, chest pain, hardening of the arteries, and heart attack, which together 
accounted for >15% of all admissions through the ED. Stroke and irregular heart 
beat ranked seventh and eighth, respectively.46
• Among the 1 492 200 nursing home residents each day in 2004, CVD was the 
leading primary diagnosis; approximately one fourth of nursing home residents 
had a primary diagnosis of CVD at admission (23.7% or 353 100 residents) or at 
the time of interview (25% or 373 000 residents) (NCHS, NNHS).47
• Among the 1 459 900 home healthcare patients each day in 2007, CVD was the 
leading primary diagnosis; almost one fifth of home healthcare patients had a 
primary diagnosis of CVD at admission into home health care (18.3% or 267 300 
residents) or at the time of interview (18.9% or 275 700 residents) (NCHS, 
NHHCS). The majority (62.9% or 918 900 patients) of home healthcare patients 
each day in 2007 had any diagnosis of CVD at the time of interview.48
• Among the 1 045 100 patients discharged from hospice in 2007, CVD was the 
primary diagnosis for 15.8% (or 165 100 discharges) at admission and 15.9% (or 
165 700 discharges) at discharge. Half (50% or 523 000) of all hospice 
discharges had any diagnosis of CVD at the time of discharge.48
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Operations and Procedures
• In 2010, an estimated 7 588 000 inpatient cardiovascular operations and 
procedures were performed in the United States; 4.4 million were performed on 
males, and 3.2 million were performed on females (NHLBI tabulation of NHDS, 
NCHS).
Cost
• The estimated direct and indirect cost of CVD for 2010 is $315.4 billion (MEPS, 
NHLBI tabulation).
• By 2030, real (2012$) total direct medical costs of CVD are projected to increase 
to ≈$918 billion (unpublished AHA tabulation based on methodology described 
by Heidenreich et al3).
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14. Stroke (Cerebrovascular Disease)
ICD-9 430 to 438; ICD-10 I60 to I69. See Tables 14-1 and 14-2 and Charts 14-1 through 
14-12.
Stroke Prevalence
(See Table 14-1 and Chart 14-1.)
• An estimated 6.8 million Americans ≥20 years of age have had a stroke 
(extrapolated to 2010 by use of NHANES 2007–2010 data). Overall stroke 
prevalence during this period is an estimated 2.8% (NHANES, NHLBI).
• According to data from the 2012 BRFSS (CDC), 2.9% of men and 2.9% of 
women ≥18 years of age had a history of stroke; 3.0% of non-Hispanic whites, 
3.8% of non-Hispanic blacks, 1.9% of Asian/Pacific Islanders, 1.8% of Hispanics 
(of any race), 5.8% of American Indian/Alaska Natives, and 4.1% of other races 
or multiracial people had a history of stroke.1
• Over the time period 2006 to 2010, data from BRFSS show that the overall self-
reported stroke prevalence did not change. Older adults, blacks, people with 
lower levels of education, and people living in the southeastern United States had 
higher stroke prevalence.2
• The prevalence of silent cerebral infarction is estimated to range from 6% to 
28%, with higher prevalence with increasing age.3–5 The prevalence estimates 
also vary depending on the population studied (eg, ethnicity, sex, risk factor 
profile), definition of silent cerebral infarction, and imaging technique. It has 
been estimated that 13 million people had prevalent silent stroke in the 1998 US 
population.6,7
• The prevalence of stroke-related symptoms was found to be relatively high in a 
general population free of a prior diagnosis of stroke or TIA. On the basis of data 
from 18 462 participants enrolled in a national cohort study, 17.8% of the 
population >45 years of age reported at least 1 symptom. Stroke symptoms were 
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more likely among blacks than whites, among those with lower income and 
lower educational attainment, and among those with fair to poor perceived health 
status. Symptoms also were more likely in participants with higher Framingham 
stroke risk score (REGARDS, NINDS).8
• Projections show that by 2030, an additional 3.4 million people aged ≥18 years 
will have had a stroke, a 20.5% increase in prevalence from 2012. The highest 
increase (29%) is projected to be in Hispanic men.9
• Individuals with atherosclerotic stroke should be included among those deemed 
to be at high risk (20% over 10 years) of further atherosclerotic coronary events. 
For primary prevention, ischemic stroke should be included among CVD 
outcomes in absolute risk assessment algorithms. The inclusion of 
atherosclerotic ischemic stroke as a high-risk condition has important 
implications, because the number of patients considered to be at high risk will 
increase over time.10
Abbreviations Used in Chapter 14
ACCORD Action to Control Cardiovascular Risk in Diabetes
AF atrial fibrillation
AHA American Heart Association
AHI apnea-hypopnea index
ARIC Atherosclerosis Risk in Communities study
AHRQ Agency for Healthcare Research and Quality
BASIC Brain Attack Surveillance in Corpus Christi
BP blood pressure
BRFSS Behavioral Risk Factor Surveillance System
CDC Centers for Disease Control and Prevention
CHD coronary heart disease
CHS Cardiovascular Health Study
CI confidence interval
CLRD chronic lower respiratory disease
CREST Carotid Revascularization Endarterectomy versus Stenting Trial
CVD cardiovascular disease
DM diabetes mellitus
ED emergency department
eGFR estimated glomerular filtration rate
EMS emergency medical services
FHS Framingham Heart Study
FRS Framingham Risk Score
FUTURE Follow-up of TIA and Stroke Patients and Unelucidated Risk Factor Evaluation
GCNKSS Greater Cincinnati/Northern Kentucky Stroke Study
GFR glomerular filtration rate
GWTG Get With The Guidelines
HBP high blood pressure
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HCUP Healthcare Cost and Utilization Project
HD heart disease
HDL high-density lipoprotein
HF heart failure
HR hazard ratio
ICD-9 International Classification of Diseases, 9th Revision
ICD-10 International Classification of Diseases, 10th Revision
ICH intracerebral hemorrhage
MEPS Medical Expenditure Panel Survey
MI myocardial infarction
NCHS National Center for Health Statistics
NH non-Hispanic
NHAMCS National Hospital Ambulatory Medical Care Survey
NHANES National Health and Nutrition Examination Survey
NHDS National Hospital Discharge Survey
NHIS National Health Interview Survey
NHLBI National Heart, Lung, and Blood Institute
NINDS National Institutes of Neurological Disorders and Stroke
NOMAS Northern Manhattan Study
ONTARGET Ongoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial
OR odds ratio
PA physical activity
PAR population attributable risk
REGARDS Reasons for Geographic and Racial Differences in Stroke study
RR relative risk
SAH subarachnoid hemorrhage
SPS3 Secondary Prevention of Small Subcortical Strokes
SBP systolic blood pressure
SWITCH Stroke With Transfusions Changing to Hydroxyurea
TIA transient ischemic attack
tPA tissue-type plasminogen activator
Stroke Incidence
(See Table 14-1 and Charts 14-2 through 14-5.)
• Each year, ≈795 000 people experience a new or recurrent stroke. Approximately 
610 000 of these are first attacks, and 185 000 are recurrent attacks (GCNKSS, 
NINDS, and NHLBI; GCNKSS and NINDS data for 1999 provided July 9, 2008; 
estimates compiled by NHLBI).
• Of all strokes, 87% are ischemic and 10% are ICH strokes, whereas 3% are SAH 
strokes (GCNKSS, NINDS, 1999).
• On average, every 40 seconds, someone in the United States has a stroke (AHA 
computation based on the latest available data).
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• Each year, ≈55 000 more women than men have a stroke (GCNKSS, NINDS).11
• Women have a higher lifetime risk of stroke than men. In the FHS, lifetime risk 
of stroke among those 55 to75 years of age was 1 in 5 for women (20% to 21%) 
and ≈1 in 6 for men (14% to 17%).12
• Women have lower age-adjusted stroke incidence than men; however, sex 
differences in stroke risk may be modified by age.13 Data from FHS demonstrate 
that compared with white men, white women 45 to 84 years of age have lower 
stroke risk than men, but this association is reversed in older ages such that 
women >85 years of age have elevated risk compared with men.14 Similarly, a 
population-based study in Sweden found stroke incidence to be lower for women 
than for men at ages 55 to 64 years, but at 75 to 85 years of age, this association 
reversed, and women had a higher incidence than men.15 Other studies report an 
excess risk of stroke in men compared with women that persists throughout the 
life course or that diminishes but does not reverse with age.16–20
• Temporal trend data from the BASIC Project for the time period 2000 through 
2010 demonstrated that ischemic stroke rates declined significantly in people 
aged ≥60 years but remained largely unchanged over time in those aged 45 to 59 
years. Rates of decline did not differ significantly for non-Hispanic whites and 
Mexican Americans in any age group. Therefore, ethnic disparities in stroke rates 
in the 45- to 59-year-old and 60- to 74-year-old age groups persist.21
• In the national REGARDS cohort, in 27 744 participants followed up for 4.4 
years (2003–2010), the overall age- and sex-adjusted black/white incidence rate 
ratio was 1.51, but for ages 45 to 54 years, it was 4.02, whereas for those ≥85 
years of age, it was 0.86.22 Similar trends for decreasing black/white incidence 
rate ratio with age were seen in the GCNKSS.23
• Analysis of data from the FHS suggests that stroke incidence is declining over 
time in this largely white cohort. Data from 1950 to 1977, 1978 to 1989, and 
1990 to 2004 showed that the age-adjusted incidence of first stroke per 1000 
person-years in each of the 3 periods was 7.6, 6.2, and 5.3 in men and 6.2, 5.8, 
and 5.1 in women, respectively. Lifetime risk for incident stroke at 65 years of 
age decreased significantly in the latest data period compared with the first, from 
19.5% to 14.5% in men and from 18.0% to 16.1% in women.24
• In a similar fashion, data from the most recent GCNKSS show that compared 
with the 1990s, when incidence rates of stroke were stable, stroke incidence in 
2005 was decreased for whites. A similar decline was not seen in blacks. These 
changes for whites were driven by a decline in ischemic strokes. There were no 
changes in incidence of ischemic stroke for blacks or of hemorrhagic strokes in 
blacks or whites.11
• In an analysis of temporal trends in ischemic stroke incidence stratified by age, 
the GCNKSS found an increased incidence of ischemic stroke over time for both 
blacks and whites aged 20 to 54 years, especially in 2005 compared with earlier 
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time periods. There were declining incidence rates in the oldest age groups for 
both race groups.25
• The BASIC Project (NINDS) demonstrated an increased incidence of stroke 
among Mexican Americans compared with non-Hispanic whites in a community 
in southeast Texas. The crude 3-year cumulative incidence (2000–2002) was 16.8 
per 1000 in Mexican Americans and 13.6 per 1000 in non-Hispanic whites. 
Specifically, Mexican Americans had a higher cumulative incidence for ischemic 
stroke at younger ages (45–59 years of age: RR, 2.04; 95% CI, 1.55–2.69; 60–74 
years of age: RR, 1.58; 95% CI, 1.31–1.91) but not at older ages (≥75 years of 
age: RR, 1.12; 95% CI, 0.94–1.32). Mexican Americans also had a higher 
incidence of ICH and SAH than non-Hispanic whites, after adjustment for age.26
• The age-adjusted incidence of first ischemic stroke per 1000 was 0.88 in whites, 
1.91 in blacks, and 1.49 in Hispanics according to data from NOMAS (NINDS) 
for 1993 to 1997. Among blacks, compared with whites, the relative rate of 
intracranial atherosclerotic stroke was 5.85; of extracranial atherosclerotic stroke, 
3.18; of lacunar stroke, 3.09; and of cardioembolic stroke, 1.58. Among 
Hispanics (primarily Cuban and Puerto Rican), compared with whites, the 
relative rate of intracranial atherosclerotic stroke was 5.00; of extracranial 
atherosclerotic stroke, 1.71; of lacunar stroke, 2.32; and of cardioembolic stroke, 
1.42.27
• Among 4507 American Indian participants without a prior stroke in the Strong 
Heart Study in 1989 to 1992, the age- and sex-adjusted incidence of stroke 
through 2004 was 6.79 per 100 person-years, with 86% of incident strokes being 
ischemic.28
• In the GCNKSS, the annual incidence of anticoagulant-associated ICH per 100 
000 people increased from 0.8 (95% CI, 0.3–1.3) in 1988 to 1.9 (95% CI, 1.1–
2.7) in 1993/1994 and 4.4 (95% CI, 3.2–5.5) in 1999 (P<0.001 for trend). 
Among people ≥80 years of age, the rate of anticoagulant-associated ICH 
increased from 2.5 (95% CI, 0–7.4) in 1988 to 45.9 (95% CI, 25.6–66.2) in 1999 
(P<0.001 for trend).29
TIA: Prevalence, Incidence, and Prognosis
• In a nationwide survey of US adults, the estimated prevalence of self-reported 
physician-diagnosed TIA was 2.3%, which translates to ≈5 million people. The 
true prevalence of TIA is greater, because many patients who experience 
neurological symptoms consistent with a TIA fail to report it to their healthcare 
provider.30
• In the GCNKS, according to data from 1993 and 1994, the age-, sex-, and race-
adjusted incidence rate for TIA was 0.83 per 10 000.31 The age- and sex-adjusted 
incidence rate for TIA in Rochester, MN, was estimated at 0.68 per 1000 for the 
years 1985 through 1989.32 In a more recent Italian community-based registry 
conducted in 2007 to 2009, the crude TIA incidence rate was 0.52 per 1000.33
et al. Page 174
Circulation. Author manuscript; available in PMC 2017 April 28.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
• The prevalence of physician-diagnosed TIA increases with age.30 Incidence of 
TIA increases with age and varies by sex and race/ethnicity. Men, blacks, and 
Mexican Americans have higher rates of TIA than their female and non-Hispanic 
white counterparts.26,31,33
• Approximately 15% of all strokes are heralded by a TIA.34
• TIAs confer a substantial short-term risk of stroke, hospitalization for CVD 
events, and death. Of 1707 TIA patients evaluated in the ED of Kaiser 
Permanente Northern California, a large, integrated healthcare delivery system, 
180 (11%) experienced a stroke within 90 days. Ninety-one patients (5%) had a 
stroke within 2 days. Predictors of stroke included age >60 years, DM, focal 
symptoms of weakness or speech impairment, and TIA that lasted >10 
minutes.35
• Meta-analyses of cohorts of patients with TIA have shown the short-term risk of 
stroke after TIA to be ≈3% to 10% at 2 days and 9% to 17% at 90 days.36,37
• Individuals who have a TIA and survive the initial high-risk period have a 10-
year stroke risk of roughly 19% and a combined 10-year stroke, MI, or vascular 
death risk of 43% (4% per year).38
• Within 1 year of TIA, ≈12% of patients will die.31
• It is estimated that one third of episodes characterized as TIA according to the 
classic definition (ie, focal neurological deficits that resolve within 24 hours) 
would be considered infarctions on the basis of diffusion-weighted magnetic 
resonance imaging findings.39
Recurrent Stroke
• In a cohort of 10 399 patients discharged with a primary diagnosis of stroke in 
the state of South Carolina in 2002, recurrent stroke rates were 1.8% at 1 month, 
5% at 6 months, 8% at 1 year, and 18.1% at 4 years.40
• In the REGARDS cohort with 5 years of follow-up, participants with self-
reported stroke symptoms, TIA, distant stroke, or recent stroke all had increased 
risk of future stroke compared with those with no symptoms. After risk factor 
adjustment, there was a monotonically increasing risk of subsequent stroke 
across this symptomatic spectrum.41
• Annual recurrent stroke rates in control arms of stroke prevention trials fell from 
8.71% in trials launched in the 1960s to 6.10% in the 1970s, 5.41% in the 1980s, 
4.04% in the 1990s, and 4.98% in the 2000s. Assuming a continued linear 
decline, the annual recurrent stroke rate in trial control arms in the coming 
decade is projected to be 2.25%.42
• From 1994 to 2002, 1-year recurrent ischemic stroke rates declined by almost 
5% among elderly Medicare beneficiaries, but declines were heterogeneous 
across geographic regions of the United States.43
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• Among 600 Scandinavian stroke patients followed up for 2 years, 55 (9.2%) had 
had a recurrent stroke, 15 (2.5%) had a TIA, 4 (0.7%) had a coronary event, and 
24 (4.0%) had died. Recurrent stroke occurred in 19.2% of patients with index 
stroke caused by large-artery disease, 4.9% with small-vessel disease, 8.2% with 
cardioembolic cause, 5.6% with cryptogenic cause, and 12.8% of other and 
undetermined cause combined.44
• Recurrent stroke is associated with a greater number of risk factors and a higher 
incidence of large-artery atherosclerosis than the first stroke.45
• Among 1626 first-ever stroke patients in the South London Register,46 first 
stroke recurrence rates during the first, second, third, fourth, and fifth years were 
8% (95% CI, 6.5%–9.8%), 3.3% (2.2%–4.9%), 3.5% (2.1%–5.8%), 1.2% (0.4%–
3.7%), and 1.8% (0.4%–7.4%). Cumulative risks of first stroke recurrence were 
2.6% (1.9%–3.7%) at 3 months, 8.0% (6.5%–9.8%) at 1 year, 14.1% (11.8 %–
16.7%) at 3 years, and 16.6% (13.5%–20.4%) at 5 years.46
Stroke Mortality
(See Table 14-1 and Charts 14-6 and 14-7.)
• On average, every 4 minutes, someone dies of a stroke (NCHS, NHLBI).47
• Stroke accounted for ≈1 of every 19 deaths in the United States in 2010.47
• When considered separately from other CVDs, stroke ranks No. 4 among all 
causes of death, behind diseases of the heart, cancer, and CLRD (NCHS 
mortality data). The number of deaths with stroke as an underlying cause in 2010 
was 129 476; any-mention mortality in 2010 was 217 621, and the age-adjusted 
death rate for stroke as an underlying cause of death was 39.1 per 100 000.47
• Approximately 55% of stroke deaths in 2010 occurred out of the hospital 
(unpublished tabulation from NCHS 2010 mortality data set).
• More women than men die of stroke each year because of the larger number of 
elderly women. Women accounted for almost 60% of US stroke deaths in 2010 
(AHA tabulation).47
• From 2000 to 2010, the annual stroke death rate decreased 35.8% and the actual 
number of stroke deaths declined 22.8% (AHA computation).47,48
• Conclusions about changes in stroke death rates from 1981 to 2009 are as 
follows:
– There was a greater decline in stroke death rates in men than in women, 
with a male-to-female ratio that decreased from 1.11 to 1.05 (age 
adjusted).
– Stroke death rates declined more in people aged 45 to 64 years 
(−51.7%) than in those ≥65 years of age (−48.3%) or those aged 18 to 
44 years (−37.8%).49
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• The decline in stroke mortality over the past several decades, a major 
improvement in population health observed for both sexes and all race and age 
groups, is the result of reduced stroke incidence and lower case fatality rates. The 
significant improvements in stroke outcomes are concurrent with cardiovascular 
risk factor control interventions. The hypertension control efforts initiated in the 
1970s appear to have had the most substantial influence on the accelerated 
decline in stroke mortality, with lower blood pressure distributions in the 
population. Control of DM and dyslipidemia, as well as smoking cessation 
programs, particularly in combination with hypertension treatment, also appear 
to have contributed to the decline in stroke mortality.50
• In examining trends in stroke mortality by US census divisions between 1999 
and 2007 for people ≥45 years of age, the rate of decline varied by geographic 
region and race/ ethnic group. Among black and white women and white men, 
rates declined by ≥2% annually in every census division, but among black men, 
rates declined little in the East and West South Central divisions.51
• From 1995 to 1998, age-standardized mortality rates for ischemic stroke, SAH, 
and ICH were higher among blacks than whites. Death rates attributable to ICH 
also were higher among Asians/Pacific Islanders than among whites. All 
minority populations had higher death rates attributable to SAH than did whites. 
Among adults 25 to 44 years of age, blacks and American Indian/Alaska Natives 
had higher risk ratios for stroke mortality than did whites for all 3 stroke 
subtypes. Age-standardized mortality rates for ischemic stroke and ICH were 
lower for Hispanics than for whites.52
• In 2002, death certificate data showed that the mean age at stroke death was 79.6 
years; however, males had a younger mean age at stroke death than females. 
Blacks, American Indian/Alaska Natives, and Asian/Pacific Islanders had 
younger mean ages than whites, and the mean age at stroke death was also 
younger among Hispanics than non-Hispanics.53
• A report released by the CDC in collaboration with the Centers for Medicare & 
Medicaid Services, the Atlas of Stroke Hospitalizations Among Medicare 
Beneficiaries, found that in Medicare beneficiaries over the time period 1995 to 
2002, the 30-day mortality rate varied by age: 9% in patients 65 to 74 years of 
age, 13.1% in those 74 to 84 years of age, and 23% in those ≥85 years of age.54
• The Netherlands FUTURE study enrolled 959 consecutive patients aged 18 to 50 
years who had been admitted to a single academic center with first-ever TIA 
(n=262), ischemic stroke (n=606), or ICH (n=91). Over a mean follow-up of 11.1 
years (follow-up rate of 97%), among 30-day survivors, the observed 20-year 
mortality for each stroke type exceeded the expected mortality in the general 
population. Among the patients, mortality ranged from 1.2% to 2.9% at 1 year to 
2.5% to 6.1% at 5 years, 9.2% to 12.4% at 10 years, and 13.7% to 26.8% at 20 
years. Among the stroke cases, the relative excess of deaths compared with the 
general population was greatest among the youngest subjects, but the absolute 
excess of deaths was highest among the older subjects.55
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• There are substantial geographic disparities in stroke mortality, with higher rates 
in the southeastern United States, known as the “stroke belt.” This area is usually 
defined to include the 8 southern states of North Carolina, South Carolina, 
Georgia, Tennessee, Mississippi, Alabama, Louisiana, and Arkansas. These 
geographic differences have existed since at least 1940,56 and despite some 
minor shifts,57 they persist.54,58,59 Within the stroke belt, a “buckle” region 
along the coastal plain of North Carolina, South Carolina, and Georgia has been 
identified with an even higher stroke mortality rate than the remainder of the 
stroke belt. The overall average stroke mortality is ≈20% higher in the stroke belt 
than in the rest of the nation and ≈40% higher in the stroke buckle.60
Stroke Risk Factors
(See Table 14-2 and Chart 14-8.)
For prevalence and other information on any of these specific risk factors, refer to the 
specific risk factor chapters.
High Blood Pressure—(See Chapter 9 for more information.)
• BP is a powerful determinant of risk for both ischemic stroke and intracranial 
hemorrhage.
– Approximately 77% of those who have a first stroke have BP >140/90 
mm Hg (NHLBI unpublished estimates from ARIC, CHS, and FHS 
Cohort and Offspring studies).
– Diabetic subjects with BP <120/80 mm Hg have approximately half the 
lifetime risk of stroke of subjects with hypertension. The treatment and 
lowering of BP among diabetic hypertensive individuals was associated 
with a significant reduction in stroke risk.61
• In the REGARDS study (NINDS), between the ages of 45 and 64 years (an age 
group in which African Americans are at 2 to 3 times the risk of stroke as 
whites), ≈40% of the excess stroke risk in African Americans is attributable to 
traditional stroke risk factors, with levels of SBP accounting for approximately 
one half of this impact.62 For each 10 mm Hg increase in levels of SBP, the 
increased stroke risk in whites is ≈8%; however, a similar 10 mm Hg increase in 
SBP in African Americans is associated with a 24% increase in stroke risk, an 
impact 3 times greater than in whites.63
• Cross-sectional baseline data from the SPS3 trial showed that more than half of 
all symptomatic lacunar stroke patients had uncontrolled hypertension at 2.5 
months after stroke.64
• A meta-analysis of 12 prospective cohort studies (including 518 520 participants) 
found that prehypertension is associated with incident stroke. The risk is 
particularly noted in nonelderly people and for those with BP values in the 
higher prehypertension range.65
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• Blacks with hypertension were more aware and treated than whites, but were less 
likely than whites to have their BP controlled.66
• The higher stroke risk for the stroke belt compared with other regions does not 
appear to be attributable to hypertension management, because treatment and 
control rates were similar for the 2 geographic areas.66
• Several studies have shown significantly lower rates of recurrent stroke with 
lower BPs. Most recently, the BP-reduction component of the SPS3 trial showed 
that targeting an SBP <130 mm Hg was likely to reduce recurrent stroke by 
≈20% (P=0.08) and significantly reduced ICH by two thirds.67,68
Diabetes Mellitus—(See Chapter 10 for more information.)
• DM increases ischemic stroke incidence at all ages, but this risk is most 
prominent (risk ratio for ischemic stroke conferred by DM >5) before 65 years of 
age in both blacks and whites. According to data from the GCNKSS in 2005, the 
risk ratio for ischemic stroke in blacks <65 years of age was 5.2 compared with 
12.0 for whites; the trend for greater risk conferred by DM at age <65 years in 
whites was noted in all 3 prior study periods. Overall, ischemic stroke patients 
with DM are younger, more likely to be black, and more likely to have HBP, MI, 
and high cholesterol than nondiabetic patients.69
• In people with a history of TIA or minor stroke, impaired glucose tolerance 
nearly doubled the stroke risk compared with those with normal glucose levels 
and tripled the risks for those with DM.70
• A meta-analysis of prospective randomized controlled trials of interventions that 
targeted prediabetic patients revealed a 24% relative risk reduction in fatal and 
nonfatal strokes (HR, 0.76; 95% CI, 0.58–0.99).71
• Data from the US Nationwide Inpatient Sample revealed that from 1997 to 2006, 
the absolute number of acute ischemic stroke hospitalizations declined by 17% 
(from 489 766 in 1997 to 408 378 in 2006); however, the absolute number of 
acute ischemic stroke hospitalizations with comorbid DM rose by 27% (from 97 
577 [20%] in 1997 to 124 244 [30%] in 2006). The rise in comorbid DM was 
more pronounced in individuals who were relatively younger, black or “other” 
race, on Medicaid, or admitted to hospitals located in the South. Factors 
independently associated with higher odds of DM in acute ischemic stroke 
patients were black or “other” (versus white) race, CHF, peripheral vascular 
disease, and history of MI, renal disease, or hypertension.72
• A population-based study of 12 375 first-ever stroke patients 25 to 74 years old 
who were followed up for ≤23 years found that diabetic patients had a higher risk 
of death than nondiabetic patients (adjusted HR, 1.67; 95% CI, 1.58–1.76). The 
reduced survival of diabetic stroke patients was more pronounced in women 
(P=0.02) and younger individuals (P <0.001).73
• A retrospective analysis of diabetic patients with acute ischemic stroke revealed 
that those who had been taking and continued taking sulfonylureas were less 
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likely to experience symptomatic hemorrhagic transformation than those who did 
not take sulfonylureas (P=0.016).74
• The ACCORD study showed that in patients with type 2 DM, targeting SBP to 
<120 mm Hg did not reduce the rate of cardiovascular events compared with 
subjects in whom the SBP target was <140 mm Hg, except for the end point of 
stroke, for which intensive therapy reduced the risk of any stroke (HR, 0.59; 95% 
CI, 0.39–0.89) and nonfatal stroke (HR, 0.63; 95% CI, 0.41–0.96).61
• The ONTARGET trial revealed that in both patients with and without DM, the 
adjusted risk of stroke continued to decrease down to achieved SBP values of 
115 mm Hg, whereas there was no benefit for other fatal or nonfatal 
cardiovascular outcomes below an SBP of 130 mm Hg.75
Disorders of Heart Rhythm—(See Chapter 16 for more information.)
• AF is a powerful risk factor for stroke, independently increasing risk ≈5-fold 
throughout all ages. The percentage of strokes attributable to AF increases 
steeply from 1.5% at 50 to 59 years of age to 23.5% at 80 to 89 years of age.76,77
• Because AF is often asymptomatic77a,77b and likely frequently undetected 
clinically,78 the stroke risk attributed to AF may be substantially 
underestimated.79 Screening for AF in patients with cryptogenic stroke or TIA 
by use of outpatient telemetry for 21 to 30 days has resulted in an AF detection 
rate of 12% to 23%.78–80
• Among 2580 participants ≥65 years of age with hypertension in whom a cardiac 
rhythm device that included an atrial lead was implanted, 35% developed 
subclinical tachyarrhythmias (defined as an atrial rate ≥190 beats per minute that 
lasted ≥6 minutes). These subclinical events were independently associated with 
a 2.5-fold increased risk of ischemic stroke or systemic embolism.81
• Important risk factors for stroke in the setting of AF include advancing age, 
hypertension, HF, DM, previous stroke or TIA, vascular disease, and female 
sex.82–84 Additional biomarkers, including high levels of troponin and B-type 
natriuretic peptide, increase the risk of stroke in the setting of AF independent of 
those well-established clinical characteristics.85
High Blood Cholesterol and Other Lipids—(See Chapter 8 for more information.)
For clarity, different types of cholesterol (total cholesterol, subfractions) are described here 
and are bolded in each bullet point.
• An association between total cholesterol and ischemic stroke has been found in 
some prospective studies,86–88 but not others.89–91
• Data from the Honolulu Heart Program//NHLBI found that in Japanese men 71 
to 93 years of age, low concentrations of HDL cholesterol were more likely to 
be associated with a future risk of thromboembolic stroke than were high 
concentrations.92 However, a meta-analysis of 23 studies performed in the Asia-
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Pacific Region showed no significant association between low HDL cholesterol 
and stroke risk.93
• In an analysis by the Emerging Risk Factors Collaboration of individual records 
on 302 430 people without initial vascular disease from 68 long-term prospective 
studies, HRs for ischemic stroke were 1.02 (95% CI, 0.94–1.11) with 
triglyceride, 0.93 (95% CI, 0.84–1.02) with HDL cholesterol, and 1.12 (95% 
CI, 1.04–1.20) with non-HDL cholesterol.94
• A Finish study of 27 703 men and 30 532 women followed up for >20 years for 
ischemic stroke found an independent inverse association of HDL cholesterol 
with the risks of total and ischemic stroke in women.91
• Among 13 951 patients in the Copenhagen Heart Study followed up for 33 years 
for ischemic stroke, increasing stepwise levels of nonfasting triglycerides were 
associated with increased risk of ischemic stroke in both men and women. 
Stepwise increasing levels of total cholesterol were not associated with risk of 
ischemic stroke in women, but levels >9.00 mmol/L were in men.95
Smoking—(See Chapter 3 for more information.)
• Current smokers have a 2 to 4 times increased risk of stroke compared with 
nonsmokers or those who have quit for >10 years.96,97
• Cigarette smoking is a risk factor for ischemic stroke and SAH, but the data for 
ICH are less consistent.96,97
• Smoking is perhaps the most important modifiable risk factor in preventing SAH, 
with the highest PAR of any SAH risk factor.98
• Data also support a dose-response relationship across old and young age 
groups.96,99
• Discontinuation of smoking has been shown to reduce stroke risk across sex, 
race, and age groups.99
• Exposure to secondhand smoke (also termed passive smoking or environmental 
tobacco smoke) is a risk factor for stroke. Meta-analyses have estimated a pooled 
RR of 1.25 for exposure to spousal smoking (or nearest equivalent) and risk of 
stroke. A dose-response relationship between exposure to secondhand smoke and 
stroke risk has also been reported.100,101
Physical Inactivity—(See Chapter 4 for more information.)
• In NOMAS, a prospective cohort that included white, black, and Hispanic adults 
in an urban setting followed up for a median of 9 years, moderate to vigorous PA 
was associated with an overall 35% reduction in risk of ischemic stroke.102
• The NOMAS study found that only moderate- to vigorous-intensity exercise was 
associated with reduced stroke incidence, whereas light exercise (such as 
walking) showed no benefit.102
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• Timing of PA in relation to stroke onset has also been examined in several 
studies. In a hospital-based case-control study from Heidelberg, Germany, recent 
activity (within the prior months) was associated with reduced odds of having a 
stroke or TIA, whereas sports activity during young adulthood that was not 
continued showed no benefit.104 In a Danish case-control study, ischemic stroke 
patients were less physically active in the week preceding the stroke than age- 
and sex-matched control subjects, with the highest activity scores associated with 
the greatest reduction in odds of stroke.105
• Recent results from REGARDS found that participants reporting PA <4 times 
per week had a 20% increased risk of incident stroke over a mean of 5.7 years 
compared with those exercising ≥4 times per week. This relationship, which was 
more pronounced in men than in women, may be explained in large part by the 
effect of PA on reducing traditional risk factors, such as obesity and DM.106
Nutrition—(See Chapter 5 for more information.)
• Adherence to a Mediterranean-style diet that was higher in nuts and olive oil was 
associated with a reduced risk of stroke (HR, 0.54; 95% CI, 0.35–0.84) in a 
randomized clinical trial conducted in Spain. The protective benefit of the 
Mediterranean diet observed was greater for strokes than for MI, but stroke 
subtype was not available.107
• In the Nurses Health and Health Professionals Follow-up Studies, each 1-serving 
increase in sugar-sweetened soda beverage was associated with a 13% increased 
risk of ischemic stroke but not hemorrhagic stroke. Conversely, each 1-serving 
increase in low-calorie or diet soda was associated with a 7% increased risk of 
ischemic stroke and 27% increased risk of hemorrhagic stroke.108
• A meta-analysis of >94 000 people with 34 817 stroke events demonstrated that 
eating ≥5 servings of fish per week versus eating <1 serving per week was 
associated with a 12% reduction in stroke risk; however, these results were not 
consistent across all cohort studies.109
• Using registry data from Sweden, people eating ≥7 servings of fruits and 
vegetables per day had a 19% reduced risk of stroke compared with those only 
eating 1 serving per day. This effect was only seen in people who did not have 
hypertension.110
Family History and Genetics—(See Chapter 7 for more information.)
• In the FHS, a documented parental ischemic stroke by the age of 65 years was 
associated with a 3-fold increase in ischemic stroke risk in offspring, even after 
adjustment for other known stroke risk factors. The absolute magnitude of the 
increased risk was greatest in those in the highest quintile of the FRS. By age 65 
years, people in the highest FRS quintile with an early parental ischemic stroke 
had a 25% risk of stroke compared with a 7.5% risk of ischemic stroke for those 
without such a history.111
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Chronic Kidney Disease—(See Chapter 12 for more information.)
• The CHS (NHLBI) showed that people with creatinine ≥1.5 mg/dL were at 
increased risk for stroke, with an adjusted HR of 1.77 (95% CI, 1.08–2.91).112
• Participants in REGARDS with a reduced eGFR were also shown to have 
increased risk of stroke symptoms,113 and a meta-analysis of >280 000 patients 
showed a 43% increased incident stroke risk among patients with a GFR <60 
mL·min−1·1.73 m−2.114
• In a study of 539 287 Swedish men and women followed up for 12 years,115 HRs 
for ICH were as follows: for GFR 60 to 90 mL·min−1·1.73 m−2 (mild), 1.04 
(95% CI, 0.93–1.15); for GFR 30 to 60 mL·min−1·1.73 m−2 (moderate), 1.26 
(95% CI, 0.96–1.64); and for GFR 15 to 30 mL·min−1·1.73 m−2 (severe 
impairment), 2.31 (95% CI, 1.10–4.87). Among 128 patients with ICH, the 
presence of GFR <45 mL·min−1·1.73 m−2 is associated with larger, lobar 
hematomas and poor outcome.116
• A urinary albumin to creatinine ratio >30 mg/g was associated with a 40% 
increased risk of stroke in black participants but not white participants in the 
REGARDS study.117
Risk Factor Issues Specific to Women
• On average, women are older at stroke onset than men (≈75 years compared with 
71 years).14
• In the setting of AF, women have a significantly higher risk of stroke than 
men.118–122
• Analysis of data from the FHS found that women with natural menopause before 
42 years of age had twice the ischemic stroke risk of women with natural 
menopause after 42 years of age.123
• Investigators from the Nurse’s Health Study, however, did not find an association 
between age at natural menopause and risk of ischemic or hemorrhagic stroke.124
• Overall, randomized clinical trial data indicate that the use of estrogen plus 
progestin, as well as estrogen alone, increases stroke risk in postmenopausal, 
generally healthy women and provides no protection for postmenopausal women 
with established CHD125–128 and recent stroke or TIA.129
• In a nested case-control study of the United Kingdom’s General Practice 
Research Database, stroke risk was not increased for users of low-dose (≤50 μg) 
estrogen patches (RR, 0.81; 95% CI, 0.62–1.05) but was increased for users of 
high-dose (>50 μg) patches (RR, 1.89; 95% CI, 1.15–3.11) compared with 
nonusers.130
• Low-estrogen-dose oral contraceptives are associated with a 93% increased risk 
of ischemic stroke, but the absolute increased risk is small, (4.1 ischemic strokes 
per 100 000 nonsmoking, normotensive women).131,132
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• Migraine with aura is associated with ischemic stroke in younger women, 
particularly if they smoke or use oral contraceptives. The combination of all 3 
factors increases the risk ≈9-fold compared with women without any of these 
factors.133,134
• The risk of ischemic stroke or ICH during pregnancy and the first 6 weeks after 
giving birth was 2.4 times greater than for nonpregnant women of similar age 
and race, according to the Baltimore-Washington Cooperative Young Stroke 
Study. The risk of ischemic stroke during pregnancy was not increased during 
pregnancy per se but was increased 8.7-fold during the first 6 postpartum weeks. 
ICH showed a small RR of 2.5 during pregnancy that increased dramatically to 
an RR of 28.3 in the first 6 postpartum weeks. The excess risk of stroke (all types 
except SAH) attributable to the combined pregnancy/postpregnancy period was 
8.1 per 100 000 pregnancies.135
• Analyses of the US Nationwide Inpatient Sample from 1994 to 1995 and from 
2006 to 2007 show a temporal increase in the proportion of pregnancy 
hospitalizations that were associated with a stroke, with a 47% increase for 
antenatal hospitalizations and an 83% increase for postpartum hospitalizations, 
but no increase for delivery hospitalizations. Increases in the prevalence of HD 
and hypertensive disorders accounted for almost all the increase in postpartum 
stroke hospitalizations but not the antenatal stroke hospitalizations.86
• Preeclampsia is a risk factor for ischemic stroke remote from pregnancy.136 The 
subsequent stroke risk of pre-eclampsia maybe mediated by a 3.6- to 6.1-fold 
higher later risk of hypertension and a 3.1- to 3.7-fold higher later risk of DM, 
depending on whether the preeclampsia was mild or severe.137
Sleep Apnea
• The prevalence of sleep-disordered breathing, defined as an AHI >5, has been 
estimated to be 24% for men and 9% for women aged 30 to 60 years.138
• In the Sleep Heart Health Study, obstructive sleep apnea measured by the 
obstructive AHI was associated with risk of incident ischemic stroke in men after 
adjustment for confounders (P=0.016 for linear trend associated with quartiles of 
AHI) but not in women. Compared with men in the lowest quartile of AHI, men 
in the highest quartile (AHI >19) had an adjusted HR of 2.9 (95% CI, 1.1–
7.4).139
• In the Victoria Sleep Project, severe sleep apnea (AHI ≥30) was associated with 
increased risk of incident ischemic stroke in community-dwelling elderly (HR, 
2.5; 95% CI, 1.0–6.0).140
• Obstructive sleep apnea is associated with poststroke mortality.141–143
• Sleep apnea is common after stroke, with prevalence in excess of 50%.144
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• No definitive study has been conducted to determine whether treatment with 
continuous positive airway pressure prevents stroke or improves poststroke 
outcomes.
Awareness of Stroke Warning Signs and Risk Factors
• Correct knowledge of at least 1 stroke warning sign increased from 48% in 1995 
to 68% in 2000, with no significant improvement to 2005 (68%) on the basis of a 
telephone survey conducted in a biracial population in the greater Cincinnati/
Northern Kentucky region. Knowledge of 3 correct warning signs was low but 
increased over time: 5.4% in 1995, 12.0% in 2000, and 15.7% in 2005. 
Knowledge of at least 1 stroke risk factor increased from 59% in 1995 to 71% in 
2000, but there was no improvement to 2005 (71%). Only 3.6% of those 
surveyed were able to independently identify tPA as an available drug therapy, 
and only 9% of these were able to identify a window of <3 hours for 
treatment.145
• In the 2009 NHIS, 51.2% of subjects were aware of 5 stroke warning symptoms 
and would first call 9-1-1 if they thought that someone was having a stroke. 
Awareness of all 5 stroke warning symptoms and calling 9-1-1 was higher among 
whites than blacks and Hispanics (55.9%, 47.1%, and 36.5%, respectively), 
women than men (53.6% versus 48.6%), and people with higher versus lower 
educational attainment (59.0% for people with a bachelor’s degree or more 
compared with 51.4% for people with a high school diploma or some college and 
36.7% for those who had not received a high school diploma; unpublished 
NHLBI tabulation).
• A study was conducted of patients admitted to an ED with possible stroke to 
determine their knowledge of the signs, symptoms, and risk factors of stroke. Of 
the 163 patients able to respond, 39% did not know a single sign or symptom. 
Patients ≥65 years of age were less likely than those <65 years old to know a 
sign or symptom of stroke (28% versus 47%), and 43% did not know a single 
risk factor. Overall, almost 40% of patients did not know the signs, symptoms, 
and risk factors for stroke.146
• In 2004, 800 adults ≥45 years of age were surveyed to assess their perceived risk 
for stroke and their history of stroke risk factors. Overall, 39% perceived 
themselves to be at risk. Younger age, current smoking, a history of DM, HBP, 
high cholesterol, HD, and stroke/TIA were independently associated with 
perceived risk for stroke. Respondents with AF were no more likely to report 
being at risk than were respondents without AF. Perceived risk for stroke 
increased as the number of risk factors increased; however, 46% of those with ≥3 
risk factors did not perceive themselves to be at risk.147
• A study of patients who had experienced a stroke found that only 60.5% were 
able to accurately identify 1 stroke risk factor and that 55.3% were able to 
identify 1 stroke symptom. Patients’ median delay time from onset of symptoms 
to admission in the ED was 16 hours, and only 31.6% accessed the ED in <2 
et al. Page 185
Circulation. Author manuscript; available in PMC 2017 April 28.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
hours. Analysis showed that the appearance of nonmotor symptoms as the 
primary symptom and nonuse of the 9-1-1 system were significant predictors of 
delay >2 hours. Someone other than the patient made the decision to seek 
treatment in 66% of the cases.148
• Spanish-speaking Hispanics are less likely to know all stroke symptoms than 
English-speaking Hispanics, non-Hispanic blacks, and non-Hispanic whites. 
Lack of English proficiency is strongly associated with lack of stroke knowledge 
among Hispanics.149
Aftermath
(See Charts 14-9 through 14-11.)
• Stroke is a leading cause of serious long-term disability in the United States 
(Survey of Income and Program Participation, a survey of the US Census 
Bureau).150
• Stroke was among the top 18 diseases contributing to years lived with disability 
in 2010; of these 18 causes, only the age-standardized rates for stroke increased 
significantly between 1990 and 2010 (P<0.05).151
• Among Medicare patients discharged from the hospital after stroke, ≈45% return 
directly home, 24% are discharged to inpatient rehabilitation facilities, and 31% 
are discharged to skilled nursing facilities. Of stroke patients returning directly 
home, 32% use home healthcare services.152 For Medicare patients (including, 
but not limited to, stroke survivors), the likelihood of receiving inpatient 
rehabilitation facility care versus skilled nursing facility care is substantially 
influenced by the distance to and availability of inpatient rehabilitation facility 
beds.153
• Approximately one third of stroke survivors experience poststroke depression.154
• In the NHLBI’s FHS, among ischemic stroke survivors who were ≥65 years of 
age, the following disabilities were observed at 6 months after stroke155:
– 50% had some hemiparesis
– 30% were unable to walk without some assistance
– 46% had cognitive deficits
– 35% had depressive symptoms
– 19% had aphasia
– 26% were dependent in activities of daily living
– 26% were institutionalized in a nursing home
• Visual impairments persist in 21% of stroke survivors 90 days after stroke.156
• Initial severity of upper limb weakness is the best predictor of ultimate recovery 
of upper limb motor function.157
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• Data from the BRFSS (CDC) 2005 survey on stroke survivors in 21 states and 
the District of Columbia found that 30.7% of stroke survivors received outpatient 
rehabilitation. The findings indicated that the prevalence of stroke survivors 
receiving outpatient stroke rehabilitation was lower than would be expected if 
clinical practice guideline recommendations for all stroke patients had been 
followed.158
• After stroke, women have greater disability than men. A cross-sectional analysis 
of 5888 community-living elderly people (>65 years of age) in the CHS who 
were ambulatory at baseline found that women were half as likely to be 
independent in activities of daily living after stroke, even after controlling for 
age, race, education, and marital status.159 A prospective study from a Michigan-
based stroke registry found that women had a 63% lower probability of achieving 
independence in activities of daily living 3 months after discharge, even after 
controlling for age, race, subtype, prestroke ambulatory status, and other patient 
characteristics.160
• Black stroke survivors had greater limitations in ambulation than did white 
stroke survivors, after adjustment for age, sex, and educational attainment but not 
stroke subtype, according to data from the NHIS (2000–2001, NCHS) as 
analyzed by the CDC.161 A national study of inpatient rehabilitation after first 
stroke found that blacks were younger, had a higher proportion of hemorrhagic 
stroke, and were more disabled on admission. Compared with non-Hispanic 
whites, blacks and Hispanics also had a poorer functional status at discharge but 
were more likely to be discharged to home rather than to another institution, even 
after adjustment for age and stroke subtype. After adjustment for the same 
covariates, compared with non-Hispanic whites, blacks also had less 
improvement in functional status per inpatient day.162
Stroke in Children
• On the basis of pathogenic differences, pediatric strokes are typically classified 
as either perinatal (occurring at ≤28 days of life and including in utero strokes) or 
(later) childhood.
• Estimates of the overall annual incidence of stroke in US children are 6.4 per 100 
000 children (0 to 15 years) in 1999 in the GCNKSS163 and 4.6 per 100 000 
children (0 to 19 years) in 1997 to 2003 according to data from Kaiser 
Permanente of Northern California, a large, integrated health-care delivery 
system.164 Approximately half of all incident childhood strokes are 
hemorrhagic.163–165
• The prevalence of perinatal strokes is 29 per 100 000 live births, or 1 per 3500 
live births in the 1997 to 2003 Kaiser Permanente of Northern California 
population.164
• A history of infertility, preeclampsia, prolonged rupture of membranes, and 
chorioamnionitis are independent maternal risk factors for perinatal arterial 
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ischemic stroke.166 However, maternal health and pregnancies are normal in 
most cases.167
• The most common cause of arterial ischemic stroke in children is a cerebral 
arteriopathy, found in more than half of all cases.168,169
• HD confers an 8- to 16-fold increased risk of arterial ischemic stroke but was 
present in only 8% of children with stroke in a population-based cohort.170
• Exposure to minor infection in the prior month is an independent risk factor for 
childhood arterial ischemic stroke, present in one third of cases (adjusted OR, 
3.9; 95% CI, 2.0–7.4). Head or neck trauma in the prior week is an even stronger 
risk factor (adjusted OR, 36; 95% CI, 5–281), present in 10% of cases.170
• Thrombophilias (genetic and acquired) are risk factors for childhood stroke, with 
summary ORs ranging from 1.6 to 8.8 in a meta-analysis.171
• In a prospective Swiss registry,172 atherosclerotic risk factors were less common 
in children with arterial ischemic stroke than in young adults; the most common 
of these factors in children was hyperlipidemia (15%). However, an analysis of 
the Nationwide Inpatient Sample suggests a low but rising prevalence of these 
factors among US adolescents and young adults hospitalized for ischemic stroke 
(1995 versus 2008).173
• From 1979 to 1998 in the United States, childhood mortality resulting from 
stroke declined by 58% overall, with reductions in all major subtypes.174
• The incidence of stroke in children has been stable over the past 10 years, 
whereas 30-day case fatality rates declined from 18% in 1988 to 1989 to 9% in 
1993 to 1994 and 9% in 1999 in the GCNKSS population.163
• Compared with girls, boys have a 1.28-fold higher risk of stroke.175 Compared 
with white children, black children have a 2-fold risk of both incident stroke and 
death attributable to stroke.174,175 The increased risk among blacks is not fully 
explained by the presence of sickle cell disease, nor is the excess risk among 
boys fully explained by trauma.175
• Among young adult survivors of childhood stroke, 37% had a normal modified 
Rankin score, 42% had mild deficits, 8% had moderate deficits, and 15% had 
severe deficits.176 Concomitant involvement of the basal ganglia, cerebral cortex, 
and posterior limb of the internal capsule predicts a persistent hemiparesis.177 
Basilar artery thrombosis is found in <5% of children with arterial ischemic 
strokes, but half result in a poor outcome (moderate or severe disability or 
death).178
• Despite current treatment, 1 of 10 children with ischemic or hemorrhagic stroke 
will have a recurrence within 5 years.178a,178b The 5-year recurrence risk is as 
high as 60% among children with cerebral arteriopathy. The recurrence risk after 
perinatal stroke, however, is negligible.179
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• Among 59 long-term survivors of pediatric brain aneurysms, 41% developed new 
or recurrent aneurysm during a median follow-up of 34 years; of those, one third 
developed multiple aneurysms.180
• More than 25% of survivors of perinatal ischemic strokes develop delayed 
seizures within 3 years; children with larger strokes are at higher risk.181 The 
cumulative risk of delayed seizures after later childhood stroke is 13% at 5 years 
and 30% at 10 years.182
• The SWITCH trial reported that chronic blood transfusion therapy remains the 
superior option (over hydroxyurea) for secondary stroke prevention in children 
with sickle cell disease.183 A similar trial of hydroxyurea as an alternative to 
blood transfusion for primary stroke prevention is near completion.
Stroke in the Very Elderly
• Stroke patients >85 years of age make up 17% of all stroke patients.184
• Very elderly patients have a higher risk-adjusted mortality,185 have higher 
disability,185 have longer hospitalizations,186 receive less evidenced-based 
care,186a,186b and are less likely to be discharged to their original place of 
residence.186,187
• According to analyses from the US Nationwide Inpatient Sample, over the past 
decade, in-hospital mortality rates after stroke have declined for every age/sex 
group except men aged >84 years.188
• Over the next 40 years (2010–2050), the number of incident strokes is expected 
to more than double, with the majority of the increase among the elderly (aged 
≥75 years) and minority groups.189
Barriers to Stroke Care
• On the basis of NHIS data from 2000 to 2006, elderly Mexican American and 
non-Hispanic black stroke survivors had less access to physician care (generalist 
and specialist physician visits) and medications than whites; however, for 
patients aged 45 to 64 years, these differences were present only for specialist 
care. Lack of health insurance conferred the highest adjusted odds for reduced 
access in both age groups.190
• GWTG data from 2003 to 2009 found that less than half of patients presenting 
with stroke symptoms received imaging within the recommended 25 minutes of 
hospital arrival. Factors significantly associated with longer time to imaging 
included older age, being female, non-white race, having DM, and arrival by 
means other than EMS.191
• Data from the Paul Coverdell National Acute Stroke Registry found that more 
patients were transported by ambulance than by other means (43.6%). 
Significantly fewer blacks (42.4%) arrived within 2 hours of symptom onset than 
did whites (49.5%), and significantly fewer nonambulance patients (36.2%) 
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arrived within 2 hours of symptom onset than did patients transported by 
ambulance (58.6%).192
• Data from the GWTG-Stroke program examining trends in time from symptom 
onset to hospital arrival between 2002 and 2009 found that there had been little 
overall improvement in the proportion of ischemic stroke patients arriving within 
2 hours of symptom onset during this time period; only 20.6% of the 413 000 
subjects arrived within 2 hours, although this increased to 26.9% when the time 
period was extended to 3.5 hours.193
• Recent data have shown a steady increase in the proportion of ischemic stroke 
patients who are treated with tPA therapy. For example, data from 2 US 
administrative databases in 2009 found that between 3.4% and 5.2% of acute 
ischemic strokes were treated with tPA, which was approximately double the 
treatment rate observed in the same data sources in 2005.194
• Data obtained from the Nationwide Inpatient Sample between 2004 and 2009 
from 25 states showed that tPA treatment rates were higher in Joint 
Commission–certified primary stroke centers (6.7%) compared with noncertified 
hospitals (2.2%); however, over this 6-year period, tPA treatment rates increased 
faster in noncertified hospitals (1.4%–3.3%) than in primary stroke centers 
(6.5%–6.7%).195
• NHIS data from 1998 to 2002 found that younger stroke survivors (aged 45–64 
years) self-reported worse access to physician care and medication affordability 
than older stroke survivors. Compared with older patients, younger stroke 
survivors were more likely to be male (52% versus 47%), to be black (19% 
versus 10%), and to lack health insurance (11% versus 0.4%). Lack of health 
insurance was associated with reduced access to care.196
• Results from the BASIC project found that women were less likely to arrive at 
the ED within 3 hours of stroke symptom onset than men (OR, 0.7; 95% CI, 0.5–
0.9). Mexican Americans were 40% less likely to arrive by EMS than non-
Hispanic whites, even after adjustment for age, National Institutes of Health 
Stroke Scale score, education, history of stroke, and insurance status. Language 
fluency was not associated with time to hospital arrival or use of EMS. The 
receipt of tPA was low (1.5%) but did not differ by sex or ethnicity.197
Hospital Discharges/Ambulatory Care Visits
(See Table 14-1.)
• From 2000 to 2010, the number of inpatient discharges from short-stay hospitals 
with stroke as the first-listed diagnosis remained about the same, with discharges 
of 981 000 and 1 015 000, respectively (NHDS, NHLBI tabulation).198
• Data from 2010 from the NHDS of the NCHS showed that the average length of 
stay for discharges with stroke as the first-listed diagnosis was 6.1 days (median, 
3 days) compared with 9.5 days (median, 6 days) in 1990 (NHDS, NHLBI 
tabulation).198
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• In 2010, men and women accounted for roughly the same number of hospital 
stays for stroke in the 18- to 44-year-old age group. Among people 45 to 64 
years of age, 57.1% of stroke patients were men. After 65 years of age, women 
were the majority. Among people 65 to 84 years of age, 53.4% of stroke patients 
were women, whereas among those ≥85 years of age, women constituted 66.2% 
of all stroke patients.199
• A first-ever county-level Atlas of Stroke Hospitalizations Among Medicare 
Beneficiaries was released in 2008 by the CDC in collaboration with the Centers 
for Medicare & Medicaid Services. It found that the stroke hospitalization rate 
for blacks was 27% higher than for the US population in general, 30% higher 
than for whites, and 36% higher than for Hispanics. In contrast to whites and 
Hispanics, the highest percentage of strokes in blacks (42.3%) occurred in the 
youngest Medicare age group (65–74 years of age).54
• In 2010, there were 671 000 ED visits and 257 000 out-patient department visits 
with stroke as the first-listed diagnosis. In 2010, physician office visits for a first-
listed diagnosis of stroke totaled 2 207 000 (NHAMCS, unpublished NHLBI 
tabulation).200
Operations and Procedures
(See Chart 14-12.)
• In 2010, an estimated 100 000 inpatient endarterectomy procedures were 
performed in the United States. Carotid endarterectomy is the most frequently 
performed surgical procedure to prevent stroke (NHDS, NHLBI tabulation).
• Although rates of carotid endarterectomy have decreased between 1997 and 
2010, the use of carotid stenting has increased dramatically (Nationwide 
Inpatient Sample, HCUP, AHRQ).
• The practice of carotid stenting in the United States is expanding, from <3% of 
all carotid artery revascularization procedures in 1998 to 13% in 2008.201
• The randomized CREST study compared carotid endarterectomy and stenting for 
symptomatic and asymptomatic carotid stenosis. There was no overall difference 
in the primary end point of stroke, MI, or death; however, carotid endarterectomy 
showed superiority with increasing age, with the crossover point at 
approximately age 70, and was associated with fewer strokes, which had a 
greater impact on quality of life than MI.202,203
• In-hospital mortality for carotid endarterectomy has decreased steadily from 
1993 to 2010 (Nationwide Inpatient Sample, HCUP, AHRQ).
• In the Medicare population, in-hospital stroke rate and mortality are similar for 
carotid endarterectomy and carotid stenting.204
• Carotid stenting is associated with significantly higher costs than carotid 
endarterectomy in asymptomatic patients205 and may be less cost-effective in 
general.206
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• The percentage of patients undergoing carotid endarterectomy within 2 weeks of 
the onset of stroke increased from 13% in 2007 to 47% in 2010.207
Cost
(See Table 14-1.)
• The direct and indirect cost of stroke in 2010 was $36.5 billion (MEPS, NHLBI 
tabulation).
• The estimated direct medical cost of stroke for 2010 is $20.6 billion. This 
includes hospital outpatient or office-based provider visits, hospital inpatient 
stays, ED visits, prescribed medicines, and home health care.208
• The mean expense per patient for direct care for any type of service (including 
hospital inpatient stays, outpatient and office-based visits, ED visits, prescribed 
medicines, and home health care) in the United States in 2010 was estimated at 
$5455.208
• The mean lifetime cost of ischemic stroke in the United States is estimated at 
$140 048. This includes inpatient care, rehabilitation, and follow-up care 
necessary for lasting deficits. (All numbers were converted to 1999 dollars by 
use of the medical component of the Consumer Price Index.)209
• Between 2012 and 2030, total direct medical stroke-related costs are projected to 
triple, from $71.6 billion to $184.1 billion, with the majority of the projected 
increase in costs arising from those 65 to 79 years of age.9
• Inpatient hospital costs for an acute stroke event account for 70% of first-year 
poststroke costs.209
• The largest components of short-term care costs were room charges (50%), 
medical management (21%), and diagnostic costs (19%).210
• Death within 7 days, SAH, and stroke while hospitalized for another condition 
are associated with higher costs in the first year. Lower costs are associated with 
mild cerebral infarctions or residence in a nursing home before the stroke.211
• Demographic variables (age, sex, and insurance status) are not associated with 
stroke cost. Severe strokes (National Institutes of Health Stroke Scale score >20) 
cost twice as much as mild strokes, despite similar diagnostic testing. 
Comorbidities such as ischemic HD and AF predict higher costs.210,211a
• The total cost of stroke from 2005 to 2050, in 2005 dollars, is projected to be 
$1.52 trillion for non-Hispanic whites, $313 billion for Hispanics, and $379 
billion for blacks. The per capita cost of stroke estimate is highest in blacks ($25 
782), followed by Hispanics ($17 201) and non-Hispanic whites ($15 597). Loss 
of earnings is expected to be the highest cost contributor in each race/ ethnic 
group.212
• During 2001 to 2005, the average cost for outpatient stroke rehabilitation 
services and medications the first year after inpatient rehabilitation discharge was 
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$11 145. The corresponding average yearly cost of medication was $3376, 
whereas the average cost of yearly rehabilitation service utilization was 
$7318.212a
• Recurrent stroke patients had 38% higher costs per patient 1 year after discharge 
from index hospitalization than new stroke patients.213
• In adjusted models that controlled for relevant covariates, the attributable 1-year 
cost of poststroke aphasia was estimated at $1703 in 2004 dollars.214
• Data from Sweden show that healthcare costs associated with stroke survivors 
with spasticity are 4-fold higher than for stroke survivors without spasticity.215
• The estimated cost of acute pediatric stroke in the United States was $42 million 
in 2003. The mean cost of short-term hospital care was $20 927 per discharge.216
• After adjustment for routine healthcare costs, the average 5-year cost of a 
neonatal stroke was $51 719 and that of a childhood stroke was $135 161. Costs 
among children with stroke continued to exceed those in age-matched control 
children even in the fifth year by an average of $2016.217
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15. Congenital Cardiovascular Defects and Kawasaki Disease
ICD-9 745 to 747, ICD-10 Q20 to Q28. See Tables 15-1 through 15-4.
Congenital cardiovascular defects, also known as congenital heart defects, are structural 
problems that arise from abnormal formation of the heart or major blood vessels. ICD-9 lists 
25 congenital heart defect codes, of which 21 designate specific anatomic or hemodynamic 
lesions.
Defects range in severity from tiny pinholes between chambers that may resolve 
spontaneously to major malformations that can require multiple surgical procedures before 
school age and may result in death in utero, in infancy, or in childhood. The common 
complex defects include the following:
• TOF
• TGA
• AV septal defects
• Coarctation of the aorta
• HPLHS
Congenital heart defects are serious and common conditions that have a significant impact 
on morbidity, mortality, and healthcare costs in children and in adults.1 As health outcomes 
improve and survival increases for children living with congenital HD, the burden of care is 
shifting toward adult populations.2,3
Incidence
The most commonly reported incidence of congenital heart defects in the United States is 
between 4 and 10 per 1000, clustering around 8 per 1000 live births.4,5 Continental 
variations in birth prevalence have been reported, from 6.9 per 1000 births in Europe to 9.3 
per 1000 in Asia.6 Variations in reported number of incident cases are largely accounted for 
by the age at detection and the method of diagnosis. Major defects may be apparent in the 
prenatal or neonatal period, but minor defects may not be detected until adulthood. 
Detection rates have increased since the advent of cardiac ultrasound7 and pulse oximetry.8 
Thus, true measures of the incidence of congenital HD would need to record new cases of 
defects that present from fetal life onward. Because most estimates are available for new 
cases detected between birth and the first year of life, birth prevalence is the best proxy for 
incidence of congenital heart defects. These are typically reported as cases per 1000 live 
births per year and do not distinguish between tiny defects that resolve without treatment 
and major malformations. To distinguish more serious defects, some studies also report new 
cases of sufficient severity to require an invasive procedure or that result in death within the 
first year of life. Despite the absence of true incidence figures, some data are available and 
are provided in Table 15-2.
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Abbreviations Used in Chapter 15
ASD atrial septal defect
AV atrioventricular
BMI body mass index
CDC Centers for Disease Control and Prevention
CHD coronary heart disease
CI confidence interval
DM diabetes mellitus
HCUP Healthcare Cost and Utilization Project
HD heart disease
HPLHS hypoplastic left heart syndrome
ICD-9 International Classification of Diseases, 9th Revision
ICD-10 International Classification of Diseases, 10th Revision
MACDP Metropolitan Atlanta Congenital Defects Program
NCHS National Center for Health Statistics
NH non-Hispanic
NHLBI National Heart, Lung, and Blood Institute
OR odds ratio
RR relative risk
STS Society of Thoracic Surgeons
TGA transposition of the great arteries
TOF tetralogy of Fallot
VSD ventricular septal defect
• Using population-based data from the MACDP in metropolitan Atlanta, GA, 
congenital heart defects occurred in 1 of every 111 to 125 births (live, still, or 
>20 weeks’ gestation) from 1995 to 1997 and from 1998 to 2005, with variations 
in sex and racial distribution of some lesions.4
• Data collected in Alberta, Canada, found the total prevalence of CHD to be 12.42 
per 1000 total births (live, still, or >20 weeks’ gestation).9
• The National Birth Defects Prevention Network for 13 states from 2004 to 2006 
showed the average prevalence of 21 selected major birth defects. These data 
indicated that there are >6100 estimated annual cases of 5 cardiovascular defects: 
truncus arteriosus (0.7/10 000 births), TGA (3.0/10 000 births), TOF (4.0/10 000 
births), AV septal defect (4.7/10 000 births), and HPLHS (2.3/10 000 births).10
• Analysis of contemporary birth cohorts with MACDP data revealed that the most 
common defects at birth were VSD (4.2/1000 births), ASD (1.3/1000 births), 
valvar pulmonic stenosis (0.6/1000 births); TOF (0.5/1000 births), aortic 
coarctation (0.4/1000 births), AV septal defect (0.4/1000 births), and TGA 
(0.2/1000 births).4,11
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• An estimated minimum of 32 000 infants are expected to be affected with 
congenital HD each year in the United States. Of these, an approximate 25%, or 
2.4 per 1000 live births, require invasive treatment in the first year of life.12
• Estimates also are available for bicuspid aortic valves, which occur in 13.7 per 
1000 people; these defects may not require treatment in infancy but can cause 
problems later in adulthood.13
Prevalence
(See Tables 15-1 through 15-3.)
The 32nd Bethesda Conference estimated that the total number of adults living with 
congenital HD in the United States in 2000 was 800 000.1,14 In the United States, 1 in 150 
adults are expected to have some form of congenital HD.3 In population data from Canada, 
the measured prevalence of congenital cardiac defects in the general population was 11.89 
per 1000 children and 4.09 per 1000 adults in the year 2000.15 Extrapolated to the US 
population in the same year, this yields published estimates of 859 000 children and 850 000 
adults for the year 2000.11 The expected growth rates of the congenital heart defects 
population vary from 1% to 5% per year depending on the age and distribution of lesions.13
Estimates of the distribution of lesions in the congenital heart defects population using 
available data vary with assumptions made. If all those born with lesions between 1940 and 
2002 were treated, there would be 750 000 survivors with simple lesions, 400 000 with 
moderate lesions, and 180 000 with complex lesions; in addition, there would be 3.0 million 
subjects alive with bicuspid aortic valves.16 Without treatment, the number of survivors in 
each group would be 400 000, 220 000, and 30 000, respectively. The actual numbers 
surviving were projected to be between these 2 sets of estimates as of 1 decade ago.16 Using 
measurements from population data in Canada, the prevalence of severe forms of congenital 
heart defects increased 85% in adults and 22% in children from 1985 to 2000.15 The most 
common types of defects in children are (at a minimum) VSD, 620 000 people; ASD, 235 
000 people; valvular pulmonary stenosis, 185 000 people; and patent ductus arteriosus, 173 
000 people.16 The most common lesions seen in adults are ASD and TOF.14
Risk Factors
• Numerous intrinsic and extrinsic nongenetic risk factors contribute to CHD.17
• Attributable risks or fractions have been shown to include paternal anesthesia in 
TOF (3.6%), sympathomimetic medication for coarctation of the aorta (5.8%), 
pesticides for VSD (5.5%), and solvents for HPLHS (4.6%).18
• A study of infants born with heart defects unrelated to genetic syndromes who 
were included in the National Birth Defects Prevention Study found that women 
who reported smoking in the month before becoming pregnant or in the first 
trimester were more likely to give birth to a child with a septal defect. Compared 
with the infants of mothers who did not smoke during pregnancy, infants of 
mothers who were heavy smokers (≥25 cigarettes daily) were twice as likely to 
have a septal defect.19
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• Data from the Baltimore-Washington Infant Study showed that maternal smoking 
during the first trimester of pregnancy was associated with a ≥30% increased risk 
of the following lesions in the fetus: ASD, pulmonary valvar stenosis, truncus 
arteriosus, and TGA.20
• Maternal periconceptional smoking, exposure to secondhand smoke,21 and binge 
drinking22 are associated with an increased risk of congenital cardiac defects. 
Mothers who smoke and report any binge drinking in the 3 months before 
pregnancy are at an increased risk of giving birth to a child with a congenital 
cardiac defect (adjusted OR, 12.65).22 A greater risk of congenital heart defects 
is also seen in women who both have a high BMI and report periconceptional 
smoking.23
• Associations between exposure to air pollutants during first-trimester pregnancy 
and risks of congenital heart defects were documented from 1986 to 2003 by the 
MACDP that related carbon monoxide, nitrogen dioxide, and sulfur dioxide 
measurements to the risk of ASD, VSD, TGA, and TOF.24
• The results of a population-based study examining pregnancy obesity found a 
weak to moderate positive association of maternal obesity with 7 of 16 categories 
of birth defects, including heart defects.25
• Although folic acid supplementation is recommended during pregnancy to 
potentially reduce the risk of congenital heart defects,17 there has been only 1 US 
population-based case-control study, performed with the Baltimore-Washington 
Infant Study between 1981 and 1989, that showed an inverse relationship 
between folic acid use and the risk of TGA.26 A study from Quebec, Canada, 
that analyzed 1.3 million births from 1990 to 2005 found a significant 6% per 
year reduction in severe congenital heart defects using a time-trend analysis 
before and after public health measures were instituted that mandated folic acid 
fortification of grain and flour products in Canada.27
• Pregestational DM was significantly associated with cardiac defects, both 
isolated and multiple. Gestational DM was associated with a limited group of 
birth defects.28
• Paternal risk of occupational exposure was addressed in a study published in 
2012 that documented a higher incidence of congenital HD with paternal 
exposure to phthalates.29
Mortality
(See Tables 15-1 and 15-4.)
Mortality related to congenital cardiovascular defects in 2010 was 3196 deaths. Any-
mention mortality related to congenital cardiovascular defects in 2010 was 5018 deaths.30
• In 2010, congenital cardiovascular defects were the most common cause of 
infant death resulting from birth defects; 26.6% of infants who died of a birth 
defect had a heart defect.31
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• The 2010 age-adjusted death rate (deaths per 100 000 people) attributable to 
congenital cardiovascular defects was 1.1. Death rates were 1.1 for white males, 
1.4 for black males, 0.9 for white females, and 1.2 for black females. Crude 
infant (<1 year of age) mortality rates were 32.5 for white infants and 43.2 for 
black infants.31,32
• Death rates attributed to congenital heart defects decrease as gestational age 
advances toward 40 weeks,33 and similarly, in-hospital death of infants with 
major congenital HDs is independently associated with late-preterm birth (OR, 
2.70; 95% CI, 1.69–4.33) compared with delivery at later gestational ages.34
• In a study that investigated mortality in very low-birth-weight infants, the 
mortality rate of very low-birth-weight infants with serious congenital HD was 
44% compared with 12.7% in very low-birth-weight infants without serious 
congenital HD.35
• The death rate attributable to congenital heart defects in the United States has 
continued to decline from 1979 to 1997 and from 1999 to 2006. Age-adjusted 
death rates attributable to all congenital heart defects declined 21% to 39%, and 
deaths tended to occur at progressively older ages. Although 1-year survival for 
infants with congenital heart defects has increased from 67.4% (1979–1993) to 
82.5% (1994–2005),36 mortality in infants <1 year of age continues to account 
for nearly half of the deaths associated with congenital heart defects.36a
• When CDC data on multiple causes of death were used to examine mortality in 
cyanotic and acyanotic lesions between 1979 and 2005, all-age death rates had 
declined by 60% for VSD and 40% for TOF.37
• In population-based data from Canada, 8123 deaths occurred in 71 686 
congenital HD patients followed up for nearly 1 million patient-years. Overall 
mortality decreased by 31%, and the median age of death increased from 2 to 23 
years between 1987 and 2005.3
• Mortality after congenital heart surgery also differs between races/ethnicities 
after adjustment for access to care. The risk of in-hospital mortality for minority 
patients compared with white patients is 1.22 (95% CI, 1.05–1.41) for Hispanics, 
1.27 (95% CI, 1.09–1.47) for non-Hispanic blacks, and 1.56 (95% CI, 1.37–1.78) 
for other non-Hispanics.38 Similarly, another study found that a higher risk of in-
hospital mortality was associated with nonwhite race (OR, 1.36; 95% CI, 1.19–
1.54), as well as Medicaid insurance (OR, 1.26; 95% CI, 1.09–1.46).39
• According to CDC multiple-cause death data, from 1999 to 2006, sex differences 
in mortality over time varied with age. Between the ages of 18 and 34 years, 
mortality over time decreased significantly in females but not in males.40
• On the basis of data from HCUP’s Kids’ Inpatient Database from 2000, 2003, 
and 2006, male children had more congenital heart defect surgeries in infancy, 
more high-risk surgeries, and more procedures to correct multiple congenital 
heart defects. Female infants with high-risk congenital heart defects had a 39% 
higher adjusted mortality.41
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• In 2007, 189 000 life-years were lost before 55 years of age because of deaths 
attributable to congenital cardiovascular defects. This is almost as many life-
years as were lost from leukemia and asthma combined (NHLBI tabulation of 
NCHS mortality data).
• Data from studies conducted in 15 North American centers by the Pediatric 
Heart Network revealed that even in lesions associated with the highest mortality 
among congenital lesions, such as HPLHS, aggressive palliation can lead to an 
increase in the 12-month survival rate, from 64% to 74%.42
• Data analysis for the STS Congenital Heart Surgery Database, a voluntary 
registry with self-reported data for a 4-year cycle (2007–2010) from 103 centers 
performing congenital heart surgery (98 from the United States, 3 from Canada, 
and 1 from Japan),43 showed that of 95 357 total operations, the overall 
aggregate hospital discharge mortality rate was 3.5%.44 Specifically, the 
mortality rate was 10.1% for neonates (0–30 days of age),45 2.9% for infants (31 
days to 1 year of age),46 1.1% for children (>1 year to 18 years of age),47 and 
1.9% for adults (>18 years of age).48
• Using the Nationwide Inpatient Sample 1988 to 2003, mortality was examined 
for 12 congenital heart defect procedures. A total of 30 250 operations were 
identified, which yielded a national estimate of 152 277±7875 operations. Of 
these, 27% were performed in patients ≥18 years of age. The overall in-hospital 
mortality rate for adult patients with congenital heart defects was 4.71% (95% 
CI, 4.19%– 5.23%), with a significant reduction in mortality observed when 
surgery was performed on such adult patients by pediatric versus nonpediatric 
heart surgeons (1.87% versus 4.84%; P<0.0001).49
Hospitalizations
(See Table 15-1.)
In 2004, birth defects accounted for >139 000 hospitalizations, representing 47.4 stays per 
100 000 people. Cardiac and circulatory congenital anomalies accounted for 34% of all 
hospital stays for birth defects. Although the most common congenital lesions were shunts, 
including patent ductus arteriosus, VSDs, and ASDs, TOF accounted for a higher proportion 
of in-hospital death than any other birth defect. Between 1997 and 2004, hospitalization 
rates increased by 28.5% for cardiac and circulatory congenital anomalies.50
Cost
• From data from the HCUP 2003 Kids’ Inpatient Database and 2003 information 
on birth defects in the Congenital Malformations Surveillance Report, it was 
found that the most expensive average neonatal hospital charges were for 2 
congenital heart defects: HPLHS ($199 597) and common truncus arteriosus 
($192 781). Two other cardiac defects, coarctation of the aorta and TGA, were 
associated with average hospital charges in excess of $150 000. For the 11 
selected cardiovascular congenital defects (of 35 birth defects considered), there 
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were 11 578 hospitalizations in 2003 and 1550 in-hospital deaths (13.4%). 
Estimated total hospital charges for these 11 conditions were $1.4 billion.51
• In 2004, hospital costs for congenital cardiovascular defect conditions totaled 
$2.6 billion. The highest aggregate costs were for stays related to cardiac and 
circulatory congenital anomalies, which accounted for ≈$1.4 billion, more than 
half of all hospital costs for birth defects.50
• Data from 1941 neonates with HPLHS showed a median cost of $99 070 for 
stage 1 palliation (Norwood or Sano procedure), $35 674 for stage 2 palliation 
(Glenn procedure), $36 928 for stage 3 palliation (Fontan procedure), and $289 
292 for transplantation.52
• In 2124 patients undergoing congenital heart operations between 2001 and 2007, 
total costs for the surgeries were $12 761 (ASD repair), $18 834 (VSD repair), 
$28 223 (TOF repair), and $55 430 (arterial switch operation).53
Kawasaki Disease
ICD-9 446.1; ICD-10 M30.3.
Mortality—8. Any-mention mortality—12.
• The incidence of Kawasaki disease is rising worldwide, including in the United 
States, where the hospitalization rate rose from 17.5/100 000 children aged <5 
years to 20.8/100 000 children <5 years in 2006.54 In 2010, Japan experienced its 
highest-ever incidence rate of 239.6 cases per 100 000 children aged <4 years,55 
and in Korea, the rate reached 113.1/100 000 children <5 years old in 2008.56 A 
recent study reports a rate of 164.6/100 000 in children <5 years old in Taiwan.57
• In addition to geographic variation in the incidence of Kawasaki disease, the age 
of children affected may also differ. In northern Europe (Finland, Sweden, and 
Norway), 67.8% of patients with Kawasaki disease were <5 years of age, 
compared with 86.4% of patients in Japan (P<0.001).58
• US states with higher Asian American populations have higher rates of Kawasaki 
disease; for example, rates are 2.5-fold higher in Hawaii than in the continental 
United States.59
• Boys have a 1.5-fold higher incidence of Kawasaki disease than girls.59
• An estimated 5523 hospitalizations for Kawasaki disease occurred in the United 
States in 2006, with a mean patient age of 3 years. Race-specific incidence rates 
indicate that Kawasaki disease is most common among Americans of Asian and 
Pacific Island descent (30.3/100 000 children <5 years of age), occurs with 
intermediate frequency in non- Hispanic blacks (17.5/100 000 children <5 years 
of age) and Hispanics (15.7/100 000 children <5 years of age), and is least 
common in whites (12.0/100 000 children <5 years of age).60
• Kawasaki disease is more common during the winter and early spring months, 
except in Hawaii, where no clear seasonal trend is seen61; it occurs more often in 
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boys than girls at a ratio of ≈1.5:1, and 76.8% of children with Kawasaki disease 
are <5 years of age.54,59,60
• Data from the Kids’ Inpatient Database59 show a hospitalization rate for 
Kawasaki disease for children <5 years of
– 19 per 100 000 in 2009
– 20.8 per 100 000 in 2006
– 17.3 per 100 000 in 2003
– 17.5 per 100 000 in 2000
• Addition of prednisolone to the standard regimen of intravenous immunoglobulin 
for patients with severe Kawasaki disease appears to result in a substantial 
reduction in the incidence of coronary artery anomalies (RR, 0.20; 95% CI, 
0.12–0.28).62
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16. Disorders of Heart Rhythm
See Tables 16-1 and 16-2.
Bradyarrhythmias
ICD-9 426.0, 426.1, 427.81; ICD-10 I44.0 to I44.3, I49.5.
Mortality—841. Any-mention mortality—4927. Hospital discharges—110 000.
AV Block
Prevalence and Incidence
• The prevalence of first-degree AV block in NHANES III was 3.7%.1
• In a healthy sample of subjects from the ARIC study (mean age 53 years), the 
prevalence of first-degree AV block was 7.8% in black men, 3.0% in black 
women, 2.1% in white men, and 1.3% in white women.2 Lower prevalence 
estimates were noted in the relatively younger population (mean age 45 years) of 
the CARDIA study at its year 20 follow-up examination: 2.6% in black men, 
1.9% in black women, 1.2% in white men, and 0.1% in white women.2
• Mobitz II second-degree AV block is rare in healthy individuals (≈0.003%), 
whereas Mobitz I (Wenckebach) is observed in 1% to 2% of healthy young 
people, especially during sleep.2
• The prevalence of third-degree AV block in the general adult population is 
≈0.02% to 0.04%.3,4
• Third-degree AV block is very rare in apparently healthy individuals. Johnson et 
al5 found only 1 case among >67 000 symptom-free individuals; Rose et al,6 in 
their study of >18 000 civil servants, did not find any cases. On the other hand, 
among 293 124 patients with DM and 552 624 with hypertension enrolled with 
Veterans Health Administration hospitals, third-degree AV block was present in 
1.1% and 0.6% of those patients, respectively.7
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• Congenital complete AV block is estimated to occur in 1 of 15 000 to 25 000 live 
births.2
Abbreviations Used in Chapter 16
AF atrial fibrillation
AHA American Heart Association
AMI acute myocardial infarction
ARIC Atherosclerosis Risk in Communities study
ASSERT Asymptomatic Atrial Fibrillation and Stroke Evaluation in Pacemaker Patients and the Atrial 
Fibrillation Reduction Atrial Pacing Trial
AV atrioventricular
BMI body mass index
BP blood pressure
CABG coronary artery bypass graft
CAD coronary artery disease
CARDIA Coronary Artery Risk Development in Young Adults
CASQ2 calsequestrin 2
CHD coronary heart disease
CHS Cardiovascular Health Study
CI confidence interval
CKD chronic kidney disease
CPR cardiopulmonary resuscitation
CVD cardiovascular disease
DM diabetes mellitus
ECG electrocardiogram
ED emergency department
EMPHASIS-HF Eplerenone in MildPatients Hospitalization And Survival Study in Heart Failure
EMS emergency medical services
FHS Framingham Heart Study
GBD Global Burden of Diseases, Injuries, and Risk Factors Study
GWTG Get With The Guidelines
HCM hypertrophic cardiomyopathy
HD heart disease
HF heart failure
HR hazard ratio
ICD-9 International Classification of Diseases, 9th Revision
ICD-10 International Classification of Diseases, 10th Revision
MI myocardial infarction
IHCA in-hospital cardiac arrest
NCHS National Center for Health Statistics
NHANES National Health and Nutrition Examination Survey
NHDS National Hospital Discharge Survey
NHLBI National Heart, Lung, and Blood Institute
OR odds ratio
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PA physical activity
PAR population attributable risk
PVT polymorphic ventricular tachycardia
RR relative risk
RYR2 ryanodine type 2 receptor
SBP systolic blood pressure
SD standard deviation
SVT supraventricular tachycardia
TdP torsade de pointes
VF ventricular fibrillation
VT ventricular tachycardia
YLL years of life lost
Risk Factors
• Although first-degree AV block and Mobitz type I second-degree AV block can 
occur in apparently healthy individuals, presence of Mobitz II second-degree or 
third-degree AV block usually indicates underlying HD, including CHD and HF.2
• Reversible causes of AV block include electrolyte abnormalities, drug-induced 
AV block, perioperative AV block attributable to hypothermia, or inflammation 
near the AV conduction system after surgery in this region. Some conditions may 
warrant pacemaker implantation because of the possibility of disease progression 
even if the AV block reverses transiently (eg, sarcoidosis, amyloidosis, and 
neuromuscular diseases).8
• Long sinus pauses and AV block can occur during sleep apnea. In the absence of 
symptoms, these abnormalities are reversible and do not require pacing.9
Prevention
• Detection and correction of reversible causes of acquired AV block could be of 
potential importance in preventing symptomatic bradycardia and other 
complications of AV block.8
• In utero detection of congenital AV block is possible by echocardiography.10
Aftermath
• In the FHS, PR interval prolongation (>200 ms) was associated with an increased 
risk of AF (HR, 2.06; 95% CI, 1.36–3.12),11,12 pacemaker implantation (HR, 
2.89; 95% CI, 1.83–4.57),12 and all-cause mortality (HR, 1.44; 95% CI, 1.09–
1.91).12 Compared with individuals with a PR ≤200 ms, individuals with a PR 
interval >200 ms had an absolute increased risk per year of 1.04% for AF, 0.55% 
for pacemaker implantation, and 2.05% for death.
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• Patients with abnormalities of AV conduction may be asymptomatic or may 
experience serious symptoms related to bradycardia, ventricular arrhythmias, or 
both.
• Decisions about the need for a pacemaker are influenced by the presence or 
absence of symptoms directly attributable to bradycardia. Permanent pacing 
improves survival in patients with third-degree AV block, especially if syncope 
has occurred.8 Nevertheless, the overall prognosis depends to a large extent on 
the underlying HD.
• Although there is little evidence to suggest that pacemakers improve survival in 
patients with isolated first-degree AV block,13 it is now recognized that marked 
first-degree AV block (PR >300 ms) can lead to symptoms even in the absence of 
higher degrees of AV block.14
Prognosis
• Investigators at Northwestern University compared older adult (age >60 years) 
outpatients with (n=470) and without (n=2090) asymptomatic bradycardia. Over 
a mean followup of 7.2 years, patients with asymptomatic bradycardia had a 
higher adjusted incidence of pacemaker insertion (HR, 2.14; 95% CI, 1.30–3.51; 
P=0.003), which appeared after a lag time of 4 years. However, the absolute rate 
of pacemaker implantation was low (<1% per year), and asymptomatic 
bradycardia was not associated with a higher risk of death.15
Sinus Node Dysfunction
Prevalence and Incidence
• The prevalence of sinus node dysfunction has been estimated to be between 403 
and 666 per million, with an incidence rate of 63 per million per year requiring 
pacemaker therapy.16
• Sinus node dysfunction occurs in 1 of every 600 cardiac patients >65 years of 
age and accounts for ≈50% of implantations of pacemakers in the United 
States.17,17a
• Sinus node dysfunction is commonly present with other causes of 
bradyarrhythmias (carotid sinus hypersensitivity in 33% of patients and advanced 
AV conduction abnormalities in 17%).18,19
Risk Factors
• The causes of sinus node dysfunction can be classified as intrinsic (secondary to 
pathological conditions involving the sinus node) or extrinsic (caused by 
depression of sinus node function by external factors such as drugs or autonomic 
influences).20
• Sinus node dysfunction may occur at any age but is primarily a disease of the 
elderly, with the average being ≈68 years of age.17
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• Idiopathic degenerative disease is probably the most common cause of sinus 
node dysfunction.21
• Collected data from 28 different studies on atrial pacing for sinus node 
dysfunction showed a median annual incidence of complete AV block of 0.6% 
(range, 0%–4.5%) with a total prevalence of 2.1% (range, 0%–11.9%). This 
suggests that the degenerative process also affects the specialized conduction 
system, although the rate of progression is slow and does not dominate the 
clinical course of disease.22
• Ischemic HD can be responsible for one third of cases of sinus node dysfunction. 
Transient sinus node dysfunction can complicate MI; it is common during 
inferior MI and is caused by autonomic influences. Cardiomyopathy, long-
standing hypertension, infiltrative disorders (eg, amyloidosis and sarcoidosis), 
collagen vascular disease, and surgical trauma can also result in sinus node 
dysfunction.23,24
Aftermath
• The course of sinus node dysfunction is typically progressive, with 57% of 
patients experiencing symptoms over a 4-year period if untreated, and a 23% 
prevalence of syncope over the same time frame.25
• Approximately 50% of patients with sinus node dysfunction develop tachy-brady 
syndrome over a lifetime; such patients have a higher risk of stroke and death. 
The survival of patients with sinus node dysfunction appears to depend primarily 
on the severity of underlying cardiac disease and is not significantly changed by 
pacemaker therapy.26–28
• In a retrospective study,29 patients with sinus node dysfunction who had 
pacemaker therapy were followed up for 12 years; at 8 years, mortality among 
those with ventricular pacing was 59% compared with 29% among those with 
atrial pacing. This discrepancy may be attributed to selection bias. For instance, 
the physiological or anatomic disorder (eg, fibrosis of conductive tissue) that led 
to the requirement for the particular pacemaker may have influenced prognosis, 
rather than the type of pacemaker used.
• The incidence of sudden death is extremely low, and sinus node dysfunction does 
not appear to affect survival whether untreated or treated with pacemaker 
therapy.8
• SVT including AF occurs in 47% to 53% of patients with sinus node 
dysfunction.28,30
• On the basis of records from the NHDS, age-adjusted pacemaker implantation 
rates increased progressively from 370 per million in 1990 to 612 per million in 
2002. This escalating implantation rate is attributable to increasing implantation 
for isolated sinus node dysfunction; implantation for sinus node dysfunction 
increased by 102%, whereas implantation for all other indications did not 
increase.31
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SVT (Excluding AF and Atrial Flutter)
ICD-9 427.0; ICD-10 I47.1.
Mortality—132. Any-mention mortality—1206. Hospital discharges—23 000.
Prevalence and Incidence
• Data from the Marshfield Epidemiologic Study Area in Wisconsin suggested the 
incidence of documented paroxysmal SVT is 35 per 100 000 person-years. The 
mean age at SVT onset was 57 years, and both female sex and age >65 years 
were significant risk factors.32
• A review of ED visits from 1993 to 2003 revealed that 550 000 visits were for 
SVT (0.05% of all visits; 95% CI, 0.04%–0.06%), or ≈50 000 visits per year. Of 
these patients, 24% (95% CI, 15%–34%) were admitted to the hospital, and 44% 
(95% CI, 32%–56%) were discharged without specific follow-up.33
• The prevalence of SVT that is clinically undetected is likely much greater than 
the estimates from ED visits and electrophysiology procedures would suggest. 
For example, among a random sample of 604 participants in Finland, 7 (1.2%) 
fulfilled the diagnostic criteria for inappropriate sinus tachycardia.34
• Of 1383 participants in the Baltimore Longitudinal Study of Aging undergoing 
maximal exercise testing, 6% exhibited SVT during the test; increasing age was a 
significant risk factor. Only 16% exhibited >10 beats of SVT, only 4% were 
symptomatic, and the SVT participants were more likely to develop spontaneous 
SVT or AF.35
• From the surface ECG, the prevalence of atrial tachycardia is estimated to be 
0.34% in asymptomatic patients and 0.46% in symptomatic patients.36
Aftermath
• The primary consequence of SVT for the majority of patients is a decline in 
quality of life.37 However, rare cases of incessant SVT can lead to a tachycardia-
induced cardiomyopathy, 38 and rare cases of sudden death attributed to SVT as a 
trigger have been described.39
Specific Types
• Among those presenting for invasive electrophysiological study and ablation, AV 
nodal reentrant tachycardia (a circuit that requires 2 AV nodal pathways) is the 
most common mechanism of SVT40,41 and usually represents the majority of 
cases (56% of 1 series of 1754 cases from Loyola University Medical Center).41
• AV reentrant tachycardia (an arrhythmia that requires the presence of an 
extranodal connection between the atria and ventricles or specialized conduction 
tissue) is the second most common42,43 type of SVT (27% in the Loyola 
series),41 and atrial tachycardia is the third most common (17% in the Loyola 
series).41
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• In the pediatric population, AV reentrant tachycardia is the most common SVT 
mechanism, followed by AV nodal reentrant tachycardia and then atrial 
tachycardia.44
• AV reentrant tachycardia prevalence decreases with age, whereas AV nodal 
reentrant tachycardia and atrial tachycardia prevalences increase with advancing 
age.41
• The majority of AV reentrant tachycardia patients in the Loyola series were men 
(55%), whereas the majority of patients with AV nodal reentrant tachycardia 
(70%) or atrial tachycardia (62%) were women.41
• Multifocal atrial tachycardia is an arrhythmia that is commonly confused with 
AF and is characterized by 3 distinct P-wave morphologies, irregular R-R 
intervals, and a rate >100 beats per minute. It is uncommon in both children42 
and adults,43 with a prevalence in hospitalized adults estimated at 0.05% to 
0.32%.45,46 The average age in adults is 70 to 72 years. Adults with multifocal 
atrial tachycardia have a mortality rate that is high, with estimates around 45%, 
but this is generally ascribed to the underlying condition(s).43,47
Wolff-Parkinson-White Syndrome
• Wolff-Parkinson-White syndrome, a diagnosis reserved for those with both 
ventricular preexcitation (evidence of an anterograde conducting AV accessory 
pathway on a 12-lead ECG) and tachyarrhythmias,37 deserves special attention 
because of the associated risk of sudden death. Sudden death is generally 
attributed to rapid heart rates in AF conducting down an accessory pathway and 
leading to VF.48,49 Of note, AF is common in Wolff-Parkinson-White patients, 
and surgical or catheter ablation of the accessory pathway often results in 
elimination of the AF.50
• Ventricular preexcitation with or without tachyarrhythmia was observed in 
0.11% of 47 358 ECGs in adults participating in 4 large Belgian epidemiological 
studies45 and in 0.17% of 32 837 Japanese high school students in ECGs 
obtained by law before the students entered school.46
• Asymptomatic adults with ventricular preexcitation appear to be at no increased 
risk of sudden death compared with the general population,48,49,51,52 although 
certain characteristics found during invasive electrophysiological study 
(including inducibility of AV reentrant tachycardia or AF, accessory pathway 
refractory period, and the shortest R-R interval during AF) can help risk stratify 
these patients.49,53
• In a meta-analysis of 20 studies involving 1869 asymptomatic patients with a 
Wolff-Parkinson-White ECG pattern followed up for a total of 11 722 person-
years, the risk of sudden death in a random effects model that was used because 
of heterogeneity across studies was estimated to be 1.25 (95% CI, 0.57–2.19) per 
1000 person-years. Risk factors for sudden death included male sex, inclusion in 
a study of children (<18 years of age), and inclusion in an Italian study.54
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• Symptomatic adult patients with the Wolff-Parkinson-White syndrome are at a 
higher risk of sudden death. In a study of 60 symptomatic patients in Olmsted 
County, MN, including some who underwent curative surgery, 2 (3.3%) 
experienced sudden death over a 13-year period. Of 690 Wolff-Parkinson- White 
syndrome patients referred to a single hospital in the Netherlands, 15 (2.2%) had 
aborted sudden death, and VF was the first manifestation of the disease in 8 
patients.55
• Of 379 Wolff-Parkinson-White patients with induced AV reentrant tachycardia 
during electrophysiology study who did not undergo ablation, 29 (8%) exhibited 
a “malignant presentation” over a mean 3.6 years of follow-up: syncope/
presyncope in 25 patients, rapid preexcited AF causing hemodynamic collapse in 
3 patients, and VF in 1 patient.56 Those with such a presentation were more often 
male, had a shorter accessory pathway effective refractory period during 
electrophysiology study, more often had AV reentrant tachycardia that triggered 
AF during electrophysiology study, and more often had >1 accessory pathway.
• Although some studies in asymptomatic children with ventricular preexcitation 
suggest a benign prognosis,51,57 others suggest that electrophysiological testing 
can identify a group of asymptomatic children with a risk of sudden death or VF 
as high as 11% over 19 months of follow-up.58
Subclinical Atrial Tachyarrhythmias and Unrecognized AF
Pacemakers and defibrillators have increased clinician awareness of the frequency of 
subclinical AF and atrial high-rate episodes in individuals without a documented history of 
AF. Several studies have suggested that device-detected high-rate atrial tachyarrhythmias are 
surprisingly frequent and are associated with an increased risk of AF,53 
thromboembolism,53,59 and total mortality.53
• Investigators in the ASSERT study prospectively enrolled 2580 patients with a 
recent pacemaker or defibrillator implantation who were ≥65 years of age, had a 
history of hypertension, and had no history of AF. They classified individuals by 
presence versus absence of subclinical atrial tachyarrhythmias (defined as atrial 
rate >190 beats per minute for >6 minutes in the first 3 months) and conducted 
follow- up for 2.5 years.60 Subclinical atrial tachyarrhythmias in the first 3 
months occurred in 10.1% of the patients and were associated with the 
following:
– An almost 6-fold higher risk of clinical AF (HR, 5.56; 95% CI, 3.78–
8.17; P<0.001)
– A more than doubling in the adjusted risk of the primary end point, 
ischemic stroke or systemic embolism (HR, 2.50; 95% CI, 1.28–4.89; 
P<0.008)
– An annual ischemic stroke or systemic embolism rate of 1.69% (versus 
0.69% in those without)
– A 13% PAR for ischemic stroke or systemic embolism
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• Over the subsequent 2.5 years of follow-up, an additional 34.7% of the patients 
had subclinical atrial tachyarrhythmias, which were 8-fold more frequent than 
clinical AF episodes.
• The appropriate therapy of subclinical atrial tachyarrhythmias has not been 
rigorously studied.
• In a community-based study in Sweden, all inhabitants aged 75 to 76 years were 
invited to a stepwise screening program for AF. Of 848 participants, 10 had 
clinically unrecognized AF diagnosed on a 12-lead ECG. Of 403 individuals 
with ≥2 stroke risk factors who completed a 2-week once-a-day handheld ECG 
event recorder, an additional 30 were diagnosed with paroxysmal AF. The study 
suggests that the burden of unrecognized AF in the community is higher than 
appreciated.61
AF and Atrial Flutter
ICD-9 427.3; ICD-10 I48.
Prevalence
• Estimates of the prevalence of AF in the United States ranged from ≈2.7 million 
to 6.1 million in 2010, and AF prevalence is expected to rise to between ≈5.6 and 
12 million in 2050.62,63
• Data from a California health plan suggest that compared with whites, blacks 
(OR, 0.49; 95% CI, 0.47–0.52), Asians (OR, 0.68; 95% CI, 0.64–0.72), and 
Hispanics (OR, 0.58; 95% CI, 0.55–0.61) have significantly lower adjusted 
prevalences of AF.64
• Data from the NHDS/NCHS (1996–2001) on cases that included AF as a 
primary discharge diagnosis found the following:
– Approximately 44.8% of patients were men.
– The mean age for men was 66.8 years versus 74.6 years for women.
– The racial breakdown for admissions was 71.2% white, 5.6% black, and 
2.0% other races (20.8% were not specified).
– Black patients were much younger than patients of other races.
• Among Medicare patients aged ≥65 years, diagnosed from 1993 to 2007, the 
prevalence of AF increased ≈5% per year, from ≈41.1 per 1000 beneficiaries to 
85.5 per 1000 beneficiaries.65
Incidence
• Data from the NHDS/NCHS (1996–2001) on cases that included AF as a 
primary discharge diagnosis found the following:
et al. Page 226
Circulation. Author manuscript; available in PMC 2017 April 28.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
– The incidence in men ranged from 20.6 per 100 000 people per year for 
patients between 15 and 44 years of age to 1077.4 per 100 000 people 
per year for patients ≥85 years of age.
– In women, the incidence ranged from 6.6 per 100 000 people per year 
for patients between 15 and 44 years of age to 1203.7 per 100 000 
people per year for those ≥85 years of age.
• In Olmsted County, MN
– The age-adjusted incidence of clinically recognized AF in a white 
population increased by 12.6% between 1980 and 2000.66,67
– The incidence of AF was greater in men (incidence ratio for men over 
women 1.86) and increased markedly with older age.63
• In a Medicare sample, the incidence of AF was ≈28 per 1000 person-years and 
did not change substantively between 1993 and 2007. Of individuals with 
incident AF in 2007, ≈55% were women, 91% were white, 84% had 
hypertension, 36% had HF, and 30% had cerebrovascular disease.65
Mortality
• In 2010, AF was mentioned on 107 335 US death certificates and was the 
underlying cause in 16 454 of those deaths (NCHS, NHLBI).
• In adjusted analyses from the FHS, AF was associated with an increased risk of 
death in both men (OR, 1.5; 95% CI, 1.2–1.8) and women (OR, 1.9; 95% CI, 
1.5–2.2).68 Furthermore, there was an interaction with sex, such that AF 
appeared to diminish the survival advantage typically observed in women.
• In Medicare beneficiaries ≥65 years of age with new-onset AF, mortality 
decreased modestly but significantly between 1993 and 2007. In 2007, the age- 
and sex-adjusted mortality at 30 days was 11%, and at 1 year, it was 25%.65
• A study of >4600 patients diagnosed with first AF showed that risk of death 
within the first 4 months after the AF diagnosis was high. The most common 
causes of CVD death were CAD, HF, and ischemic stroke, which accounted for 
22%, 14%, and 10%, respectively, of the early deaths (within the first 4 months) 
and 15%, 16%, and 7%, respectively, of the late deaths.69
• AF is also associated with mortality in individuals with other cardiovascular 
conditions and procedures, including HF,66,70 MI,67,71 CABG,72,73 and stroke,74 
and with noncardiovascular conditions such as sepsis75 and noncardiac surgery.76
Lifetime Risk and Cumulative Risk
• Participants in the NHLBI-sponsored FHS were followed up from 1968 to 1999. 
At 40 years of age, remaining lifetime risks for AF were 26.0% for men and 
23.0% for women. At 80 years of age, lifetime risks for AF were 22.7% for men 
and 21.6% for women. In further analysis, counting only those who had 
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development of AF without prior or concurrent HF or MI, lifetime risk for AF 
was ≈16%.77
• Investigators from the NHLBI-sponsored ARIC study observed that the 
cumulative risk of AF was 21% in white men, 17% in white women, and 11% in 
African Americans of both sexes by 80 years of age.78
Risk Factors
• Standard risk factors
– Both ARIC71 and FHS (http://www.framinghamheart-study.org/risk/
atrial.html)11,79 have developed risk prediction models to predict new-
onset AF. Predictors of increased risk of new-onset AF include 
advancing age, European ancestry, body size (greater height and BMI), 
electrocardiography features (left ventricular hypertrophy, left atrial 
enlargement), DM, BP (SBP and hypertension treatment), and presence 
of CVD (CHD, HF, valvular HD).
– More recently, the ARIC, CHS, and FHS investigators developed and 
validated a risk prediction model.73
– Other consistently reported risk factors for AF include clinical and 
subclinical hyperthyroidism,80,81 CKD,82 and heavy alcohol 
consumption.83
• Family history
– Although unusual, early-onset familial lone AF has long been 
recognized as a risk factor.84,85
– In the past decade, the heritability of AF in the community has been 
appreciated. In studies from the FHS
♦ Adjusted for coexistent risk factors, having at least 1 parent 
with AF was associated with a 1.85-fold increased risk of AF 
in the adult offspring (multivariable- adjusted 95% CI, 1.12–
3.06; P=0.02).86
♦ A history of a first-degree relative with AF also was associated 
with an increased risk of AF (HR, 1.40; 95% CI, 1.13–1.74).72 
The risk was greater if the first-degree relative’s age of onset 
was ≤65 years (HR, 2.01; 95% CI, 1.49–2.71) and with each 
additional affected first-degree relative (HR, 1.24; 95% CI, 
1.05–1.46).87
• Genetics
– Mutations in genes coding channels (sodium and potassium), gap 
junction proteins, and signaling have been described, often in lone AF 
or familial AF series, but they are responsible for few cases of AF in the 
community.88
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– Meta-analyses of genome-wide association studies have revealed 
single-nucleotide polymorphisms on chromosomes 4q25 (upstream of 
PITX2),89–91 16q22 (ZFHX3),90,92 and 1q21 (KCNN3),91 as well as 6 
other novel susceptibility loci (near PRRX1, CAV1, C9orf3, 
SYNPO2L, SYNE2, and HCN4).93 Although an area of intensive 
inquiry, the causative single-nucleotide polymorphisms and the 
functional basis of the associations have not been revealed.
Awareness
• In a US national biracial study of individuals with AF, compared with whites, 
blacks had approximately one third the likelihood (OR, 0.32; 95% CI, 0.20–0.52) 
of being aware that they had AF.94
Prevention
• Data from the ARIC study indicated that having at least 1 elevated risk factor 
explained 50% and having at least 1 borderline risk factor explained 6.5% of 
incident AF cases. The estimated overall incidence rate per 1000 person-years at 
a mean age of 54.2 years was 2.19 for those with optimal risk, 3.68 for those 
with borderline risk, and 6.59 for those with elevated risk factors.95
• Hypertension accounted for ≈14%96 to 22%95 of AF cases.
• Observational data from the CHS suggested that moderate-intensity exercise 
(such as regular walking) was associated with a lower risk of AF (HR, 0.72).97 
However, data from many studies suggested that vigorous-intensity exercise 5 to 
7 days a week was associated with a slightly increased risk of AF (HR, 1.20; 
P=0.04).98
• Meta-analyses have suggested that renin-angiotensin system blockers may be 
useful in primary and secondary (recurrences) prevention of AF in trials of 
hypertension, after MI, in HF, and after cardioversion.74,99 However, the studies 
were primarily secondary or post hoc analyses, and the results were fairly 
heterogeneous. Recently, in an analysis of the EMPHASIS-HF trial, in one of 
many secondary outcomes, eplerenone was nominally observed to reduce the 
incidence of new-onset AF.100
• Although heterogeneous in their findings, modest-sized short-term studies 
suggested that the use of statins might prevent AF; however, larger longer-term 
studies do not provide support that statins are effective in AF prevention.101
• The NHLBI sponsored a workshop highlighting important research areas to 
advance the prevention of AF.102
Aftermath
• Hospitalization
– Hospital discharges—479 000.
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♦ From 1996 to 2001, hospitalizations with AF as the first-listed 
diagnosis increased by 34%.103
♦ On the basis of Medicare and MarketScan databases, annually, 
individuals with AF (37.5%) are approximately twice as likely 
to be hospitalized as age- and sex-matched control subjects 
(17.5%).104
• Stroke
– Stroke rates per 1000 patient-years declined in AF patients taking 
anticoagulants, from 46.7 in 1992 to 19.5 in 2002, for ischemic stroke 
but remained fairly steady for hemorrhagic stroke (1.6–2.9).105
– When standard stroke risk factors were accounted for, AF was 
associated with a 4- to 5-fold increased risk of ischemic stroke.106
– Although the RR of stroke associated with AF did not vary (≈3–5-fold 
increased risk) substantively with advancing age, the proportion of 
strokes attributable to AF increased significantly. In FHS, AF accounted 
for ≈1.5% of strokes in individuals 50 to 59 years of age and ≈23.5% in 
those 80 to 89 years of age.106
– Paroxysmal, persistent, and permanent AF all appeared to increase the 
risk of ischemic stroke to a similar degree.99
– AF was also an independent risk factor for ischemic stroke severity, 
recurrence, and mortality.74 In one study, people who had AF and were 
not treated with anticoagulants had a 2.1-fold increase in risk for 
recurrent stroke and a 2.4- fold increase in risk for recurrent severe 
stroke.107
– Studies have demonstrated an underutilization of warfarin therapy. In a 
recent meta-analysis, men and individuals with prior stroke were more 
likely to receive warfarin, whereas factors associated with lower use 
included alcohol and drug abuse, noncompliance, warfarin 
contraindications, dementia, falls, both gastrointestinal and intracranial 
hemorrhage, renal impairment, and advancing age.108
• Cognition
– Individuals with AF have an adjusted 2-fold increased risk of 
dementia.109
– A meta-analysis suggested that the risk was consistently high in the 7 
studies of patients with recent stroke and a history of AF (OR, 2.4; 95% 
CI, 1.7–3.5; P<0.001; I2=87%). There was significant heterogeneity in 
the 7 studies of individuals without a history of stroke (OR, 1.6; 95% 
CI, 1.0–2.7; P=0.05; I2=87%).110
– In individuals with AF in Olmsted County, MN, the cumulative rate of 
dementia at 1 and 5 years was 2.7% and 10.5%, respectively.100
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• Heart failure
– AF and HF share many antecedent risk factors, and ≈40% of 
individuals with either AF or HF will develop the other condition.66
– In the community, estimates of the incidence of HF in individuals with 
AF ranged from.3.366 to 4.4111 per 100 person-years of follow-up.
Global Burden
• The vast majority of research on the epidemiology of AF has been conducted in 
Europe and North America. The GBD study estimated annual deaths and 
disability-adjusted life-years globally for hundreds of diseases, including AF.
– Standardizing by age, the investigators estimated that between 1990 and 
2010, the death rate (per 100 000) increased 89.6%, from 0.9 (0.7–1.1) 
to 1.7 (1.4–2.1) over all ages.112
– The investigators estimated that between 1990 and 2010, the disability-
adjusted life-years (summing the YLL and the years lived with 
disability; in 1000s) increased 94.5%, from 1854 (95% CI, 1377–2429) 
to 3598 (95% CI, 2756–4578).113
Cost—Investigators examined Medicare and MarketScan databases (2004–2006) to 
estimate costs attributed to AF in 2008 US dollars:
• Annual total direct costs for AF patients were ≈$20 670 versus ≈$11 965 in the 
control group, for an incremental per-patient cost of $8705.104
• Extrapolating to the US population, it is estimated that the incremental cost of 
AF was ≈$26 billion, of which $6 billion was attributed to AF, $9.9 billion to 
other cardiovascular expenses, and $10.1 billion to noncardiovascular 
expenses.104
Tachycardia
ICD-9 427.0, 427.1, 427.2.
Mortality—599. Any-mention mortality—5994. Hospital discharges—78 000.
Monomorphic VT
Prevalence and Incidence
• Of 150 consecutive patients with wide-complex tachycardia subsequently studied 
by invasive electrophysiological study, 122 (81%) had VT; the remainder had 
SVT.114
• Of patients with ventricular arrhythmias presenting for invasive 
electrophysiological studies, 11% to 21% had no structural HD, and the majority 
of those with structural HD had CAD.115,116
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• In 634 patients with implantable cardioverter-defibrillators who had structural 
HD (including both primary and secondary prevention patients) followed up for a 
mean 11±3 months, ≈80% of potentially clinically relevant ventricular 
tachyarrhythmias were attributable to VT amenable to antitachycardia pacing 
(implying a stable circuit and therefore monomorphic VT).117 Because therapy 
may have been delivered before spontaneous resolution occurred, the proportion 
of these VT episodes with definite clinical relevance is not known.
• Of those with VT in the absence of structural HD, right ventricular outflow tract 
VT is the most common form.118
Aftermath
• Although the prognosis of those with VT or frequent premature ventricular 
contractions in the absence of structural HD is good,115,118 a potentially 
reversible cardiomyopathy may develop in patients with very frequent premature 
ventricular contractions,119,120 and some cases of sudden death attributable to 
short-coupled premature ventricular contractions have been described.121,122
Polymorphic VT
Prevalence and Incidence
• The true prevalence and incidence of PVT in the US general population are not 
known.
• During ambulatory cardiac monitoring, PVT prevalence ranged from 0.01% to 
0.15%123,124; however, among patients who developed sudden cardiac death 
during ambulatory cardiac monitoring, PVT was detected in 30% to 43%.124–126
• A prevalence range of 15% to 19% was reported during electrophysiological 
study in patients resuscitated from cardiac arrest.126–128
• In the setting of AMI, the prevalence of PVT ranged from 1.2% to 2%.129,130
• Out-of-hospital PVT is estimated to be present in ≈25% of all cardiac arrest 
cases involving VT.131,132
Risk Factors
• PVT in the setting of a normal QT interval is most frequently seen in the context 
of acute ischemia or MI.133,134
• Less frequently, PVT with a normal QT interval can occur in patients without 
apparent structural HD. Catecholaminergic PVT, which is discussed under 
inherited arrhythmic syndromes, is one such disorder.
• A prolonged QT interval, whether acquired (drug induced) or congenital, is a 
common cause of PVT. Drug-induced prolongation of the QT interval that causes 
PVT is discussed under TdP, whereas congenital prolonged QT interval is 
discussed under inherited arrhythmic syndromes.
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Aftermath
• The presentation of PVT can range from a brief, asymptomatic, self-terminating 
episode to recurrent syncope or sudden cardiac death.135
• The overall hospital discharge rate (survival) of PVT has been estimated to be 
≈28%.136
Prevention
• Prompt detection and correction of myocardial ischemia would potentially 
minimize the risk of PVT with normal QT interval in the setting of AMI.
Torsade de Pointes
Prevalence and Incidence
• The true incidence and prevalence of drug-induced TdP in the US general 
population are largely unknown.
• By extrapolating data from non-US registries,137 it has been estimated that 12 
000 cases of drug-induced TdP occur annually in the United States.129
• The prevalence of drug-induced prolongation of QT interval and TdP is 2 to 3 
times higher in women than in men.130
• With the majority of QT-interval–prolonging drugs, drug-induced TdP may occur 
in 3% to 15% of patients.126
• Antiarrhythmic drugs with QT-interval–prolonging potential carry a 1% to 3% 
risk of TdP over 1 to 2 years of exposure.138
Risk Factors
• TdP is usually related to administration of QT-interval– prolonging drugs.139 An 
up-to-date list of drugs with the potential to cause TdP may be found at http://
www.azcert.org/medical-pros/drug-lists/drug-lists.cfm, a Web site maintained by 
the University of Arizona Center for Education and Research on Therapeutics.
• Specific risk factors for drug-induced TdP include prolonged QT interval, female 
sex, advanced age, bradycardia, hypokalemia, hypomagnesemia, left ventricular 
systolic dysfunction, and conditions that lead to elevated plasma concentrations 
of causative drugs, such as kidney disease, liver disease, drug interactions, or 
some combination of these.129,140,141
• Predisposition was also noted in patients who had a history of ventricular 
arrhythmia and who experienced a recent symptomatic increase in the frequency 
and complexity of ectopy.142
• Drug-induced TdP rarely occurs in patients without concomitant risk factors. An 
analysis of 144 published articles describing TdP associated with noncardiac 
drugs revealed that 100% of the patients had at least 1 risk factor, and 71% had at 
least 2 risk factors.143
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• Both common and rare genetic variants have been shown to increase the 
propensity to drug-induced QT interval prolongation.144,145
Aftermath
• Drug-induced TdP may result in morbidity that requires hospitalization and in 
mortality attributable to sudden cardiac death in ≤31% of patients.129,146
• Patients with advanced HF with a history of drug-induced TdP had a 
significantly higher risk of sudden cardiac death during therapy with amiodarone 
than amiodarone-treated patients with no history of drug-induced TdP (55% 
versus 15%).147 Current use of antipsychotic drugs was associated with a 
significant increase in the risk of sudden cardiac death attributable to TdP (OR, 
3.3; 95% CI, 1.8–6.2).148
• Hospitalization was required in 47% and death occurred in 8% of patients with 
QT interval prolongation and TdP caused by administration of methadone.149
Prevention
• Keys to reducing the incidence of drug-induced cardiac arrhythmias include 
increased awareness among the medical, pharmaceutical, and nursing professions 
of the potential problems associated with the use of certain agents.
• Appropriate monitoring when a QT-interval–prolonging drug is administered is 
essential. Also, prompt withdrawal of the offending agent should be initiated.150
VF and Ventricular Flutter
ICD-9 427.4; ICD-10 I49.0.
Mortality—1090. Any-mention mortality—9076.
Out-of-Hospital Cardiac Arrest: Adults
Out-of-hospital cardiac arrest is defined as a sudden and unexpected pulseless condition 
attributable to cessation of cardiac mechanical activity.151 There are wide variations in the 
reported incidence of and outcomes for out-of-hospital cardiac arrest. These differences are 
caused in part by differences in definition and ascertainment of cardiac arrest data, as well as 
differences in treatment after the onset of cardiac arrest.
For additional details on out-of-hospital cardiac arrest treatment, please refer to Chapter 22, 
Quality of Care.
Incidence—(See Table 16-1.)
• The incidence of nontraumatic EMS-assessed, EMS-treated cardiac arrest and 
bystander-witnessed VF among individuals of any age during 2011 in the United 
States is best characterized by an ongoing registry from the Resuscitation 
Outcomes Consortium.
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• The total resident population of the United States is 316 302 564 individuals 
(www.census.gov, accessed July 23, 2013). Extrapolation of the incidence and 
case-fatality rate of EMS-assessed out-of-hospital cardiac arrest reported by the 
Resuscitation Outcomes Consortium (Resuscitation Outcomes Consortium 
Investigators, unpublished data, July 23, 2013) to the total population of the 
United States suggests that each year, 424 000 (quasi CI, 417 000–432 000) 
people experience EMS-assessed out-of-hospital cardiac arrests in the United 
States.
• Approximately 60% of out-of-hospital cardiac arrests are treated by EMS 
personnel.152
• Twenty-five percent of those with EMS-treated out-of-hospital cardiac arrest 
have no symptoms before the onset of arrest.153
• Among EMS-treated out-of-hospital cardiac arrests, 23% have an initial rhythm 
of VF or VT or are shockable by an automated external defibrillator.154
• The incidence of cardiac arrest with an initial rhythm of VF is decreasing over 
time; however, the incidence of cardiac arrest with any initial rhythm is not 
decreasing.155
Risk Factors
• A study conducted in New York City found the age-adjusted incidence of out-of-
hospital cardiac arrest per 10 000 adults was 10.1 among blacks, 6.5 among 
Hispanics, and 5.8 among whites.156
• Prior HD is a major risk factor for cardiac arrest. A study of 1275 health 
maintenance organization enrollees 50 to 79 years of age who had cardiac arrest 
showed that the incidence of out-of-hospital cardiac arrest was 6.0 per 1000 
person-years in subjects with any clinically recognized HD compared with 0.8 
per 1000 person-years in subjects without HD. In subgroups with HD, incidence 
was 13.6 per 1000 person-years in subjects with prior MI and 21.9 per 1000 
person-years in subjects with HF.157
• A family history of cardiac arrest in a first-degree relative is associated with an 
≈2-fold increase in risk of cardiac arrest.158,159
• In a study of 81 722 women in the Nurses’ Health Study, the PAR of sudden 
death associated with 4 lifestyle factors (smoking, PA, diet, and weight) was 81% 
(95% CI, 52%–93%).160
Aftermath
• Survival to hospital discharge in 2011 after EMS-treated nontraumatic cardiac 
arrest with any first recorded rhythm was 10.4% (95% CI, 9.7%–11.2%) for 
patients of any age, 10.7% (95% CI, 9.9%–11.5%) for adults, and 5.4% (2.4%–
8.4%) for children (Resuscitation Outcomes Consortium Investigators, 
unpublished data, July 23, 2013). Survival after bystander-witnessed VF was 
31.7% (95% CI, 28.3%–35.2%) for patients of any age, 31.7% (95% CI, 28.2%–
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35.1%) for adults, and 26.7% (95% CI, 4.3%–49.0%) for children (Resuscitation 
Outcomes Consortium Investigators, unpublished data, July 23, 2013).
• In a study using US Nationwide Inpatient Sample data, inhospital mortality for 
patients hospitalized for cardiac arrest declined 11.8%, from 69.6% in 2001 to 
57.8% in 2009.161
• A 9-year retrospective cohort study of 5958 people who received EMS-initiated 
resuscitation demonstrated that 16.8% (n=1001) were alive at hospital discharge. 
In people discharged alive, 5-year survival was better in those who received 
percutaneous intervention (78.7% versus 54.4% for those not treated) and in 
those who received therapeutic hypothermia (77.5% versus 60.4% in those not 
treated).162
• In a retrospective follow-up study of 2 randomized trials of EMS dispatcher CPR 
instruction, 5-year survival was higher in people who received chest 
compressions alone (10.2%) than in those who received chest compressions and 
rescue breathing (8.5%).163
• A study conducted in New York City found the age-adjusted survival to 30 days 
after discharge was more than twice as poor for blacks as for whites, and survival 
among Hispanics was also lower than among whites.156
• Seventy-nine percent of the lay public are confident that they know what actions 
to take in a medical emergency; 98% recognize an automated external 
defibrillator as something that administers an electric shock to restore a normal 
heartbeat among victims of sudden cardiac arrest; and 60% are familiar with 
CPR (Harris Interactive survey conducted on behalf of the AHA among 1132 US 
residents ≥18 years of age, January 8, 2008–January 21, 2008).
• A nationwide prospective Danish study observed that family members of 
individuals who had premature (age <60 years) sudden cardiac death had a 
significantly elevated 1.72 standardized risk of subsequent CVD compared with 
the general population.164
Out-of-Hospital Cardiac Arrest: Athletics
• Among 10.9 million registered participants in 40 marathons and 19 half 
marathons, the overall incidence of cardiac arrest was 0.54 per 100 000 
participants (95% CI, 0.41–0.70).165 Those with cardiac arrest were more often 
male and were running a marathon versus a half marathon. Seventy-one percent 
of those with cardiac arrest died; those who died were younger (mean 39±9 years 
of age) than those who did not die (mean 49±10 years of age), were more often 
male, and were more often running a full marathon.
Out-of-Hospital Cardiac Arrest: Children
(See Table 16-1.)
• The incidence of out-of-hospital cardiac arrest among individuals <18 years of 
age in the United States is best characterized by an ongoing registry 
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(Resuscitation Outcomes Consortium Investigators, unpublished data, July 23, 
2013).
• Most sudden deaths in young athletes were attributable to CVD (56%). Of the 
cardiovascular deaths that occurred, 29% occurred in blacks, 54% in high school 
students, and 82% with physical exertion during competition/training; only 11% 
occurred in females, although this proportion has increased over time.158
• A longitudinal study of students 17 to 24 years of age participating in National 
Collegiate Athletic Association sports showed that the incidence of nontraumatic 
out-of-hospital cardiac arrest was 1 per 22 903 athlete participant-years. The 
incidence of cardiac arrest tended to be higher among blacks than among whites 
and among men than among women.159
In-Hospital Cardiac Arrest
(See Table 16-2.)
• Extrapolation of the incidence of in-hospital cardiac arrest reported by GWTG-
Resuscitation to the total population of hospitalized patients in the United States 
suggests that each year, 209 000 (quasi CI, 192 000–211 000) people are treated 
for in-hospital cardiac arrest.166
• According to the GWTG-Resuscitation Investigators (unpublished data, July 27, 
2013), 22.7% (95% CI, 22.0%– 23.4%) of adults and 36.8% (95% CI, 32.6%–
41.0%) of children (excluding neonates) who experienced in-hospital cardiac 
arrest with any first recorded rhythm in 2011 survived to discharge.
• In 2011, 41.5% (95% CI, 39.3%–43.7%) of adults and 33.3% (95% CI, 15.5%–
51.1%) of children (excluding neonates) survived to discharge after in-hospital 
cardiac arrest with VF or pulseless VT as the first recorded rhythm (GWTG-
Resuscitation Investigators, unpublished data, July 27, 2013). For additional 
details on in-hospital arrest treatment, please refer to Chapter 22, Quality of 
Care.
Inherited Syndromes Associated With Sudden Cardiac Death
Long-QT Syndrome
• The hereditary long-QT syndrome is a genetic channelopathy characterized by 
prolongation of the QT interval (typically >460 ms) and susceptibility to 
ventricular tachyarrhythmias that lead to syncope and sudden cardiac death. 
Investigators have identified mutations in 13 genes leading to this phenotype 
(LQT1 through LQT13). LQT1 (KCNQ1), LQT2 (KCNH2), and LQT3 
(SCN5A) mutations account for the majority (≈80%) of the typed 
mutations.167,168
• Prevalence of long-QT syndrome is estimated at 1 per 2000 live births from 
ECG-guided molecular screening of ≈44 000 mostly white infants born in 
Italy.169 A similar prevalence was found among nearly 8000 Japanese school 
children screened by use of an ECG-guided molecular screening approach.170
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• Long-QT syndrome has been reported among those of African descent, but its 
prevalence is not well assessed.171
• There is variable penetrance and a sex-time interaction for long-QT syndrome 
symptoms. Risk of cardiac events is higher among boys than girls (21% among 
boys and 14% among girls by age 12 years). Risk of events during adolescence is 
equivalent between sexes (≈25% for both sexes from ages 12–18 years). 
Conversely, risk of cardiac events in young adulthood is higher among women 
than men (39% among women from ages 18–40 years and 16% among men).168
• In addition to age and sex, the clinical course is influenced by prior syncope or 
aborted cardiac arrest, family history, QT-interval duration, genotype, number of 
mutations, and congenital deafness.167,168,172
• Risk of cardiac events is decreased during pregnancy but increased during the 9-
month postpartum period.173
• The mainstay of therapy and prevention is β-blockade treatment.172,174 
Implantable defibrillators are considered for high-risk individuals.175
• Individuals may be risk-stratified for increased risk of sudden cardiac death176 
according to their specific long-QT mutation and their response to β-blockers.174
Short-QT Syndrome
• Short-QT syndrome is a recently described inherited mendelian condition 
characterized by shortening of the QT interval (typically QT <320 ms) and 
predisposition to AF and ventricular tachyarrhythmias and sudden death. 
Mutations in 5 ion channel genes have been described (SQT1–SQT5).177
• In a population of 41 767 young predominantly male Swiss transcripts, 0.02% of 
the population had a QT interval shorter than 320 ms.178
• Among 53 patients from the European Short QT Syndrome Registry (75% males, 
median age 26 years), a familial or personal history of cardiac arrest was present 
in 89%. Twenty-four patients received an implantable cardioverter-defibrillator, 
and 12 received long-term prophylaxis with hydroquinidine. During a median 
follow-up of 64 months, 2 patients received an appropriate implantable 
cardioverter-defibrillator shock, and 1 patient experienced syncope. 
Nonsustained PVT was recorded in 3 patients.179
The Brugada Syndrome
• The Brugada syndrome is an inherited channelopathy characterized by persistent 
ST-segment elevation in the precordial leads (V1–V3), right bundle-branch block, 
and susceptibility to ventricular arrhythmias and sudden cardiac death.180
• Mutations in several ion channel–related genes have been identified that lead to 
Brugada syndrome.180
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• Prevalence is estimated at 1 to 5 per 10 000 individuals. Prevalence is higher in 
Southeast Asian countries, including Thailand and the Philippines. There is a 
strong male predominance (80% male).180–185
• Cardiac event rates for Brugada syndrome patients followed up prospectively in 
northern Europe (31.9 months) and Japan (48.7 months) were similar: 8% to 
10% in patients with prior aborted sudden death, 1% to 2% in those with history 
of syncope, and 0.5% in asymptomatic patients.186,187 Predictors of poor 
outcome included family history of sudden death and early repolarization pattern 
on ECG.188,189
Catecholaminergic PVT
• Catecholaminergic PVT is a familial condition characterized by adrenergically 
induced ventricular arrhythmias associated with syncope and sudden death. It is 
associated with frequent ectopy, bidirectional VT, and PVT with exercise or 
catecholaminergic stimulation (such as emotion, or medicines such as 
isoproterenol).
• Mutations in genes encoding RYR2190,191 are found in the majority, and 
mutations in genes encoding CASQ2192,193 are found in a small minority.186 
However, a substantial proportion of individuals with catecholaminergic PVT do 
not have an identified mutation.
• Statistics regarding catecholaminergic PVT are primarily from case series. Of 
101 patients with catecholaminergic PVT, the majority had experienced 
symptoms before 21 years of age.186
• In small series (n=27 to n=101) of patients followed up over a mean of 6.8 to 7.9 
years, 27% to 62% experienced cardiac symptoms, and fatal or near-fatal events 
occurred in 13% to 31%.186,187,190
• Risk factors for cardiac events included younger age of diagnosis and absence of 
β-blocker therapy. A history of aborted cardiac arrest and absence of β-blocker 
therapy were risk factors for fatal or near-fatal events.186
Arrhythmogenic Right Ventricular Cardiomyopathy
• Arrhythmogenic right ventricular cardiomyopathy is a form of genetically 
inherited structural HD that presents with fibrofatty replacement of the 
myocardium, with clinical presentation of palpitations, syncope, and sudden 
death.191
• Twelve arrhythmogenic right ventricular cardiomyopathy loci have been 
described (ARVC1–ARVC12). Disease-causing genes for 8 of these loci have 
been identified, the majority of which are in desmosomally related proteins.191
• Prevalence is estimated at 2 to 10 per 10 000 individuals. 194,195 Of 100 patients 
reported on from the Johns Hopkins Arrhythmogenic Right Ventricular 
Dysplasia Registry, 51 were men and 95 were white, with the rest being of black, 
Hispanic, or Middle Eastern origin. Twenty-two percent of index cases had 
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evidence of the familial form of arrhythmogenic right ventricular 
cardiomyopathy.192
• The most common presenting symptoms were palpitations (27%), syncope 
(26%), and sudden cardiac death (23%).192
• During a median follow-up of 6 years, 47 patients received an implantable 
cardioverter-defibrillator, 29 of whom received appropriate implantable 
cardioverter-defibrillator shocks. At the end of follow-up, 66 patients were alive. 
Twenty-three patients died at study entry, and 11 died during follow-up (91% of 
deaths were attributable to sudden cardiac arrest).192 Similarly, the annual 
mortality rate was 2.3% for 130 patients with arrhythmogenic right ventricular 
cardiomyopathy from Paris, France, who were followed up for a mean of 8.1 
years.193
Hypertrophic Cardiomyopathy—(Please refer to Chapter 19, Cardiomyopathy and 
Heart Failure, for statistics regarding the general epidemiology of HCM.)
• Over a mean follow-up of 8±7 years, 6% of HCM patients experienced sudden 
cardiac death.196
• Among 1866 sudden deaths in athletes between 1980 and 2006, HCM was the 
most common cause of cardiovascular sudden death (in 251 cases, or 36% of the 
690 deaths that could be reliably attributed to a cardiovascular cause).158
• The risk of sudden death increases with increasing maximum left ventricular 
wall thickness,197,198 and the risk for those with wall thickness ≥30 mm is 18.2 
per 1000 patient-years (95% CI, 7.3–37.6),197 or approximately twice that of 
those with maximal wall thickness <30 mm.197,198 Of note, an association 
between maximum wall thickness and sudden death has not been found in every 
HCM population.194
• Nonsustained VT is a risk factor for sudden death,195,199 particularly in younger 
patients. Nonsustained VT in those ≤30 years of age is associated with a 4.35-
greater odds of sudden death (95% CI, 1.5–12.3).195
• A history of syncope is also a risk factor for sudden death in these patients,200 
particularly if the syncope was recent before the initial evaluation and not 
attributable to a neurally mediated event.201
• The presence of left ventricular outflow tract obstruction ≥30 mm Hg appears to 
increase the risk of sudden death by ≈2-fold.202,203 The presence of left 
ventricular outflow tract obstruction has a low positive predictive value (7%–8%) 
but a high negative predictive value (92%–95%) for predicting sudden 
death.202,204
• The rate of malignant ventricular arrhythmias detected by implantable 
cardioverter-defibrillators appears to be similar between those with a family 
history of sudden death in ≥1 first-degree relatives and those with at least 1 of the 
risk factors described above.205
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• The risk of sudden death increases with the number of risk factors.206,207
Early Repolarization Syndrome
• Early repolarization, observed in ≈4% to 19% of the population208– 211 (more 
commonly in young men121,208,210 and in athletes209) has conventionally been 
considered a benign finding.
• A clinically relevant syndrome was initially described in which ≥1-mm positive 
deflections (sometimes referred to as “J waves”) in the S wave of ≥2 consecutive 
inferior or lateral leads were found in 31% of 206 patients with idiopathic VF 
compared with 5% of control subjects (P<0.001).208 These findings have been 
validated in a second study demonstrating similar J-point elevation in 42% of 45 
patients with idiopathic VF compared with 13% of age and sex-matched control 
subjects (P=0.001).209 Given an estimated risk of idiopathic VF in the general 
population (among those aged 35–45 years) of 3.4 per 100 000, the positive 
predictive value of such J-wave findings in a person 35 to 45 years of age 
increases the chances of having idiopathic VF to 11 of 100 000.209
• In an analysis of the Social Insurance Institution’s Coronary Disease Study in 
Finland, J-point elevation was identified in 5.8% of 10 864 people.210 Those with 
inferior lead J-point elevation more often were male and more often were 
smokers; had a lower resting heart rate, lower BMI, lower BP, shorter corrected 
QT interval, and longer QRS duration; and were more likely to have ECG 
evidence of CAD. Those with lateral J-point elevation were more likely to have 
left ventricular hypertrophy. Before and after multivariable adjustment, subjects 
with J-point elevation of ≥1 mm in the inferior leads (n=384) had a higher risk of 
cardiac death (adjusted RR, 1.28; 95% CI, 1.04–1.59; P=0.03) and arrhythmic 
death (adjusted RR, 1.43; 95% CI, 1.06–1.94; P=0.03). However, these patients 
did not have a significantly higher rate of all-cause mortality. Before and after 
multivariable adjustment, subjects with J-point elevation >2 mm (n=36) had an 
increased risk of cardiac death (adjusted RR, 2.98; 95% CI, 1.85–4.92; P=0.03), 
arrhythmic death (adjusted RR, 3.94; 95% CI, 1.96–7.90; P=0.03), and death of 
any cause (adjusted RR, 1.54; 95% CI, 1.06–2.24; P=0.03).
• In CARDIA, 18.6% of 5069 participants had early repolarization restricted to the 
inferior and lateral leads at baseline; by year 20, only 4.8% exhibited an early 
repolarization pattern. 211 Younger age, black race, male sex, longer exercise 
duration and QRS duration, and lower BMI, heart rate, QT index, and Cornell 
voltage were associated cross-sectionally with the presence of baseline early 
repolarization. Predictors of maintenance of the ECG pattern from baseline to 
year 20 were black race (OR, 2.62; 95% CI, 1.61–4.25), BMI (OR, 0.62 per 1 
SD; 95% CI, 0.40–0.94), serum triglyceride levels (OR, 0.66 per 1 SD; 95% CI, 
0.45–0.98), and QRS duration (OR, 1.68 per 1 SD; 95% CI, 1.37–2.06) at 
baseline.
• Evidence from families with a high penetrance of the early repolarization 
syndrome associated with a high risk of sudden death suggests that the syndrome 
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can be inherited in an autosomal dominant fashion.212 A meta-analysis of 
genome-wide association studies performed in population-based cohorts failed to 
identify any genetic variants that met criteria for statistical significance213 (Table 
16-1).
References
1. US Department of Health and Human Services, National Center for Health Statistics. Third National 
Health and Nutrition Examination Survey (NHANES III), 1988–1994. Hyattsville, MD: Centers for 
Disease Control and Prevention; 1998. Electrocardiography data file documentation. CDROM, 
Series 11, No. 2A. ftp://ftp.cdc.gov/pub/Health_Statistics/NCHS/nhanes/nhanes3/2A/NH3ECG-
acc.pdf [Accessed July 6, 2011]
2. Wolbrette, DL., Naccarelli, GV. Bradycardias: sinus nodal dysfunction and atrioventricular 
conduction disturbances. In: Topol, EJ., editor. Textbook of Cardiovascular Medicine. 3. Baltimore, 
MD: Lippincott Williams & Wilkins; 2007. p. 1038-1049.
3. Kojic EM, Hardarson T, Sigfusson N, Sigvaldason H. The prevalence and prognosis of third-degree 
atrioventricular conduction block: the Reykjavik study. J Intern Med. 1999; 246:81–86. [PubMed: 
10447229] 
4. Quin, EM., Wharton, JM., Gold, MR. Bradyarrhythmias. In: Yan, G-X., Kowey, PR., editors. 
Management of Cardiac Arrhythmias. New York, NY: Springer Humana Press; 2010. p. 305-322.
5. Johnson RL, Averill KH, Lamb LE. Electrocardiographic findings in 67,375 asymptomatic subjects, 
VII: atrioventricular block. Am J Cardiol. 1960; 6:153–177. [PubMed: 14407510] 
6. Rose G, Baxter PJ, Reid DD, McCartney P. Prevalence and prognosis of electrocardiographic 
findings in middle-aged men. Br Heart J. 1978; 40:636–643. [PubMed: 656238] 
7. Movahed MR, Hashemzadeh M, Jamal MM. Increased prevalence of third-degree atrioventricular 
block in patients with type II diabetes mellitus. Chest. 2005; 128:2611–2614. [PubMed: 16236932] 
8. Epstein AE, DiMarco JP, Ellenbogen KA, Estes NA 3rd, Freedman RA, Gettes LS, Gillinov AM, 
Gregoratos G, Hammill SC, Hayes DL, Hlatky MA, Newby LK, Page RL, Schoenfeld MH, Silka 
MJ, Stevenson LW, Sweeney MO, Smith SC Jr, Jacobs AK, Adams CD, Anderson JL, Buller CE, 
Creager MA, Ettinger SM, Faxon DP, Halperin JL, Hiratzka LF, Hunt SA, Krumholz HM, Kushner 
FG, Lytle BW, Nishimura RA, Ornato JP, Page RL, Riegel B, Tarkington LG, Yancy CW. American 
College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing 
Committee to Revise the ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac 
Pacemakers and Antiarrhythmia Devices); American Association for Thoracic Surgery; Society of 
Thoracic Surgeons. ACC/AHA/HRS 2008 guidelines for device-based therapy of cardiac rhythm 
abnormalities: a report of the American College of Cardiology/American Heart Association Task 
Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 Guideline 
Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices): developed in 
collaboration with the American Association for Thoracic Surgery and Society of Thoracic 
Surgeons [published correction appears in Circulation. 2009;120:e34–e35]. Circulation. 2008; 
117:e350–e408. [PubMed: 18483207] 
9. Grimm W, Koehler U, Fus E, Hoffmann J, Menz V, Funck R, Peter JH, Maisch B. Outcome of 
patients with sleep apnea-associated severe bradyarrhythmias after continuous positive airway 
pressure therapy. Am J Cardiol. 2000; 86:688–692. A9. [PubMed: 10980227] 
10. Glickstein JS, Buyon J, Friedman D. Pulsed Doppler echocardiographic assessment of the fetal PR 
interval. Am J Cardiol. 2000; 86:236–239. [PubMed: 10913494] 
11. Schnabel RB, Sullivan LM, Levy D, Pencina MJ, Massaro JM, D’Agostino RB Sr, Newton-Cheh 
C, Yamamoto JF, Magnani JW, Tadros TM, Kannel WB, Wang TJ, Ellinor PT, Wolf PA, Vasan RS, 
Benjamin EJ. Lancet. 2009; 373:739–745. [PubMed: 19249635] 
12. Cheng S, Keyes MJ, Larson MG, McCabe EL, Newton-Cheh C, Levy D, Benjamin EJ, Vasan RS, 
Wang TJ. Long-term outcomes in individuals with prolonged PR interval or first-degree 
atrioventricular block. JAMA. 2009; 301:2571–2577. [PubMed: 19549974] 
13. Mymin D, Mathewson FA, Tate RB, Manfreda J. The natural history of primary first-degree 
atrioventricular heart block. N Engl J Med. 1986; 315:1183–1187. [PubMed: 3762641] 
et al. Page 242
Circulation. Author manuscript; available in PMC 2017 April 28.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
14. Barold SS. Indications for permanent cardiac pacing in first-degree AV block: class I, II, or III? 
Pacing Clin Electrophysiol. 1996; 19:747–751. [PubMed: 8734740] 
15. Goldberger JJ, Johnson NP, Gidea C. Significance of asymptomatic bradycardia for subsequent 
pacemaker implantation and mortality in patients >60 years of age. Am J Cardiol. 2011; 108:857–
861. [PubMed: 21757182] 
16. Brignole M, Menozzi C, Lolli G, Oddone D, Gianfranchi L, Bertulla A. Pacing for carotid sinus 
syndrome and sick sinus syndrome. Pacing Clin Electrophysiol. 1990; 13(pt 2):2071–2075. 
[PubMed: 1704595] 
17. Adán V, Crown LA. Diagnosis and treatment of sick sinus syndrome. Am Fam Physician. 2003; 
67:1725–1732. [PubMed: 12725451] 
17a. Rodriguez RD, Schocken DD. Update on sick sinus syndrome, a cardiac disorder of aging. 
Geriatrics. 1990; 45:26–30. 33.
18. Sutton R, Kenny RA. The natural history of sick sinus syndrome. Pacing Clin Electrophysiol. 
1986; 9(pt 2):1110–1114. [PubMed: 2432517] 
19. Brignole M. Sick sinus syndrome. Clin Geriatr Med. 2002; 18:211–227. [PubMed: 12180244] 
20. Issa, Z., Miller, J., Zipes, D. Clinical Arrhythmology and Electrophysiology: A Companion to 
Braunwald’s Heart Disease. Philadelphia, PA: Saunders Elsevier; 2008. 
21. Dobrzynski H, Boyett MR, Anderson RH. New insights into pacemaker activity: promoting 
understanding of sick sinus syndrome. Circulation. 2007; 115:1921–1932. [PubMed: 17420362] 
22. Rosenqvist M, Obel IW. Atrial pacing and the risk for AV block: is there a time for change in 
attitude? Pacing Clin Electrophysiol. 1989; 12(pt 1):97–101. [PubMed: 2464817] 
23. Kistler PM, Sanders P, Fynn SP, Stevenson IH, Spence SJ, Vohra JK, Sparks PB, Kalman JM. 
Electrophysiologic and electroanatomic changes in the human atrium associated with age. J Am 
Coll Cardiol. 2004; 44:109–116. [PubMed: 15234418] 
24. Sanders P, Kistler PM, Morton JB, Spence SJ, Kalman JM. Remodeling of sinus node function in 
patients with congestive heart failure: reduction in sinus node reserve. Circulation. 2004; 110:897–
903. [PubMed: 15302799] 
25. Menozzi C, Brignole M, Alboni P, Boni L, Paparella N, Gaggioli G, Lolli G. The natural course of 
untreated sick sinus syndrome and identification of the variables predictive of unfavorable 
outcome. Am J Cardiol. 1998; 82:1205–1209. [PubMed: 9832095] 
26. Simon AB, Janz N. Symptomatic bradyarrhythmias in the adult: natural history following 
ventricular pacemaker implantation. Pacing Clin Electrophysiol. 1982; 5:372–383. [PubMed: 
6179056] 
27. Alt E, Völker R, Wirtzfeld A, Ulm K. Survival and follow-up after pacemaker implantation: a 
comparison of patients with sick sinus syndrome, complete heart block, and atrial fibrillation. 
Pacing Clin Electrophysiol. 1985; 8:849–855. [PubMed: 2415938] 
28. Lamas GA, Lee KL, Sweeney MO, Silverman R, Leon A, Yee R, Marinchak RA, Flaker G, Schron 
E, Orav EJ, Hellkamp AS, Greer S, McAnulty J, Ellenbogen K, Ehlert F, Freedman RA, Estes NA 
3rd, Greenspon A, Goldman L. Mode Selection Trial in Sinus-Node Dysfunction. Ventricular 
pacing or dual-chamber pacing for sinus-node dysfunction. N Engl J Med. 2002; 346:1854–1862. 
[PubMed: 12063369] 
29. McComb JM, Gribbin GM. Effect of pacing mode on morbidity and mortality: update of clinical 
pacing trials. Am J Cardiol. 1999; 83(5B):211D–213D. [PubMed: 10073823] 
30. Lamas GA, Lee K, Sweeney M, Leon A, Yee R, Ellenbogen K, Greer S, Wilber D, Silverman R, 
Marinchak R, Bernstein R, Mittleman RS, Lieberman EH, Sullivan C, Zorn L, Flaker G, Schron E, 
Orav EJ, Goldman L. The Mode Selection Trial (MOST) in sinus node dysfunction: design, 
rationale, and baseline characteristics of the first 1000 patients. Am Heart J. 2000; 140:541–551. 
[PubMed: 11011325] 
31. Birnie D, Williams K, Guo A, Mielniczuk L, Davis D, Lemery R, Green M, Gollob M, Tang A. 
Reasons for escalating pacemaker implants. Am J Cardiol. 2006; 98:93–97. [PubMed: 16784928] 
32. Orejarena LA, Vidaillet H Jr, DeStefano F, Nordstrom DL, Vierkant RA, Smith PN, Hayes JJ. 
Paroxysmal supraventricular tachycardia in the general population. J Am Coll Cardiol. 1998; 
31:150–157. [PubMed: 9426034] 
et al. Page 243
Circulation. Author manuscript; available in PMC 2017 April 28.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
33. Murman DH, McDonald AJ, Pelletier AJ, Camargo CA Jr. U.S. emergency department visits for 
supraventricular tachycardia, 1993–2003. Acad Emerg Med. 2007; 14:578–581. [PubMed: 
17449792] 
34. Still AM, Raatikainen P, Ylitalo A, Kauma H, Ikäheimo M, Antero Kesäniemi Y, Huikuri HV. 
Prevalence, characteristics and natural course of inappropriate sinus tachycardia. Europace. 2005; 
7:104–112. [PubMed: 15763524] 
35. Maurer MS, Shefrin EA, Fleg JL. Prevalence and prognostic significance of exercise-induced 
supraventricular tachycardia in apparently healthy volunteers. Am J Cardiol. 1995; 75:788–792. 
[PubMed: 7717280] 
36. Poutiainen AM, Koistinen MJ, Airaksinen KE, Hartikainen EK, Kettunen RV, Karjalainen JE, 
Huikuri HV. Prevalence and natural course of ectopic atrial tachycardia. Eur Heart J. 1999; 
20:694–700. [PubMed: 10208790] 
37. Blomström-Lundqvist C, Scheinman MM, Aliot EM, Alpert JS, Calkins H, Camm AJ, Campbell 
WB, Haines DE, Kuck KH, Lerman BB, Miller DD, Shaeffer CW Jr, Stevenson WG, Tomaselli 
GF, Antman EM, Smith SC Jr, Alpert JS, Faxon DP, Fuster V, Gibbons RJ, Gregoratos G, Hiratzka 
LF, Hunt SA, Jacobs AK, Russell RO Jr, Priori SG, Blanc JJ, Budaj A, Burgos EF, Cowie M, 
Deckers JW, Garcia MA, Klein WW, Lekakis J, Lindahl B, Mazzotta G, Morais JC, Oto A, 
Smiseth O, Trappe HJ. American College of Cardiology; American Heart Association Task Force 
on Practice Guidelines; European Society of Cardiology Committee for Practice Guidelines; 
Writing Committee to Develop Guidelines for the Management of Patients With Supraventricular 
Arrhythmias. ACC/AHA/ESC guidelines for the management of patients with supraventricular 
arrhythmias: executive summary: a report of the American College of Cardiology/American Heart 
Association Task Force on Practice Guidelines and the European Society of Cardiology 
Committee for Practice Guidelines (Writing Committee to Develop Guidelines for the 
Management of Patients With Supraventricular Arrhythmias). Circulation. 2003; 108:1871–1909. 
[PubMed: 14557344] 
38. Wu EB, Chia HM, Gill JS. Reversible cardiomyopathy after radiofrequency ablation of lateral free-
wall pathway-mediated incessant supraventricular tachycardia. Pacing Clin Electrophysiol. 2000; 
23:1308–1310. [PubMed: 10962759] 
39. Wang YS, Scheinman MM, Chien WW, Cohen TJ, Lesh MD, Griffin JC. Patients with 
supraventricular tachycardia presenting with aborted sudden death: incidence, mechanism and 
long-term follow-up. J Am Coll Cardiol. 1991; 18:1711–1719. [PubMed: 1960318] 
40. Brembilla-Perrot B, Houriez P, Beurrier D, Claudon O, Burger G, Vançon AC, Mock L. Influence 
of age on the electrophysiological mechanism of paroxysmal supraventricular tachycardias. Int J 
Cardiol. 2001; 78:293–298. [PubMed: 11376833] 
41. Porter MJ, Morton JB, Denman R, Lin AC, Tierney S, Santucci PA, Cai JJ, Madsen N, Wilber DJ. 
Influence of age and gender on the mechanism of supraventricular tachycardia. Heart Rhythm. 
2004; 1:393–396. [PubMed: 15851189] 
42. Bradley DJ, Fischbach PS, Law IH, Serwer GA, Dick M 2nd. The clinical course of multifocal 
atrial tachycardia in infants and children. J Am Coll Cardiol. 2001; 38:401–408. [PubMed: 
11499730] 
43. Kastor JA. Multifocal atrial tachycardia. N Engl J Med. 1990; 322:1713–1717. [PubMed: 2188131] 
44. Anand RG, Rosenthal GL, Van Hare GF, Snyder CS. Is the mechanism of supraventricular 
tachycardia in pediatrics influenced by age, gender or ethnicity? Congenit Heart Dis. 2009; 4:464–
468. [PubMed: 19925541] 
45. De Bacquer D, De Backer G, Kornitzer M. Prevalences of ECG findings in large population based 
samples of men and women. Heart. 2000; 84:625–633. [PubMed: 11083741] 
46. Sano S, Komori S, Amano T, Kohno I, Ishihara T, Sawanobori T, Ijiri H, Tamura K. Prevalence of 
ventricular preexcitation in Japanese schoolchildren. Heart. 1998; 79:374–378. [PubMed: 
9616346] 
47. McCord J, Borzak S. Multifocal atrial tachycardia. Chest. 1998; 113:203–209. [PubMed: 9440591] 
48. Munger TM, Packer DL, Hammill SC, Feldman BJ, Bailey KR, Ballard DJ, Holmes DR Jr, Gersh 
BJ. A population study of the natural history of Wolff-Parkinson-White syndrome in Olmsted 
County, Minnesota, 1953- 1989. Circulation. 1993; 87:866–873. [PubMed: 8443907] 
et al. Page 244
Circulation. Author manuscript; available in PMC 2017 April 28.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
49. Leitch JW, Klein GJ, Yee R, Murdock C. Prognostic value of electrophysiology testing in 
asymptomatic patients with Wolff-Parkinson-White pattern [published correction appears in 
Circulation. 1991;83:1124]. Circulation. 1990; 82:1718–1723. [PubMed: 2225373] 
50. Dagres N, Clague JR, Lottkamp H, Hindricks G, Breithardt G, Borggrefe M. Impact of 
radiofrequency catheter ablation of accessory pathways on the frequency of atrial fibrillation 
during long-term follow-up: high recurrence rate of atrial fibrillation in patients older than 50 
years of age. Eur Heart J. 2001; 22:423–427. [PubMed: 11207084] 
51. Goudevenos JA, Katsouras CS, Graekas G, Argiri O, Giogiakas V, Sideris DA. Ventricular pre-
excitation in the general population: a study on the mode of presentation and clinical course. 
Heart. 2000; 83:29–34. [PubMed: 10618331] 
52. Krahn AD, Manfreda J, Tate RB, Mathewson FA, Cuddy TE. The natural history of 
electrocardiographic preexcitation in men: the Manitoba Follow- up Study. Ann Intern Med. 1992; 
116:456–460. [PubMed: 1739235] 
53. Glotzer TV, Hellkamp AS, Zimmerman J, Sweeney MO, Yee R, Marinchak R, Cook J, Paraschos 
A, Love J, Radoslovich G, Lee KL, Lamas GA. MOST Investigators. Atrial high rate episodes 
detected by pacemaker diagnostics predict death and stroke: report of the Atrial Diagnostics 
Ancillary Study of the MOde Selection Trial (MOST). Circulation. 2003; 107:1614–1619. 
[PubMed: 12668495] 
54. Obeyesekere MN, Leong-Sit P, Massel D, Manlucu J, Modi S, Krahn AD, Skanes AC, Yee R, Gula 
LJ, Klein GJ. Risk of arrhythmia and sudden death in patients with asymptomatic preexcitation: a 
meta-analysis. Circulation. 2012; 125:2308–2315. [PubMed: 22532593] 
55. Timmermans C, Smeets JL, Rodriguez LM, Vrouchos G, van den Dool A, Wellens HJ. Aborted 
sudden death in the Wolff-Parkinson-White syndrome. Am J Cardiol. 1995; 76:492–494. 
[PubMed: 7653450] 
56. Pappone C, Vicedomini G, Manguso F, Baldi M, Pappone A, Petretta A, Vitale R, Saviano M, 
Ciaccio C, Giannelli L, Calovic Z, Tavazzi L, Santinelli V. Risk of malignant arrhythmias in 
initially symptomatic patients with Wolff-Parkinson-White syndrome: results of a prospective 
long-term electrophysiological follow-up study. Circulation. 2012; 125:661–668. [PubMed: 
22215859] 
57. Inoue K, Igarashi H, Fukushige J, Ohno T, Joh K, Hara T. Long-term prospective study on the 
natural history of Wolff-Parkinson-White syndrome detected during a heart screening program at 
school. Acta Paediatr. 2000; 89:542–545. [PubMed: 10852188] 
58. Pappone C, Manguso F, Santinelli R, Vicedomini G, Sala S, Paglino G, Mazzone P, Lang CC, 
Gulletta S, Augello G, Santinelli O, Santinelli V. Radiofrequency ablation in children with 
asymptomatic Wolff-Parkinson- White syndrome. N Engl J Med. 2004; 351:1197–1205. [PubMed: 
15371577] 
59. Glotzer TV, Daoud EG, Wyse DG, Singer DE, Ezekowitz MD, Hilker C, Miller C, Qi D, Ziegler 
PD. The relationship between daily atrial tachyarrhythmia burden from implantable device 
diagnostics and stroke risk: the TRENDS study. Circ Arrhythm Electrophysiol. 2009; 2:474–480. 
[PubMed: 19843914] 
60. Healey JS, Connolly SJ, Gold MR, Israel CW, Van Gelder IC, Capucci A, Lau CP, Fain E, Yang S, 
Bailleul C, Morillo CA, Carlson M, Themeles E, Kaufman ES, Hohnloser SH. ASSERT 
Investigators. Subclinical atrial fibrillation and the risk of stroke. N Engl J Med. 2012; 366:120–
129. [PubMed: 22236222] 
61. Engdahl J, Andersson L, Mirskaya M, Rosenqvist M. Stepwise screening of atrial fibrillation in a 
75-year-old population: implications for stroke prevention. Circulation. 2013; 127:930–937. 
[PubMed: 23343564] 
62. Go AS, Hylek EM, Phillips KA, Chang Y, Henault LE, Selby JV, Singer DE. Prevalence of 
diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke 
prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA. 
2001; 285:2370–2375. [PubMed: 11343485] 
63. Miyasaka Y, Barnes ME, Gersh BJ, Cha SS, Bailey KR, Abhayaratna WP, Seward JB, Tsang TS. 
Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and 
implications on the projections for future prevalence [published correction appears in Circulation. 
2006;114:e498]. Circulation. 2006; 114:119–125. [PubMed: 16818816] 
et al. Page 245
Circulation. Author manuscript; available in PMC 2017 April 28.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
64. Shen AY, Contreras R, Sobnosky S, Shah AI, Ichiuji AM, Jorgensen MB, Brar SS, Chen W. Racial/
ethnic differences in the prevalence of atrial fibrillation among older adults–a cross-sectional 
study. J Natl Med Assoc. 2010; 102:906–913. [PubMed: 21053705] 
65. Piccini JP, Hammill BG, Sinner MF, Jensen PN, Hernandez AF, Heckbert SR, Benjamin EJ, Curtis 
LH. Incidence and prevalence of atrial fibrillation and associated mortality among Medicare 
beneficiaries, 1993–2007. Circ Cardiovasc Qual Outcomes. 2012; 5:85–93. [PubMed: 22235070] 
66. Wang TJ, Larson MG, Levy D, Vasan RS, Leip EP, Wolf PA, D’Agostino RB, Murabito JM, 
Kannel WB, Benjamin EJ. Temporal relations of atrial fibrillation and congestive heart failure and 
their joint influence on mortality: the Framingham Heart Study. Circulation. 2003; 107:2920–
2925. [PubMed: 12771006] 
67. Jabre P, Jouven X, Adnet F, Thabut G, Bielinski SJ, Weston SA, Roger VL. Atrial fibrillation and 
death after myocardial infarction: a community study. Circulation. 2011; 123:2094–2100. 
[PubMed: 21536994] 
68. Benjamin EJ, Wolf PA, D’Agostino RB, Silbershatz H, Kannel WB, Levy D. Impact of atrial 
fibrillation on the risk of death: the Framingham Heart Study. Circulation. 1998; 98:946–952. 
[PubMed: 9737513] 
69. Miyasaka Y, Barnes ME, Bailey KR, Cha SS, Gersh BJ, Seward JB, Tsang TS. Mortality trends in 
patients diagnosed with first atrial fibrillation: a 21-year community-based study. J Am Coll 
Cardiol. 2007; 49:986–992. [PubMed: 17336723] 
70. Mamas MA, Caldwell JC, Chacko S, Garratt CJ, Fath-Ordoubadi F, Neyses L. A meta-analysis of 
the prognostic significance of atrial fibrillation in chronic heart failure. Eur J Heart Fail. 2009; 
11:676–683. [PubMed: 19553398] 
71. Jabre P, Roger VL, Murad MH, Chamberlain AM, Prokop L, Adnet F, Jouven X. Mortality 
associated with atrial fibrillation in patients with myocardial infarction: a systematic review and 
meta-analysis. Circulation. 2011; 123:1587–1593. [PubMed: 21464054] 
72. Chamberlain AM, Agarwal SK, Folsom AR, Soliman EZ, Chambless LE, Crow R, Ambrose M, 
Alonso A. A clinical risk score for atrial fibrillation in a biracial prospective cohort (from the 
Atherosclerosis Risk in Communities [ARIC] study). Am J Cardiol. 2011; 107:85–91. [PubMed: 
21146692] 
73. Alonso A, Krijthe BP, Aspelund T, Stepas KA, Pencina MJ, Moser CB, Sinner MF, Sotoodehnia N, 
Fontes JD, Janssens AC, Kronmal RA, Magnani JW, Witteman JC, Chamberlain AM, Lubitz SA, 
Schnabel RB, Agarwal SK, McManus DD, Ellinor PT, Larson MG, Burke GL, Launer LJ, Hofman 
A, Levy D, Gottdiener JS, Kääb S, Couper D, Harris TB, Soliman EZ, Stricker BH, Gudnason V, 
Heckbert SR, Benjamin EJ. Simple risk model predicts incidence of atrial fibrillation in a racially 
and geographically diverse population: the CHARGE-AF consortium. J Am Heart Assoc. 2013; 
2:e000102. [PubMed: 23537808] 
74. Lin HJ, Wolf PA, Kelly-Hayes M, Beiser AS, Kase CS, Benjamin EJ, D’Agostino RB. Stroke 
severity in atrial fibrillation: the Framingham Study. Stroke. 1996; 27:1760–1764. [PubMed: 
8841325] 
75. Walkey AJ, Wiener RS, Ghobrial JM, Curtis LH, Benjamin EJ. Incident stroke and mortality 
associated with new-onset atrial fibrillation in patients hospitalized with severe sepsis. JAMA. 
2011; 306:2248–2254. [PubMed: 22081378] 
76. van Diepen S, Bakal JA, McAlister FA, Ezekowitz JA. Mortality and read-mission of patients with 
heart failure, atrial fibrillation, or coronary artery disease undergoing noncardiac surgery: an 
analysis of 38 047 patients. Circulation. 2011; 124:289–296. [PubMed: 21709059] 
77. Lloyd-Jones DM, Wang TJ, Leip EP, Larson MG, Levy D, Vasan RS, D’Agostino RB, Massaro 
JM, Beiser A, Wolf PA, Benjamin EJ. Lifetime risk for development of atrial fibrillation: the 
Framingham Heart Study. Circulation. 2004; 110:1042–1046. [PubMed: 15313941] 
78. Alonso A, Agarwal SK, Soliman EZ, Ambrose M, Chamberlain AM, Prineas RJ, Folsom AR. 
Incidence of atrial fibrillation in whites and African- Americans: the Atherosclerosis Risk in 
Communities (ARIC) study. Am Heart J. 2009; 158:111–117. [PubMed: 19540400] 
79. Schnabel RB, Aspelund T, Li G, Sullivan LM, Suchy-Dicey A, Harris TB, Pencina MJ, 
D’Agostino RB Sr, Levy D, Kannel WB, Wang TJ, Kronmal RA, Wolf PA, Burke GL, Launer LJ, 
Vasan RS, Psaty BM, Benjamin EJ, Gudnason V, Heckbert SR. Arch Intern Med. 2010; 170:1909–
1917. [PubMed: 21098350] 
et al. Page 246
Circulation. Author manuscript; available in PMC 2017 April 28.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
80. Sawin CT, Geller A, Wolf PA, Belanger AJ, Baker E, Bacharach P, Wilson PW, Benjamin EJ, 
D’Agostino RB. Low serum thyrotropin concentrations as a risk factor for atrial fibrillation in 
older persons. N Engl J Med. 1994; 331:1249–1252. [PubMed: 7935681] 
81. Cappola AR, Fried LP, Arnold AM, Danese MD, Kuller LH, Burke GL, Tracy RP, Ladenson PW. 
Thyroid status, cardiovascular risk, and mortality in older adults. JAMA. 2006; 295:1033–1041. 
[PubMed: 16507804] 
82. Alonso A, Lopez FL, Matsushita K, Loehr LR, Agarwal SK, Chen LY, Soliman EZ, Astor BC, 
Coresh J. Chronic kidney disease is associated with the incidence of atrial fibrillation: the 
Atherosclerosis Risk in Communities (ARIC) study. Circulation. 2011; 123:2946–2953. [PubMed: 
21646496] 
83. Kodama S, Saito K, Tanaka S, Horikawa C, Saito A, Heianza Y, Anasako Y, Nishigaki Y, Yachi Y, 
Iida KT, Ohashi Y, Yamada N, Sone H. Alcohol consumption and risk of atrial fibrillation: a meta-
analysis. J Am Coll Cardiol. 2011; 57:427–436. [PubMed: 21251583] 
84. Wolff L. Familial auricular fibrillation. N Engl J Med. 1943; 229:396–398.
85. Ellinor PT, Yoerger DM, Ruskin JN, MacRae CA. Familial aggregation in lone atrial fibrillation. 
Hum Genet. 2005; 118:179–184. [PubMed: 16133178] 
86. Fox CS, Parise H, D’Agostino RB Sr, Lloyd-Jones DM, Vasan RS, Wang TJ, Levy D, Wolf PA, 
Benjamin EJ. Parental atrial fibrillation as a risk factor for atrial fibrillation in offspring. JAMA. 
2004; 291:2851–2855. [PubMed: 15199036] 
87. Lubitz SA, Yin X, Fontes JD, Magnani JW, Rienstra M, Pai M, Villalon ML, Vasan RS, Pencina 
MJ, Levy D, Larson MG, Ellinor PT, Benjamin EJ. Association between familial atrial fibrillation 
and risk of new-onset atrial fibrillation. JAMA. 2010; 304:2263–2269. [PubMed: 21076174] 
88. Ellinor PT, MacRae CA. Ion channel mutations in AF: signal or noise? Heart Rhythm. 2008; 
5:436–437. [PubMed: 18313603] 
89. Gudbjartsson DF, Arnar DO, Helgadottir A, Gretarsdottir S, Holm H, Sigurdsson A, Jonasdottir A, 
Baker A, Thorleifsson G, Kristjansson K, Palsson A, Blondal T, Sulem P, Backman VM, 
Hardarson GA, Palsdottir E, Helgason A, Sigurjonsdottir R, Sverrisson JT, Kostulas K, Ng MC, 
Baum L, So WY, Wong KS, Chan JC, Furie KL, Greenberg SM, Sale M, Kelly P, Mac-Rae CA, 
Smith EE, Rosand J, Hillert J, Ma RC, Ellinor PT, Thorgeirsson G, Gulcher JR, Kong A, 
Thorsteinsdottir U, Stefansson K. Variants conferring risk of atrial fibrillation on chromosome 
4q25. Nature. 2007; 448:353–357. [PubMed: 17603472] 
90. Benjamin EJ, Rice KM, Arking DE, Pfeufer A, van Noord C, Smith AV, Schnabel RB, Bis JC, 
Boerwinkle E, Sinner MF, Dehghan A, Lubitz SA, D’Agostino RB Sr, Lumley T, Ehret GB, 
Heeringa J, Aspelund T, Newton-Cheh C, Larson MG, Marciante KD, Soliman EZ, Rivadeneira F, 
Wang TJ, Eiríksdottir G, Levy D, Psaty BM, Li M, Chamberlain AM, Hofman A, Vasan RS, 
Harris TB, Rotter JI, Kao WH, Agarwal SK, Stricker BH, Wang K, Launer LJ, Smith NL, 
Chakravarti A, Uitterlinden AG, Wolf PA, Sotoodehnia N, Köttgen A, van Duijn CM, Meitinger T, 
Mueller M, Perz S, Steinbeck G, Wichmann HE, Lunetta KL, Heckbert SR, Gudnason V, Alonso 
A, Kääb S, Ellinor PT, Witteman JC. Variants in ZFHX3 are associated with atrial fibrillation in 
individuals of European ancestry. Nat Genet. 2009; 41:879–881. [PubMed: 19597492] 
91. Ellinor PT, Lunetta KL, Glazer NL, Pfeufer A, Alonso A, Chung MK, Sinner MF, de Bakker PI, 
Mueller M, Lubitz SA, Fox E, Darbar D, Smith NL, Smith JD, Schnabel RB, Soliman EZ, Rice 
KM, Van Wagoner DR, Beckmann BM, van Noord C, Wang K, Ehret GB, Rotter JI, Hazen SL, 
Steinbeck G, Smith AV, Launer LJ, Harris TB, Makino S, Nelis M, Milan DJ, Perz S, Esko T, 
Köttgen A, Moebus S, Newton-Cheh C, Li M, Möhlenkamp S, Wang TJ, Kao WH, Vasan RS, 
Nöthen MM, MacRae CA, Stricker BH, Hofman A, Uitterlinden AG, Levy D, Boerwinkle E, 
Metspalu A, Topol EJ, Chakravarti A, Gudnason V, Psaty BM, Roden DM, Meitinger T, 
Wichmann HE, Witteman JC, Barnard J, Arking DE, Benjamin EJ, Heckbert SR, Kääb S. 
Common variants in KCNN3 are associated with lone atrial fibrillation. Nat Genet. 2010; 42:240–
244. [PubMed: 20173747] 
92. Gudbjartsson DF, Holm H, Gretarsdottir S, Thorleifsson G, Walters GB, Thorgeirsson G, Gulcher 
J, Mathiesen EB, Njølstad I, Nyrnes A, Wilsgaard T, Hald EM, Hveem K, Stoltenberg C, Kucera 
G, Stubblefield T, Carter S, Roden D, Ng MC, Baum L, So WY, Wong KS, Chan JC, Gieger C, 
Wichmann HE, Gschwendtner A, Dichgans M, Kuhlenbäumer G, Berger K, Ringelstein EB, 
Bevan S, Markus HS, Kostulas K, Hillert J, Sveinbjörnsdóttir S, Valdimarsson EM, Løchen ML, 
et al. Page 247
Circulation. Author manuscript; available in PMC 2017 April 28.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Ma RC, Darbar D, Kong A, Arnar DO, Thorsteinsdottir U, Stefansson K. A sequence variant in 
ZFHX3 on 16q22 associates with atrial fibrillation and ischemic stroke. Nat Genet. 2009; 41:876–
878. [PubMed: 19597491] 
93. Ellinor PT, Lunetta KL, Albert CM, Glazer NL, Ritchie MD, Smith AV, Arking DE, Müller-
Nurasyid M, Krijthe BP, Lubitz SA, Bis JC, Chung MK, Dörr M, Ozaki K, Roberts JD, Smith JG, 
Pfeufer A, Sinner MF, Lohman K, Ding J, Smith NL, Smith JD, Rienstra M, Rice KM, Van 
Wagoner DR, Magnani JW, Wakili R, Clauss S, Rotter JI, Steinbeck G, Launer LJ, Davies RW, 
Borkovich M, Harris TB, Lin H, Völker U, Völzke H, Milan DJ, Hofman A, Boerwinkle E, Chen 
LY, Soliman EZ, Voight BF, Li G, Chakravarti A, Kubo M, Tedrow UB, Rose LM, Ridker PM, 
Conen D, Tsunoda T, Furukawa T, Sotoodehnia N, Xu S, Kamatani N, Levy D, Nakamura Y, 
Parvez B, Mahida S, Furie KL, Rosand J, Muhammad R, Psaty BM, Meitinger T, Perz S, 
Wichmann HE, Witteman JC, Kao WH, Kathiresan S, Roden DM, Uitterlinden AG, Rivadeneira F, 
McKnight B, Sjögren M, Newman AB, Liu Y, Gollob MH, Melander O, Tanaka T, Stricker BH, 
Felix SB, Alonso A, Darbar D, Barnard J, Chasman DI, Heckbert SR, Benjamin EJ, Gudnason V, 
Kääb S. Meta-analysis identifies six new susceptibility loci for atrial fibrillation. Nat Genet. 2012; 
44:670–675. [PubMed: 22544366] 
94. Meschia JF, Merrill P, Soliman EZ, Howard VJ, Barrett KM, Zakai NA, Kleindorfer D, Safford M, 
Howard G. Racial disparities in awareness and treatment of atrial fibrillation: the REasons for 
Geographic and Racial Differences in Stroke (REGARDS) study. Stroke. 2010; 41:581–587. 
[PubMed: 20190000] 
95. Huxley RR, Lopez FL, Folsom AR, Agarwal SK, Loehr LR, Soliman EZ, Maclehose R, Konety S, 
Alonso A. Absolute and attributable risks of atrial fibrillation in relation to optimal and borderline 
risk factors: the Atherosclerosis Risk in Communities (ARIC) study. Circulation. 2011; 123:1501–
1508. [PubMed: 21444879] 
96. Benjamin EJ, Levy D, Vaziri SM, D’Agostino RB, Belanger AJ, Wolf PA. Independent risk factors 
for atrial fibrillation in a population-based cohort: the Framingham Heart Study. JAMA. 1994; 
271:840–844. [PubMed: 8114238] 
97. Mozaffarian D, Furberg CD, Psaty BM, Siscovick D. Physical activity and incidence of atrial 
fibrillation in older adults: the Cardiovascular Health Study. Circulation. 2008; 118:800–807. 
[PubMed: 18678768] 
98. Aizer A, Gaziano JM, Cook NR, Manson JE, Buring JE, Albert CM. Relation of vigorous exercise 
to risk of atrial fibrillation. Am J Cardiol. 2009; 103:1572–1577. [PubMed: 19463518] 
99. Hart RG, Pearce LA, Rothbart RM, McAnulty JH, Asinger RW, Halperin JL. Stroke Prevention in 
Atrial Fibrillation Investigators. Stroke with intermittent atrial fibrillation: incidence and predictors 
during aspirin therapy. J Am Coll Cardiol. 2000; 35:183–187. [PubMed: 10636278] 
100. Swedberg K, Zannad F, McMurray JJ, Krum H, van Veldhuisen DJ, Shi H, Vincent J, Pitt B. 
EMPHASIS-HF Study Investigators. Eplerenone and atrial fibrillation in mild systolic heart 
failure: results from the EMPHASIS- HF (Eplerenone in Mild Patients Hospitalization And 
SurvIval Study in Heart Failure) study. J Am Coll Cardiol. 2012; 59:1598–1603. [PubMed: 
22538330] 
101. Rahimi K, Emberson J, McGale P, Majoni W, Merhi A, Asselbergs FW, Krane V, Macfarlane PW. 
PROSPER Executive. Effect of statins on atrial fibrillation: collaborative meta-analysis of 
published and unpublished evidence from randomised controlled trials. BMJ. 2011; 342:d1250. 
[PubMed: 21411487] 
102. Benjamin EJ, Chen PS, Bild DE, Mascette AM, Albert CM, Alonso A, Calkins H, Connolly SJ, 
Curtis AB, Darbar D, Ellinor PT, Go AS, Goldschlager NF, Heckbert SR, Jalife J, Kerr CR, Levy 
D, Lloyd-Jones DM, Massie BM, Nattel S, Olgin JE, Packer DL, Po SS, Tsang TS, Van Wagoner 
DR, Waldo AL, Wyse DG. Prevention of atrial fibrillation: report from a National Heart, Lung, 
and Blood Institute workshop. Circulation. 2009; 119:606–618. [PubMed: 19188521] 
103. Khairallah F, Ezzedine R, Ganz LI, London B, Saba S. Epidemiology and determinants of 
outcome of admissions for atrial fibrillation in the United States from 1996 to 2001. Am J 
Cardiol. 2004; 94:500–504. [PubMed: 15325940] 
104. Kim MH, Johnston SS, Chu BC, Dalal MR, Schulman KL. Estimation of total incremental health 
care costs in patients with atrial fibrillation in the United States. Circ Cardiovasc Qual Outcomes. 
2011; 4:313–320. [PubMed: 21540439] 
et al. Page 248
Circulation. Author manuscript; available in PMC 2017 April 28.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
105. Lakshminarayan K, Solid CA, Collins AJ, Anderson DC, Herzog CA. Atrial fibrillation and 
stroke in the general Medicare population: a 10- year perspective (1992 to 2002). Stroke. 2006; 
37:1969–1974. [PubMed: 16809573] 
106. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the 
Framingham Study. Stroke. 1991; 22:983–988. [PubMed: 1866765] 
107. Penado S, Cano M, Acha O, Hernández JL, Riancho JA. Atrial fibrillation as a risk factor for 
stroke recurrence. Am J Med. 2003; 114:206–210. [PubMed: 12637135] 
108. Baczek VL, Chen WT, Kluger J, Coleman CI. Predictors of warfarin use in atrial fibrillation in the 
United States: a systematic review and meta-analysis. BMC Fam Pract. 2012; 13:5. [PubMed: 
22304704] 
109. Ott A, Breteler MM, de Bruyne MC, van Harskamp F, Grobbee DE, Hofman A. Atrial fibrillation 
and dementia in a population-based study: the Rotterdam Study. Stroke. 1997; 28:316–321. 
[PubMed: 9040682] 
110. Kwok CS, Loke YK, Hale R, Potter JF, Myint PK. Atrial fibrillation and incidence of dementia: a 
systematic review and meta-analysis. Neurology. 2011; 76:914–922. [PubMed: 21383328] 
111. Miyasaka Y, Barnes ME, Gersh BJ, Cha SS, Bailey KR, Abhayaratna W, Seward JB, Iwasaka T, 
Tsang TS. Incidence and mortality risk of congestive heart failure in atrial fibrillation patients: a 
community-based study over two decades. Eur Heart J. 2006; 27:936–941. [PubMed: 16399778] 
112. Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V, Abraham J, Adair T, 
Aggarwal R, Ahn SY, Alvarado M, Anderson HR, Anderson LM, Andrews KG, Atkinson C, 
Baddour LM, Barker-Collo S, Bartels DH, Bell ML, Benjamin EJ, Bennett D, Bhalla K, Bikbov 
B, Bin Abdulhak A, Birbeck G, Blyth F, Bolliger I, Boufous S, Bucello C, Burch M, Burney P, 
Carapetis J, Chen H, Chou D, Chugh SS, Coffeng LE, Colan SD, Colquhoun S, Colson KE, 
Condon J, Connor MD, Cooper LT, Corriere M, Cortinovis M, de Vaccaro KC, Couser W, Cowie 
BC, Criqui MH, Cross M, Dabhadkar KC, Dahodwala N, De Leo D, Degenhardt L, Delossantos 
A, Denenberg J, Des Jarlais DC, Dharmaratne SD, Dorsey ER, Driscoll T, Duber H, Ebel B, 
Erwin PJ, Espindola P, Ezzati M, Feigin V, Flaxman AD, Forouzanfar MH, Fowkes FG, Franklin 
R, Fransen M, Freeman MK, Gabriel SE, Gakidou E, Gaspari F, Gillum RF, Gonzalez-Medina D, 
Halasa YA, Haring D, Harrison JE, Havmoeller R, Hay RJ, Hoen B, Hotez PJ, Hoy D, Jacobsen 
KH, James SL, Jasrasaria R, Jayaraman S, Johns N, Karthikeyan G, Kassebaum N, Keren A, 
Khoo JP, Knowlton LM, Kobusingye O, Koranteng A, Krishnamurthi R, Lipnick M, Lipshultz 
SE, Ohno SL, Mabweijano J, MacIntyre MF, Mallinger L, March L, Marks GB, Marks R, 
Matsumori A, Matzopoulos R, Mayosi BM, McAnulty JH, McDermott MM, McGrath J, Mensah 
GA, Merriman TR, Michaud C, Miller M, Miller TR, Mock C, Mocumbi AO, Mokdad AA, 
Moran A, Mulholland K, Nair MN, Naldi L, Narayan KM, Nasseri K, Norman P, O’Donnell M, 
Omer SB, Ortblad K, Osborne R, Ozgediz D, Pahari B, Pandian JD, Rivero AP, Padilla RP, 
Perez-Ruiz F, Perico N, Phillips D, Pierce K, Pope CA 3rd, Porrini E, Pourmalek F, Raju M, 
Ranganathan D, Rehm JT, Rein DB, Remuzzi G, Rivara FP, Roberts T, De León FR, Rosenfeld 
LC, Rushton L, Sacco RL, Salomon JA, Sampson U, Sanman E, Schwebel DC, Segui-Gomez M, 
Shepard DS, Singh D, Singleton J, Sliwa K, Smith E, Steer A, Taylor JA, Thomas B, Tleyjeh IM, 
Towbin JA, Truelsen T, Undurraga EA, Venketasubramanian N, Vijayakumar L, Vos T, Wagner 
GR, Wang M, Wang W, Watt K, Weinstock MA, Weintraub R, Wilkinson JD, Woolf AD, Wulf S, 
Yeh PH, Yip P, Zabetian A, Zheng ZJ, Lopez AD, Murray CJ, AlMazroa MA, Memish ZA. 
Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a 
systematic analysis for the Global Burden of Disease Study 2010 [published correction appears 
in Lancet. 2013;381:628]. Lancet. 2012; 380:2095–2128. [PubMed: 23245604] 
113. Murray CJ, Vos T, Lozano R, Naghavi M, Flaxman AD, Michaud C, Ezzati M, Shibuya K, 
Salomon JA, Abdalla S, Aboyans V, Abraham J, Ackerman I, Aggarwal R, Ahn SY, Ali MK, 
Alvarado M, Anderson HR, Anderson LM, Andrews KG, Atkinson C, Baddour LM, Bahalim 
AN, Barker-Collo S, Barrero LH, Bartels DH, Basáñez MG, Baxter A, Bell ML, Benjamin EJ, 
Bennett D, Bernabé E, Bhalla K, Bhandari B, Bikbov B, Bin Abdulhak A, Birbeck G, Black JA, 
Blencowe H, Blore JD, Blyth F, Bolliger I, Bonaventure A, Boufous S, Bourne R, Boussinesq M, 
Braithwaite T, Brayne C, Bridgett L, Brooker S, Brooks P, Brugha TS, Bryan-Hancock C, 
Bucello C, Buchbinder R, Buckle G, Budke CM, Burch M, Burney P, Burstein R, Calabria B, 
Campbell B, Canter CE, Carabin H, Carapetis J, Carmona L, Cella C, Charlson F, Chen H, 
Cheng AT, Chou D, Chugh SS, Coffeng LE, Colan SD, Colquhoun S, Colson KE, Condon J, 
et al. Page 249
Circulation. Author manuscript; available in PMC 2017 April 28.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Connor MD, Cooper LT, Corriere M, Cortinovis M, de Vaccaro KC, Couser W, Cowie BC, 
Criqui MH, Cross M, Dabhadkar KC, Dahiya M, Dahodwala N, Damsere-Derry J, Danaei G, 
Davis A, De Leo D, Degenhardt L, Dellavalle R, Delossantos A, Denenberg J, Derrett S, Des 
Jarlais DC, Dharmaratne SD, Dherani M, Diaz-Torne C, Dolk H, Dorsey ER, Driscoll T, Duber 
H, Ebel B, Edmond K, Elbaz A, Ali SE, Erskine H, Erwin PJ, Espindola P, Ewoigbokhan SE, 
Farzadfar F, Feigin V, Felson DT, Ferrari A, Ferri CP, Fèvre EM, Finucane MM, Flaxman S, 
Flood L, Foreman K, Forouzanfar MH, Fowkes FG, Fransen M, Freeman MK, Gabbe BJ, Gabriel 
SE, Gakidou E, Ganatra HA, Garcia B, Gaspari F, Gillum RF, Gmel G, Gonzalez-Medina D, 
Gosselin R, Grainger R, Grant B, Groeger J, Guillemin F, Gunnell D, Gupta R, Haagsma J, 
Hagan H, Halasa YA, Hall W, Haring D, Haro JM, Harrison JE, Havmoeller R, Hay RJ, Higashi 
H, Hill C, Hoen B, Hoffman H, Hotez PJ, Hoy D, Huang JJ, Ibeanusi SE, Jacobsen KH, James 
SL, Jarvis D, Jasrasaria R, Jayaraman S, Johns N, Jonas JB, Karthikeyan G, Kassebaum N, 
Kawakami N, Keren A, Khoo JP, King CH, Knowlton LM, Kobusingye O, Koranteng A, 
Krishnamurthi R, Laden F, Lalloo R, Laslett LL, Lathlean T, Leasher JL, Lee YY, Leigh J, 
Levinson D, Lim SS, Limb E, Lin JK, Lipnick M, Lipshultz SE, Liu W, Loane M, Ohno SL, 
Lyons R, Mabweijano J, MacIntyre MF, Malekzadeh R, Mallinger L, Manivannan S, Marcenes 
W, March L, Margolis DJ, Marks GB, Marks R, Matsumori A, Matzopoulos R, Mayosi BM, 
McAnulty JH, McDermott MM, McGill N, McGrath J, Medina-Mora ME, Meltzer M, Mensah 
GA, Merriman TR, Meyer AC, Miglioli V, Miller M, Miller TR, Mitchell PB, Mock C, Mocumbi 
AO, Moffitt TE, Mokdad AA, Monasta L, Montico M, Moradi-Lakeh M, Moran A, Morawska L, 
Mori R, Murdoch ME, Mwaniki MK, Naidoo K, Nair MN, Naldi L, Narayan KM, Nelson PK, 
Nelson RG, Nevitt MC, Newton CR, Nolte S, Norman P, Norman R, O’Donnell M, O’Hanlon S, 
Olives C, Omer SB, Ortblad K, Osborne R, Ozgediz D, Page A, Pahari B, Pandian JD, Rivero 
AP, Patten SB, Pearce N, Padilla RP, Perez-Ruiz F, Perico N, Pesudovs K, Phillips D, Phillips 
MR, Pierce K, Pion S, Polanczyk GV, Polinder S, Pope CA 3rd, Popova S, Porrini E, Pourmalek 
F, Prince M, Pullan RL, Ramaiah KD, Ranganathan D, Razavi H, Regan M, Rehm JT, Rein DB, 
Remuzzi G, Richardson K, Rivara FP, Roberts T, Robinson C, De Leòn FR, Ronfani L, Room R, 
Rosenfeld LC, Rushton L, Sacco RL, Saha S, Sampson U, Sanchez-Riera L, Sanman E, 
Schwebel DC, Scott JG, Segui-Gomez M, Shahraz S, Shepard DS, Shin H, Shivakoti R, Singh D, 
Singh GM, Singh JA, Singleton J, Sleet DA, Sliwa K, Smith E, Smith JL, Stapelberg NJ, Steer A, 
Steiner T, Stolk WA, Stovner LJ, Sudfeld C, Syed S, Tamburlini G, Tavakkoli M, Taylor HR, 
Taylor JA, Taylor WJ, Thomas B, Thomson WM, Thurston GD, Tleyjeh IM, Tonelli M, Towbin 
JA, Truelsen T, Tsilimbaris MK, Ubeda C, Undurraga EA, van der Werf MJ, van Os J, Vavilala 
MS, Venketasubramanian N, Wang M, Wang W, Watt K, Weatherall DJ, Weinstock MA, 
Weintraub R, Weisskopf MG, Weissman MM, White RA, Whiteford H, Wiebe N, Wiersma ST, 
Wilkinson JD, Williams HC, Williams SR, Witt E, Wolfe F, Woolf AD, Wulf S, Yeh PH, Zaidi 
AK, Zheng ZJ, Zonies D, Lopez AD, AlMazroa MA, Memish ZA. Disability-adjusted life years 
(DALYs) for 291 diseases and injuries in 21 regions, 1990–2010: a systematic analysis for the 
Global Burden of Disease Study 2010 [published correction appears in Lancet. 2013;381:628]. 
Lancet. 2012; 380:2197–2223. [PubMed: 23245608] 
114. Akhtar M, Shenasa M, Jazayeri M, Caceres J, Tchou PJ. Wide QRS complex tachycardia: 
reappraisal of a common clinical problem. Ann Intern Med. 1988; 109:905–912. [PubMed: 
3190044] 
115. Sacher F, Tedrow UB, Field ME, Raymond JM, Koplan BA, Epstein LM, Stevenson WG. 
Ventricular tachycardia ablation: evolution of patients and procedures over 8 years. Circ 
Arrhythm Electrophysiol. 2008; 1:153–161. [PubMed: 19808409] 
116. Swerdlow CD, Winkle RA, Mason JW. Determinants of survival in patients with ventricular 
tachyarrhythmias. N Engl J Med. 1983; 308:1436–1442. [PubMed: 6855814] 
117. Wathen MS, DeGroot PJ, Sweeney MO, Stark AJ, Otterness MF, Adkisson WO, Canby RC, 
Khalighi K, Machado C, Rubenstein DS, Volosin KJ. PainFREE Rx II Investigators. Prospective 
randomized multicenter trial of empirical antitachycardia pacing versus shocks for spontaneous 
rapid ventricular tachycardia in patients with implantable cardioverter-defibrillators: Pacing Fast 
Ventricular Tachycardia Reduces Shock Therapies (PainFREE Rx II) trial results. Circulation. 
2004; 110:2591–2596. [PubMed: 15492306] 
et al. Page 250
Circulation. Author manuscript; available in PMC 2017 April 28.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
118. Lemery R, Brugada P, Bella PD, Dugernier T, van den Dool A, Wellens HJ. Nonischemic 
ventricular tachycardia: clinical course and long-term follow-up in patients without clinically 
overt heart disease. Circulation. 1989; 79:990–999. [PubMed: 2713978] 
119. Yarlagadda RK, Iwai S, Stein KM, Markowitz SM, Shah BK, Cheung JW, Tan V, Lerman BB, 
Mittal S. Reversal of cardiomyopathy in patients with repetitive monomorphic ventricular ectopy 
originating from the right ventricular outflow tract. Circulation. 2005; 112:1092–1097. [PubMed: 
16103234] 
120. Baman TS, Lange DC, Ilg KJ, Gupta SK, Liu TY, Alguire C, Armstrong W, Good E, Chugh A, 
Jongnarangsin K, Pelosi F Jr, Crawford T, Ebinger M, Oral H, Morady F, Bogun F. Relationship 
between burden of premature ventricular complexes and left ventricular function. Heart Rhythm. 
2010; 7:865–869. [PubMed: 20348027] 
121. Viskin S, Rosso R, Rogowski O, Belhassen B. The “short-coupled” variant of right ventricular 
outflow ventricular tachycardia: a not-so-benign form of benign ventricular tachycardia? J 
Cardiovasc Electrophysiol. 2005; 16:912–916. [PubMed: 16101636] 
122. Noda T, Shimizu W, Taguchi A, Aiba T, Satomi K, Suyama K, Kurita T, Aihara N, Kamakura S. 
Malignant entity of idiopathic ventricular fibrillation and polymorphic ventricular tachycardia 
initiated by premature extrasystoles originating from the right ventricular outflow tract. J Am 
Coll Cardiol. 2005; 46:1288–1294. [PubMed: 16198845] 
123. Denes P, Gabster A, Huang SK. Clinical, electrocardiographic and follow-up observations in 
patients having ventricular fibrillation during Holter monitoring. Role of quinidine therapy. Am J 
Cardiol. 1981; 48:9–16. [PubMed: 7246449] 
124. Panidis IP, Morganroth J. Sudden death in hospitalized patients: cardiac rhythm disturbances 
detected by ambulatory electrocardiographic monitoring. J Am Coll Cardiol. 1983; 2:798–805. 
[PubMed: 6630760] 
125. Kempf FC Jr, Josephson ME. Cardiac arrest recorded on ambulatory electrocardiograms. Am J 
Cardiol. 1984; 53:1577–1582. [PubMed: 6731302] 
126. DiMarco JP, Haines DE. Sudden cardiac death. Curr Probl Cardiol. 1990; 15:183–232. [PubMed: 
2180640] 
127. Roy D, Waxman HL, Kienzle MG, Buxton AE, Marchlinski FE, Josephson ME. Clinical 
characteristics and long-term follow-up in 119 survivors of cardiac arrest: relation to inducibility 
at electrophysiologic testing. Am J Cardiol. 1983; 52:969–974. [PubMed: 6637850] 
128. Stevenson WG, Brugada P, Waldecker B, Zehender M, Wellens HJ. Clinical, angiographic, and 
electrophysiologic findings in patients with aborted sudden death as compared with patients with 
sustained ventricular tachycardia after myocardial infarction. Circulation. 1985; 71:1146–1152. 
[PubMed: 3995708] 
129. Tisdale, JE., Miler, DA. Drug-Induced Diseases: Prevention, Detection and Management. 2. 
Bethesda, MD: American Society of Health System Pharmacists; 2010. 
130. Lehmann MH, Timothy KW, Frankovich D, Fromm BS, Keating M, Locati EH, Taggart RT, 
Towbin JA, Moss AJ, Schwartz PJ, Vincent GM. Age-gender influence on the rate-corrected QT 
interval and the QT-heart rate relation in families with genotypically characterized long QT 
syndrome. J Am Coll Cardiol. 1997; 29:93–99. [PubMed: 8996300] 
131. White RD, Wood DL. Out-of-hospital pleomorphic ventricular tachycardia and resuscitation: 
association with acute myocardial ischemia and infarction. Ann Emerg Med. 1992; 21:1282–
1287. [PubMed: 1416316] 
132. Brady W, Meldon S, DeBehnke D. Comparison of prehospital monomorphic and polymorphic 
ventricular tachycardia: prevalence, response to therapy, and outcome. Ann Emerg Med. 1995; 
25:64–70. [PubMed: 7802372] 
133. Wolfe CL, Nibley C, Bhandari A, Chatterjee K, Scheinman M. Polymorphous ventricular 
tachycardia associated with acute myocardial infarction. Circulation. 1991; 84:1543–1551. 
[PubMed: 1914096] 
134. Pellegrini CN, Scheinman MM. Clinical management of ventricular tachycardia. Curr Probl 
Cardiol. 2010; 35:453–504. [PubMed: 20887902] 
135. Passman R, Kadish A. Polymorphic ventricular tachycardia, long Q-T syndrome, and torsades de 
pointes. Med Clin North Am. 2001; 85:321–341. [PubMed: 11233951] 
et al. Page 251
Circulation. Author manuscript; available in PMC 2017 April 28.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
136. Brady WJ, DeBehnke DJ, Laundrie D. Prevalence, therapeutic response, and outcome of 
ventricular tachycardia in the out-of-hospital setting: a comparison of monomorphic ventricular 
tachycardia, polymorphic ventricular tachycardia, and torsades de pointes. Acad Emerg Med. 
1999; 6:609–617. [PubMed: 10386678] 
137. Darpö B. Spectrum of drugs prolonging QT interval and the incidence of torsades de pointes. Eur 
Heart J Suppl. 2001; 3(suppl K):K70–K80.
138. Kannankeril P, Roden DM, Darbar D. Drug-induced long QT syndrome. Pharmacol Rev. 2010; 
62:760–781. [PubMed: 21079043] 
139. Camm AJ, Janse MJ, Roden DM, Rosen MR, Cinca J, Cobbe SM. Congenital and acquired long 
QT syndrome. Eur Heart J. 2000; 21:1232–1237. [PubMed: 10924312] 
140. Gupta A, Lawrence AT, Krishnan K, Kavinsky CJ, Trohman RG. Current concepts in the 
mechanisms and management of drug-induced QT prolongation and torsade de pointes. Am 
Heart J. 2007; 153:891–899. [PubMed: 17540188] 
141. Kannankeril PJ, Roden DM. Drug-induced long QT and torsade de pointes: recent advances. Curr 
Opin Cardiol. 2007; 22:39–43. [PubMed: 17143043] 
142. Lewis BH, Antman EM, Graboys TB. Detailed analysis of 24 hour ambulatory 
electrocardiographic recordings during ventricular fibrillation or torsade de pointes. J Am Coll 
Cardiol. 1983; 2:426–436. [PubMed: 6192159] 
143. Zeltser D, Justo D, Halkin A, Prokhorov V, Heller K, Viskin S. Torsade de pointes due to 
noncardiac drugs: most patients have easily identifiable risk factors. Medicine (Baltimore). 2003; 
82:282–290. [PubMed: 12861106] 
144. Jamshidi Y, Nolte IM, Dalageorgou C, Zheng D, Johnson T, Bastiaenen R, Ruddy S, Talbott D, 
Norris KJ, Snieder H, George AL, Marshall V, Shakir S, Kannankeril PJ, Munroe PB, Camm AJ, 
Jeffery S, Roden DM, Behr ER. Common variation in the NOS1AP gene is associated with drug-
induced QT prolongation and ventricular arrhythmia. J Am Coll Cardiol. 2012; 60:841–850. 
[PubMed: 22682551] 
145. Ramirez AH, Shaffer CM, Delaney JT, Sexton DP, Levy SE, Rieder MJ, Nickerson DA, George 
AL Jr, Roden DM. Novel rare variants in congenital cardiac arrhythmia genes are frequent in 
drug-induced torsades de pointes. Pharmacogenomics J. 2013; 13:325–329. [PubMed: 22584458] 
146. Faber TS, Zehender M, Just H. Drug-induced torsade de pointes. Incidence, management and 
prevention. Drug Saf. 1994; 11:463–476. [PubMed: 7727055] 
147. Middlekauff HR, Stevenson WG, Saxon LA, Stevenson LW. Amiodarone and torsades de pointes 
in patients with advanced heart failure. Am J Cardiol. 1995; 76:499–502. [PubMed: 7653452] 
148. Straus SM, Bleumink GS, Dieleman JP, van der Lei J, ‘t Jong GW, Kingma JH, Sturkenboom 
MC, Stricker BH. Antipsychotics and the risk of sudden cardiac death [published correction 
appears in Arch Intern Med. 2004;164:1839]. Arch Intern Med. 2004; 164:1293–1297. [PubMed: 
15226162] 
149. Pearson EC, Woosley RL. QT prolongation and torsades de pointes among methadone users: 
reports to the FDA spontaneous reporting system. Pharmacoepidemiol Drug Saf. 2005; 14:747–
753. [PubMed: 15918160] 
150. Doig JC. Drug-induced cardiac arrhythmias: incidence, prevention and management. Drug Saf. 
1997; 17:265–275. [PubMed: 9352962] 
151. Jacobs I, Nadkarni V, Bahr J, Berg RA, Billi JE, Bossaert L, Cassan P, Coovadia A, D’Este K, 
Finn J, Halperin H, Handley A, Herlitz J, Hickey R, Idris A, Kloeck W, Larkin GL, Mancini ME, 
Mason P, Mears G, Monsieurs K, Montgomery W, Morley P, Nichol G, Nolan J, Okada K, 
Perlman J, Shuster M, Steen PA, Sterz F, Tibballs J, Timerman S, Truitt T, Zideman D. 
International Liaison Committee on Resuscitation; American Heart Association; European 
Resuscitation Council; Australian Resuscitation Council; New Zealand Resuscitation Council; 
Heart and Stroke Foundation of Canada; InterAmerican Heart Foundation; Resuscitation 
Councils of Southern Africa; ILCOR Task Force on Cardiac Arrest and Cardiopulmonary 
Resuscitation Outcomes. Cardiac arrest and cardiopulmonary resuscitation outcome reports: 
update and simplification of the Utstein templates for resuscitation registries: a statement for 
healthcare professionals from a task force of the International Liaison Committee on 
Resuscitation (American Heart Association, European Resuscitation Council, Australian 
Resuscitation Council, New Zealand Resuscitation Council, Heart and Stroke Foundation of 
et al. Page 252
Circulation. Author manuscript; available in PMC 2017 April 28.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Canada, InterAmerican Heart Foundation, Resuscitation Councils of Southern Africa). 
Circulation. 2004; 110:3385–3397. [PubMed: 15557386] 
152. Chugh SS, Jui J, Gunson K, Stecker EC, John BT, Thompson B, Ilias N, Vickers C, Dogra V, 
Daya M, Kron J, Zheng ZJ, Mensah G, McAnulty J. Current burden of sudden cardiac death: 
multiple source surveillance versus retrospective death certificate-based review in a large U.S. 
community. J Am Coll Cardiol. 2004; 44:1268–1275. [PubMed: 15364331] 
153. Müller D, Agrawal R, Arntz HR. How sudden is sudden cardiac death? Circulation. 2006; 
114:1146–1150. [PubMed: 16952983] 
154. Nichol G, Thomas E, Callaway CW, Hedges J, Powell JL, Aufderheide TP, Rea T, Lowe R, 
Brown T, Dreyer J, Davis D, Idris A, Stiell I. Resuscitation Outcomes Consortium Investigators. 
Regional variation in out-of-hospital cardiac arrest incidence and outcome [published correction 
appears in JAMA. 2008;300:1763]. JAMA. 2008; 300:1423–1431. [PubMed: 18812533] 
155. Cobb LA, Fahrenbruch CE, Olsufka M, Copass MK. Changing incidence of out-of-hospital 
ventricular fibrillation, 1980–2000. JAMA. 2002; 288:3008–3013. [PubMed: 12479765] 
156. Galea S, Blaney S, Nandi A, Silverman R, Vlahov D, Foltin G, Kusick M, Tunik M, Richmond N. 
Explaining racial disparities in incidence of and survival from out-of-hospital cardiac arrest. Am 
J Epidemiol. 2007; 166:534–543. [PubMed: 17584756] 
157. Rea TD, Pearce RM, Raghunathan TE, Lemaitre RN, Sotoodehnia N, Jouven X, Siscovick DS. 
Incidence of out-of-hospital cardiac arrest. Am J Cardiol. 2004; 93:1455–1460. [PubMed: 
15194012] 
158. Maron BJ, Doerer JJ, Haas TS, Tierney DM, Mueller FO. Sudden deaths in young competitive 
athletes: analysis of 1866 deaths in the United States, 1980–2006. Circulation. 2009; 119:1085–
1092. [PubMed: 19221222] 
159. Harmon KG, Asif IM, Klossner D, Drezner JA. Incidence of sudden cardiac death in National 
Collegiate Athletic Association athletes. Circulation. 2011; 123:1594–1600. [PubMed: 
21464047] 
160. Chiuve SE, Fung TT, Rexrode KM, Spiegelman D, Manson JE, Stampfer MJ, Albert CM. 
Adherence to a low-risk, healthy lifestyle and risk of sudden cardiac death among women. 
JAMA. 2011; 306:62–69. [PubMed: 21730242] 
161. Fugate JE, Brinjikji W, Mandrekar JN, Cloft HJ, White RD, Wijdicks EF, Rabinstein AA. Post-
cardiac arrest mortality is declining: a study of the US National Inpatient Sample 2001 to 2009. 
Circulation. 2012; 126:546–550. [PubMed: 22740113] 
162. Dumas F, White L, Stubbs BA, Cariou A, Rea TD. Long-term prognosis following resuscitation 
from out of hospital cardiac arrest: role of percutaneous coronary intervention and therapeutic 
hypothermia. J Am Coll Cardiol. 2012; 60:21–27. [PubMed: 22742398] 
163. Dumas F, Rea TD, Fahrenbruch C, Rosenqvist M, Faxén J, Svensson L, Eisenberg MS, Bohm K. 
Chest compression alone cardiopulmonary resuscitation is associated with better long-term 
survival compared with standard cardiopulmonary resuscitation. Circulation. 2013; 127:435–441. 
[PubMed: 23230313] 
164. Ranthe MF, Carstensen L, Oyen N, Tfelt-Hansen J, Christiansen M, McKenna WJ, Wohlfahrt J, 
Melbye M, Boyd HA. Family history of premature death and risk of early onset cardiovascular 
disease. J Am Coll Cardiol. 2012; 60:814–821. [PubMed: 22917005] 
165. Kim JH, Malhotra R, Chiampas G, d’Hemecourt P, Troyanos C, Cianca J, Smith RN, Wang TJ, 
Roberts WO, Thompson PD, Baggish AL. Race Associated Cardiac Arrest Event Registry 
(RACER) Study Group. Cardiac arrest during long-distance running races. N Engl J Med. 2012; 
366:130–140. [PubMed: 22236223] 
166. Merchant RM, Yang L, Becker LB, Berg RA, Nadkarni V, Nichol G, Carr BG, Mitra N, Bradley 
SM, Abella BS, Groeneveld PW. American Heart Association Get With The Guidelines-
Resuscitation Investigators. Incidence of treated cardiac arrest in hospitalized patients in the 
United States. Crit Care Med. 2011; 39:2401–2406. [PubMed: 21705896] 
167. Wedekind H, Burde D, Zumhagen S, Debus V, Burkhardtsmaier G, Mönnig G, Breithardt G, 
Schulze-Bahr E. QT interval prolongation and risk for cardiac events in genotyped LQTS-index 
children. Eur J Pediatr. 2009; 168:1107–1115. [PubMed: 19101729] 
et al. Page 253
Circulation. Author manuscript; available in PMC 2017 April 28.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
168. Goldenberg I, Zareba W, Moss AJ. Long QT Syndrome. Curr Probl Cardiol. 2008; 33:629–694. 
[PubMed: 18835466] 
169. Schwartz PJ, Stramba-Badiale M, Crotti L, Pedrazzini M, Besana A, Bosi G, Gabbarini F, 
Goulene K, Insolia R, Mannarino S, Mosca F, Nespoli L, Rimini A, Rosati E, Salice P, Spazzolini 
C. Prevalence of the congenital long-QT syndrome. Circulation. 2009; 120:1761–1767. 
[PubMed: 19841298] 
170. Hayashi K, Fujino N, Uchiyama K, Ino H, Sakata K, Konno T, Masuta E, Funada A, Sakamoto Y, 
Tsubokawa T, Nakashima K, Liu L, Higashida H, Hiramaru Y, Shimizu M, Yamagishi M. Long 
QT syndrome and associated gene mutation carriers in Japanese children: results from ECG 
screening examinations. Clin Sci (Lond). 2009; 117:415–424. [PubMed: 19371231] 
171. Fugate T 2nd, Moss AJ, Jons C, McNitt S, Mullally J, Ouellet G, Goldenberg I, Zareba W, 
Robinson JL. U S. portion of International Long QT Syndrome Registry Investigators. Long QT 
syndrome in African- Americans. Ann Noninvasive Electrocardiol. 2010; 15:73–76. [PubMed: 
20146785] 
172. Goldenberg I, Bradley J, Moss A, McNitt S, Polonsky S, Robinson JL, Andrews M, Zareba W. 
International LQTS Registry Investigators. Beta-blocker efficacy in high-risk patients with the 
congenital long-QT syndrome types 1 and 2: implications for patient management. J Cardiovasc 
Electrophysiol. 2010; 21:893–901. [PubMed: 20233272] 
173. Seth R, Moss AJ, McNitt S, Zareba W, Andrews ML, Qi M, Robinson JL, Goldenberg I, 
Ackerman MJ, Benhorin J, Kaufman ES, Locati EH, Napolitano C, Priori SG, Schwartz PJ, 
Towbin JA, Vincent GM, Zhang L. Long QT syndrome and pregnancy. J Am Coll Cardiol. 2007; 
49:1092–1098. [PubMed: 17349890] 
174. Barsheshet A, Goldenberg I, O-Uchi J, Moss AJ, Jons C, Shimizu W, Wilde AA, McNitt S, 
Peterson DR, Zareba W, Robinson JL, Ackerman MJ, Cypress M, Gray DA, Hofman N, Kanters 
JK, Kaufman ES, Platonov PG, Qi M, Towbin JA, Vincent GM, Lopes CM. Mutations in 
cytoplasmic loops of the KCNQ1 channel and the risk of life-threatening events: implications for 
mutation-specific response to β-blocker therapy in type 1 long-QT syndrome. Circulation. 2012; 
125:1988–1996. [PubMed: 22456477] 
175. Zareba W, Moss AJ, Daubert JP, Hall WJ, Robinson JL, Andrews M. Implantable cardioverter 
defibrillator in high-risk long QT syndrome patients. J Cardiovasc Electrophysiol. 2003; 14:337–
341. [PubMed: 12741701] 
176. Jons C, O-Uchi J, Moss AJ, Reumann M, Rice JJ, Goldenberg I, Zareba W, Wilde AA, Shimizu 
W, Kanters JK, McNitt S, Hofman N, Robinson JL, Lopes CM. Use of mutant-specific ion 
channel characteristics for risk stratification of long QT syndrome patients. Sci Transl Med. 
2011; 3:76ra28.
177. Cross B, Homoud M, Link M, Foote C, Garlitski AC, Weinstock J, Estes NA 3rd. The short QT 
syndrome. J Interv Card Electrophysiol. 2011; 31:25–31. [PubMed: 21491125] 
178. Kobza R, Roos M, Niggli B, Abächerli R, Lupi GA, Frey F, Schmid JJ, Erne P. Prevalence of long 
and short QT in a young population of 41,767 predominantly male Swiss conscripts. Heart 
Rhythm. 2009; 6:652–657. [PubMed: 19303371] 
179. Giustetto C, Schimpf R, Mazzanti A, Scrocco C, Maury P, Anttonen O, Probst V, Blanc JJ, 
Sbragia P, Dalmasso P, Borggrefe M, Gaita F. Long-term follow-up of patients with short QT 
syndrome. J Am Coll Cardiol. 2011; 58:587–595. [PubMed: 21798421] 
180. Benito B, Brugada J, Brugada R, Brugada P. Brugada syndrome [published correction appears in 
Rev Esp Cardiol. 2010;63:620]. Rev Esp Cardiol. 2009; 62:1297–1315. [PubMed: 19889341] 
181. Miyasaka Y, Tsuji H, Yamada K, Tokunaga S, Saito D, Imuro Y, Matsumoto N, Iwasaka T. 
Prevalence and mortality of the Brugada-type electrocardiogram in one city in Japan. J Am Coll 
Cardiol. 2001; 38:771–774. [PubMed: 11527631] 
182. Baron RC, Thacker SB, Gorelkin L, Vernon AA, Taylor WR, Choi K. Sudden death among 
Southeast Asian refugees: an unexplained nocturnal phenomenon. JAMA. 1983; 250:2947–2951. 
[PubMed: 6644973] 
183. Nademanee K, Veerakul G, Nimmannit S, Chaowakul V, Bhuripanyo K, Likittanasombat K, 
Tunsanga K, Kuasirikul S, Malasit P, Tansupasawadikul S, Tatsanavivat P. Arrhythmogenic 
marker for the sudden unexplained death syndrome in Thai men. Circulation. 1997; 96:2595–
2600. [PubMed: 9355899] 
et al. Page 254
Circulation. Author manuscript; available in PMC 2017 April 28.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
184. Gilbert J, Gold RL, Haffajee CI, Alpert JS. Sudden cardiac death in a southeast Asian immigrant: 
clinical, electrophysiologic, and biopsy characteristics. Pacing Clin Electrophysiol. 1986; 9(pt 1):
912–914. [PubMed: 2432493] 
185. Hermida JS, Lemoine JL, Aoun FB, Jarry G, Rey JL, Quiret JC. Prevalence of the Brugada 
syndrome in an apparently healthy population. Am J Cardiol. 2000; 86:91–94. [PubMed: 
10867101] 
186. Hayashi M, Denjoy I, Extramiana F, Maltret A, Buisson NR, Lupoglazoff JM, Klug D, Hayashi 
M, Takatsuki S, Villain E, Kamblock J, Messali A, Guicheney P, Lunardi J, Leenhardt A. 
Incidence and risk factors of arrhythmic events in catecholaminergic polymorphic ventricular 
tachycardia. Circulation. 2009; 119:2426–2434. [PubMed: 19398665] 
187. Sumitomo N, Harada K, Nagashima M, Yasuda T, Nakamura Y, Aragaki Y, Saito A, Kurosaki K, 
Jouo K, Koujiro M, Konishi S, Matsuoka S, Oono T, Hayakawa S, Miura M, Ushinohama H, 
Shibata T, Niimura I. Catecholaminergic polymorphic ventricular tachycardia: 
electrocardiographic characteristics and optimal therapeutic strategies to prevent sudden death. 
Heart. 2003; 89:66–70. [PubMed: 12482795] 
188. Probst V, Veltmann C, Eckardt L, Meregalli PG, Gaita F, Tan HL, Babuty D, Sacher F, Giustetto 
C, Schulze-Bahr E, Borggrefe M, Haissaguerre M, Mabo P, Le Marec H, Wolpert C, Wilde AA. 
Long-term prognosis of patients diagnosed with Brugada syndrome: results from the FINGER 
Brugada Syndrome Registry. Circulation. 2010; 121:635–643. [PubMed: 20100972] 
189. Kamakura S, Ohe T, Nakazawa K, Aizawa Y, Shimizu A, Horie M, Ogawa S, Okumura K, 
Tsuchihashi K, Sugi K, Makita N, Hagiwara N, Inoue H, Atarashi H, Aihara N, Shimizu W, 
Kurita T, Suyama K, Noda T, Satomi K, Okamura H, Tomoike H. Brugada Syndrome 
Investigators in Japan. Long-term prognosis of probands with Brugada-pattern ST-elevation in 
leads V1-V3. Circ Arrhythm Electrophysiol. 2009; 2:495–503. [PubMed: 19843917] 
190. Sy RW, Gollob MH, Klein GJ, Yee R, Skanes AC, Gula LJ, Leong-Sit P, Gow RM, Green MS, 
Birnie DH, Krahn AD. Arrhythmia characterization and long-term outcomes in 
catecholaminergic polymorphic ventricular tachycardia. Heart Rhythm. 2011; 8:864–871. 
[PubMed: 21315846] 
191. Hamilton RM. Arrhythmogenic right ventricular cardiomyopathy. Pacing Clin Electrophysiol. 
2009; 32(suppl 2):S44–S51. [PubMed: 19602162] 
192. Dalal D, Nasir K, Bomma C, Prakasa K, Tandri H, Piccini J, Roguin A, Tichnell C, James C, 
Russell SD, Judge DP, Abraham T, Spevak PJ, Bluemke DA, Calkins H. Arrhythmogenic right 
ventricular dysplasia: a United States experience. Circulation. 2005; 112:3823–3832. [PubMed: 
16344387] 
193. Hulot JS, Jouven X, Empana JP, Frank R, Fontaine G. Natural history and risk stratification of 
arrhythmogenic right ventricular dysplasia/cardiomyopathy. Circulation. 2004; 110:1879–1884. 
[PubMed: 15451782] 
194. Olivotto I, Gistri R, Petrone P, Pedemonte E, Vargiu D, Cecchi F. Maximum left ventricular 
thickness and risk of sudden death in patients with hypertrophic cardiomyopathy. J Am Coll 
Cardiol. 2003; 41:315–321. [PubMed: 12535828] 
195. Monserrat L, Elliott PM, Gimeno JR, Sharma S, Penas-Lado M, McKenna WJ. Non-sustained 
ventricular tachycardia in hypertrophic cardiomyopathy: an independent marker of sudden death 
risk in young patients. J Am Coll Cardiol. 2003; 42:873–879. [PubMed: 12957435] 
196. Maron BJ, Olivotto I, Spirito P, Casey SA, Bellone P, Gohman TE, Graham KJ, Burton DA, 
Cecchi F. Epidemiology of hypertrophic cardiomyopathy- related death: revisited in a large non-
referral-based patient population. Circulation. 2000; 102:858–864. [PubMed: 10952953] 
197. Spirito P, Bellone P, Harris KM, Bernabo P, Bruzzi P, Maron BJ. Magnitude of left ventricular 
hypertrophy and risk of sudden death in hypertrophic cardiomyopathy. N Engl J Med. 2000; 
342:1778–1785. [PubMed: 10853000] 
198. Elliott PM, Gimeno Blanes JR, Mahon NG, Poloniecki JD, McKenna WJ. Relation between 
severity of left-ventricular hypertrophy and prognosis in patients with hypertrophic 
cardiomyopathy. Lancet. 2001; 357:420–424. [PubMed: 11273061] 
199. Adabag AS, Casey SA, Kuskowski MA, Zenovich AG, Maron BJ. Spectrum and prognostic 
significance of arrhythmias on ambulatory Holter electrocardiogram in hypertrophic 
cardiomyopathy. J Am Coll Cardiol. 2005; 45:697–704. [PubMed: 15734613] 
et al. Page 255
Circulation. Author manuscript; available in PMC 2017 April 28.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
200. Kofflard MJ, Ten Cate FJ, van der Lee C, van Domburg RT. Hypertrophic cardiomyopathy in a 
large community-based population: clinical outcome and identification of risk factors for sudden 
cardiac death and clinical deterioration. J Am Coll Cardiol. 2003; 41:987–993. [PubMed: 
12651046] 
201. Spirito P, Autore C, Rapezzi C, Bernabò P, Badagliacca R, Maron MS, Bongioanni S, Coccolo F, 
Estes NA, Barillà CS, Biagini E, Quarta G, Conte MR, Bruzzi P, Maron BJ. Syncope and risk of 
sudden death in hypertrophic cardiomyopathy. Circulation. 2009; 119:1703–1710. [PubMed: 
19307481] 
202. Maron MS, Olivotto I, Betocchi S, Casey SA, Lesser JR, Losi MA, Cecchi F, Maron BJ. Effect of 
left ventricular outflow tract obstruction on clinical outcome in hypertrophic cardiomyopathy. N 
Engl J Med. 2003; 348:295–303. [PubMed: 12540642] 
203. Elliott PM, Gimeno JR, Tomé MT, Shah J, Ward D, Thaman R, Mogensen J, McKenna WJ. Left 
ventricular outflow tract obstruction and sudden death risk in patients with hypertrophic 
cardiomyopathy. Eur Heart J. 2006; 27:1933–1941. [PubMed: 16754630] 
204. Efthimiadis GK, Parcharidou DG, Giannakoulas G, Pagourelias ED, Charalampidis P, 
Savvopoulos G, Ziakas A, Karvounis H, Styliadis IH, Parcharidis GE. Left ventricular outflow 
tract obstruction as a risk factor for sudden cardiac death in hypertrophic cardiomyopathy. Am J 
Cardiol. 2009; 104:695–699. [PubMed: 19699347] 
205. Bos JM, Maron BJ, Ackerman MJ, Haas TS, Sorajja P, Nishimura RA, Gersh BJ, Ommen SR. 
Role of family history of sudden death in risk stratification and prevention of sudden death with 
implantable defibrillators in hypertrophic cardiomyopathy. Am J Cardiol. 2010; 106:1481–1486. 
[PubMed: 21059440] 
206. Elliott PM, Poloniecki J, Dickie S, Sharma S, Monserrat L, Varnava A, Mahon NG, McKenna 
WJ. Sudden death in hypertrophic cardiomyopathy: identification of high risk patients. J Am Coll 
Cardiol. 2000; 36:2212–2218. [PubMed: 11127463] 
207. Maron BJ, Spirito P, Shen WK, Haas TS, Formisano F, Link MS, Epstein AE, Almquist AK, 
Daubert JP, Lawrenz T, Boriani G, Estes NA 3rd, Favale S, Piccininno M, Winters SL, Santini M, 
Betocchi S, Arribas F, Sherrid MV, Buja G, Semsarian C, Bruzzi P. Implantable cardioverter-
defibrillators and prevention of sudden cardiac death in hypertrophic cardiomyopathy [published 
correction appears in JAMA. 2007;298:1516]. JAMA. 2007; 298:405–412. [PubMed: 17652294] 
208. Haïssaguerre M, Derval N, Sacher F, Jesel L, Deisenhofer I, de Roy L, Pasquié JL, Nogami A, 
Babuty D, Yli-Mayry S, De Chillou C, Scanu P, Mabo P, Matsuo S, Probst V, Le Scouarnec S, 
Defaye P, Schlaepfer J, Rostock T, Lacroix D, Lamaison D, Lavergne T, Aizawa Y, Englund A, 
Anselme F, O’Neill M, Hocini M, Lim KT, Knecht S, Veenhuyzen GD, Bordachar P, Chauvin M, 
Jais P, Coureau G, Chene G, Klein GJ, Clémenty J. Sudden cardiac arrest associated with early 
repolarization. N Engl J Med. 2008; 358:2016–2023. [PubMed: 18463377] 
209. Rosso R, Kogan E, Belhassen B, Rozovski U, Scheinman MM, Zeltser D, Halkin A, Steinvil A, 
Heller K, Glikson M, Katz A, Viskin S. J-point elevation in survivors of primary ventricular 
fibrillation and matched control subjects: incidence and clinical significance. J Am Coll Cardiol. 
2008; 52:1231–1238. [PubMed: 18926326] 
210. Tikkanen JT, Anttonen O, Junttila MJ, Aro AL, Kerola T, Rissanen HA, Reunanen A, Huikuri 
HV. Long-term outcome associated with early repolarization on electrocardiography. N Engl J 
Med. 2009; 361:2529–2537. [PubMed: 19917913] 
211. Walsh JA 3rd, Ilkhanoff L, Soliman EZ, Prineas R, Liu K, Ning H, Lloyd-Jones DM. Natural 
history of the early repolarization pattern in a biracial cohort: CARDIA (Coronary Artery Risk 
Development in Young Adults) Study. J Am Coll Cardiol. 2013; 61:863–869. [PubMed: 
23428218] 
212. Gourraud JB, Le Scouarnec S, Sacher F, Chatel S, Derval N, Portero V, Chavernac P, Sandoval 
JE, Mabo P, Redon R, Schott JJ, Le Marec H, Haïssaguerre M, Probst V. Identification of large 
families in early repolarization syndrome. J Am Coll Cardiol. 2013; 61:164–172. [PubMed: 
23273290] 
213. Sinner MF, Porthan K, Noseworthy PA, Havulinna AS, Tikkanen JT, Müller-Nurasyid M, Peloso 
G, Ulivi S, Beckmann BM, Brockhaus AC, Cooper RR, Gasparini P, Hengstenberg C, Hwang SJ, 
Iorio A, Junttila MJ, Klopp N, Kähönen M, Laaksonen MA, Lehtimäki T, Lichtner P, Lyytikäinen 
LP, Martens E, Meisinger C, Meitinger T, Merchant FM, Nieminen MS, Peters A, Pietilä A, Perz 
et al. Page 256
Circulation. Author manuscript; available in PMC 2017 April 28.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
S, Oikarinen L, Raitakari O, Reinhard W, Silander K, Thorand B, Wichmann HE, Sinagra G, 
Viikari J, O’Donnell CJ, Ellinor PT, Huikuri HV, Kääb S, Newton-Cheh C, Salomaa V. A meta-
analysis of genome-wide association studies of the electrocardiographic early repolarization 
pattern. Heart Rhythm. 2012; 9:1627–1634. [PubMed: 22683750] 
17. Subclinical Atherosclerosis
See Table 17-1 and Charts 17-1 through 17-6.
Atherosclerosis, a systemic disease process in which fatty deposits, inflammation, cells, and 
scar tissue build up within the walls of arteries, is the underlying cause of the majority of 
clinical cardiovascular events. Individuals who develop atherosclerosis tend to develop it in a 
number of different types of arteries (large and small arteries and those feeding the heart, 
brain, kidneys, and extremities), although they may have much more in some parts of the 
body than others. In recent decades, advances in imaging technology have allowed for 
improved ability to detect and quantify atherosclerosis at all stages and in multiple different 
vascular beds. Two modalities, CT of the chest for evaluation of CAC and B-mode 
ultrasound of the neck for evaluation of carotid artery IMT, have been used in large studies 
with outcomes data and may help define the burden of atherosclerosis in individuals before 
they develop clinical events such as heart attack or stroke. Another commonly used method 
for detecting and quantifying atherosclerosis in the peripheral arteries is the ABI. Data on 
cardiovascular outcomes are beginning to emerge for additional modalities that measure 
anatomic and functional measures of subclinical disease, including brachial artery reactivity 
testing, aortic and carotid magnetic resonance imaging, and tonometric methods of 
measuring vascular compliance or microvascular reactivity. Further research may help to 
define the role of these techniques in cardiovascular risk assessment. Some guidelines have 
recommended screening for subclinical atherosclerosis, especially by CAC, or IMT may be 
appropriate in people at intermediate risk for HD (eg, 10-year estimated risk of 10% to 20%) 
but not for lower-risk general population screening or for people with preexisting HD or 
most other high-risk conditions.1,2 However, a recent guideline notes those with DM who 
are ≥40 years of age may be suitable for screening of risk by coronary calcium. There are 
still limited data demonstrating whether screening with these and other imaging modalities 
can improve patient outcomes or whether it only increases downstream medical care costs. 
A recently published report in a large cohort randomly assigned to coronary calcium 
screening or not showed such screening to result in an improved risk factor profile without 
increasing downstream medical costs.3
Abbreviations Used in Chapter 17
ABI ankle-brachial index
AF atrial fibrillation
ARIC Atherosclerosis Risk in Communities study
BMI body mass index
BP blood pressure
CAC coronary artery calcification
CAD coronary artery disease
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CARDIA Coronary Artery Risk Development in Young Adults
CHD coronary heart disease
CHS Cardiovascular Health Study
CI confidence interval
CONFIRM Coronary CT Angiography Evaluation for Clinical Outcomes: An International Multicenter Registry
CRP C-reactive protein
CT computed tomography
CVD cardiovascular disease
DBP diastolic blood pressure
DM diabetes mellitus
FHS Framingham Heart Study
FMD flow-mediated dilation
FRS Framingham Risk Score
HDL high-density lipoprotein
HD heart disease
HR hazard ratio
IMT intima-media thickness
JUPITER Justification for the Use of Statins in Primary Prevention: An Intervention Trial Evaluating Rosuvastatin
LDL low-density lipoprotein
MESA Multi-Ethnic Study of Atherosclerosis
MI myocardial infarction
NHLBI National Heart, Lung, and Blood Institute
RR relative risk
SBP systolic blood pressure
SD standard deviation
Coronary Artery Calcification
Background
• CAC is a measure of the burden of atherosclerosis in the heart arteries and is 
measured by CT. Other components of the atherosclerotic plaque, including fatty 
(eg, cholesterol- rich components) and fibrotic components, often accompany 
CAC and may be present even in the absence of CAC.
• The presence of any CAC, which indicates that at least some atherosclerotic 
plaque is present, is defined by an Agatston score >0. Clinically significant 
plaque, frequently an indication for more aggressive risk factor management, is 
often defined by an Agatston score ≥100 or a score ≥75th percentile for one’s 
age and sex. An Agatston score ≥400 has been noted to be an indication for 
further diagnostic evaluation (eg, exercise testing or myocardial perfusion 
imaging) for CAD.
Prevalence—(See Table 17-1 and Charts 17-1 and 17-2.)
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• The NHLBI’s FHS reported CAC measured in 3238 white adults in age groups 
ranging from <45 years of age to ≥75 years of age.4
– Overall, 32.0% of women and 52.9% of men had prevalent CAC.
– Among participants at intermediate risk according to FRS, 58% of 
women and 67% of men had prevalent CAC.
• The NHLBI’s CARDIA study measured CAC in 3043 black and white adults 33 
to 45 years of age (at the CARDIA year 15 examination).5
– Overall, 15.0% of men and 5.1% of women, 5.5% of those 33 to 39 
years of age and 13.3% of those 40 to 45 years of age, had prevalent 
CAC. Overall, 1.6% of participants had an Agatston score that exceeded 
100.
– Chart 17-1 shows the prevalence of CAC by ethnicity and sex. The 
prevalence of CAC was lower in black men than in white men but was 
similar in black and white women at these ages.
• The NHLBI’s MESA measured CAC in 6814 participants 45 to 84 years of age, 
including white (n=2619), black (n=1898), Hispanic (n=1494), and Chinese 
(n=803) men and women.6
– Chart 17-2 shows the prevalence of CAC by sex and ethnicity.
– The prevalence and 75th percentile levels of CAC were highest in white 
men and lowest in black and Hispanic women. Significant ethnic 
differences persisted after adjustment for risk factors, with the RR of 
coronary calcium being 22% less in blacks, 15% less in Hispanics, and 
8% less in Chinese than in whites.
– Table 17-1 shows the 75th percentile levels of CAC by sex and race at 
selected ages. These might be considered cut points above which more 
aggressive efforts to control risk factors (eg, elevated cholesterol or BP) 
could be implemented and/or at which treatment goals might be more 
aggressive (eg, LDL cholesterol <100 mg/dL instead of <130 mg/dL).
• The prevalence of CAC varies widely according to FRS. In a report from 
MESA,7 the prevalence of CAC among individuals with very low FRS (10-year 
risk <5%) was low. These findings may have important implications for 
population screening for subclinical atherosclerosis.
• Investigators from the NHLBI’s CARDIA study examined the association 
between neighborhood attributes and subclinical atherosclerosis in younger adult 
populations. Using 2000 US Census block-group-level data, among women, 
higher odds of CAC were associated with higher neighborhood deprivation and 
lower neighborhood cohesion. Among all men, neither neighborhood deprivation 
nor neighborhood cohesion was associated with CAC, whereas among men in 
deprived neighborhoods, low cohesion was associated with higher odds of CAC.8
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CAC and Incidence of Cardiovascular Events—(See Charts 17-3 and 17-4.)
• The NHLBI’s MESA recently reported on the association of CAC scores with 
first CHD events over a median followup of 3.9 years among a population-based 
sample of 6722 men and women (39% white, 27% black, 22% Hispanic, and 
12% Chinese).9
– Chart 17-3 shows the HRs associated with CAC scores of 1 to 100, 101 
to 300, and >300 compared with those without CAC (score=0), after 
adjustment for standard risk factors. People with CAC scores of 1 to 
100 had ≈4 times greater risk and those with CAC scores >100 were 7 
to 10 times more likely to experience a coronary event than those 
without CAC.
– CAC provided similar predictive value for coronary events in whites, 
Chinese, blacks, and Hispanics (HRs ranging from 1.15–1.39 for each 
doubling of coronary calcium).
• In another report of a community-based sample, not referred for clinical reasons, 
the South Bay Heart Watch examined CAC in 1461 adults (average age 66 years) 
with coronary risk factors, with a median of 7.0 years of follow-up.10
– Chart 17-4 shows the HRs associated with increasing CAC scores 
(relative to CAC=0 and <10% risk category) in low-risk (<10%), 
intermediate-risk (10%–15% and 16%–20%), and high-risk (>20%) 
FRS categories of estimated risk for CHD in 10 years. Increasing CAC 
scores further predicted risk in intermediate- and highrisk groups.
• In a study of healthy adults 60 to 72 years of age who were free of clinical CAD, 
predictors of the progression of CAC were assessed. Predictors tested included 
age, sex, race/ethnicity, smoking status, BMI, family history of CAD, CRP, 
several measures of DM, insulin levels, BP, and lipids. Insulin resistance, in 
addition to the traditional cardiac risk factors, independently predicts progression 
of CAC.11 Clinically, however, it is not yet recommended to conduct serial 
scanning of CAC to measure effects of therapeutic interventions.
• A recent publication from MESA also used CAC, in particular, and carotid IMT 
to stratify CHD and CVD event risk in people with metabolic syndrome and DM; 
those with low levels of CAC or carotid IMT have CHD and CVD event rates as 
low as many people without metabolic syndrome and DM. Those with DM who 
have CAC scores <100 have annual CHD event rates of <1%.12
• It is noteworthy, as recently demonstrated in MESA in 5878 participants with a 
median of 5.8 years of follow-up, that the addition of CAC to standard risk 
factors resulted in significant improvement of classification of risk for incident 
CHD events, placing 77% of people in the highest or lowest risk categories 
compared with 69% based on risk factors alone. An additional 23% of those who 
experienced events were reclassified as high risk, and 13% with events were 
reclassified as low risk.13
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• The contribution of CAC to risk prediction has also been observed in other 
cohorts, including both the Heinz Nixdorf Recall Study14 and the Rotterdam 
Study.15
• An absence of CAC, observed in 40% to 50% of individuals, confers a very low 
risk for future cardiovascular events. In a recent meta-analysis of 13 studies 
assessing the relationship of CAC with adverse cardiovascular outcomes that 
included 71 595 asymptomatic patients, 29 312 patients (41%) did not have any 
evidence of CAC.16 In a follow-up that averaged 3 to 5 years, 154 of 29 312 
patients without CAC (0.47%) experienced a cardiovascular event compared with 
1749 of 42 283 patients with CAC (4.14%). The cumulative RR ratio was 0.15 
(95% CI, 0.11–0.21; P<0.001). These findings were confirmed in MESA, which 
reported a rate of 0.52% for CHD events during a median of 4 years of follow-up 
among people with no detectable CAC.17
• A recent meta-analysis18 also highlighted the utility of CAC testing in the 
diabetic population. In this meta-analysis, 8 studies were included (n=6521; 802 
events; mean followup, 5.18 years). The RR for all-cause mortality or 
cardiovascular events or both comparing a total CAC score ≥10 with a score <10 
was 5.47 (95% CI, 2.59–11.53; I2=82.4%, P<0.001). For people with a CAC 
score <10, the posttest probability of the composite outcome was ≈1.8%, which 
represents a 6.8-fold reduction from the pretest probability, which suggests that 
those with low or absent CAC may facilitate risk stratification by enabling the 
identification of people at low risk within this high-risk population.18
• In the Heinz Nixdorf Recall Study,19 CAC independently predicted stroke during 
a mean follow-up of 7.9 years. Cox proportional hazards regressions were used 
to examine CAC as a predictor of stroke in addition to established vascular risk 
factors (age, sex, SBP, LDL, HDL, DM, smoking, and AF). Study participants 
who had a stroke had significantly higher CAC values at baseline than the 
remaining subjects (median, 104.8 [quartile 1, 14.0; quartile 3, 482.2] versus 
11.2 [quartile 1, 0; quartile 3, 106.2]; P<0.001). In a multivariable Cox 
regression, log10(CAC+1) was an independent stroke predictor (HR, 1.52; 95% 
CI, 1.19–1.92; P=0.001). CAC discriminated stroke risk specifically in 
participants in the low (<10%) and intermediate (10%– 20%) FRS categories.19
CAC Progression and Risk
• A recent report in 4609 individuals who had baseline and repeat cardiac CT 
found that progression of CAC provided incremental information over baseline 
score, demographics, and cardiovascular risk factors in predicting future allcause 
mortality.20
• More recently, data from 6778 people in MESA showed annual CAC progression 
was an average of 25 Agatston units, and among those without CAC at baseline, 
a 5-U annual change in CAC was associated with HRs of 1.4 and 1.5 for total 
and hard CHD events, respectively. Among those with CAC >0 at baseline, HRs 
per 100-U annual change in CAC were 1.2 and 1.3, respectively, and for those 
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with annual progression ≥300 versus no progression, HRs were 3.8 and 6.3, 
respectively.21 Progression of CAC in MESA was also shown to be greater in 
those with metabolic syndrome and DM than in those with neither condition, and 
progression of CAC in each of these conditions was associated with a greater 
future risk of CHD events.22
• In MESA, greater adherence to a healthy lifestyle based on a healthy lifestyle 
score was associated with slower progression of CAC and lower mortality rates 
relative to those with the most unhealthy lifestyle.23
Carotid IMT
Background
• Carotid IMT measures the thickness of 2 layers (the intima and media) of the 
wall of the carotid arteries, the largest conduits of blood going to the brain. 
Carotid IMT is thought to be an even earlier manifestation of atherosclerosis than 
CAC, because thickening precedes the development of frank atherosclerotic 
plaque. Carotid IMT methods are still being refined, so it is important to know 
which part of the artery was measured (common carotid, internal carotid, or 
bulb) and whether near and far walls were both measured. This information can 
affect the average-thickness measurement that is usually reported.
• Unlike CAC, everyone has some thickness to the layers of their arteries, but 
people who develop atherosclerosis have greater thickness. Ultrasound of the 
carotid arteries can also detect plaques and determine the degree of narrowing of 
the artery they may cause. Epidemiological data, including the data discussed 
below, have indicated that high-risk levels of thickening might be considered as 
those in the highest quartile or quintile for one’s age and sex, or ≥1 mm.
• Although ultrasound is commonly used to diagnose plaque in the carotid arteries 
in people who have had strokes or who have bruits (sounds of turbulence in the 
artery), guidelines are limited as to screening of asymptomatic people with 
carotid IMT to quantify atherosclerosis or predict risk. However, some 
organizations have recognized that carotid IMT measurement by B-mode 
ultrasonography may provide an independent assessment of coronary risk.24
Prevalence and Association With Incident Cardiovascular Events—(See Charts 
17-5 and 17-6.)
• The Bogalusa Heart Study measured carotid IMT in 518 black and white men 
and women at a mean age of 32±3 years. These men and women were healthy 
but overweight.25
– The mean values of carotid IMT for the different segments are shown in 
Chart 17-5 by sex and race. Men had significantly higher carotid IMT 
in all segments than women, and blacks had higher common carotid and 
carotid bulb IMTs than whites.
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– Even at this young age, after adjustment for age, race, and sex, carotid 
IMT was associated significantly and positively with waist 
circumference, SBP, DBP, and LDL cholesterol. Carotid IMT was 
inversely correlated with HDL cholesterol levels. Participants with 
greater numbers of adverse risk factors (0, 1, 2, 3, or more) had 
stepwise increases in mean carotid IMT levels.
• In a subsequent analysis, the Bogalusa investigators examined the association of 
risk factors measured since childhood with carotid IMT measured in these young 
adults.26 Higher BMI and LDL cholesterol levels measured at 4 to 7 years of age 
were associated with increased risk for being >75th percentile for carotid IMT in 
young adulthood. Higher SBP and LDL cholesterol and lower HDL cholesterol 
in young adulthood were also associated with having high carotid IMT. These 
data highlight the importance of adverse risk factor levels in early childhood and 
young adulthood in the early development of atherosclerosis.
• Among both women and men in MESA, blacks had the highest common carotid 
IMT, but they were similar to whites and Hispanics in internal carotid IMT. 
Chinese participants had the lowest carotid IMT, in particular in the internal 
carotid, of the 4 ethnic groups (Chart 17-6).
• The NHLBI’s CHS reported follow-up of 4476 men and women ≥65 years of age 
(mean age 72 years) who were free of CVD at baseline.27
– Mean maximal common carotid IMT was 1.03±0.20 mm, and mean 
internal carotid IMT was 1.37±0.55 mm.
– After a mean follow-up of 6.2 years, those with maximal combined 
carotid IMT in the highest quintile had a 4- to 5-fold greater risk for 
incident heart attack or stroke than those in the bottom quintile. After 
adjustment for other risk factors, there was still a 2- to 3-fold greater 
risk for the top versus the bottom quintile.
• A study of 441 individuals ≤65 years of age without a history of CAD, DM, or 
hyperlipidemia who were examined for carotid IMT found 42% had high-risk 
carotid ultrasound findings (carotid IMT ≥75th percentile, adjusted for age, sex, 
and race or presence of plaque). Among those with an FRS ≤5%, 38% had high-
risk carotid ultrasound findings.28
• Conflicting data have been reported on the contribution of carotid IMT to risk 
prediction. In 13 145 participants in the NHLBI’s ARIC study, the addition of 
carotid IMT combined with identification of plaque presence or absence to 
traditional risk factors reclassified risk in 23% of individuals overall, with a net 
reclassification improvement of 9.9%. There was a modest but statistically 
significant improvement in the area under the receiver operating characteristic 
curve, from 0.742 to 0.755.29 In contrast, data reported recently from the Carotid 
Atherosclerosis Progression Study observed a net reclassification improvement 
of −1.4% that was not statistically significant.30
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• A recent study from a consortium of 14 population-based cohorts consisting of 
45 828 individuals followed up for a median of 11 years demonstrated little 
additive value of common carotid IMT to FRS for purposes of discrimination and 
reclassification as far as incident MI and stroke were concerned. The C statistics 
of the model with FRS alone (0.757; 95% CI, 0.749–0.764) and with addition of 
common carotid IMT (0.759; 95% CI, 0.752–0.766) were similar. The net 
reclassification improvement with the addition of common carotid IMT was 
small (0.8%; 95% CI, 0.1%–1.6%). In those at intermediate risk, the net 
reclassification improvement was 3.6% among all individuals (95% CI, 2.7%–
4.6%).31
CAC and Carotid IMT
• In the NHLBI’s MESA, a study of white, black, Chinese, and Hispanic adults 45 
to 84 years of age, carotid IMT and CAC were found to be commonly associated, 
but patterns of association differed somewhat by sex and race.32
– Common and internal carotid IMT were greater in women and men 
who had CAC than in those who did not, regardless of ethnicity.
– Overall, CAC prevalence and scores were associated with carotid IMT, 
but associations were somewhat weaker in blacks than in other ethnic 
groups.
– In general, blacks had the thickest carotid IMT of all 4 ethnic groups, 
regardless of the presence of CAC.
– Common carotid IMT differed little by race/ethnicity in women with 
any CAC, but among women with no CAC, IMT was higher among 
blacks (0.86 mm) than in the other 3 groups (0.76–0.80 mm).
• In a more recent analysis from the NHLBI’s MESA study, the investigators 
reported on follow-up of 6698 men and women in 4 ethnic groups over 5.3 years 
and compared the predictive utility of carotid IMT and CAC.33
– CAC was associated more strongly than carotid IMT with the risk of 
incident CVD.
– After adjustment for each other (CAC score and IMT) and for 
traditional CVD risk factors, the HR for CVD increased 2.1-fold for 
each 1-SD increment of log-transformed CAC score versus 1.3-fold for 
each 1-SD increment of the maximum carotid IMT.
– For CHD events, the HRs per 1-standard deviation increment increased 
2.5-fold for CAC score and 1.2-fold for IMT.
– A receiver operating characteristic curve analysis also suggested that 
CAC score was a better predictor of incident CVD than was IMT, with 
areas under the curve of 0.81 versus 0.78, respectively.
– Investigators from the NHLBI’s CARDIA and MESA studies examined 
the burden and progression of subclinical atherosclerosis among adults 
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<50 years of age. Ten-year and lifetime risks for CVD were estimated 
for each participant, and the participants were stratified into 3 groups: 
(1) those with low 10-year (<10%) and low lifetime (<39%) predicted 
risk for CVD; (2) those with low 10-year (<10%) but high lifetime 
(≥39%) predicted risk; and (3) those with high 10-year risk (>10%). 
The latter group had the highest burden and greatest progression of 
subclinical atherosclerosis. Given the young age of those studied, ≈90% 
of participants were at low 10-year risk, but of these, half had high 
predicted lifetime risk. Compared with those with low short-term/low 
lifetime predicted risks, those with low short-term/high lifetime 
predicted risk had significantly greater burden and progression of CAC 
and significantly greater burden of carotid IMT, even at these younger 
ages. These data confirm the importance of early exposure to risk 
factors for the onset and progression of subclinical atherosclerosis.34
CT Angiography
• CT angiography is widely used by cardiologists to aid in the diagnosis of CAD, 
particularly when other test results may be equivocal. It is also of interest 
because of its ability to detect and possibly quantitate overall plaque burden and 
certain characteristics of plaques that may make them prone to rupture, such as 
positive remodeling or low attenuation.
• Compared with the established value of CAC scanning for risk reclassification in 
asymptomatic patients, there are limited data regarding the utility of CT 
angiography in asymptomatic people. This was recently assessed by the 
investigators of the CONFIRM registry,35 from which >7500 asymptomatic 
subjects with CAC and CT angiography were followed up for death and nonfatal 
MI for a median of 2 years. Overall, 2.2% either died or experienced nonfatal 
MI, and in multivariable models, compared with those without atherosclerosis, 
there was increasing risk across groups with increasing degrees of atherosclerosis 
measured by CT angiography. However, after the inclusion of CAC in the 
multivariable risk model, CT angiography did not provide incremental prognostic 
value over this short period of follow-up.35
• Because of the limited outcome data in asymptomatic people, as well as the 
associated expense and risk of CT angiography (including generally higher 
radiation levels than CT scanning to detect CAC), current guidelines do not 
recommend its use as a screening tool for assessment of cardiovascular risk in 
asymptomatic people.2
Measures of Vascular Function and Incident CVD Events
Background
• Measures of arterial tonometry (stiffness) are based on the concept that pulse 
pressure has been shown to be an important risk factor for CVD. Arterial 
tonometry offers the ability to directly and noninvasively measure central pulse 
wave velocity in the thoracic and abdominal aorta.
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• Brachial FMD is a marker for nitric oxide release from the endothelium that can 
be measured by ultrasound. Impaired FMD is an early marker of CVD.
• Recommendations have not been specific, however, as to which, if any, measures 
of vascular function may be useful for CVD risk stratification in selected patient 
subgroups. Because of the absence of significant prospective data relating these 
measures to outcomes, latest guidelines do not currently recommend measuring 
either FMD or arterial stiffness for cardiovascular risk assessment in 
asymptomatic adults.2
Arterial Tonometry and CVD
• The Rotterdam Study measured arterial stiffness in 2835 elderly participants 
(mean age 71 years).36 They found that as aortic pulse wave velocity increased, 
the risk of CHD was 1.72 (second versus first tertile) and 2.45 (third versus first 
tertile). Results remained robust even after accounting for carotid IMT, ABI, and 
pulse pressure.
• A study from Denmark of 1678 individuals aged 40 to 70 years found that each 
1-SD increment in aortic pulse wave velocity (3.4 m/s) increased CVD risk by 
16% to 20%.37
• The FHS measured several indices of arterial stiffness, including pulse wave 
velocity, wave reflection, and central pulse pressure.38 They found that not only 
was higher pulse wave velocity associated with a 48% increased risk of incident 
CVD events, but pulse wave velocity additionally improved CVD risk prediction 
(integrated discrimination improvement of 0.7%, P<0.05).
FMD and CVD
• MESA measured FMD in 3026 participants (mean age 61 years) who were free 
of CVD. As FMD increased (ie, improved brachial function), the risk of CVD 
was 16% lower.39 FMD also improved CVD risk prediction compared with the 
FRS by improving net reclassification by 29%.
Comparison of Measures
• In MESA, a comparison of 6 risk markers—CAC, ABI, high-sensitivity CRP, 
carotid IMT, brachial FMD, and family history of CHD—and their clinical utility 
over FRS was evaluated in 1330 intermediate-risk individuals. After 7.6 years of 
follow-up, CAC, ABI, high-sensitivity CRP, and family history were 
independently associated with incident CHD in multivariable analyses (HRs of 
2.6, 0.79, 1.28, and 2.18, respectively), but carotid IMT and brachial FMD were 
not. CAC provided the highest incremental improvement over the FRS (0.784 for 
both CAC and FRS versus 0.623 for FRS alone), as well as the greatest net 
reclassification improvement (0.659).40
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Utility for Risk Stratification for Treatment
• CAC has been examined for its potential to identify those most likely to benefit 
from treatment.
• In a recent report, 950 participants from MESA who met JUPITER clinical trial 
entry criterion (risk factors plus LDL cholesterol <130 mg/dL and CRP ≥2 mg/L) 
were identified and stratified according to CAC scores of 0, 1 to 100, or >100; 
CHD event rates were calculated, and the number needed to treat was calculated 
by applying the benefit found in JUPITER to the event rates found in each of 
these groups. For CHD, the predicted 5-year number needed to treat was 549 for 
those with CAC of 0, 94 for scores of 1 to 100, and 24 for scores >100, thus 
showing the utility of CAC in identifying those most likely to benefit from statin 
treatment with an appropriate number needed to treat..41
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18. Coronary Heart Disease, Acute Coronary Syndrome, and Angina 
Pectoris
See Tables 18-1 and 18-2 and Charts 18-1 through 18-10; see Glossary (Chapter 26) for 
details and definitions.
Coronary Heart Disease
ICD-9 410 to 414, 429.2; ICD-10 I20 to I25; including MI ICD-10 I21 to I22.
Abbreviations Used in Chapter 18
ACC American College of Cardiology ACS acute coronary syndrome
ACTION Acute Coronary Treatment and Intervention Outcomes Network
AHA American Heart Association
AMI acute myocardial infarction
AP angina pectoris
ARIC Atherosclerosis Risk in Communities study
BMI body mass index
BP blood pressure
BRFSS Behavioral Risk Factor Surveillance System
CABG coronary artery bypass graft
CAD coronary artery disease
CDC Centers for Disease Control and Prevention
CHD coronary heart disease
CHS Cardiovascular Health Study
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CI confidence interval
CRUSADE Can Rapid Risk Stratification of Unstable Angina Patients Suppress Adverse Outcomes With Early 
Implementation of the ACC/AHA Guidelines
CVD cardiovascular disease
DM diabetes mellitus
ECG electrocardiogram/electrocardiographic
ED emergency department
EHS-ACS-II second Euro Heart Survey on ACS
EMS emergency medical services
FHS Framingham Heart Study
GRACE Global Registry of Acute Coronary Events
GWTG Get With The Guidelines
HCUP Healthcare Cost and Utilization Project
HD heart disease
HDL-C high-density lipoprotein-cholesterol
HF heart failure
ICD-9 International Classification of Diseases, 9th Revision
ICD-10 International Classification of Diseases, 10th Revision
MEPS Medical Expenditure Panel Survey
MI myocardial infarction
NAMCS National Ambulatory Medical Care Survey
NCDR National Cardiovascular Data Registry
NCHS National Center for Health Statistics
NH non-Hispanic
NHAMCS National Hospital Ambulatory Medical Care Survey
NHANES National Health and Nutrition Examination Survey
NHDS National Hospital Discharge Survey
NHIS National Health Interview Study
NHLBI National Heart, Lung, and Blood Institute
NRMI-4 National Registry of Myocardial Infarction 4
NSTEMI non–ST-segment–elevation myocardial infarction
OR odds ratio
PCI percutaneous coronary intervention
SBP systolic blood pressure
STEMI ST-segment–elevation myocardial infarction
UA unstable angina
WISE Women’s Ischemia Syndrome Evaluation
YLL years of life lost
Prevalence—(See Table 18-1 and Charts 18-1 and 18-2.)
• On the basis of data from NHANES 2007 to 2010 (NHLBI tabulation), an 
estimated 15.4 million Americans ≥20 years of age have CHD.
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– Total CHD prevalence is 6.4% in US adults ≥20 years of age. CHD 
prevalence is 7.9% for men and 5.1% for women.
– Among non-Hispanic whites, CHD prevalence is 8.2% for men and 
4.6% for women.
– Among non-Hispanic blacks, CHD prevalence is 6.8% for men and 
7.1% for women.
– Among Mexican Americans, CHD prevalence is 6.7% for men and 
5.3% for women.
• On the basis of data from the 2012 NHIS
– Among Hispanic or Latino individuals ≥18 years of age, CHD 
prevalence is 5.9%.1
– Among American Indian/Alaska Natives ≥18 years of age, it is 
estimated that 8.1% have CHD, and among Asians ≥18 years of age, the 
estimate is 4.5%.1
• According to data from NHANES 2007 to 2010 (NHLBI tabulation), the overall 
prevalence for MI is 2.9% in US adults ≥20 years of age. MI prevalence is 4.2% 
for men and 1.7% for women.
– Among non-Hispanic whites, MI prevalence is 4.4% for men and 1.5% 
for women.
– Among non-Hispanic blacks, MI prevalence is 3.9% for men and 2.3% 
for women.
– Among Mexican Americans, MI prevalence is 3.6% for men and 1.7% 
for women.
• Data from the BRFSS 2011 survey indicated that 4.3% of respondents had been 
told that they had had an MI. The highest prevalence was in Arkansas (6.4%) and 
West Virginia (6.2%). The lowest prevalence was in Colorado (2.7%) and Utah 
(3.0%). In the same survey, 4.2% of respondents were told that they had angina 
or CHD. The highest prevalence was in West Virginia (6.6%), and the lowest was 
in Colorado (2.4%).2
• Projections show that by 2030, prevalence of CHD will increase ≈18% from 
2013 estimates (AHA computation, based on methodology described in 
Heidenreich et al).3
Incidence—(See Table 18-1 and Charts 18-3 through 18-5.)
• Approximately every 44 seconds, an American will have an MI (AHA 
computation).
• On the basis of data from the ARIC study4 of the NHLBI
– This year, ≈620 000 Americans will have a new coronary attack 
(defined as first hospitalized MI or CHD death), and ≈295 000 will 
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have a recurrent attack. It is estimated that an additional 150 000 silent 
MIs occur each year. That assumes that ≈21% of the 720 000 first and 
recurrent MIs are silent.5,6
– The estimated annual incidence of MI is 515 000 new attacks and 205 
000 recurrent attacks.
– Average age at first MI is 64.9 years for men and 72.3 years for women.
• On the basis of the NHLBI-sponsored FHS
– CHD makes up more than half of all cardiovascular events in men and 
women <75 years of age.5
– The incidence of CHD in women lags behind men by 10 years for total 
CHD and by 20 years for more serious clinical events such as MI and 
sudden death.5
• In the NHLBI-sponsored ARIC study, in participants 35 to 84 years of age, the 
average age-adjusted first MI or fatal CHD rates per 1000 population were as 
follows: white men, 3.6; black men, 5.6; white women, 2.1; and black women, 
3.8 (unpublished data from ARIC Surveillance 2005–2010, NHLBI).
• Incidence rates for MI in the NHLBI-sponsored ARIC study are displayed in 
Charts 18-3 and 18-4, stratified by age, race, and sex. The annual age-adjusted 
rates per 1000 population of first MI (2005–2010) were 4.8 in black men, 3.2 in 
white men, 3.3 in black women, and 1.9 in white women (unpublished data from 
ARIC Surveillance 2005– 2010, NHLBI).
• Among American Indians 65 to 74 years of age, the annual rates per 1000 
population of new and recurrent MIs were 7.6 for men and 4.9 for women.7
• On the basis of data from the NHDS, since the mid-1990s, the rate of 
hospitalization for MI and in-hospital case fatality rates have decreased.8
• From 2002 to 2007, the rates of hospitalization for MI decreased among 
Medicare beneficiaries; however, the degree of reduction was more significant in 
whites than in African Americans.9
Trends in Incidence
• Analysis of >40 years of physician-validated AMI data in the NHLBI’s FHS 
found that AMI rates diagnosed by electrocardiographic criteria declined ≈50%, 
with a concomitant 2-fold increase in rates of AMI diagnosed by blood markers. 
These findings may explain the paradoxical stability of AMI rates in the United 
States despite concomitant improvements in CHD risk factors.10
• Data from the Worcester Heart Attack Study showed that incidence rates for 
AMI were 277 per 100 000 person-years in 1975 and 209 per 100 000 person-
years in 2005 (P=0.42 for overall trend). The incidence rate rose from 1975 to 
1981, decreased from 1981 to 1988, increased from 1981 to 2001, and decreased 
from 2001 to 2005.11
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• In Olmsted County, MN, no significant change in the overall age- and sex-
adjusted incidence rate for hospitalized MI was noted (186 per 100 000 person-
years in 1987 and 180 per 100 000 person-years in 2006; P=0.171), but a 
significant decline in the age- and sex-adjusted incidence rate for hospitalized MI 
based on creatine kinase/creatine kinase- MB markers, to 141 per 100 000 
person-years (P=0.020), was observed in 2006, which represents a 20% decrease 
during the study period.12
• Data from Kaiser Permanente Northern California showed that the age- and sex-
adjusted incidence rate of hospitalizations for MI changed from 274 per 100 000 
person-years in 1999 to 208 per 100 000 person-years in 2008. Furthermore, the 
age- and sex-adjusted incidence rate of hospitalizations for STEMI changed from 
133 per 100 000 person-years in 1999 to 50 per 100 000 person-years in 2008 (P 
linear trend <0.001). The trajectory of the age- and sex-adjusted incidence rate of 
hospitalizations for NSTEMI did not change significantly.13
• From 1987 to 2008, the age- and biomarker-adjusted incidence rates of 
hospitalization for AMI or fatal CHD decreased by 4.9% per year (95% CI, 
5.3%–4.5%) among white men, 3.9% per year (95% CI, 4.5%–3.4%) among 
white women, 1.8% per year (95% CI, 2.6%–1.0%) among black men, and 3.5% 
per year (95% CI, 4.4%–2.6%) among black women in the ARIC study.14
Predicted Risk
Ten-Year Predicted Risk
• Analysis of data from NHANES III (1988–1994) and NHANES 1999 to 2002 
(NCHS) showed that in adults 20 to 74 years of age, the overall distribution of 
10-year risk of developing CHD changed little during this time. Among the 3 
racial/ethnic groups, blacks had the highest proportion of participants in the 
high-risk group.15
• Another analysis of NHANES data concluded that 10-year predicted risk for 
CHD among adults 30 to 74 years of age decreased from 10.0% during 1976 to 
1980 to 7.9% during 1988 to 1994 (P<0.001) and to 7.4% during 1999 to 2004 
(P <0.001).16
• More recently, it was reported that the mean predicted 10-year risk for CHD 
among adults aged 30 to 74 years decreased from 7.2% during 1999 to 2000 to 
6.5% during 2009 to 2010 (P=0.005).17 Mean predicted risk declined among 
men, women, whites, and adults 40 to 59, 50 to 59, and 60 to 74 years of age. 
Risk increased nonsignificantly among African American adults.
• A survey of US family physicians, general internists, and cardiologists found that 
41% of respondents reported using global CHD risk assessment at least 
occasionally.18
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Lifetime Risk
• The lifetime risk of developing CHD after 40 years of age is 49% for men and 
32% for women.19
• Lifetime risk for CHD varies drastically as a function of risk factor profile. With 
an optimal risk factor profile, lifetime risk for CHD is 3.6% for men and <1% for 
women; with ≥2 major risk factors, it is 37.5% for men and 18.3% for women.20
Mortality
• CHD was an underlying cause of death in ≈1 of every 6 deaths in the United 
States in 2010.
• In 2010, CHD mortality was 379 559,21 and CHD any-mention mortality was 
545 259.22
• In 2010, MI mortality was 122 071.21 MI any-mention mortality was 158 998 
(NCHS, NHLBI tabulation).22
• In 2010, the overall CHD death rate per 100 000 was 113.6.21 From 2000 to 
2010, the annual death rate attributable to CHD declined 39.2% and the actual 
number of deaths declined 26.3% (CDC computation).21,22 CHD death rates per 
100 000 were 151.9 for white males and 169.0 for black males; for white 
females, the rate was 83.8, and for black females, it was 104.9.21
• In 2010, 73% of CHD deaths occurred out of the hospital. According to NCHS 
mortality data, 278 000 CHD deaths occur out of the hospital or in hospital EDs 
annually (NCHS, AHA tabulation).22
• Approximately every 34 seconds, an American will experience a coronary event, 
and approximately every 1 minute 23 seconds, someone will die of one (AHA 
computation).
• Approximately 34% of the people who experience a coronary attack in a given 
year will die of it, and ≈15% who experience a heart attack (MI) will die of it 
(AHA computation).
• A study of 1275 health maintenance organization enrollees 50 to 79 years of age 
who had cardiac arrest showed that the incidence of out-of-hospital cardiac arrest 
was 6.0/1000 subject-years in subjects with any clinically recognized HD 
compared with 0.8/1000 subject-years in subjects without HD. Among enrollees 
with HD, incidence was 13.6 and 21.9 per1000 subject-years in those with prior 
MI and with HF, respectively.23
• Approximately 80% of people who die of CHD are ≥65 years of age (NCHS; 
AHA computation).
• The estimated average number of YLL because of an MI death is 17.2 (NCHS, 
NHLBI tabulation).
• On the basis of data from the FHS of the NHLBI5
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– Fifty percent of men and 64% of women who die suddenly of CHD 
have no previous symptoms of this disease. Between 70% and 89% of 
sudden cardiac deaths occur in men, and the annual incidence is 3 to 4 
times higher in men than in women; however, this disparity decreases 
with advancing age.
– People who have had an MI have a sudden death rate 4 to 6 times that 
of the general population.
• Researchers investigating variation in hospital-specific 30-day risk-stratified 
mortality rates for patients with AMI found teaching status, number of hospital 
beds, AMI volume, cardiac facilities available, urban/rural location, geographic 
region, hospital ownership type, and socioeconomic status profile of the patients 
were all significantly associated with mortality rates. However, a substantial 
proportion of variation in outcomes for patients with AMI between hospitals 
remains unexplained by measures of hospital characteristics.24
Temporal Trends in CHD Mortality
• The decline in CHD mortality rates in part reflects the shift in the pattern of 
clinical presentations of AMI. In the past decade, there has been a marked 
decline in STEMI (from 133 to 50 cases per 100 000 person-years).13
• According to data from the National Registry of Myocardial Infarction:
– From 1990 to 1999, in-hospital AMI mortality declined from 11.2% to 
9.4%.25
– From 1990 to 2006, in-hospital AMI mortality declined from 10.4% to 
6.3% (P<0.001; STEMI: 11.5% to 8.0%, P<0.001; NSTEMI: 7.1% to 
5.2%, P<0.001). Approximately 37% of the decline in annual mortality 
for patients with NSTEMI and 21% for patients with STEMI was 
judged to be attributable to improvements in acute treatments.26
– Mortality rate increases for every 30 minutes that elapses before a 
patient with ST-segment elevation is recognized and treated.25
• Other studies also reported declining case fatality rates after MI:
– In Olmsted County, MN, the age- and sex-adjusted 30-day case fatality 
rate decreased by 56% from 1987 to 2006.12
– In Worcester, MA, the hospital case fatality rates, 30-day postadmission 
case fatality rates, and 1-year postdischarge case fatality rates for 
STEMI were 11.1%, 13.2%, and 10.6%, respectively, in 1997 and 
9.7%, 11.4%, and 8.4%, respectively, in 2005. The hospital case fatality 
rates, 30-day postadmission case fatality rates, and 1-year postdischarge 
case fatality rates for NSTEMI were 12.9%, 16.0%, and 23.1%, 
respectively, in 1997 and 9.5%, 14.0%, and 18.7%, respectively, in 
2005.27
et al. Page 276
Circulation. Author manuscript; available in PMC 2017 April 28.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
– Among enrollees of the Kaiser Permanente Northern California 
healthcare delivery system, the age- and sex-adjusted 30-day mortality 
rate for MI dropped from 10.5% in 1999 to 7.8% in 2008, and the 30-
day mortality rate for NSTEMI dropped from 10.0% in 1999 to 7.6% in 
2008.13
– A recent analysis of Centers for Medicare & Medicaid Services data 
suggests that between 1995 and 2006, the 30-day mortality rate 
attributable to MI decreased, as did hospital variation in mortality 
attributable to MI.28
– Data from the Nationwide Inpatient Sample database suggest that 
mortality attributable to MI has decreased since 1988.29
• CHD death rates have fallen from 1968 to the present. Analysis of NHANES 
(NCHS) data compared CHD death rates between 1980 and 2000 to determine 
how much of the decline in deaths attributable to CHD over that period could be 
explained by the use of medical and surgical treatments versus changes in CVD 
risk factors (resulting from lifestyle/behavior). After 1980 and 2000 data were 
compared, it was estimated that ≈47% of the decrease in CHD deaths was 
attributable to treatments, including the following30:
– Secondary preventive therapies after MI or revascularization (11%)
– Initial treatments for AMI or UA (10%)
– Treatments for HF (9%)
– Revascularization for chronic angina (5%)
– Other therapies (12%), including antihypertensive and lipid-lowering 
primary prevention therapies
• It was also estimated that a similar amount of the reduction in CHD deaths, 
≈44%, was attributable to changes in risk factors, including the following30:
– Lower total cholesterol (24%)
– Lower SBP (20%)
– Lower smoking prevalence (12%)
– Decreased physical inactivity (5%)
– Nevertheless, these favorable improvements in risk factors were offset 
in part by increases in BMI and in DM prevalence, which accounted for 
an increased number of deaths (8% and 10%, respectively).
• Between 1980 and 2002, death rates attributable to CHD among men and women 
≥35 years of age fell by 52% in men and 49% in women. Among men, the death 
rate declined on average by 2.9% per year in the 1980s, 2.6% per year during the 
1990s, and 4.4% per year from 2000 to 2002. Among women, death rates fell by 
2.6%, 2.4%, and 4.4%, respectively; however, when stratified by age, among 
men 35 to 54 years of age, the average annual rate of death fell by 6.2%, 2.3%, 
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and 0.5%, respectively. Among women 35 to 54 years of age, the average annual 
rate of death fell by 5.4% and 1.2% and then increased by 1.5%, respectively. 
This increase was not statistically significant; however, in even younger women 
(35–44 years of age), the rate of death has been increasing by an average of 1.3% 
annually between 1997 and 2002, which is statistically significant.31
• In an analysis of 28 studies published from 1977 to 2007, significantly improved 
survival was described in patients with nonacute CAD treated with 
revascularization by CABG or PCI in conjunction with medical therapy 
compared with patients treated with medical therapy alone.32
Risk Factors
• Risk factors for CHD act synergistically to increase CHD risk, as shown in the 
examples in Charts 18-6 and 18-7.
Awareness of Warning Signs and Risk Factors for HD
• Among people in 14 states and Washington, DC, participating in the 2005 
BRFSS, only 27% were aware of 5 heart attack warning signs and symptoms (1, 
pain in jaw, neck, or back; 2, weak, lightheaded, or faint; 3, chest pain or 
discomfort; 4, pain or discomfort in arms or shoulder; and 5, shortness of breath) 
and indicated that they would first call 9-1-1 if they thought someone was having 
a heart attack or stroke. Significant variation in the percentage of participants 
who were aware of all 5 heart attack warning signs and symptoms and who 
would call 9-1-1 as their initial action varied by race or ethnicity (30.2% for non-
Hispanic whites, 16.2% for non-Hispanic blacks and 14.3% for Hispanics), sex 
(30.8% for women and 22.5% for men), and educational status (33.4% for those 
with a college education or more and 15.7% for those with less than a high 
school education). In addition, significant interstate variation was also present 
(highest in West Virginia [35.5%] and lowest in Washington, DC [16.0%]).33
• Data from the Women Veterans Cohort showed that 42% of women ≥35 years of 
age were concerned about HD.34
• Women’s awareness that CVD is their leading cause of death increased from 
30% in 1997 to 56% in 2012.
– Depending on age, 44% to 50% identified HD/heart attack as the 
leading cause of death for women, a significant increase from 16% to 
34% in the original 1997 survey.
– The percentages of women identifying warning signs for a heart attack 
were as follows: pain in the chest, neck, shoulder, and arm—56%; 
shortness of breath—38%; chest tightness—17%; nausea—18%; and 
fatigue—10%.
– The 5 most commonly cited HD prevention strategies in 2012 were 
maintaining a healthy BP (78%), seeing the doctor (78%), and 
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increasing fiber intake, eating food with antioxidants, and maintaining 
healthy cholesterol levels (each 66%).
– Among online survey participants, 21% responded that their doctor had 
talked to them about HD risk. Rates were lower among Hispanic 
women (12%) than whites (22%) or blacks (22%) and increased with 
age from 6% (25–34 years) to 33% (≥65 years).35
• A 2004 national study of physician awareness and adherence to CVD prevention 
guidelines showed low awareness that the annual number of deaths from CVD 
among women exceeded that among men (fewer than 1 in 5 physicians knew 
this).36
Delays Between Symptom Onset and Arrival at Hospital
• A recent community surveillance study in 4 US communities reported that in 
2000, 49.5% of people arrived at the hospital ≥4 hours after the onset of AMI 
symptoms. From 1987 to 2000, the percentage of patients arriving at the hospital 
≥4 hours after symptoms began did not change significantly, indicating that there 
had been little improvement in the speed at which patients with MI symptoms 
arrived at the hospital after symptom onset. Although the proportion of patients 
with MI who arrived at the hospital by EMS increased over this period, from 
37.1% in 1987 to 44.5% in 2000, the total time between onset and hospital 
arrival did not change appreciably.37
• System improvements in Dallas County, TX, resulted in decreases in the median 
time from symptom onset to balloon (catheterization) from the fourth quarter of 
2010 to the first quarter of 2012.38
• Data from CRUSADE and the NCDR ACTION Registry–GWTG showed a 
longer median time to hospital presentation in men (3 hours) than in women (2.8 
hours; P<0.001). From 2002 to 2007, presentation time did not change 
significantly in men or women.39
• Individuals with documented CHD have 5 to 7 times the risk of having a heart 
attack or dying as the general population. Survival rates improve after a heart 
attack if treatment begins within 1 hour; however, most patients are admitted to 
the hospital 2.5 to 3 hours after symptoms begin. More than 3500 patients with a 
history of CHD were asked to identify possible symptoms of heart attack. 
Despite their history of CHD, 44% had low knowledge levels. Among these 
high-risk participants, 43% underestimated their risk for a future AMI (men 
47%, women 36%).40
• Data from Worcester, MA, indicate that the average time from symptom onset to 
hospital arrival has not improved and that delays in hospital arrival are associated 
with less receipt of guidelines-based care. Mean and median prehospital delay 
times from symptom onset to arrival at the hospital were 4.1 and 2.0 hours in 
1986 and 4.6 and 2.0 hours in 2005, respectively. Receipt of thrombolytic 
therapy and PCI within 90 minutes of hospital arrival was less likely among 
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patients who arrived within ≥2 hours of symptom onset than among those who 
arrived <2 hours after onset.41
• In an analysis from ARIC, low neighborhood household income (OR, 1.46; 95% 
CI, 1.09–1.96) and being a Medicaid recipient (OR, 1.87; 95% CI, 1.10–3.19) 
were associated with increased odds of having prolonged prehospital delays from 
symptom onset to hospital arrival for AMI compared with individuals with 
higher neighborhood household income and other insurance providers, 
respectively.42
• An analysis of data from the NCDR ACTION Registry–GWTG showed that 
60% of 37 634 STEMI patients used EMS to get to the hospital. Older adults, 
women, adults with comorbidities, and sicker patients were more likely to use 
EMS than their counterparts. Hospital arrival time was shorter for those who 
used EMS (89 minutes) than self-transport (120 minutes).43
Aftermath
• Depending on their sex and clinical outcome, people who survive the acute stage 
of an MI have a chance of illness and death 1.5 to 15 times higher than that of the 
general population. Among these people, the risk of another MI, sudden death, 
AP, HF, and stroke—for both men and women—is substantial (FHS, NHLBI).5
• On the basis of pooled data from the FHS, ARIC, and CHS studies of the NHLBI 
(1986–2007), within 1 year after a first MI:
– At ≥45 years of age, 19% of men and 26% of women will die.
– At 45 to 64 years of age, 5% of white men, 8% of white women, 14% 
of black men, and 9% of black women will die.
– At ≥65 years of age, 25% of white men, 30% of white women, 25% of 
black men, and 30% of black women will die.
– In part because women have MIs at older ages than men, they are more 
likely to die of MIs within a few weeks.
• Within 5 years after a first MI:
– At ≥45 years of age, 36% of men and 47% of women will die.
– At 45 to 64 years of age, 11% of white men, 18% of white women, 22% 
of black men, and 28% of black women will die.
– At ≥65 years of age, 46% of white men, 53% of white women, 54% of 
black men, and 58% of black women will die.
• Of those who have a first MI, the percentage with a recurrent MI or fatal CHD 
within 5 years is as follows:
– At 45 to 64 years of age, 15% of men and 22 of women
– At ≥65 years of age, 22% of men and women
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– At 45 to 64 years of age, 14% of white men, 18% of white women, 22% 
of black men, and 28% of black women
– At ≥65 years of age, 21% of white men and women, 33% of black men, 
and 26% of black women
• The percentage of people with a first MI who will have HF in 5 years is as 
follows:
– At 45 to 64 years of age, 8% of men and 18% of women
– At ≥65 years of age, 20% of men and 23% of women
– At 45 to 64 years of age, 7% of white men, 15% of white women, 13% 
of black men, and 25% of black women
– At ≥65 years of age, 19% of white men, 23% of white women, 31% of 
black men, and 24% of black women
• The percentage of people with a first MI who will have a stroke within 5 years is 
as follows:
– At 45 to 64 years of age, 2% of men and 6% of women
– At ≥65 years of age, 5% of men and 8% of women
– At 45 to 64 years of age, 2% of white men, 4% of white women, 3% of 
black men, and 10% of black women
– At ≥65 years of age, 5% of white men, 8% of white women, 9% of 
black men, and 10% of black women
• The median survival time (in years) after a first MI is
– At 55 to 64 years of age, 17.0 for men and 13.3 for women
– At 65 to 74 years of age, 9.3 for men and 8.8 for women
– At ≥75 years of age, 3.2 for men and 3.2 for women
• A Mayo Clinic study found that cardiac rehabilitation after an MI is underused, 
particularly in women and the elderly. Women were 55% less likely than men to 
participate in cardiac rehabilitation, and older study patients were less likely to 
participate than younger participants. Only 32% of men and women ≥70 years of 
age participated in cardiac rehabilitation compared with 66% of those 60 to 69 
years of age and 81% of those <60 years of age.44
• Among survivors of an MI, in 2005, 34.7% of BRFSS respondents participated 
in outpatient cardiac rehabilitation. The prevalence of cardiac rehabilitation was 
higher among older age groups (≥50 years of age), among men versus women, 
among Hispanics, among those who were married, among those with higher 
education, and among those with higher levels of household income.45
• A recent analysis of Medicare claims data revealed that only 13.9% of Medicare 
beneficiaries enroll in cardiac rehabilitation after an AMI, and only 31% enroll 
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after CABG. Older people, women, nonwhites, and individuals with 
comorbidities were less likely to enroll in cardiac rehabilitation programs.46
Hospital Discharges and Ambulatory Care Visits—(See Table 18-1 and Chart 18-8.)
• From 2000 to 2010, the number of inpatient discharges from short-stay hospitals 
with CHD as the first-listed diagnosis decreased from 2 165 000 to 1 346 000 
(NHDS, NHLBI tabulation).
• In 2010, there were 11 921 000 ambulatory care visits with CHD as the first-
listed diagnosis (NCHS, NAMCS, NHAMCS). There were 10 570 000 physician 
office visits, 587 000 ED visits, and 764 000 outpatient department visits with a 
primary diagnosis of CHD (NHAMCS, NHLBI tabulation). The majority of 
these visits (77.7%) were for coronary atherosclerosis.47
• The age-adjusted hospitalization rate for MI per 100 000 people was 215 in 1979 
to 1981, increased to 342 in 1985 to 1987, stabilized for the next decade, and 
then declined after 1996 to 242 during the period from 2003 to 2005. The rate for 
men exceeded that for women by almost a factor of 2. Hospitalization rates 
increased strongly with age.8
• An analysis of data from HCUP found that 48.3% of hospitalizations for 
circulatory disease in 2003 occurred among women, but among patients >65 
years of age, women constituted the majority. Furthermore, the percentage of 
hospitalized patients who were female increased from 24.1% of those 18 to 44 
years of age to 63.7% of those ≥85 years of age for MI, from 31.4% of people 18 
to 44 years of age to 60.7% of those ≥85 years of age for coronary 
atherosclerosis, and from 45.1% of those 18 to 44 years of age to 73.9% of those 
≥85 years of age for nonspecific chest pain. For MI, in-hospital mortality was 
9.3% among women and 6.2% among men.48
Operations and Procedures
• In 2010, an estimated 954 000 inpatient PCI procedures, 397 000 inpatient 
bypass procedures, 1 029 000 inpatient diagnostic cardiac catheterizations, 97 
000 inpatient implantable defibrillator procedures, and 370 000 pacemaker 
procedures were performed for inpatients in the United States (NHLBI 
tabulation).
Cost—(See Table 18-1.)
• The estimated direct and indirect cost of heart disease in 2010 was $204.4 billion 
(MEPS, NHLBI tabulation).
• In 2006, $11.7 billion was paid to Medicare beneficiaries for in-hospital costs 
when CHD was the principal diagnosis ($14 009 per discharge for AMI, $12 977 
per discharge for coronary atherosclerosis, and $10 630 per discharge for other 
ischemic HD).42
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• Between 2013 and 2030, medical costs of CHD (real 2010$) are projected to 
increase by ≈100%
– Indirect costs for all CVD (real 2010$) are projected to increase 52% 
(from $202.5 billion to $308.2 billion) between 2013 and 2030. Of 
these indirect costs, CHD is projected to account for ≈43% and has the 
largest indirect costs (AHA computation, based on methodology 
described by Heidenreich et al3).
Acute Coronary Syndrome
ICD-9 410, 411; ICD-10 I20.0, I21, I22.
The term acute coronary syndrome is increasingly used to describe patients who present 
with either AMI or UA. (UA is chest pain or discomfort that is accelerating in frequency or 
severity and may occur while at rest but does not result in myocardial necrosis.) The 
discomfort may be more severe and prolonged than typical AP, or it may be the first time a 
person has had AP. UA, NSTEMI, and STEMI share common pathophysiological origins 
related to coronary plaque progression, instability, or rupture with or without luminal 
thrombosis and vasospasm.
• A conservative estimate for the number of discharges with ACS from hospitals in 
2010 is 625 000. Of these, an estimated 363 000 are males and 262 000 are 
females. This estimate is derived by adding the first-listed inpatient hospital 
discharges for MI (595 000) to those for UA (30 000; NHDS, NHLBI).
• When secondary discharge diagnoses in 2010 were included, the corresponding 
number of inpatient hospital discharges was 1 141 000 unique hospitalizations 
for ACS; 653 000 were males, and 488 000 were females. Of the total, 813 000 
were for MI alone, 322 000 were for UA alone, and 6000 hospitalizations 
received both diagnoses (NHDS, NHLBI).
• Among commercially insured adults 18 to 64 years of age, the 1-year medical 
costs for an ACS event during 2004 to 2005 were $34 087 for those who were 
treated with medical management, $52 673 for those who were treated with 
percutaneous intervention, and $86 914 for those who had coronary artery bypass 
surgery. The 1-year short-term disability costs were $6048, $9221, and $17 335, 
respectively, and the 1-year absenteeism costs were $9826, $9460, and $14 960, 
respectively.49 Another study of the same database using adults 18 to 64 years of 
age who had a principal inpatient diagnosis of ACS during 2003 to 2006 
estimated that the incremental annual direct cost was $40 671 and the 
incremental short-term disability cost was $999.50
Decisions about medical and interventional treatments are based on specific findings noted 
when a patient presents with ACS. Such patients are classified clinically into 1 of 3 
categories according to the presence or absence of ST-segment elevation on the presenting 
ECG and abnormal (“positive”) elevations of myocardial biomarkers, such as troponins, as 
follows:
• STEMI
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• NSTEMI
• UA
The percentage of ACS or MI cases with ST-segment elevation varies in different registries/
databases and depends heavily on the age of patients included and the type of surveillance 
used. According to NRMI-4, ≈29% of patients with MI are patients with STEMI.51 The 
AHA GWTG project found that 32% of the patients with MI in the CAD module were 
patients with STEMI (personal communication from AHA GWTG staff, October 1, 2007). 
The GRACE study, which includes US patient populations, found that 38% of ACS patients 
have STEMI, whereas the EHS-ACS-II reported that ≈47% of patients with ACS have 
STEMI.52
In addition, the percentage of ACS or MI cases with ST-segment elevation appears to be 
declining. In an analysis of 46 086 hospitalizations for ACS in the Kaiser Permanente 
Northern California study, the percentage of MI cases with ST-segment elevation decreased 
from 47.0% to 22.9% between 1999 and 2008.13
• Analysis of data from the GRACE multinational observational cohort study of 
patients with ACS found evidence of a change in practice for both 
pharmacological and interventional treatments in patients with either STEMI or 
non–ST-segment–elevation ACS. These changes have been accompanied by 
nonsignificant decreases in the rates of in-hospital death, cardiogenic shock, and 
new MI among patients with non–ST-segment–elevation ACS. The use of 
evidence-based therapies and PCI interventions increased in the STEMI 
population. This increase was matched by a statistically significant decrease in 
the rates of death, cardiogenic shock, and HF or pulmonary edema.53
• A study of hospital process performance in 350 centers of nearly 65 000 patients 
enrolled in the CRUSADE National Quality Improvement Initiative found that 
ACC/AHA guideline– recommended treatments were adhered to in 74% of 
eligible instances.54 A better composite guideline adherence rate was 
significantly associated with decreased in-hospital mortality among all patients 
with ACS and those with NSTEMI.
• After adjustment for clinical differences and the severity of CAD by angiogram, 
30-day mortality after ACS is similar in men and women.55
Angina Pectoris
ICD-9 413; ICD-10 I20.1 to I20.9.
Prevalence—(See Table 18-2 and Chart 18-9.)
• A study of 4 national cross-sectional health examination studies found that 
among Americans 40 to 74 years of age, the age-adjusted prevalence of AP was 
higher among women than men. Increases in the prevalence of AP occurred for 
Mexican American men and women and African American women but were not 
statistically significant for the latter.56
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Incidence—(See Table 18-2 and Chart 18-10.)
• Only 18% of coronary attacks are preceded by long-standing AP (NHLBI 
computation of FHS follow-up since 1986).
• The annual rates per 1000 population of new episodes of AP for nonblack men 
are 28.3 for those 65 to 74 years of age, 36.3 for those 75 to 84 years of age, and 
33.0 for those ≥85 years of age. For nonblack women in the same age groups, the 
rates are 14.1, 20.0, and 22.9, respectively. For black men, the rates are 22.4, 
33.8, and 39.5, and for black women, the rates are 15.3, 23.6, and 35.9, 
respectively (CHS, NHLBI).57
• On the basis of 1987 to 2001 data from the ARIC study of the NHLBI, the 
annual rates per 1000 population of new episodes of AP for nonblack men are 
8.5 for those 45 to 54 years of age, 11.9 for those 55 to 64 years of age, and 13.7 
for those 65 to 74 years of age. For nonblack women in the same age groups, the 
rates are 10.6, 11.2, and 13.1, respectively. For black men, the rates are 11.8, 
10.6, and 8.8, and for black women, the rates are 20.8, 19.3, and 10.0, 
respectively.57
Mortality
• A small number of deaths resulting from CHD are coded as being attributable to 
AP. These are included as a portion of total deaths attributable to CHD.
Cost
• For women with nonobstructive CHD enrolled in the WISE study of the NHLBI, 
the average lifetime cost estimate was ≈$770 000 and ranged from $1.0 to $1.1 
million for women with 1- to 3-vessel CHD.58
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19. Cardiomyopathy and Heart Failure
See Table 19-1 and Charts 19-1 through 19-3.
Abbreviations Used in Chapter 19
ABC Health Aging, and Body Composition Study
ARIC Atherosclerosis Risk in Communities Study
BMI body mass index
BP blood pressure
CAD coronary artery disease
CARDIA Coronary Artery Risk Development in Young Adults Study
CHS Cardiovascular Health Study
CI confidence interval
CRP C-reactive protein
CVD cardiovascular disease
DM diabetes mellitus
ED emergency department
EF ejection fraction
FHS Framingham Heart Study
HbA1c hemoglobin A1c (glycosylated hemoglobin)
HBP high blood pressure
HCM hypertrophic cardiomyopathy
HF heart failure
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HR hazard ratio
ICD-9 International Classification of Diseases, 9th Revision
ICD-10 International Classification of Diseases, 10th Revision
MESA Multi-Ethnic Study of Atherosclerosis
MI myocardial infarction
NCHS National Center for Health Statistics
NH non-Hispanic
NHAMCS National Hospital Ambulatory Medical Care Survey
NHANES National Health and Nutrition Examination Survey
NHDS National Hospital Discharge Survey
NHLBI National Heart, Lung, and Blood Institute
PAR population attributable risk
Cardiomyopathy
ICD-9 425; ICD-10 I42.
Mortality—23 712. Any-mention mortality—46 821. Hospital discharges—34 000.
• Since 1996, the NHLBI-sponsored Pediatric Cardiomyopathy Registry has 
collected data on all children with newly diagnosed cardiomyopathy in New 
England and the Central Southwest (Texas, Oklahoma, and Arkansas).1
– The overall incidence of cardiomyopathy is 1.13 cases per 100 000 
among children <18 years of age.
– Among children <1 year of age, the incidence is 8.34, and among 
children 1 to 18 years of age, it is 0.70 per 100 000.
– The annual incidence is lower in white than in black children, higher in 
boys than in girls, and higher in New England (1.44 per 100 000) than 
in the Central Southwest (0.98 per 100 000).
• HCM is the most common inherited heart defect, occurring in 1 of 500 
individuals. In the United States, ≈500 000 people have HCM, yet most are 
unaware of it.2 See Chapter 16, Disorders of Heart Rhythm, for statistics 
regarding sudden death in HCM.
• In a recent report of the Pediatric Cardiomyopathy Registry, the overall annual 
incidence of HCM in children was 4.7 per 1 million children. There was a higher 
incidence in the New England than in the Central Southwest region, in boys than 
in girls, and in children diagnosed at <1 year of age than in older children.3
• Dilated cardiomyopathy is the most common form of cardiomyopathy. The 
Pediatric Cardiomyopathy Registry recently reported an annual incidence of 
dilated cardiomyopathy in children <18 years of age of 0.57 per 100 000 overall. 
The annual incidence was higher in boys than in girls (0.66 versus 0.47 cases per 
100 000), in blacks than in whites (0.98 versus 0.46 cases per 100 000), and in 
infants (<1 year of age) than in children (4.40 versus 0.34 cases per 100 000). 
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The majority of children (66%) had idiopathic disease. The most common known 
causes were myocarditis (46%) and neuromuscular disease (26%).4
• Risk factors for death and transplantation in children varied by cause of dilated 
cardiomyopathy. For idiopathic dilated cardiomyopathy, increased left 
ventricular end-diastolic dimension was associated with increased transplantation 
risk but not mortality. Short stature was significantly related to death but not 
transplantation.5
• The 5-year incidence rate of sudden cardiac death among children with dilated 
cardiomyopathy is 3%.6
• Tachycardia-induced cardiomyopathy develops slowly and appears reversible, 
but recurrent tachycardia causes rapid decline in left ventricular function and 
development of HF. Sudden death is possible.7
• Data from Kaiser Permanente indicate that the incidence of peripartum 
cardiomyopathy is 4.84 per 10 000 live births (95% CI, 3.98–5.83), and 
peripartum cardiomyopathy is associated with higher maternal and neonatal 
death rates and worse neonatal outcomes.8
Heart Failure
ICD-9 428; ICD-10 I50.
Prevalence—(See Table 19-1 and Chart 19-1.)
• On the basis of data from NHANES 2007 to 2010, an estimated 5.1 million 
Americans ≥20 years of age have HF (NHLBI tabulation).
• Projections show that the prevalence of HF will increase 46% from 2012 to 2030, 
resulting in >8 million people ≥18 years of age with HF.9
Incidence—(See Table 19-1 and Chart 19-2.)
• On the basis of data from the community surveillance component of the ARIC 
study of the NHLBI:
– There are 825 000 new HF cases annually.
– At ages <75 years, HF incidence is higher in blacks than whites.
• Data from the NHLBI-sponsored FHS10 indicate the following:
– HF incidence approaches 10 per 1000 population after 65 years of age.
– Seventy-five percent of HF cases have antecedent hypertension.
– At 40 years of age, the lifetime risk of developing HF for both men and 
women is 1 in 5. At 80 years of age, remaining lifetime risk for 
development of new HF remains at 20% for men and women, even in 
the face of a much shorter life expectancy.
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– At 40 years of age, the lifetime risk of HF occurring without antecedent 
MI is 1 in 9 for men and 1 in 6 for women.
– The lifetime risk for people with BP >160/90 mm Hg is double that of 
those with BP <140/90 mm Hg.
• The annual rates per 1000 population of new HF events for white men are 15.2 
for those 65 to 74 years of age, 31.7 for those 75 to 84 years of age, and 65.2 for 
those ≥85 years of age. For white women in the same age groups, the rates are 
8.2, 19.8, and 45.6, respectively. For black men, the rates are 16.9, 25.5, and 50.6 
(unreliable estimate), and for black women, the estimated rates are 14.2, 25.5, 
and 44.0 (unreliable estimate), respectively (CHS, NHLBI).11
• In MESA, African Americans had the highest risk of developing HF, followed by 
Hispanic, white, and Chinese Americans (4.6, 3.5, 2.4, and 1.0 per 1000 person-
years, respectively). This higher risk reflected differences in the prevalence of 
hypertension, DM, and socioeconomic status. African Americans had the highest 
proportion of incident HF not preceded by clinical MI (75%).12
• In Olmsted County, MN, the incidence of HF did not decline between 1979 and 
2000.13
• In the NHLBI’s ARIC study, the age-adjusted incidence rate per 1000 person-
years was 3.4 for white women, less than for all other groups, that is, white men 
(6.0), black women (8.1), and black men (9.1). The 30-day, 1-year, and 5-year 
case fatality rates after hospitalization for HF were 10.4%, 22%, and 42.3%, 
respectively. Blacks had a greater 5-year case fatality rate than whites (P<0.05). 
HF incidence rates in black women were more similar to those of men than of 
white women. The greater HF incidence in blacks than in whites is explained 
largely by blacks’ greater levels of atherosclerotic risk factors.14
• Data from Kaiser Permanente indicated an increase in the incidence of HF 
among the elderly, with the effect being greater in men.15
• Data from hospitals in Worcester, MA, indicate that during 2000, the incidence 
and attack rates for HF were 219 per 100 000 and 897 per 100 000, respectively. 
HF was more frequent in women and the elderly. The hospital fatality rate was 
5.1%.16
• In the CARDIA study, HF before 50 years of age was more common among 
blacks than whites. Hypertension, obesity, and systolic dysfunction are important 
risk factors that may be targets for prevention.17
• The lifetime risks of HF were assessed in a diverse large group of 39 578 
participants in several cohorts (Chicago Heart Association Detection Project in 
Industry, ARIC, and CHS). At age 45 years, lifetime risks for HF through age 75 
or 95 years were 30% to 42% in white men, 20% to 29% in black men, 32% to 
39% in white women, and 24% to 46% in black women. HBP and higher BMI at 
all ages in both blacks and whites led to higher lifetime risks.18
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Mortality—(See Table 19-1.)
• In 2010, HF any-mention mortality was 279 098 (126 776 males and 152 322 
females). HF was the underlying cause in 57 757 of those deaths in 2010.19 Table 
19-1 shows the numbers of these deaths that are coded for HF as the underlying 
cause.
• The 2010 overall any-mention death rate for HF was 84.0. Any-mention death 
rates were 99.9 for white males, 101.7 for black males, 74.1 for white females, 
and 79.1 for black females.19
• One in 9 deaths has HF mentioned on the death certificate (NCHS, NHLBI).
• The number of any-mention deaths attributable to HF was approximately as high 
in 1995 (287 000) as it was in 2010 (279 000; NCHS, NHLBI).20
• Survival after HF diagnosis has improved over time, as shown by data from the 
FHS21 and the Olmsted County Study.13 However, the death rate remains high: 
≈50% of people diagnosed with HF will die within 5 years.13,19
• In the elderly, data from Kaiser Permanente indicate that survival after the onset 
of HF has also improved.15
• In the CHS, depression and amino-terminal pro-B-type natriuretic peptide were 
independent risk factors for CVD-related and all-cause mortality.22
• Among Medicare beneficiaries, the overall 1-year mortality rate declined slightly 
over the past decade but remains high.23 Changes were uneven across states.
Risk Factors
• In the NHLBI-sponsored FHS, B-type natriuretic peptide, urinary albumin-to-
creatinine ratio, elevated serum γ-glutamyl transferase, and higher levels of 
hematocrit were identified as risk factors for HF.24–26
• In the Framingham Offspring Study, among 2739 participants, increased 
circulating concentrations of resistin were associated with incident HF 
independent of prevalent coronary disease, obesity, insulin resistance, and 
inflammation.27
• Among 20 900 male physicians in the Physicians Health Study, the lifetime risk 
of HF was higher in men with hypertension; healthy lifestyle factors (normal 
weight, not smoking, regular exercise, moderate alcohol intake, consumption of 
breakfast cereals, and consumption of fruits and vegetables) were related to 
lower risk of HF.28 Adiponectin was also associated with risk of HF (J-shaped 
relationship).29
• Among 2934 participants in the ABC study, the incidence of HF was 13.6 per 
1000 person-years. Men and black participants were more likely to develop HF. 
Coronary disease (PAR 23.9% for white participants, 29.5% for black 
participants) and uncontrolled BP (PAR 21.3% for white participants, 30.1% for 
black participants) had the highest PARs in both races. There was a higher 
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proportion of HF attributable to modifiable risk factors in black than in white 
participants (67.8% versus 48.9%).30 Inflammatory markers (interleukin-6 and 
tumor necrosis factor-α), serum albumin levels, and cigarette smoking exposure 
were also associated with HF risk.31–33
• In the CHS, baseline cardiac troponin and changes in cardiac troponin levels 
measured by a sensitive assay were significantly associated with incident HF.34 
Circulating individual and total omega-3 fatty acid concentrations were 
associated with lower incidence of HF.35
• In the ARIC study, white blood cell count, CRP, albuminuria, HbA1c among 
individuals without DM, cardiac troponin measured with a sensitive assay, 
ventricular premature complexes, and socioeconomic position over the life 
course were all identified as risk factors for HF.36–41
• In the MESA study, plasma N-terminal pro-B-type natriuretic peptide provided 
incremental prognostic information beyond the traditional risk factors and the 
magnetic resonance imaging–determined left ventricular mass index for incident 
symptomatic HF.42
Left Ventricular Function
• Data from Olmsted County, MN, indicate the following:
– Among asymptomatic individuals, the prevalence of left ventricular 
diastolic dysfunction was 21% for mild diastolic dysfunction and 7% 
for moderate or severe diastolic dysfunction. The prevalence of systolic 
dysfunction was 6%. The presence of any left ventricular dysfunction 
(systolic or diastolic) was associated with an increased risk of 
developing overt HF, and diastolic dysfunction was predictive of all-
cause death.43 After 4 years of follow-up, the prevalence of diastolic 
dysfunction increased to 39.2%. Diastolic dysfunction was associated 
with development of HF during 6 years of subsequent follow-up after 
adjustment for age, hypertension, DM, and CAD (HR, 1 .81; 95% CI, 
1.01–3.48).44
– Among individuals with symptomatic HF, the prevalence of left 
ventricular diastolic dysfunction was 6% for mild diastolic dysfunction 
and 75% for moderate or severe diastolic dysfunction.45 The proportion 
of people with HF and preserved EF increased over time. Survival 
improved over time among individuals with reduced EF but not among 
those with preserved EF.46
Hospital Discharges/Ambulatory Care Visits—(See Table 19-1 and Chart 19-3.)
• Hospital discharges for HF were essentially unchanged from 2000 to 2010, with 
first-listed discharges of 1 008 000 and 1 023 000, respectively (NHDS, NHLBI 
tabulation).47
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• In 2010, there were 1 801 000 physician office visits with a primary diagnosis of 
HF.47 In 2010, there were 676 000 ED visits and 236 000 outpatient department 
visits for HF (NHAMCS, NHLBI tabulation).48
• Among 1077 patients with HF in Olmsted County, MN, hospitalizations were 
common after HF diagnosis, with 83% patients hospitalized at least once and 
43% hospitalized at least 4 times. More than one half of all hospitalizations were 
related to noncardiovascular causes.49
• Among Medicare beneficiaries, the overall HF hospitalization rate declined 
substantially from 1998 to 2008 but at a lower rate for black men.23 Changes 
were uneven across states.
Cost
• In 2012, total cost for HF was estimated to be $30.7 million. Of this total, 68% 
was attributable to direct medical costs.9
• Projections show that by 2030, the total cost of HF will increase almost 127% to 
$69.7 billion from 2012. This equals ≈$244 for every US adult.9
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20. Valvular, Venous, and Aortic Diseases
See Tables 20-1 and 20-2 and Chart 20-1.
Mortality and any-mention mortality in this section are for 2010. “Mortality” is the number 
of deaths in 2010 for the given underlying cause based on ICD-10. Prevalence data are for 
2006. Hospital discharge data are from the NHDS/NCHS; data include inpatients discharged 
alive, dead, or status unknown. Hospital discharge data for 2010 are based on ICD-9 codes.
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Valvular Heart Disease
(See Table 20-1.)
ICD-9 424; ICD-10 I34 to I38.
Mortality—22 777. Any-mention mortality—46 426. Hospital discharges—85 000.
Two important factors have contributed to the changing epidemiology of valvular heart 
disease in the United States over the past few decades: aging of the population and the 
increased ability to diagnose valvular heart disease by echocardiography.
• A large population-based epidemiological study with systematic use of 
echocardiography on 16 501participants from Olmsted County, MN, showed an 
overall age-adjusted prevalence of clinically diagnosed (moderate or greater) 
valvular heart disease of 1.8%.1
• Prevalence of any valve disease increased with age1
– 18 to 44 years: 0.3% (95% CI, 0.2%–0.3%)
– 45 to 54 years: 0.7% (95% CI, 0.6%–0.9%)
– 55 to 64 years: 1.6% (95% CI, 1.4%–1.9%)
– 65 to 75 years: 4.4% (95% CI, 3.9%–4.9%)
– ≥75 years: 11.7% (95% CI, 11.0%–12.5%)
• Pooled echocardiographic data from 11 911 participants from CARDIA (4351), 
ARIC (2435), and CHS (5125) demonstrated a similar increase in prevalence 
with age (Table 20-1).1
– 18 to 44 years: 0.7% (95% CI, 0.5%–1.0%)
– 45 to 54 years: 0.4% (95% CI, 0.1%–1.3%)
– 55 to 64 years: 1.9% (95% CI, 1.2%–2.8%)
– 65 to 75 years: 8.5% (95% CI, 7.6%–9.4%)
– ≥75 years: 13.3% (95% CI, 11.7%–15.0%)
• Adjusted to the entire US population, these data suggest that the prevalence of 
any valve disease is 2.5% (95% CI, 2.2%–2.7%), with no difference between 
men (2.4% [95% CI, 2.1%–2.8%]) and women (2.5% [95% CI, 2.1%–2.9%]). 
Within this sample, 0.4% had aortic stenosis, 0.5% had aortic regurgitation, 0.1% 
had mitral stenosis, and 1.7% had mitral regurgitation.1
• In CARDIA, ARIC, and CHS, survival of participants with valve disease was 
79% (SE 2%) at 5 years and 68% (1.9%) at 8 years compared with 93% (0.2%) 
and 86% (0.4%) in participants without valve disease.
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Abbreviations Used in Chapter 20
AAA abdominal aortic aneurysm
AHA American Heart Association
AVR aortic valve replacement
ARIC Atherosclerosis Risk in Communities study
BMI body mass index
CARDIA Coronary Artery Risk Development in Young Adults
CHD coronary heart disease
CHS Cardiovascular Health Study
CI confidence interval
CT computed tomography
DM diabetes mellitus
DVT deep vein thrombosis
GBD Global Burden of Diseases, Injuries, and Risk Factors Study
HD heart disease
HR hazard ratio
ICD International Classification of Diseases
ICD-9 International Classification of Diseases, 9th Revision
ICD-10 International Classification of Diseases, 10th Revision
IE infective endocarditis
IRAD International Registry of Acute Aortic Dissection
MESA Multi-Ethnic Study of Atherosclerosis
NCHS National Center for Health Statistics
NH non-Hispanic
NHDS National Hospital Discharge Survey
NHLBI National Heart, Lung, and Blood Institute
OVER Open Versus Endovascular Repair
PAD peripheral artery disease
PARTNER Placement of Aortic Transcatheter Valves
PE pulmonary embolism
RR relative risk
SD standard deviation
STS Society of Thoracic Surgeons
TAVR transcatheter aortic valve replacement
TIA transient ischemic attack
VTE venous thromboembolism
WHO World Health Organization
YLL years of life lost
Aortic Valve Disorders
ICD-9 424.1; ICD-10 I35.
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Mortality—15 276 Any-mention mortality—30 736. Hospital discharges—55 000.
• The prevalence of moderate or severe aortic stenosis in patients ≥75 years old is 
2.8% (95% CI, 2.1%–3.7%), and the prevalence of moderate or severe aortic 
regurgitation in patients ≥75 years is 2.0% (95% CI, 1.4%–2.7%).1
• In MESA participants aged 45 to 84 years (n=5880), aortic valve calcium was 
quantified with serial CT images. During a mean follow-up of 2.4 years, 210 
(4.1%) of the 5142 participants with no aortic valve calcium had a mean 
incidence rate of progression of 1.7% per year, which increased with age. 
Incident aortic valve calcium was associated with several conventional 
cardiovascular risk factors, including age, male sex, BMI, and smoking.2
• Approximately 50% of patients with severe aortic stenosis are referred for 
cardiothoracic surgery, and ≈40% undergo AVR according to data from 10 US 
centers of various sizes and geographic distribution. Reasons for not undergoing 
AVR included high perioperative risk, age, lack of symptoms, and patient/family 
refusal.3
• On the basis of data from the PARTNER B cohort that compared TAVR with 
medical therapy in patients who were not surgical candidates for AVR, 2-year 
mortality rates were 43.3% and 68% (P<0.001) and 2-year hospitalization rates 
were 35% and 72.5% (P<0.001), respectively.4
• One-year costs of TAVR were higher than with medical therapy ($106 076 versus 
$53 621), with an incremental cost-effectiveness of $50 200 per life-year gained 
and $61 889 per quality-adjusted life-year gained.5
• In a cohort of 416 community-based participants from Olmsted County, MN, 
with bicuspid aortic valves followed up for a mean (SD) of 16 (7) years, the 
incidence of aortic dissection in individuals ≥50 years of age at baseline was 17.4 
(95% CI, 2.9–53.6) cases per 10 000 patient years. For patients aged ≥50 years 
with a bicuspid valve and a baseline aortic aneurysm, the incidence of aortic 
dissection was 44.9 (95% CI, 7.5–138.5) cases per 10 000 patient-years. In the 
remaining participants without baseline aortic aneurysm, the incidence of 
aneurysm was 84.9 (95% CI, 63.3–110.9) cases per 10 000 patient-years, for an 
age-adjusted RR of 86.2 (95% CI, 65.1–114) compared with the general 
population.6
Aortic Valve Interventions
• Lipid-lowering therapy does not appear to reduce aortic stenosis progression on 
the basis of any echocardiographic measures of aortic stenosis, as reported by a 
meta-analysis of 4 randomized controlled trials by Teo and colleagues.7
• Immediate postoperative and 1-, 3-, 5-, and 10-year pooled survival rates from 48 
studies of 13 216 octogenarians were 93.7%, 87.6%, 78.7%, 65.4%, and 29.7%, 
respectively.8
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• TAVR has emerged as an innovative technology for treatment of aortic stenosis 
in patients at high risk for perioperative complications.
– A systematic review9 of TAVR from 16 studies that included 3519 
patients and reported at least 1 outcome using the Valve Academic 
Research Consortium’s definitions demonstrated the following:
♦ Device success 92.1% (88.7–95.5%)
♦ 30-day all-cause mortality 7.8% (5.5%-11.1%)
♦ 1-year all-cause mortality 22.1% (17.9–26.9%)
♦ Major vascular complications 11.9% (8.6%-16.4%)
♦ Major stroke 3.2% (2.1%-4.8%)
– More recent data from the PARTNER A cohort that compared TAVR 
with surgical AVR showed that 2-year mortality rates were 33.9% and 
35% (P=0.78), respectively. Stroke or TIA rates were higher in the 
TAVR arm (11.2% versus 6.5%, P=0.05) than in the surgical AVR arm, 
as were major vascular complications (11.6% versus 3.8%, P<0.001).10
Mitral Valve Disorders
ICD-9 424.0; ICD-10 I34.
Mortality—2279. Any-mention mortality—5185. Hospital discharges—22 000.
Prevalence—(See Table 20-1.)
• In pooled data from CARDIA, ARIC, and CHS, mitral valve disease was the 
most common valvular lesion. At least moderate mitral regurgitation occurred at 
a frequency of 1.7% as adjusted to the US adult population of 2000, increasing 
from 0.5% in participants aged 18 to 44 years to 9.3% in participants aged ≥75 
years.1
• A systematic review by de Marchena and colleagues11 found that in the US 
population, the prevalence of mitral regurgitation according to Carpentier’s 
functional classification system was as follows:
– Type I (congenital mitral regurgitation and endocarditis): <20 per 1 
million
– Type II (myxomatous mitral regurgitation): 15 000 per 1 million
– Type IIIa (rheumatic HD, systemic lupus erythematosus, 
antiphospholipid syndrome): 10 520 per 1 million
– Type IIIb (ischemic mitral regurgitation, left ventricular dysfunction, 
dilated cardiomyopathy): 23 250 per 1 million
• Data from the STS adult cardiac surgery database of 14 604 isolated, 
nonemergent mitral valve repair operations demonstrate an operative mortality 
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rate of 2.59%. Over a mean (SD) follow-up of 5.9 (3.9) years and a mean (SD) 
age of 73.3 (5.5) years, survival was 74.9%. The 10-year actuarial survival rate 
of 57.4% was similar to the matched US population.12
Pulmonary Valve Disorders
ICD-9 424.3; ICD-10 I37.
Mortality—17. Any-mention mortality—44.
Tricuspid Valve Disorders
ICD-9 424.2; ICD-10 I36.
Mortality—9. Any-mention mortality—93.
Rheumatic Fever/Rheumatic HD
(See Table 20-2 and Chart 20-1.)
ICD-9 390 to 398; ICD-10 I00 to I09.
Mortality—2987. Any-mention mortality—5747. Hospital discharges—20 000.
• Rheumatic HD is uncommon in high-income countries such as the United States 
but remains endemic in Africa, Asia, and the Pacific, affecting >15 million 
individuals and causing 233 000 deaths annually.13
• The reported prevalence of rheumatic HD is increasing in all regions of the world 
except Europe.14
• Recent echocardiography-based screening studies in schoolchildren have 
demonstrated rheumatic HD prevalence rates ranging from 14.8 (95% CI, 7.3–
22.3) per 1000 (Uganda)15 to 20.4 (95% CI, 16.9–23.9) per 1000 in northern 
India16 to 21.5 (95% CI, 16.8–26.2) per 1000 in Cambodia and 30.4 (95% CI, 
23.2–37.6) per 1000 (Mozambique).17
– Echocardiography reveals a 3- to 10-fold higher prevalence of 
rheumatic HD than clinical examination.15,17
• Acute rheumatic fever incidence is decreasing in all WHO regions except for the 
Americas, where it appears to be increasing slightly, and the Western Pacific, 
where it appears to be increasing steadily.14
• In 1950, ≈15 000 Americans (adjusted for changes in ICD codes) died of 
rheumatic fever/rheumatic HD compared with ≈3100 annually in the present era 
(NCHS/NHLBI).
• The 2009 overall death rate for rheumatic fever/rheumatic HD was 1.1 per 100 
000. Death rates varied across race/ethnic groups but were generally low: white, 
1.2 per 100 000; black or African American, 0.7 per 100 000; Asian or Pacific 
Islander, 0.6 per 100 000; American Indian or Alaska Native, 0.6 per 100 000; 
and Hispanic or Latino origin individuals, 0.4 per 100 000.18
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Bacterial Endocarditis
ICD-9 421.0; ICD-10 I33.0.
Mortality—1060. Any-mention mortality—2197. Hospital discharges—34 000, primary plus 
secondary diagnoses.
• The 2007 AHA guidelines on prevention of IE15 state that IE is thought to result 
from the following sequence of events: (1) Formation of nonbacterial thrombotic 
endocarditis on the surface of a cardiac valve or elsewhere that endothelial 
damage occurs; (2) bacteremia; and (3) adherence of the bacteria in the 
bloodstream to nonbacterial thrombotic endocarditis and proliferation of bacteria 
within a vegetation. Viridans group streptococci are part of the normal skin, oral, 
respiratory, and gastrointestinal tract flora, and they cause ≥50% of cases of 
community-acquired native valve IE not associated with intravenous drug use.19
• Although the absolute risk for acquiring IE from a dental procedure is impossible 
to measure precisely, the best available estimates are as follows: If dental 
treatment causes 1% of all cases of viridans group streptococcal IE annually in 
the United States, the overall risk in the general population is estimated to be as 
low as 1 case of IE per 14 million dental procedures. The estimated absolute risk 
rates for acquiring IE from a dental procedure in patients with underlying cardiac 
conditions are as follows20:
– Mitral valve prolapse: 1 per 1.1 million procedures
– CHD: 1 per 475 000
– Rheumatic HD: 1 per 142 000
– Presence of a prosthetic cardiac valve: 1 per 114 000
– Previous IE: 1 per 95 000 dental procedures
• Cessation of antibiotic prophylaxis for IE before dental procedures has not led to 
a change in pediatric cases of endocarditis. Using 2003 to 2010 data from 37 
centers in the Pediatric Health Information Systems Database, Pasquali and 
colleagues21 did not demonstrate a significant difference in the number of IE 
hospitalizations after the guidelines were implemented in 2007 (1.6% difference 
after versus before guideline implementation; 95% CI, −6.4% to 10.3%; P=0.7).
• A systematic review that included 161 studies and 27 354 patients from 1960 to 
2011 demonstrated that in hospital-based studies (143 studies; 23 877 patients), 
staphylococcal endocarditis has increased over time (coagulase-negative 
Staphylococcus 2% to 10%, P<0.001), with recent increases in Staphylococcus 
aureus (21% to 30%, P<0.05) over the past decade and a corresponding decrease 
in streptococcal endocarditis (32% to 17%) over the same time period.22
• Cardiac device IE appears to be present in 6.4% (95% CI, 5.5%–7.4%) of 
patients with definite IE, according to data from the International Collaboration 
on Endocarditis–Prospective Cohort Study (2000–2006). Nearly half (45.8%; 
95% CI, 38.3%–53.4%) of such cases are associated with healthcare-associated 
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infection. In-hospital and 1-year mortality rates for these patients were 14.7% 
(26/177; 95% CI, 9.8%–20.8%) and 23.2% (41/177; 95% CI, 17.2%–30.1%), 
respectively.23
Endocarditis, Valve Unspecified
ICD-9 424.9; ICD-10 I38.
Mortality—5196. Any-mention mortality—10 582.
VTE Epidemiology (Including DVT and PE)24
Pulmonary Embolism—ICD-9 415.1; ICD-10 I26.
Mortality—7322. Any-mention mortality—29 392. Hospital discharges—186 000.
Deep Vein Thrombosis—ICD-9 451.1; ICD-10 I80.2.
Mortality—2484. Any-mention mortality—12 952.
Incidence
• The average annual incidence of VTE among whites is 108 per 100 000 person-
years, with 250 000 incident cases occurring annually among US whites.
• VTE incidence appears to be similar or higher among African Americans and 
lower among Asian Americans and Native Americans than among whites.
• After adjustment for the different age and sex distribution of African Americans, 
VTE incidence is 78 per 100 000, which suggests that 27 000 incident VTE cases 
occur annually among US blacks.
• VTE incidence has not changed significantly over the past 25 years.
• Incidence rates increase exponentially with age for both men and women and for 
both DVT and PE.
• Incidence rates are higher in women during childbearing years, whereas 
incidence rates after age 45 years are higher in men.
• PE accounts for an increasing proportion of VTE with increasing age in both 
sexes.
• VTE event type (DVT versus PE) has a common familial background and shared 
genetic susceptibility.25
Survival
• For almost one quarter of PE patients, the initial clinical presentation is sudden 
death.
• Thirty-day VTE survival is 74 .8% (DVT alone, 96 .2%; PE with or without 
DVT, 59.1%).26
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• PE is an independent predictor of reduced survival for ≤3 months.
• Because most PE deaths are sudden and usually attributed to underlying disease 
(eg, cancer; other chronic heart, lung, or renal disease), secular trends in VTE 
survival are confounded by autopsy rates.
Recurrence
• VTE is a chronic disease with episodic recurrence; ≈30% of patients develop 
recurrence within the next 10 years.
• Independent predictors of early (within 180 days) recurrence include active 
cancer, proportion of time spent taking heparin with a heparin level ≥0.2 anti-Xa 
U/mL, and proportion of time spent taking warfarin with an international 
normalized ratio ≥2. Two-week case fatality for recurrent DVT alone and 
recurrent PE with or without DVT is 2% and 11%, respectively.27
Complications
• The 20-year cumulative incidence of venous stasis syndrome and venous ulcer 
after proximal DVT is 40% and 3.7%, respectively.
• The incidence of chronic thromboembolic pulmonary hypertension is 6.5 per 
million person-years; ≈1400 incident cases occur annually among US whites.
Risk Factors
• Independent VTE risk factors include increasing patient age, surgery, trauma/
fracture, hospital or nursing home confinement, active cancer, central vein 
catheterization or transvenous pacemaker, prior superficial vein thrombosis, 
infection, varicose veins, and neurological disease with leg paresis, and among 
women, use of oral contraceptives, pregnancy/postpartum period, and hormone 
therapy.28
• Together, these risk factors account for >75% of all incident VTE that occurs in 
the community.
• Compared with residents in the community, hospitalized residents have a >130-
fold higher VTE incidence (71 versus 9605 per 100 000 person-years).29
• Hospitalization and nursing home residence together account for almost 60% of 
incident VTE events that occur in the community.
• Among patients hospitalized for acute medical illness, independent risk factors 
for VTE include prior VTE, thrombophilia, cancer, age >60 years, leg paralysis, 
immobilization ≥7 days, and admission to an intensive care unit or coronary care 
unit.30
• Among cancer patients beginning chemotherapy, tumor site, BMI, hemoglobin, 
platelet and white blood cell count, and plasma D-dimer and soluble P-selectin 
levels are predictors of VTE in the next 6 months.31
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• In a large cohort study of middle-aged women, including women undergoing 
surgery, current smoking increased the risk for hospitalization for or death 
attributable to VTE.32 However, whether smoking represents an independent 
VTE risk factor remains uncertain.
• In a case-crossover study, novel predictors of hospitalization for VTE included 
recent infection, erythropoiesis-stimulating agents, and blood transfusion.33
• Hospitalization for an autoimmune disorder (particularly immune 
thrombocytopenia, polyarteritis nodosa, polymyositis or dermatomyositis, 
systemic lupus erythematosus, and rheumatoid arthritis34) is associated with an 
increased risk for VTE in the year after hospitalization.35
• An association between systemic, intestinal, or inhaled glucocorticoids and VTE 
was reported recently36; however, this association may be spurious because of 
residual confounding.
• Among patients with immune thrombocytopenia, splenectomy was associated 
with an increased incidence of abdominal vein thrombosis within 90 days after 
surgery and an increased incidence of leg DVT and PE.37 Whether these 
associations are independent of immune thrombocytopenia disease activity is 
uncertain.
• Pregnancy-associated VTE incidence is 200 per 100 000 woman-years; 
compared with nonpregnant women of childbearing age, the RR for VTE is 
increased 4-fold. VTE risk appears to be higher for pregnancies after in vitro 
fertilization compared with natural pregnancies.38
• VTE risk during the postpartum period is ≈5-fold higher than during pregnancy.
Arteries, Diseases of
ICD-9 440 to 448; ICD-10 I70 to I78. Includes PAD.
Penetrating Aortic Ulcers
• A single-center evaluation of 388 penetrating aortic ulcers found on CT 
angiography (2003–2009) demonstrated penetrating aortic ulcers in the aortic 
arch (6.8%), descending thoracic aorta (61.2%), and abdominal aorta (29.7%). 
Nearly 2 of every 3 penetrating aortic ulcers (57.7%) did not have a saccular 
aneurysm or intramural hematoma, whereas ≈1 in 4 (27.8%) had associated 
saccular aneurysms, and ≈1 in 7 (14.4%) had an associated intramural 
hematoma. Rupture was present in ≈1 in 25 penetrating aortic ulcers (4.1%).39
Aortic Aneurysm—ICD-9 441; ICD-10 I71.
Mortality—10 431. Any-mention mortality—16 877. Hospital discharges—64 000.
• According to the GBD, the age-standardized death rate attributable to aortic 
aneurysm was 3.4 (95% CI, 2.5–4.8), with a 27% median decrease since 1990. 
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The YLL because of aortic aneurysms was 57.4 (95% CI, 43.8–80.4), with a 
29% median decrease since 1990.40
• Although the definition varies somewhat by age and body surface area, generally 
an AAA is considered to be present when the anteroposterior diameter of the 
aorta reaches 3.0 cm.41
• The prevalence of AAAs that are 2.9 to 4.9 cm in diameter ranges from 1.3% in 
men 45 to 54 years of age to 12.5% in men 75 to 84 years of age. For women, the 
prevalence ranges from 0% in the youngest to 5.2% in the oldest age groups.41
• A meta-analysis of 15 475 individuals from 18 studies on small AAAs (3.0–5.4 
cm) demonstrated that mean aneurysm growth rate was 2.21 mm per year and 
was independent of age and sex. Growth rates were higher in smokers (by 0.35 
mm/y) and lower in patients with DM (by 0.51 mm/y).42
• Rupture rates range from 0.71 to 11.03 per 1000 person-years, with higher 
rupture rates in smokers (pooled HR, 2.02; 95% CI, 1.33–3.06) and women 
(pooled HR, 3.76; 95% CI, 2.58–5.47).42
• Data from IRAD demonstrate that the rate of mesenteric malperfusion in 1809 
patients with type A acute dissections was 3.7%, with a higher mortality rate 
than for patients without malperfusion (63.2% versus 23.8%, P<0.001).43
• Data from IRAD suggest that patients with acute type B aortic dissection have 
heterogeneous in-hospital outcomes. In-hospital mortality in patients with and 
without complications (such as mesenteric ischemia, renal failure, limb ischemia, 
or refractory pain) was 20.0% and 6.1%, respectively. In patients with 
complications, in-hospital mortality associated with surgical and endovascular 
repair was 28.6% and 10.1% (P=0.006), respectively.44
Thoracic Aortic Aneurysm Treatment
• A sample of 12 573 and 2732 Medicare patients who underwent open thoracic 
aortic aneurysm and endovascular repair demonstrated higher perioperative 
mortality for open repair in both intact (7.1% versus 6.1%, P=0.07) and ruptured 
(46% versus 28%, P<0.01) thoracic aortic aneurysms but higher 1-year (87% 
versus 82%, P=0.001) and 5-year (72% versus 62%, P=0.001) survival rates.45
• Perioperative mortality rates for open thoracic aortic aneurysms were higher for 
black Medicare patients than for white Medicare patients (18% versus 10%, 
P<0.001), but rates were similar for endovascular repair (8% versus 9%, 
P=0.56).46
AAA Treatment
• A 2011 meta-analysis of 46 studies that included 1397 studies of patients with 
ruptured AAA demonstrated that endovascular repair was associated with a 
perioperative mortality rate of 24.3%.47
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• Long-term results from the OVER trial that compared open AAA repair to 
endovascular repair demonstrated no survival difference between open and 
endovascular repair at a median follow-up of 9 years (HR, 0.97; 95% CI, 0.77–
1.22) despite reductions in mortality from endovascular repair at 2 years (HR, 
0.63; 95% CI, 0.40–0.98) and 3 years (HR, 0.72; 95% CI, 0.51–1.00).48
• After multivariable adjustment, Medicare patients who underwent open AAA 
repair had a higher risk of all-cause mortality (HR, 1.24; 95% CI, 1.05–1.47) and 
AAA-related mortality (HR, 4.37; 95% CI, 2.51–7.66) at 1 year than patients 
who underwent endovascular repair.49
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21. Peripheral Artery Disease
ICD-9: 440.20 to 440.24, 440.30 to 440.32, 440.4, 440.9, 443.9, 445.02; ICD-10: I70.2, 
I70.9, I73.9, I74.3, I74.4. See Table 21-1 and Charts 21-1 and 21-2.
Prevalence and Incidence
(See Table 21-1 and Charts 21-1 and 21-2.)
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• PAD affects ≈8.5 million Americans aged ≥40 years and is associated with 
significant morbidity and mortality.1
• The age-standardized prevalence rate of PAD per 100 000 in 2010 was 185.6 
(95% CI, 150.3–226.1), with minimal change (median percent change, 0.19% 
[95% CI, −24.1% to 31.6%]) since 1990. The age-standardized disability-
adjusted life-year rate of PAD per 100 000 in 2010 was 23.9 (95% CI, 15.7–
38.3), with a median change of 24.9% since 1990.2
• The highest prevalence of PAD has been observed among elderly people, non-
Hispanic blacks, and women. In a multivariable age-, sex-, and race/ethnicity-
adjusted regression model, hypertension, DM, CKD, and smoking were 
associated with incident PAD (P≤0.05 for each).3,4
• A 2003 to 2008 sample of US national insurance claims of adults aged >40 years 
demonstrated that 263 270 eligible individuals had a PAD diagnosis, with an 
annual incidence and prevalence of 2.76% (95% CI, 2.75%–2.77%) and 12.29% 
(95% CI, 12.8%–12.31%), respectively.5
• In the general population, only ≈10% of people with PAD have the classic 
symptom of intermittent claudication. Approximately 40% do not complain of 
leg pain, whereas the remaining 50% have a variety of leg symptoms different 
from classic claudication.6,7 Data from NHANES 1999 to 2002 suggest that up 
to two thirds of US adults with PAD who are ≥40 years old are asymptomatic, 
with one fourth having severe PAD (ABI <0.7).8 In an older, disabled population 
of women, as many as two thirds of individuals with PAD had no exertional leg 
symptoms.9
Abbreviations Used in Chapter 21
ABI ankle brachial index
AHA American Heart Association
Amer. American
CHD coronary heart disease
CI confidence interval
CKD chronic kidney disease
CVD cardiovascular disease
DM diabetes mellitus
ED emergency department
GBD Global Burden of Diseases, Injuries, and Risk Factors Study
HR hazard ratio
ICD-9 International Classification of Diseases, 9th Revision
ICD-10 International Classification of Diseases, 10th Revision
MI myocardial infarction
NCHS National Center for Health Statistics
NH non-Hispanic
NHANES National Health and Nutrition Examination Survey
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NHAMCS National Hospital Ambulatory Medical Care Survey
NHDS National Hospital Discharge Survey
NHLBI National Heart, Lung, and Blood Institute
OR odds ratio
PA physical activity
PAD peripheral artery disease
REACH Reduction of Atherothrombosis for Continued Health
RR relative risk
YLL years of life lost
Mortality
(See Table 21-1.)
• In 2010, PAD any-mention mortality was 62 955 (29 213 males and 33 742 
females). PAD was the underlying cause in 13 854 of those deaths in 2010.10 
Table 21-1 shows the numbers of these deaths that were coded for PAD as the 
underlying cause.
• The 2010 overall any-mention age-adjusted death rate for PAD was 18.9 per 100 
000. Any-mention death rates were 22.3 for white males, 26.9 for black males, 
16.4 for white females, and 19.6 for black females.11
• The number of any-mention deaths attributable to PAD was higher in 2000 (96 
551) than in 2010 (62 955; NCHS, AHA).11
• Data from the GBD project suggest that the age-standardized death rate 
attributable to PAD was 1.7 (95% CI, 1.0–2.9) per 100 000, with a 42% median 
increase since 1990. The YLL because of PAD was 21.2 (95% CI, 13.4–35.9), 
with a 29% median increase since 1990.2
• A 2008 meta-analysis of 24 955 men and 23 339 women demonstrated that the 
association of the ABI with mortality has a reverse J-shaped distribution in 
which participants with an ABI of 1.11 to 1.40 are at lowest risk for mortality. 
Low ABI (≤0.9) carried a 3-fold (RR, 3.33; 95% CI, 2.74–4.06) risk of all-cause 
death compared with men with normal ABI (1.11–1.40) and a similar risk in 
women (RR, 2.71; 95% CI, 2.03–3.62).12
• Among 508 patients (449 men) identified from 2 vascular laboratories in San 
Diego, CA, a decline in ABI of >0.15 within a 10-year period was associated 
with a subsequent increased risk of all-cause mortality (RR, 2.4; 95% CI, 1.2–
4.8) and CVD mortality (RR, 2.8; 95% CI, 1.3–6.0) at 3 years’ follow-up.13
• Among 440 patients with PAD, male sex and smoking were more associated with 
aortoiliac (proximal) disease than with infrailiac (distal) disease. In addition, 
aortoiliac disease was associated with an increased risk of mortality or 
cardiovascular events compared with infrailiac disease (adjusted HR, 3.28; 95% 
CI, 1.87–5.75).14
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Risk Factors
• The risk factors for PAD are similar but not identical to those for CHD. DM and 
cigarette smoking are stronger risk factors for PAD than for CHD.15 ORs for 
associations of DM and smoking with symptomatic PAD are ≈3.0 to 4.0. Most 
studies suggest that the prevalence of PAD is similar in men and women.16
• Pooled data from 11 studies in 6 countries found that PAD (defined by ABI <0.9) 
is a marker for systemic atherosclerotic disease. The pooled age-, sex-, risk 
factor–, and CVD-adjusted RR for all-cause death was 1.60 (95% CI, 1.32–1.95), 
the RR for cardiovascular mortality was 1.96 (95% CI, 1.46–2.64), the RR for 
CHD was 1.45 (95% CI, 1.08–1.93), and the RR for stroke was 1.35 (95% CI, 
1.10–1.65).17
Awareness and Aftermath
• A cross-sectional, population-based telephone survey of >2500 adults ≥50 years 
of age, with oversampling of blacks and Hispanics, found that 26% expressed 
familiarity with PAD. Of these, half were not aware that DM and smoking 
increase the risk of PAD. One in 4 knew that PAD is associated with increased 
risk of MI and stroke, and only 14% were aware that PAD could lead to 
amputation. All knowledge domains were lower in individuals with lower 
income and education levels.18
• People with PAD have impaired function and quality of life. This is true even for 
people who do not report leg symptoms. Furthermore, patients with PAD, 
including those who are asymptomatic, experience a significant decline in lower-
extremity functioning over time.19–21
• Among patients with established PAD, higher PA levels during daily life are 
associated with better overall survival rate, a lower risk of death because of 
CVD, and slower rates of functional decline.22,23 In addition, better 6-minute 
walk performance and faster walking speed are associated with lower rates of all-
cause mortality, cardiovascular mortality, and mobility loss.24,25
• From 2000 to 2008, the overall use of lower-extremity amputation decreased 
significantly during the study period, from 7258 to 5790 per 100 000 Medicare 
beneficiaries with PAD. There was significant geographic variation in the rate of 
lower-extremity amputation, from 8400 amputations per 100 000 patients with 
PAD in the East South Central region to 5500 amputations per 100 000 patients 
with PAD in the Mountain region. After adjustment for clustering at the US 
Census Bureau level, geographic variation in lower-extremity amputations 
remained. Lower-extremity amputation was performed more often in the East 
South Central region (adjusted OR, 1.152; 95% CI, 1.131–1.174; P< 0.001) and 
West South Central region (adjusted OR, 1.115; 95% CI, 1.097–1.133; P<0.001) 
and less often in the Middle Atlantic region (OR, 0.833; 95% CI, 0.820–0.847; 
P<0.001) than in the South Atlantic region.26
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• A 2003 to 2008 sample of US national insurance claims of adults >40 years of 
age demonstrated that 44 431 patients had a critical limb ischemic diagnosis over 
the study period, with an annual incidence and prevalence of 0.47% (95% CI, 
0.46–0.47) and 1.90% (95% CI, 1.89–1.91), respectively.5
Interventions
• Data from the REACH registry of 8273 PAD participants suggest that only 70% 
of PAD patients receive lipid-lowering therapy and only 82% receive antiplatelet 
therapy for secondary CVD prevention.27
• A 2011 systematic review evaluated lower-extremity aerobic exercise against 
usual care and demonstrated a range of benefits, including the following28:
– Increased claudication time by 71 seconds (79%) to 918 seconds 
(422%)
– Increased claudication distance by 15 m (5.6%) to 232 m (200%)
– Increased walking distance/time by 67% to 101% after 40 minutes of 
walking 2 to 3 times per week
Hospital Discharges—(See Table 21-1.)
• Hospital discharges for PAD slightly increased from 2000 to 2010, with first-
listed discharges of 135 000 and 146 000, respectively (unreliable estimate, 
NHDS, NHLBI tabulation).29
• In 2010, there were 1 539 000 physician office visits with a primary diagnosis of 
PAD.29 In 2010, there were 20 000 ED visits and 109 000 outpatient department 
visits for PAD (NHAMCS, NHLBI tabulation).30
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22. Quality of Care
See Tables 22-1 through 22-14.
The Institute of Medicine defines quality of care as “the degree to which health services for 
individuals and populations increase the likelihood of desired health outcomes and are 
consistent with current professional knowledge.”1 The Institute of Medicine has defined 6 
specific domains for improving health care, including care that is safe, effective, patient-
centered, timely, efficient, and equitable.
In the following sections, data on quality of care will be presented based on the 6 domains of 
quality as defined by the Institute of Medicine. This is intended to highlight current care and 
to stimulate efforts to improve the quality of cardiovascular care nationally. Where possible, 
data are reported from recently published literature or standardized quality indicators from 
quality-improvement registries (ie, those consistent with the methods for quality 
performance measures endorsed by the ACC and the AHA).2 Additional data on aspects of 
quality of care, such as adherence to ACC/AHA clinical practice guidelines, are also 
included to provide a spectrum of quality-of-care data. The data selected are meant to 
provide examples of the current quality of care as reflected by the Institute of Medicine 
domains and are not meant to be comprehensive given the sheer number of publications 
yearly.
Abbreviations Used in Chapter 22
ACC American College of Cardiology
ACE angiotensin-converting enzyme
ACEI angiotensin-converting enzyme inhibitor
ACS acute coronary syndrome
ACTION Acute Coronary Treatment and Intervention Outcomes Network
AED automated external defibrillator
AF atrial fibrillation
AHA American Heart Association
AMI acute myocardial infarction
ARB angiotensin receptor blocker
BMI body mass index
BP blood pressure
CABG coronary artery bypass grafting
CAD coronary artery disease
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CHD coronary heart disease
CHF congestive heart failure
CI confidence interval
COURAGE Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation
CPR cardiopulmonary resuscitation
CRUSADE Can Rapid Risk Stratification of Unstable Angina Patients Suppress Adverse Outcomes With Early 
Implementation of the ACC/AHA Guidelines
CVD cardiovascular disease
D2B Door-to-Balloon (Alliance)
DES drug-eluting stent
DM diabetes mellitus
DVT deep vein thrombosis
ECG electrocardiogram
ED emergency department
EF ejection fraction
EMS emergency medical services
GBD Global Burden of Diseases, Injuries, and Risk Factors Study
GWTG Get With The Guidelines
HbA1c hemoglobin A1c (glycosylated hemoglobin)
HD heart disease
HF heart failure
HIQR Hospital Inpatient Quality Reporting
HR hazard ratio
IV intravenous
LDL low-density lipoprotein
LV left ventricular
LVEF left ventricular ejection fraction
LVSD left ventricular systolic dysfunction
MI myocardial infarction
N/A not available or not applicable
NCDR National Cardiovascular Data Registry
NHANES National Health and Nutrition Examination Survey
NM not measured
NSTEMI non–ST-segment–elevation myocardial infarction
OR odds ratio
PAD peripheral artery disease
PCI percutaneous coronary intervention
PINNACLE Practice Innovation and Clinical Excellence
RR relative risk
SBP systolic blood pressure
SCD-HeFT Sudden Cardiac Death in Heart Failure Trial
STEMI ST-segment–elevation myocardial infarction
STS Society of Thoracic Surgeons
TAVR transcatheter aortic valve replacement
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tPA tissue-type plasminogen activator
TVR target-vessel revascularization
TVT transcatheter valve therapy
UFH unfractionated heparin
VHA Veterans Health Administration
YLL years of life lost
• The safety domain has been defined as avoiding injuries to patients from the care 
that is intended to help them. The following are several publications that have 
focused on safety issues:
– In a small, single-center study conducted over a 2-month period in the 
cardiac care unit of a tertiary center, Rahim et al3 demonstrated that 
iatrogenic adverse events were common (99 of 194 patients), of which 
bleeding (27%) was the most common preventable iatrogenic adverse 
event.
– Using the NCDR CathPCI Registry, Tsai et al4 found that almost one 
fourth of dialysis patients undergoing PCI (n=22 778) received a 
contraindicated antithrombotic agent, specifically enoxaparin, 
eptifibatide, or both. Patients who received a contraindicated 
antithrombotic agent had an increased risk of in-hospital bleeding (OR, 
1.63; 95% CI, 1.35–1.98) and a trend toward increased mortality (OR, 
1.15; 95% CI, 0.97–1.36).4
– Using data from the ACTION Registry-GWTG, Mathews and 
colleagues developed a contemporary model to stratify in-hospital 
bleeding risk for patients after STEMI and NSTEMI.5 The 12 factors 
associated with major bleeding in the model were heart rate, baseline 
hemoglobin, female sex, baseline serum creatinine, age, 
electrocardiographic changes, HF or shock, DM, PAD, body weight, 
SBP, and home warfarin use. The risk model discriminated well in the 
derivation (C statistic= 0.73) and validation (C statistic=0.71) cohorts, 
and the risk score for major bleeding corresponded well with observed 
bleeding.5
– In a random sample of medical and surgical long-term care adult 
patients in Massachusetts hospitals, López et al6 assessed the 
association between disclosure of an adverse event and patients’ 
perception of quality of care. Overall, only 40% of adverse events were 
disclosed. Higher quality ratings were associated with disclosure of an 
adverse event. Conversely, lower patient perception of quality of care 
was associated with events that were preventable and with events that 
caused discomfort.6
– Using prospective propensity-matched cohort analysis of 7 newly 
introduced cardiovascular devices, Resnic et al7 showed the feasibility 
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of automated prospective surveillance to identify low-frequency safety 
signals in a cardiovascular registry. In this study, 3 of the 21 safety 
alerts triggered sustained alerts in 2 implantable devices.7
• Effective care has been defined as providing services based on scientific 
knowledge to all who could benefit and refraining from providing services to 
those not likely to benefit. It also encompasses monitoring results of the care 
provided and using them to improve care for all patients.1 There are many 
quality-improvement registries that have been developed for inpatient 
cardiovascular/stroke care, and the data on these are provided in subsequent 
tables. Similar efforts are under way for quality-of-care registries in the 
outpatient setting.
– According to data from NHANES 1988 to 1994 and 1999 to 2008, 
prevalence of hypertension increased from 23.9% in 1988 to 1994 to 
29.0% in 2007 to 2008, and hypertension control among hypertensive 
adults has increased from 27.3% in 1988 to 1994 to 50.1% in 2007 to 
2008. In addition, among people with hypertension, BP has decreased 
from 143.0/80.4 to 135.2/74.1 mm Hg.8
– Weintraub et al9 reported results from a comparative effectiveness study 
of PCI versus CABG using observational data among patients ≥65 years 
of age with 2- or 3-vessel CAD without AMI. Their results showed that 
at 1 year, there was no significant difference in adjusted mortality 
between groups (6.24% in the CABG group versus 6.55% in the PCI 
group). At 4 years, there was lower mortality in the CABG group than 
in the PCI group (16.4% versus 20.8%; RR, 0.79; 95% CI, 0.76–0.82).9
– Appel et al10 reported results of a randomized controlled trial 
comparing the effectiveness of 2 behavioral weight loss interventions 
with controls. The interventions included either remote weight loss 
intervention (delivered through the telephone, a study-specific Web site, 
and e-mail) or in-person support (individual and group sessions along 
with the 3 means of remote support). At 24 months, the mean change in 
weight from baseline was −0.8 kg in the control group, −4.6 kg in the 
group with remote support only (P<0.001 for comparison with the 
control group), and −5.1 kg in the group receiving in-person support 
(P<0.001 for comparison with the control group). The change in weight 
from baseline did not differ significantly between the 2 intervention 
groups at the end of the trial.
– Choudhry et al11 reported results of a cluster randomized trial that 
evaluated the impact of eliminating out-of-pocket costs (full 
prescription coverage) on medication adherence and cardiovascular 
outcomes in patients discharged after MI. Compared with the usual 
prescription coverage, rates of adherence to statins, β-blockers, ACE 
inhibitors, and ARBs were on average 4% to 6% higher in the full-
coverage group. There was no significant difference in the primary 
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outcome (first major vascular event or revascularization) between the 2 
groups (17.6 per 100 person years in the full-coverage group versus 
18.8 in the usual-coverage group; HR, 0.93; 95% CI, 0.82–1.04). The 
rates of secondary outcomes of total major vascular events or 
revascularization were significantly reduced in the full-coverage group 
(21.5 versus 23.3; HR, 0.89; 95% CI, 0.90–0.99), as was the rate of first 
major vascular event (11 versus 12.8; HR, 0.86; 95% CI, 0.74–0.99). 
The elimination of copayments did not increase total spending, 
although patient costs were reduced for drugs and other services.
– Data from the ACC PINNACLE outpatient registry12 of patients with 
CAD (n=38 775) showed that 77.8% of the patients (30 160) were 
prescribed statins, 2042 (5.3%) were treated only with nonstatin lipid-
lowering medications, and 6573 (17%) were not taking any lipid-
lowering medication. Lack of medical insurance (RR, 0.94; 95% CI, 
0.89–1.00) was associated with a lower likelihood of statin treatment, 
whereas male sex (RR, 1.10; 95% CI, 1.07–1.13), coexisting 
hypertension (RR, 1.07; 95% CI, 1.02–1.12), prior CABG (RR, 1.09; 
95% CI, 1.05–1.14), and prior PCI (RR, 1.11; 95% CI, 1.06–1.16) were 
associated with a higher likelihood of statin treatment.
– In patients recently hospitalized with HF, a randomized clinical trial did 
not show improvement in the primary end point (readmission for any 
reason or death of any cause within 180 days after enrollment) or the 
secondary end points (hospitalization for HF, number of days in the 
hospital, and number of hospitalizations) with the use of 
telemonitoring.13 Similar results were seen in a randomized clinical 
trial of remote telemedical management in patients with chronic HF.14
– Heisler et al15 reported results of a prospective, multisite, cluster 
randomized trial that evaluated the effectiveness of a pharmacist-led 
intervention that targeted medication management and adherence 
counseling to improve BP control in patients with DM in 2 high-
performing integrated healthcare systems. Although the mean SBP of 
patients in the intervention arm was 2.4 mm Hg lower (95% CI, −3.4 to 
−1.5; P<0.001) immediately after the intervention than that of patients 
in the control arm, the mean SBP decrease from 6 months before to 6 
months after the intervention (primary outcome) was similar in 
magnitude (≈9 mm Hg) in both arms.15
– In 2013, investigators from the GBD 2010 study described their 
findings of a systematic analysis of disease burden, injuries, and leading 
risk factors in the United States and compared them with those of 34 
countries in the Organisation for Economic Co-operation and 
Development.16 Their findings showed that the US life expectancy for 
both sexes combined increased from 75.2 years in 1990 to 78.2 years in 
2010. During the same time period, healthy life expectancy (the number 
et al. Page 323
Circulation. Author manuscript; available in PMC 2017 April 28.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
of years that a person at a given age can expect to live in good health, 
taking into account mortality and disability) increased from 65.8 years 
to 68.1 years in the United States. Despite declines in the YLLs because 
of premature mortality secondary to ischemic HD and stroke, 15.9% of 
YLLs were related to ischemic HD and 4.3% of YLLs were related to 
stroke in the United States in 2010, which highlights the continued 
dominance of CVD in causing premature death. Despite these absolute 
improvements, the US rank among 34 countries in the Organisation for 
Economic Co-operation and Development changed from 18th to 27th 
for the age-standardized death rate, from 20th to 27th for life 
expectancy at birth, from 14th to 26th for healthy life expectancy, and 
from 23rd to 28th for the age-standardized YLL. These results indicate 
that improvements in population health in the United States have not 
kept pace with advances in population health in other wealthy nations.
– Outcome measures of 30-day mortality and 30-day readmission after 
hospitalization for AMI or HF have been developed that adjust for 
patient mix (eg, comorbidities) so that comparisons can be made across 
hospitals.17 Using national Medicare data from 2008 through 2010, the 
median (10th, 90th percentile) hospital risk-standardized mortality rate 
was 15.7% (13.7%, 17.7%) for AMI and 11.5% (9.7%, 13.5%) for HF. 
The median risk-standardized readmission rate was 19.7% (18.0%, 
21.7%) for AMI and 24.7% (22.6%, 27.3%) for HF. Distinct regional 
patterns were seen for both measures and both conditions. The median 
risk-standardized mortality rate for AMI decreased by 0.7% from 2008 
to 2010, whereas the median risk-standardized mortality rate for HF 
increased by 0.4%. The median risk-standardized readmission rate for 
AMI and HF declined by 0.5% and 0.3%, respectively, from 2008 to 
2010.17
– A study of 30 947 patients admitted with ischemic strokes showed that 
admission to a designated stroke center compared with admission to a 
nondesignated hospital was associated with more frequent use of 
thrombolytic therapy (4.8% versus 1.7%, P<0.001) and lower 30-day 
all-cause mortality (10.1% versus 12.5%, P<0.001).18
– A study of 458 hospitals participating in the STS National Cardiac 
Database showed that an intervention of receiving quality-improvement 
educational material designed to influence the prescription rates of 4 
medication classes (aspirin, β-blockers, lipid-lowering therapy, and 
ACE inhibitors) after CABG discharge in addition to site-specific 
feedback reports led to a significant improvement in adherence for all 4 
secondary prevention medications at the intervention sites compared 
with the control sites.19
– In 2011, the ACC Foundation/AHA/American Medical Association–
Physician Consortium for Performance Improvement published a joint 
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report on performance measures for CAD and hypertension.20 The 9 
performance measures for CAD care included BP control, lipid control, 
symptom and activity assessment, symptom management, tobacco use 
(screening, cessation, and intervention), antiplatelet therapy, β-blocker 
therapy, ACE inhibitor/ARB therapy, and cardiac rehabilitation patient 
referral from an outpatient setting. For hypertension care, the 
performance measures included BP control. This set was an update to 
the 2005 ACC Foundation/AHA performance measures for CAD and 
hypertension and included modifications to 7 of the 2005 performance 
measures. Screening for DM was retired from the CAD set published in 
2005, whereas symptom management and cardiac rehabilitation referral 
were added to the 2011 CAD set. Similarly, the ACC Foundation/AHA/
American Medical Association–Physician Consortium for Performance 
Improvement published a report on performance measures for HF,21 
which was an update to the 2005 report.22 Eight measures from the 
2005 report were retired, β-blocker use in patients with HF was 
expanded as a performance measure for the inpatient setting, symptom 
management and counseling about implantable cardioverter-
defibrillators were added as new quality metrics, and patient education 
was changed from a performance measure to a quality metric.
– A study from the PINNACLE registry of NCDR showed that uninsured 
patients with CAD were 9%, 12%, and 6% less likely to receive 
treatment with a β-blocker, an ACE inhibitor/ARB, and lipid-lowering 
therapy, respectively, than privately insured CAD patients, and CAD 
patients with public insurance were 9% less likely to be prescribed ACE 
inhibitor/ARB therapy. Most of the differences were attenuated after 
adjustment for the site providing care.23
– A randomized controlled trial of Transcendental Meditation or health 
education in 201 black men and women with CHD showed that the 
Transcendental Meditation program was associated with a 48% 
reduction in RR (11.2% absolute risk reduction) for the composite 
primary end point of all-cause mortality, MI, or stroke (HR, 0.52; 95% 
CI, 0.29–0.92) during an average follow-up of 5.4 years.24
– In 2013, a TVT registry was created through a partnership between the 
STS and the ACC.25 The objective of this registry is to provide an 
“objective, comprehensive, and scientifically based resource to improve 
the quality of patient care, to monitor the safety and effectiveness of 
TVT devices, to serve as an analytic resource for TVT research, and to 
enhance communication among key stake holders.”
– Inpatient ACS, HF, and stroke quality-of-care measures data, including 
trends in care data, where available from national registries, are given in 
Tables 22-1 through 22-6.
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– Selected outpatient quality-of-care measures from the National 
Committee for Quality Assurance for 2011 appear in Table 22-7.
– Quality-of-care measures for patients who had out-of-hospital cardiac 
arrest and were enrolled in the Resuscitation Outcomes Consortium 
cardiac arrest registry in 2011 (Resuscitation Outcomes Consortium 
Investigators, unpublished data, July 25, 2013) are given in Tables 22-8 
and 22-9.
– Quality-of-care measures for patients who had inhospital cardiac arrest 
and were enrolled in the AHA’s GWTG-Resuscitation quality-
improvement project in 2012 (GWTG-Resuscitation Investigators, 
unpublished data, July 27, 2013) are given in Table 22-10.
• Patient-centered care has been defined as the provision of care that is respectful 
of and responsive to individual patient preferences, needs, and values and that 
ensures that patient values guide all clinical decisions. Dimensions of patient-
centered care include the following: (1) Respect for patients’ values, preferences, 
and expressed needs; (2) coordination and integration of care; (3) information, 
communication, and education; (4) physical comfort; (5) emotional support; and 
(6) involvement of family and friends. Studies that focused on some of these 
aspects of patient-centered care are highlighted below.
– The COURAGE trial,26 which investigated a strategy of PCI plus 
optimal medical therapy versus optimal medical therapy alone, 
demonstrated that both groups had significant improvement in health 
status during follow-up. By 3 months, health status scores had increased 
in the PCI group compared with the medical therapy group, to 76±24 
versus 72±23 for physical limitation (P=0.004), 77±28 versus 73±27 for 
angina stability (P=0.002), 85±22 versus 80±23 for angina frequency 
(P<0.001), 92±12 versus 90±14 for treatment satisfaction (P<0.001), 
and 73±22 versus 68±23 for quality of life (P<0.001). The PCI plus 
optimal medical therapy group had a small but significant incremental 
benefit compared with the optimal medical therapy group early on, but 
this benefit disappeared by 36 months.
– In SCD-HeFT,27 a study of a single-lead implantable cardioverter-
defibrillator versus amiodarone for moderately symptomatic HF, 
patients with implantable cardioverter-defibrillators had improvement in 
quality of life compared with patients who received medical therapy at 
3 and 12 months but not at 30 months. Implantable cardioverter-
defibrillator shocks in the month preceding a scheduled assessment 
were associated with a decrease in quality of life in multiple domains. 
The authors concluded that the presence of a single-lead implantable 
cardioverter-defibrillator was not associated with any detectably 
adverse quality of life during 30 months of follow-up.
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– Peikes et al28 reported on 15 care-coordination programs as part of a 
Medicare demonstration project for patients with CHF, CAD, DM, and 
other conditions. Thirteen of the 15 programs did not show a difference 
in hospitalization rates, and none of the programs demonstrated net 
savings. The interventions tested varied significantly, but the majority 
of the interventions included patient education to improve adherence to 
medication, diet, exercise, and self-care regimens and improving care 
coordination through various approaches. These programs overall had 
favorable effects on none of the adherence measures and only a few of 
the many quality-of-care indicators examined. The authors concluded 
that programs with substantial in-person contact that target moderately 
to severely ill patients can be cost-neutral and improve some aspects of 
care.
– Hernandez et al29 showed that patients with outpatient follow-up within 
7 days of discharge for an HF hospitalization were less likely to be 
readmitted within 30 days in the GWTG-HF registry of patients who 
were ≥65 years of age. The median length of stay was 4 days 
(interquartile range, 2–6 days), and 21.3% of patients were readmitted 
within 30 days. At the hospital level, the median percentage of patients 
who had early follow-up after discharge from the index hospitalization 
was 38.3% (interquartile range, 32.4%–44.5%).
– Smolderen et al30 assessed whether health insurance status affects 
decisions to seek care for AMI. Uninsured and insured patients with 
financial concerns were more likely to delay seeking care during AMI 
and had prehospital delays of >6 hours (48.6% of uninsured patients 
and 44.6% of insured patients with financial concerns compared with 
39.3% of insured patients without financial concerns). Lack of health 
insurance and financial concerns about accessing care among those with 
health insurance were each associated with delays in seeking 
emergency care for AMI.
– Using a cohort (n=192) nested within a randomized trial at a university-
affiliated ambulatory practice, Murray et al31 demonstrated that refill 
adherence of <40% was associated with a 3-fold higher incidence of HF 
hospitalization than refill adherence of ≥80% (P=0.002). In 
multivariable analysis, prescription label–reading skills were associated 
with a lower incidence of HF-specific emergency care (incidence rate 
ratio, 0.76; 95% CI, 0.19–0.69), and participants with adequate health 
literacy had a lower risk of HF hospitalization (incidence rate ratio, 
0.34; 95% CI, 0.15–0.76).
– Reynolds et al32 reported results on health-related quality of life after 
TAVR in inoperable patients with severe aortic stenosis compared with 
those receiving standard therapy. Health-related quality of life was 
assessed at baseline and at 1, 6, and 12 months with the Kansas City 
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Cardiomyopathy Questionnaire and the 12-item Short Form-12 General 
Health Survey. Although the Kansas City Cardiomyopathy 
Questionnaire summary scores improved in both groups, the extent of 
improvement was greater in the TAVR group than in the standard-care 
group at 1 month (mean between-group difference, 13 points; 95% CI, 
8–19), with larger benefits at 6 months (mean difference, 21 points; 
95% CI, 15–27 points) and 12 months (mean difference, 26 points; 95% 
CI, 19–33). At 12 months, TAVR patients also reported higher physical 
and mental health scores on the 12-item Short Form-12 General Health 
Survey, with a mean difference of 5.7 and 6.4 points, respectively 
(P<0.001 for both comparisons) compared with standard care.32
– In 2012, the AHA published a scientific statement on decision making 
in advanced HF. This statement discusses the clinical trajectory of HF, 
importance and process of shared decision making in advanced HF, 
timing of discussion, discussion on outcomes beyond survival (ie, major 
adverse events, symptom burden, functional limitations, loss of 
independence, quality of life, and obligations for caregivers), 
discussions regarding end-of-life issues, and assessment and integration 
of emotional readiness of the patient and family in these discussions.33
– In 2013, the AHA published a scientific statement on the importance of 
measuring patient-reported health status across 3 domains (symptom 
burden, functional status, and health-related quality of life).34 The 
statement discusses why it is important to measure patient-reported 
health status measures, the association between measures of patient-
reported health status and cardiovascular outcomes, and the currently 
available tools to measure health status of patients with CVD.
– In 2012, the ACC Foundation published a policy statement on patient-
centered care in cardiovascular medicine. This policy statement 
discusses and provides recommendations on topics such as enhanced 
clinician-patient communication, health literacy, clinician-directed 
patient education, assessment of patient-centered outcomes, process of 
shared decision making, collaborative care planning and goal setting, 
and patient empowerment and self-management. The policy statement 
also discusses newer paradigms and challenges in patient-centered care, 
such as the impact of technology, complexity of care strategies with 
self-care, a systemic approach to episodic care, and barriers to patient-
centered care.35
• The timely care domain relates to reducing waits and sometimes harmful delays 
for both those who receive and those who give care. Timeliness is an important 
characteristic of any service and is a legitimate and valued focus of improvement 
in health care and other industries.
– Data from the CRUSADE national quality-improvement initiative 
showed that median delay from onset of symptoms to hospital 
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presentation for patients presenting with NSTEMI was 2.6 hours and 
was significantly associated with in-hospital mortality but did not 
change over time from 2001 to 2006.36
– Bradley et al37 demonstrated that participation in the D2B Alliance led 
to a reduction in door-to-balloon time to within 90 minutes for patients 
with STEMI. By March 2008, >75% of patients had door-to-balloon 
times of ≤90 minutes compared with only approximately one fourth of 
patients in April 2005.
– Using data between 2005 and 2007 from the NCDR CathPCI Registry, 
Wang et al38 demonstrated that among STEMI patients, only 10% of 
the transfer patients received PCI within 90 minutes (versus 63% for 
direct-arrival patients; P<0.0001).
– Glickman et al39 showed that a year-long implementation of 
standardized protocols as part of a statewide regionalization program 
was associated with a significant improvement in median door-in–door-
out times among 436 STEMI patients who presented at non-PCI 
hospitals who required transfer (before intervention: 97 minutes, 
interquartile range 56–160 minutes; after intervention: 58 minutes, 
interquartile range 35–90 minutes; P<0.0001).
– A recent study40 of 204 591 patients with ischemic and hemorrhagic 
strokes admitted to 1563 GTWG-Stroke participating hospitals between 
April 1, 2003, and June 30, 2010, showed that 63.7% of the patients 
arrived by EMS in the hospital. Older patients, those with Medicaid and 
Medicare, and those with severe strokes were more likely to activate 
EMS. Conversely, minority race/ethnicity (black, Hispanic, Asian) and 
living in rural communities were associated with a lower likelihood of 
EMS use. EMS transport was independently associated with an onset-
to-door time ≤3 hours, a higher proportion of patients meeting door-to-
imaging time of ≤25 minutes, more patients meeting a door-to-needle 
time of ≤60 minutes, and more eligible patients being treated with tPA 
if onset of symptoms was ≤2 hours. The authors concluded that 
although EMS use was associated with rapid evaluation and treatment 
of stroke, more than one third of stroke patients fail to use EMS.
– Data on time to reperfusion for STEMI or ischemic stroke are provided 
from national registries in Table 22-11.
• Efficiency has been defined as avoiding waste, in particular waste of equipment, 
supplies, ideas, and energy. In an efficient healthcare system, resources are used 
to get the best value for the money spent.
– The AHA and ACC have jointly developed a scientific statement that 
outlines standards for measures to be used for public reporting of 
efficiency in health care. The group identified 4 standards important to 
the development of any efficiency performance measure, including (1) 
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integration of quality and cost, (2) valid cost measurement and analysis, 
(3) no or minimal incentive to provide poor-quality care, and (4) no or 
proper attribution of the measure. In the statement, 4 examples were 
provided of hospital-based efficiency measures, as well as information 
on how each of the measures fared within the 4 domains recommended. 
The examples were length of stay, 30-day readmission, hospitalization 
costs, and nonrecommended imaging tests.41
– Using data from the NCDR CathPCI registry from 2004 through 2010, 
Amin et al42 examined the association between risk of TVR and use of 
DES and the cost-effectiveness of lower use of DES in patients at low 
risk of TVR (<10% TVR risk). The authors showed a marked variation 
in physicians’ use of DES (range, 2%–100%). Even in groups with low 
TVR risk, 73.9% of the patients received DES. The authors projected 
that by reducing the use of DES by 50% in patients at low risk of TVR, 
US health-care costs could be lowered by $205 million, whereas the 
overall TVR event rate would be increased by 0.5%.
– At an urban, tertiary care, academic medical center ED, elements of 
departmental work flow were redesigned to streamline patient 
throughput before implementation of a fully integrated ED information 
system with patient tracking, computerized charting and order entry, 
and direct access to patient historical data from the hospital data 
repository. Increasing the clinical information available at the bedside 
and improving departmental work flow through ED information system 
implementation and process redesign led to decreased patient 
throughput times and improved ED efficiency (eg, the length of stay for 
all patients [from arrival to time patient left the ED] decreased by 1.94 
hours, from 6.69 hours [n=508] before the intervention to 4.75 hours 
[n=691] after the intervention; P<0.001).43
– Himmelstein et al44 analyzed whether more-computerized hospitals had 
lower costs of care or administration or better quality, to address a 
common belief that computerization improves healthcare quality, 
reduces costs, and increases administrative efficiency. They found that 
hospitals that increased computerization faster had more rapid 
administrative cost increases (P=0.0001); however, higher overall 
computerization scores correlated weakly with better quality scores for 
AMI (r=0.07, P=0.003) but not for HF, pneumonia, or the 3 conditions 
combined. In multivariate analyses, more-computerized hospitals had 
slightly better quality. The authors concluded that hospital computing 
might modestly improve process measures of quality but does not 
reduce administrative or overall costs.
– In a retrospective cohort study of cases (111 707) submitted to the 
NCDR ICD (implantable cardioverter-defibrillator) Registry between 
January 1, 2006, and June 30, 2009, 25 145 (22.5%) received non–
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evidence-based implantable cardioverter-defibrillator therapy. Patients 
who received non–evidence-based implantable cardioverter-defibrillator 
therapy had a significantly higher risk of in-hospital death (0.57% 
versus 0.18%, P<0.001) and any postprocedure complication (3.23% 
versus 2.41%, P<0.001) than those who received evidence-based 
implantable cardioverter-defibrillator therapy.45
– In a multicenter study of patients within the NCDR undergoing PCI, 
Chan et al46 reported results of the appropriateness of PCI for both 
acute and nonacute indications. Among patients undergoing PCI for 
acute indications (71.1% of the cohort), 98.5% of the procedures were 
classified as appropriate, 0.3% as uncertain, and 1.1% as inappropriate. 
Among patients undergoing PCI for nonacute indications (28.9% of the 
cohort), 50.4% of the procedures were classified as appropriate, 38% as 
uncertain, and 11.6% as inappropriate. There was also substantial 
variation for inappropriate nonacute PCI across hospitals (median 
hospital rate 10.8%; interquartile range 6.0%–16.7%).
• Equitable care means the provision of care that does not vary in quality because 
of personal characteristics such as sex, ethnicity, geographic location, and 
socioeconomic status. The aim of equity is to secure the benefits of quality health 
care for all the people of the United States. With regard to equity in caregiving, 
all individuals rightly expect to be treated fairly by local institutions, including 
health-care organizations.
– Chan et al47 demonstrated that rates of survival to discharge were lower 
for black patients (25.2%) than for white patients (37.4%) after in-
hospital cardiac arrest. Lower rates of survival to discharge for blacks 
reflected lower rates of both successful resuscitation (55.8% versus 
67.4%) and postresuscitation survival (45.2% versus 55.5%). 
Adjustment for the hospital site at which patients received care 
explained a substantial portion of the racial differences in successful 
resuscitation (adjusted RR, 0.92; 95% CI, 0.88–0.96; P<0.001) and 
eliminated the racial differences in postresuscitation survival (adjusted 
RR, 0.99; 95% CI, 0.92–1.06; P=0.68). The authors concluded that 
much of the racial difference was associated with the hospital center in 
which black patients received care.
– Kapoor et al48 evaluated 99 058 HF admissions from 244 sites between 
January 2005 and September 2009. Patients were grouped on the basis 
of payer status (private/health maintenance organization, no insurance, 
Medicare, or Medicaid). Compared with private/health maintenance 
organization group, the other 3 groups were less likely to receive 
evidence-based therapies (β-blockers, implantable cardioverter-
defibrillators, anticoagulation for AF, ACE inhibitors, or ARBs) and 
had longer hospital stays. Higher adjusted rates of in-hospital mortality 
were also seen in patients with Medicaid (OR, 1.22; 95% CI, 1.06–
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1.41) and in patients with reduced EF and no insurance (OR, 1.61; 95% 
CI, 1.15–2.25).
– Cohen et al49 demonstrated that among hospitals engaged in a national 
quality monitoring and improvement program, evidence-based care for 
AMI appeared to improve over time for patients irrespective of race/
ethnicity, and differences in care by race/ethnicity care were reduced or 
eliminated. They analyzed 142 593 patients with AMI (121 528 whites, 
10 882 blacks, and 10 183 Hispanics) at 443 hospitals participating in 
the GWTG-CAD program. Overall, defect-free care was 80.9% for 
whites, 79.5% for Hispanics (adjusted OR versus whites, 1.00; 95% CI, 
0.94–1.06; P=0.94), and 77.7% for blacks (adjusted OR versus whites, 
0.93; 95% CI, 0.87–0.98; P=0.01). A significant gap in defect-free care 
was observed for blacks during the first half of the study but was no 
longer present during the remainder of the study. Overall, progressive 
improvements in defect-free care were observed regardless of race/
ethnic groups.
– Thomas et al50 analyzed data among hospitals that voluntarily 
participated in the AHA’s GWTG-HF program from January 2005 
through December 2008. Relative to white patients, Hispanic and black 
patients hospitalized with HF were significantly younger (median age 
78, 63, and 64 years, respectively) but had lower EFs (mean EF 41.1%, 
38.8%, and 35.7%, respectively) with a higher prevalence of DM 
(40.2%, 55.7%, and 43.8%, respectively) and hypertension (70.6%, 
78.4%, and 82.8%, respectively). The provision of guideline-based care 
was comparable for white, black, and Hispanic patients. Black (1.7%) 
and Hispanic (2.4%) patients had lower in-hospital mortality than white 
patients (3.5%). Improvement in adherence to all-or-none HF measures 
increased annually from year 1 to year 3 for all 3 racial/ethnic groups.50
– Al-Khatib et al51 analyzed implantable cardioverter-defibrillator use for 
primary prevention among 11 880 patients with a history of HF, left 
ventricular EF<35%, and age >65 years enrolled in the GWTG-HF 
registry from January 2005 through December 2009. From 2005 to 
2007, overall implantable cardioverter-defibrillator use increased from 
30.2% to 42.4% and then remained unchanged in 2008 to 2009. After 
adjustment for confounders, implantable cardioverter-defibrillator use 
increased significantly in the overall study population during 2005 to 
2007 (OR, 1.28; 95% CI, 1.11–1.48 per year; P=0.0008) and in black 
women (OR, 1.82; 95% CI, 1.28–2.58 per year; P=0.0008), white 
women (OR, 1.30; 95% CI, 1.06–1.59 per year; P=0.010), black men 
(OR, 1.54; 95% CI, 1.19–1.99 per year; P=0.0009), and white men 
(OR, 1.25; 95% CI, 1.06–1.48 per year; P=0.0072). The increase in 
implantable cardioverter-defibrillator use was greatest among blacks. 
They concluded that although previously described racial disparities in 
the use of implantable cardioverter-defibrillators were no longer present 
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in their study by the end of the study period, a sex difference in their 
use persisted.51
– In 2013, the AHA published an advisory that provided a 
recommendation on improving bystander CPR in communities with low 
bystander CPR rates (in the United States, rates ranged from 10%–
65%) and the metrics to evaluate the impact of community-based CPR 
training programs.52
– GWTG data by race, sex, and ethnicity are provided in Tables 22-12 
through 22-14.
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Committee, Council on Cardiopulmonary, Critical Care, Perioperative and Resuscitation, Council 
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providers, policymakers, public health departments, and community leaders. Circulation. 2013; 
127:1342–1350. [PubMed: 23439512] 
23. Medical Procedures
See Tables 23-1 and 23-2 and Charts 23-1 through 23-4.
Trends in Operations and Procedures
(See Tables 23-1 and 23-2 and Charts 23-1 and 23-2.)
• The total number of inpatient cardiovascular operations and procedures increased 
28%, from 5 939 000 in 2000 to 7 588 000 in 2010 (NHLBI computation based 
on NCHS annual data). Data from the NHDS were examined for trends from 
1990 to 2004 for use of PCI and CABG and in-hospital mortality rate attributable 
to PCI and CABG by sex1:
– Discharge rates (per 10 000 population) for PCI increased 58%, from 
37.2 in 1990 to 1992 to 59.2 in 2002 to 2004.
– Discharge rates for CABG increased from 34.1 in 1990 to 1992 to 38.6 
in 1996 to 1998, then declined to 25.2 in 2002 to 2004.
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– In 1990 to 1992, discharge rates for CABG were 53.5 for males and 
18.1 for females; these rates increased through 1996 to 1998, then 
declined to 38.8 and 13.6, respectively, in 2002 to 2004. The magnitude 
of these declines decreased by age decile and were essentially flat for 
both men and women ≥75 years of age.
– PCI discharge rates increased from 54.5 for males and 23.0 for females 
to 83.0 and 38.7, respectively, over the 15-year time interval. In 2002 to 
2004, discharge rates for men and women 65 to 74 years of age were 
135.1 and 64.0, respectively. For those ≥75 years of age, the rates were 
128.7 and 69.0, respectively.
– In-hospital mortality rate (deaths per 100 CABG discharges) declined 
from 4.3 to 3.5 between 1990 to 1992 and 2002 to 2004 despite an 
increase in Charlson comorbidity index. The mortality rate declined in 
all age and sex subsets, but especially in women.
• Data from the Acute Care Tracker database were used to estimate the population-
based rates per 100 000 population for PCI and CABG procedures from 2002 to 
2005, standardized to the 2005 US population2:
– Adjusted for age and sex, the overall rate for coronary revascularization 
declined from 382 to 358 per 100 000. PCI rates during hospitalization 
increased from 264 to 267 per 100 000, whereas CABG rates declined 
from 121 to 94.
• Data from men and women enrolled in Medicare from 1992 to 2001 suggest that 
efforts to eliminate racial disparities in the use of high-cost cardiovascular 
procedures (PCI, CABG, and carotid endarterectomy) were unsuccessful.3
– In 1992, among women, the age-standardized rates of carotid 
endarterectomy were 1.59 per 1000 enrollees for whites and 0.64 per 
1000 enrollees for blacks. By 2002, the rates were 2.42 per 1000 
enrollees among white women and 1.15 per 1000 enrollees among 
black women. For men, the difference in rates between whites and 
blacks remained the same. In 1992, the rates were 3.13 per 1000 
enrollees among white men and 0.82 per 1000 enrollees among black 
men; in 2001, the rates were 4.42 and 1.44, respectively.
Abbreviations Used in Chapter 23
CABG coronary artery bypass graft
CHF congestive heart failure
D2B Door-to-Balloon Alliance
DES drug-eluting stent
GWTG-CAD Get With The Guidelines–Coronary Artery Disease
HCUP Healthcare Cost and Utilization Project
HD heart disease
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HPLHS hypoplastic left heart syndrome
ICD-9-CM International Classification of Diseases, 9th Revision, Clinical Modification
NCHS National Center for Health Statistics
NHDS National Hospital Discharge Survey
NHLBI National Heart, Lung, and Blood Institute
PCI percutaneous coronary intervention
PTCA percutaneous transluminal coronary angioplasty
STEMI ST-segment–elevation myocardial infarction
STS Society of Thoracic Surgeons
TOF tetralogy of Fallot
VSD ventricular septal defect
Cardiac Catheterization and PCI
(See Tables 23-1 and 23-2.)
• From 2000 to 2010, the number of cardiac catheterizations decreased slightly, 
from 1 221 000 to 1 029 000 annually (NHDS, NHLBI tabulation).
• In 2010, an estimated 492 000 patients underwent PCI (previously referred to as 
percutaneous transluminal coronary angioplasty, or PTCA) procedures in the 
United States (NHDS, NHLBI tabulation).
• In 2010, ≈67% of PCI procedures were performed on men, and ≈51% were 
performed on people ≥65 years of age (NHDS, NHLBI tabulation).
• In-hospital death rates for PCI have remained stable, although comorbidities 
increased for patients who received the procedure.1
• In 2010, ≈75% of stents implanted during PCI were DES compared with 25% 
that were bare-metal stents (NHDS, NHLBI computation).
• In a study of nontransferred patients with STEMI treated with primary PCI from 
July 2006 to March 2008, there was significant improvement over time in the 
percentage of patients receiving PCI within 90 minutes, from 54.1% from July to 
September 2006 to 74.1% from January to March 2008, among hospitals 
participating in the GWTG-CAD program. This improvement was seen whether 
or not hospitals joined the D2B Alliance during that period.4
• The rate of any cardiac stent procedure rose by 61% from 1999 to 2006, then 
declined by 27% between 2006 and 2009.5
Cardiac Open Heart Surgery
The NHDS (NCHS) estimates that in 2010, in the United States, 219 000 patients underwent 
a total of 397 000 coronary artery bypass procedures (defined by procedure codes). CABG 
volumes have declined nationally since 1998. Risk-adjusted mortality for CABG has 
declined significantly over the past decade.
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• Data from the STS Adult Cardiac Surgery Database, which voluntarily collects 
data from ≈80% of all hospitals that perform CABG in the United States, 
indicate that a total of 158 008 procedures involved CABG in 2010.6
• Data from the STS Adult Cardiac Surgery Database document a 50% decline in 
the risk-adjusted mortality rate despite a significant increase in preoperative 
surgical risk.7
Congenital Heart Surgery, 1998 to 2002 (From STS)
• There were 103 664 procedures performed from July 2006 to June 2010. The in-
hospital mortality rate was 3.2% in 2010. The 5 most common diagnoses were 
the following: patent ductus arteriosus (7.4%); HPLHS (6.9%); VSD, type 2 
(6.3%); cardiac, other (5.3%); and TOF (4.9%).8
• There were 16 920 procedures performed from 1998 to 2002 at 18 centers. In 
2002, there were 4208 procedures performed. The in-hospital mortality rate 
ranged from 5.7% in 1998 to 4.3% in 2002. Of these procedures, ≈46% were 
performed in children >1 year old, ≈32% in infants between 29 days and 1 year 
of age, and ≈22% in neonates (<29 days old). The conditions for which these 
procedures were most commonly performed were the following: patent ductus 
arteriosus (6.5%), VSD (6.4%), and TOF (6.0%).8
Heart Transplantations
(See Charts 23-3 and 23-4.)
In 2012, 2378 heart transplantations were performed in the United States (Chart 23-3). There 
are 247 transplant hospitals in the United States, 129 of which performed heart 
transplantations (based on Organ Procurement and Transplantation Network data as of April 
10, 2013).
• Of the recipients in 2012, 69.7% were male, and 65.9% were white; 19.6% were 
black, whereas 9.0% were Hispanic. Heart transplantations by recipient age are 
shown in Chart 23-4.
• As of April 11, 2013, for transplants that occurred between 2009 and 2010, the 
1-year survival rate was 90.8% for males and 90.6% for females; the 5-year rates 
between 2005 and 2010 were 77.5% for males and 75.6% for females; and the 
10-year rates between 2000 and 2010 were 58.9% for males and 57.6% for 
females. The 1-, 5-, and 10-year survival rates for white cardiac transplant 
patients were 91.2%, 79.1%, and 61.0%, respectively. For black patients, they 
were 88.3%, 68.6%, and 47.5%, respectively. For Hispanic patients, they were 
91.9%, 76.3%, and 59.7%, respectively.
• As of June 4, 2013, 3497 patients were on the transplant waiting list for a heart 
transplant, and 50 patients were on the list for a heart/lung transplant.
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Cardiovascular Healthcare Expenditures
An analysis of claims and enrollment data from the Continuous Medicare History Sample 
and from physician claims from 1995 to 2004 was used to evaluate the conditions that 
contributed to the most expensive 5% of Medicare beneficiaries.8
• Ischemic HD, CHF, and cerebrovascular disease, respectively, constituted 13.8%, 
5.9%, and 5.7% of the conditions of all beneficiaries in 2004. In patients in the 
top 5% overall for all expenditures, the respective figures were 39.1%, 32.7%, 
and 22.3% for these cardiovascular conditions.
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24. Economic Cost of Cardiovascular Disease
See Tables 24-1 and 24-2 and Charts 24-1 through 24-5.
The annual direct and indirect cost of CVD and stroke in the United States is an estimated 
$315.4 billion (Table 24-1; Chart 24-1). This figure includes $193.4 billion in expenditures 
(direct costs, which include the cost of physicians and other professionals, hospital services, 
prescribed medication, and home health care, but not the cost of nursing home care) and 
$122.0 billion in lost future productivity attributed to premature CVD and stroke mortality in 
2010 (indirect costs).
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The direct costs for CVD and stroke are the healthcare expenditures for 2010 available on 
the Web site of the nationally representative MEPS of the AHRQ.1 Details on the advantages 
or disadvantages of using MEPS data are provided in the “Heart Disease and Stroke 
Statistics–2011 Update.”2 Indirect mortality costs are estimated for 2010 by multiplying the 
number of deaths that year attributable to CVD and strokes, in age and sex groups, by 
estimates of the present value of lifetime earnings for those age and sex groups as of 2010. 
Mortality data are from the National Vital Statistics System of the NCHS.3 The present 
values of lifetime earnings are unpublished estimates furnished by the Institute on Health 
and Aging, University of California at San Francisco, by Wendy Max, PhD, on April 25, 
2012. Those estimates have a 3% discount rate, the recommended percentage.4 The discount 
rate removes the effect of inflation in income over the lifetime of earnings. The estimates are 
for 2009, inflated to 2010 by 3% to account for the 2009 to 2010 change in hourly worker 
compensation in the business sector reported by the US Bureau of Labor Statistics.5
The indirect costs exclude lost productivity costs attributable to CVD and stroke illness 
during 2010 among workers, people keeping house, people in institutions, and people unable 
to work. Those morbidity costs were substantial in very old studies, but an adequate update 
could not be made.
Most Costly Diseases
(See Table 24-2 and Chart 24-2.)
CVD and stroke accounted for 15% of total health expenditures in 2010, more than any 
major diagnostic group.1,6 That is also the case for indirect mortality costs. By way of 
comparison, CVD total direct and indirect costs shown in Table 24-1 are higher than the 
official National Cancer Institute estimates for cancer and benign neoplasms in 2008, which 
were cited as $228 billion total ($93 billion in direct costs, $19 billion in indirect morbidity 
costs, and $116 billion in indirect mortality costs).7
Table 24-2 shows direct and indirect costs for CVD by sex and by 2 broad age groups. Chart 
24-2 shows total direct costs for the 14 leading chronic diseases in the MEPS list. HD is the 
most costly condition.1
Abbreviations Used in Chapter 24
AHA American Heart Association
AHRQ Agency for Healthcare Research and Quality
CHD coronary heart disease
CHF congestive heart failure
COPD chronic obstructive pulmonary disease
CVD cardiovascular disease
GI gastrointestinal (tract)
HBP high blood pressure
HD heart disease
HF heart failure
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MEPS Medical Expenditure Panel Survey
NCHS National Center for Health Statistics
Projections
(See Charts 24-3 through 24-5.)
The AHA developed methodology to project future costs of care for HBP, CHD, HF, stroke, 
and all other CVD.8
• By 2030, 43.9% of the US population is projected to have some form of CVD.
• Between 2012 and 2030, total direct medical costs of CVD are projected to 
increase from $396 billion to $918 billion (2012 $ in billions). Of this total, 
60.5% is attributable to hospital costs, 15.6% to medications, 10.8% to 
physicians, 6.8 % to nursing home care, 5.3% to home health care, and 1.1% to 
other costs.
• Indirect costs (attributable to lost productivity) for all CVDs are estimated to 
increase from $183 billion in 2012 to $290 billion in 2030 (2012 $ in billions), 
an increase of 58%.
These data indicate that CVD prevalence and costs are projected to increase substantially.
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25. At-a-Glance Summary Tables
See Tables 25-1 through 25-4.
Sources: See the following summary tables and charts for complete details:
• Smoking—Table 3-1
• Physical activity —Table 4-1
• Overweight/obesity—Table 6-1; Chart 6-1
• Blood cholesterol—Table 8-1
• High blood pressure—Table 9-1
• Diabetes mellitus—Table 10-1
• Total cardiovascular diseases—Table 13-1
• Stroke—Table 14-1
• Congenital heart defects—Table 15-1
• Coronary heart disease—Table 18-1
• Heart failure—Table 19-1
26. Glossary
Age-adjusted rates Used mainly to compare the rates of ≥2 communities or population groups or the 
nation as a whole over time. The American Heart Association (AHA) uses a 
standard population (2000), so these rates are not affected by changes or 
differences in the age composition of the population. Unless otherwise noted, all 
death rates in this publication are age adjusted per 100 000 population and are 
based on underlying cause of death.
Agency for Healthcare Research 
and Quality (AHRQ)
A part of the US Department of Health and Human Services, this is the lead agency 
charged with supporting research designed to improve the quality of health care, 
reduce the cost of health care, improve patient safety, decrease the number of 
medical errors, and broaden access to essential services. The Agency for 
Healthcare Research and Quality sponsors and conducts research that provides 
evidence-based information on healthcare outcomes, quality, cost, use, and access. 
The information helps healthcare decision makers (patients, clinicians, health 
system leaders, and policy makers) make more informed decisions and improve the 
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quality of health-care services. The Agency for Healthcare Research and Quality 
conducts the Medical Expenditure Panel Survey (MEPS; ongoing).
Bacterial endocarditis An infection of the heart’s inner lining (endocardium) or of the heart valves. The 
bacteria that most often cause endocarditis are streptococci, staphylococci, and 
enterococci.
Body mass index (BMI) A mathematical formula to assess body weight relative to height. The measure 
correlates highly with body fat. It is calculated as weight in kilograms divided by 
the square of the height in meters (kg/m2).
Centers for Disease Control and 
Prevention/National Center for 
Health Statistics (CDC/NCHS)
CDC is an agency within the US Department of Health and Human Services. The 
CDC conducts the Behavioral Risk Factor Surveillance System (BRFSS), an 
ongoing survey. The CDC/NCHS conducts or has conducted these surveys (among 
others):
• National Health Examination Survey (NHES I, 1960–1962; NHES 
II, 1963–1965; NHES III, 1966–1970)
• National Health and Nutrition Examination Survey I (NHANES I; 
1971–1975)
• National Health and Nutrition Examination Survey II (NHANES II; 
1976–1980)
• National Health and Nutrition Examination Survey III (NHANES 
III; 1988–1994)
• National Health and Nutrition Examination Survey (NHANES; 1999 
to …) (ongoing)
• National Health Interview Survey (NHIS) (ongoing)
• National Hospital Discharge Survey (NHDS) (1965–2010)
• National Ambulatory Medical Care Survey (NAMCS) (ongoing)
• National Hospital Ambulatory Medical Care Survey (NHAMCS) 
(ongoing)
• National Nursing Home Survey (periodic)
• National Home and Hospice Care Survey (periodic)
• National Vital Statistics System (ongoing)
Centers for Medicare & 
Medicaid Services, formerly 
Health Care Financing 
Administration
The federal agency that administers the Medicare, Medicaid, and Child Health 
Insurance programs.
Comparability ratio Provided by the NCHS to allow time-trend analysis from one International 
Classification of Diseases (ICD) revision to another. It compensates for the 
“shifting” of deaths from one causal code number to another. Its application to 
mortality based on one ICD revision means that mortality is “comparability 
modified” to be more comparable to mortality coded to the other ICD revision.
Coronary heart disease (CHD) 
(ICD-10 codes I20–I25)
This category includes acute myocardial infarction (I21–I22), other acute ischemic 
(coronary) heart disease (I24), angina pectoris (I20), atherosclerotic cardiovascular 
disease (I25.0), and all other forms of chronic ischemic coronary heart disease 
(I25.1–I25.9).
Death rate The relative frequency with which death occurs within some specified interval of 
time in a population. National death rates are computed per 100 000 population. 
Dividing the total number of deaths by the total population gives a crude death rate 
for the total population. Rates calculated within specific subgroups, such as age-
specific or sex-specific rates, are often more meaningful and informative. They 
allow well-defined subgroups of the total population to be examined. Unless 
otherwise stated, all death rates in this publication are age adjusted and are per 100 
000 population.
Diseases of the circulatory 
system (ICD codes I00–I99)
Included as part of what the AHA calls “cardiovascular disease.” (“Total 
cardiovascular disease” in this Glossary.)
Diseases of the heart Classification the NCHS uses in compiling the leading causes of death. Includes 
acute rheumatic fever/chronic rheumatic heart diseases (I00–I09), hypertensive 
heart disease (I11), hypertensive heart and renal disease (I13), coronary heart 
disease (I20–I25), pulmonary heart disease and diseases of pulmonary circulation 
(I26–I28), heart failure (I50), and other forms of heart disease (I29–I49, I50.1–I51). 
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“Diseases of the heart” are not equivalent to “total cardiovascular disease,” which 
the AHA prefers to use to describe the leading causes of death.
Health Care Financing 
Administration
See Centers for Medicare & Medicaid Services.
Hispanic origin In US government statistics, “Hispanic” includes people who trace their ancestry to 
Mexico, Puerto Rico, Cuba, Spain, the Spanish-speaking countries of Central or 
South America, the Dominican Republic, or other Spanish cultures, regardless of 
race. It does not include people from Brazil, Guyana, Suriname, Trinidad, Belize, 
or Portugal, because Spanish is not the first language in those countries. Most of 
the data in this update are for Mexican Americans or Mexicans, as reported by 
government agencies or specific studies. In many cases, data for all Hispanics are 
more difficult to obtain.
Hospital discharges The number of inpatients (including newborn infants) discharged from short-stay 
hospitals for whom some type of disease was the first-listed diagnosis. Discharges 
include those discharged alive, dead, or “status unknown.”
International Classification of 
Diseases (ICD) codes
A classification system in standard use in the United States. The International 
Classification of Diseases is published by the World Health Organization. This 
system is reviewed and revised approximately every 10 to 20 years to ensure its 
continued flexibility and feasibility. The 10th revision (ICD-10) began with the 
release of 1999 final mortality data. The ICD revisions can cause considerable 
change in the number of deaths reported for a given disease. The NCHS provides 
“comparability ratios” to compensate for the “shifting” of deaths from one ICD 
code to another. To compare the number or rate of deaths with that of an earlier 
year, the “comparability-modified” number or rate is used.
Incidence An estimate of the number of new cases of a disease that develop in a population, 
usually in a 1-year period. For some statistics, new and recurrent attacks, or cases, 
are combined. The incidence of a specific disease is estimated by multiplying the 
incidence rates reported in community- or hospital-based studies by the US 
population. The rates in this report change only when new data are available; they 
are not computed annually.
Major cardiovascular diseases Disease classification commonly reported by the NCHS; represents ICD codes I00 
to I78. The AHA does not use “major cardiovascular diseases” for any calculations. 
See “Total cardiovascular disease” in this Glossary.
Metabolic syndrome Metabolic syndrome is defined* as the presence of any 3 of the following 5 
diagnostic measures: Elevated waist circumference (≥102 cm in men or ≥88 cm in 
women), elevated triglycerides (≥150 mg/dL [1.7 mmol/L] or drug treatment for 
elevated triglycerides), reduced high-density lipoprotein cholesterol (<40 mg/dL 
[0.9 mmol/L] in men, <50 mg/dL [1.1 mmol/L] in women, or drug treatment for 
reduced high-density lipoprotein cholesterol), elevated blood pressure (≥130 mm 
Hg systolic blood pressure, ≥85 mm Hg diastolic blood pressure, or drug treatment 
for hypertension), and elevated fasting glucose (≥100 mg/dL or drug treatment for 
elevated glucose).
Morbidity Incidence and prevalence rates are both measures of morbidity (ie, measures of 
various effects of disease on a population).
Mortality Mortality data for states can be obtained from the NCHS Web site (http://cdc.gov/
nchs/), by direct communication with the CDC/NCHS, or from the AHA on 
request. The total number of deaths attributable to a given disease in a population 
during a specific interval of time, usually 1 year, are reported. These data are 
compiled from death certificates and sent by state health agencies to the NCHS. 
The process of verifying and tabulating the data takes ≈2 years.
National Heart, Lung, and Blood 
Institute (NHLBI)
An institute in the National Institutes of Health in the US Department of Health and 
Human Services. The National Heart, Lung, and Blood Institute conducts such 
studies as the following:
• Framingham Heart Study (FHS; 1948 to …) (ongoing)
• Honolulu Heart Program (HHP) (1965–1997)
• Cardiovascular Health Study (CHS; 1988 to …) (ongoing)
• Atherosclerosis Risk in Communities (ARIC) study (1985 to …) 
(ongoing)
• Strong Heart Study (SHS) (1989–1992, 1991–1998)
• The National Heart, Lung, and Blood Institute also published reports 
of the Joint National Committee on Prevention, Detection, 
Evaluation, and Treatment of High Blood Pressure and the Third 
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Report of the Expert Panel on Detection, Evaluation, and Treatment 
of High Blood Cholesterol in Adults (Adult Treatment Panel III).
National Institute of 
Neurological Disorders and 
Stroke (NINDS)
An institute in the National Institutes of Health of the US Department of Health 
and Human Services. The National Institute of Neurological Disorders and Stroke 
sponsors and conducts research studies such as these:
• Greater Cincinnati/Northern Kentucky Stroke Study (GCNKSS)
• Rochester (Minnesota) Stroke Epidemiology Project
• Northern Manhattan Study (NOMAS)
• Brain Attack Surveillance in Corpus Christi (BASIC) Project
Physical activity Any bodily movement produced by the contraction of skeletal muscle that increases 
energy expenditure above a basal level.
Physical fitness The ability to perform daily tasks with vigor and alertness, without undue fatigue, 
and with ample energy to enjoy leisure-time pursuits and respond to emergencies. 
Physical fitness includes a number of components consisting of cardiorespiratory 
endurance (aerobic power), skeletal muscle endurance, skeletal muscle strength, 
skeletal muscle power, flexibility, balance, speed of movement, reaction time, and 
body composition.
Prevalence An estimate of the total number of cases of a disease existing in a population 
during a specified period. Prevalence is sometimes expressed as a percentage of 
population. Rates for specific diseases are calculated from periodic health 
examination surveys that government agencies conduct. Annual changes in 
prevalence as reported in this statistical update reflect changes in the population 
size. Changes in rates can be evaluated only by comparing prevalence rates 
estimated from surveys conducted in different years. Note: In the data tables, which 
are located in the different disease and risk factor categories, if the percentages 
shown are age adjusted, they will not add to the total.
Race and Hispanic origin Race and Hispanic origin are reported separately on death certificates. In this 
publication, unless otherwise specified, deaths of people of Hispanic origin are 
included in the totals for whites, blacks, American Indians or Alaska Natives, and 
Asian or Pacific Islanders according to the race listed on the decedent’s death 
certificate. Data for Hispanic people include all people of Hispanic origin of any 
race. See “Hispanic origin” in this Glossary.
Stroke (ICD-10 codes I60–I69) This category includes subarachnoid hemorrhage (I60); intracerebral hemorrhage 
(I61); other nontraumatic intracranial hemorrhage (I62); cerebral infarction (I63); 
stroke, not specified as hemorrhage or infarction (I64); occlusion and stenosis of 
pre-cerebral arteries not resulting in cerebral infarction (I65); occlusion and 
stenosis of cerebral arteries not resulting in cerebral infarction (I66); other 
cerebrovascular diseases (I67); cerebrovascular disorders in diseases classified 
elsewhere (I68); and sequelae of cerebrovascular disease (I69).
Total cardiovascular disease 
(ICD-10 codes I00–I99, Q20–
Q28)
This category includes rheumatic fever/rheumatic heart disease (I00–I09); 
hypertensive diseases (I10–I15); ischemic (coronary) heart disease (I20–I25); 
pulmonary heart disease and diseases of pulmonary circulation (I26–I28); other 
forms of heart disease (I30–I52); cerebrovascular disease (stroke) (I60–I69); 
atherosclerosis (I70); other diseases of arteries, arterioles, and capillaries (I71–I79); 
diseases of veins, lymphatics, and lymph nodes not classified elsewhere (I80–I89); 
and other and unspecified disorders of the circulatory system (I95–I99). When data 
are available, we include congenital cardiovascular defects (Q20–Q28).
Underlying cause of death or 
any-mention cause of death
These terms are used by the NCHS when defining mortality. Underlying cause of 
death is defined by the World Health Organization as “the disease or injury which 
initiated the chain of events leading directly to death, or the circumstances of the 
accident or violence which produced the fatal injury.” Contributing cause of death 
would be any other disease or condition that the decedent may also have had and 
that was reported on the death certificate but was not part of the chain of events 
leading directly to death.
*According to criteria established by the American Heart Association/National Heart, Lung, and Blood Institute and 
published in Circulation (Circulation. 2005;112:2735–2752).
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Chart 2-1. 
Prevalence (unadjusted) estimates for poor, intermediate, and ideal cardiovascular health for 
each of the 7 metrics of cardiovascular health in the American Heart Association 2020 goals 
among US children aged 12 to 19 years, National Health and Nutrition Examination Survey 
2009 to 2010.
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Chart 2-2. 
Age-standardized prevalence estimates for poor, intermediate, and ideal cardiovascular 
health for each of the 7 metrics of cardiovascular health in the American Heart Association 
2020 goals among US adults aged ≥20 years, National Health and Nutrition Examination 
Survey 2009 to 2010.
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Chart 2-3. 
Proportion (unadjusted) of US children aged 12 to 19 years meeting different numbers of 
criteria for ideal cardiovascular health, overall and by sex, National Health and Nutrition 
Examination Survey 2009 to 2010.
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Chart 2-4. 
Age-standardized prevalence estimates of US adults aged ≥20 years meeting different 
numbers of criteria for ideal cardiovascular health, overall and by age and sex subgroups, 
National Health and Nutrition Examination Survey 2009 to 2010.
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Chart 2-5. 
Age-standardized prevalence estimates of US adults aged ≥20 years meeting different 
numbers of criteria for ideal cardiovascular health, overall and in selected race subgroups 
from National Health and Nutrition Examination Survey 2009 to 2010.
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Chart 2-6. 
Prevalence estimates of meeting ≥5 criteria for ideal cardiovascular health among US adults 
aged ≥20 years (age standardized), overall and by sex and race, and US children aged 12 to 
19 years (unadjusted), by sex, National Health and Nutrition Examination Survey 2009 to 
2010.
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Chart 2-7. 
Age-standardized prevalence estimates of US adults meeting different numbers of criteria 
for ideal and poor cardiovascular health for each of the 7 metrics of cardiovascular health in 
the American Heart Association 2020 goals, among US adults aged ≥20 years, National 
Health and Nutrition Examination Survey 2009 to 2010.
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Chart 2-8. 
Age-standardized cardiovascular health status by US states, Behavioral Risk Factor 
Surveillance System, 2009. A, Age-standardized prevalence of population with ideal 
cardiovascular health by states. B, Age-standardized percentage of population with 0 to 2 
cardiovascular health metrics by states. C, Age-standardized mean score of cardiovascular 
health metrics by states. Reprinted from Fang et al2 with permission. Copyright © 2012, 
American Heart Association, Inc.
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Chart 2-9. 
Trends in prevalence (unadjusted) of meeting criteria for ideal cardiovascular health for each 
of the 7 metrics of cardiovascular health in the American Heart Association 2020 goals 
among US children aged 12 to 19 years, National Health and Nutrition Examination Survey 
(NHANES) 1999 to 2000 through 2009 to 2010. *Because of changes in the physical 
activity questionnaire between different cycles of the NHANES survey, trends over time for 
this indicator should be interpreted with caution and statistical comparisons should not be 
attempted. †Data for the Healthy Diet Score, based on a 2-day average intake, were only 
available for the 2005 to 2006, 2007 to 2008, and 2009 to 2010 NHANES cycles at the time 
of this analysis.
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Chart 2-10. 
Age-standardized trends in prevalence of meeting criteria for ideal cardiovascular health for 
each of the 7 metrics of cardiovascular health in the American Heart Association 2020 goals 
among US adults aged ≥20 years, National Health and Nutrition Examination Survey 
(NHANES) 1999 to 2000 through 2009 to 2010. *Because of changes in the physical 
activity questionnaire between different cycles of the NHANES survey, trends over time for 
this indicator should be interpreted with caution and statistical comparisons should not be 
attempted. †Data for the Healthy Diet Score, based on a 2-day average intake, were only 
available for the 2005 to 2006, 2007 to 2008, and 2009 to 2010 NHANES cycles at the time 
of this analysis.
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Chart 2-11. 
Prevalence of ideal, intermediate, and poor cardiovascular health metrics in 2006 (American 
Heart Association 2020 Impact Goals baseline year) and 2020 projections assuming current 
trends continue. The 2020 targets for each cardiovascular health metric assume a 20% 
relative increase in ideal cardiovascular health prevalence metrics and a 20% relative 
decrease in poor cardiovascular health prevalence metrics for men and women. Reprinted 
from Huffman et al3 with permission. Copyright © 2012, American Heart Association, Inc.
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Chart 2-12. 
US age-standardized death rates* attributable to CVD, 2000 to 2010. *Directly standardized 
to the age distribution of the 2000 US standard population. †Total CVD: International 
Classification of Diseases, 10th Revision (ICD-10) I00 to I99 and Q20 to Q28. §Stroke (all 
cerebrovascular disease): ICD-10 I60 to I69. ¶CHD: ICD-10 I20 to I25. **Other CVD: 
ICD-10 I00 to I15, I26 to I51, I70 to I78, I80 to I89, and I95 to I99. CHD indicates coronary 
heart disease; and CVD, cardiovascular disease. Source: Centers for Disease Control and 
Prevention, National Center for Health Statistics.5
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Chart 2-13. 
Incidence of cardiovascular disease according to the number of ideal health behaviors and 
health factors. Reprinted from Folsom et al7 with permission from Elsevier. Copyright © 
2011, American College of Cardiology Foundation.
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Chart 3-1. 
Prevalence (%) of students in grades 9 to 12 reporting current cigarette use by sex and race/
ethnicity (Youth Risk Behavior Surveillance System, 2011). NH indicates non-Hispanic. 
Data derived from MMWR: Morbidity and Mortality Weekly Report.3
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Chart 3-2. 
Prevalence (%) of current smoking for adults >18 years of age by race/ethnicity and sex 
(National Health Interview Survey: 2009–2011). All percentages are age adjusted. AIAN 
indicates American Indian/Alaska Native; and NH, non-Hispanic. *Includes both Hispanics 
and non-Hispanics. Data derived from Centers for Disease Control and Prevention/National 
Center for Health Statistics, Health Data Interactive.10
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Chart 4-1. 
Prevalence of students in grades 9 to 12 who did not participate in ≥60 minutes of physical 
activity on any day by race/ethnicity and sex (Youth Risk Behavior Surveillance: 2011). NH 
indicates non-Hispanic. Data derived from MMWR Surveillance Summaries.3
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Chart 4-2. 
Percentage of students in grades 9 to 12 who used a computer for ≥3 hours a day by race/
ethnicity and sex (Youth Risk Behavior Surveillance: 2011). NH indicates non-Hispanic. 
Data derived from MMWR Surveillance Summaries.3
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Chart 4-3. 
Prevalence of students in grades 9 to 12 who met currently recommended levels of physical 
activity during the past 7 days by race/ethnicity and sex (Youth Risk Behavior Surveillance: 
2011). “Currently recommended levels” was defined as activity that increased their heart 
rate and made them breathe hard some of the time for a total of ≥60 minutes per day on 5 of 
the 7 days preceding the survey. NH indicates non-Hispanic. Data derived from MMWR 
Surveillance Summaries.3
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Chart 4-4. 
Prevalence of children 6 to 19 years of age who attained sufficient moderate to vigorous 
physical activity to meet public health recommendations (≥60 minutes per day on 5 or more 
of the 7 days preceding the survey), by sex and age (National Health and Nutrition 
Examination Survey: 2003–2004). Source: Troiano et al.5
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Chart 4-5. 
Prevalence of meeting the aerobic guidelines of the 2008 Federal Physical Activity 
Guidelines among adults ≥18 years of age by race/ethnicity and sex (National Health 
Interview Survey: 2012). NH indicates non-Hispanic. Percentages are age adjusted. The 
aerobic guidelines of the 2008 Federal Physical Activity Guidelines recommend engaging in 
moderate leisure-time physical activity for ≥150 minutes per week or vigorous activity ≥75 
minutes per week or an equivalent combination. Source: Blackwell et al.7
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Chart 5-1. 
Age-adjusted trends in macronutrients and total calories consumed by US adults (20–74 
years of age), 1971 to 2008. Data derived from National Center for Health Statistics14 and 
Wright and Wang.55
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Chart 5-2. 
Per capita calories consumed from different beverages by US adults (≥19 years of age), 1965 
to 2010. Source: Nationwide Food Consumption Surveys (1965, 1977–1978) and National 
Health and Nutrition Examination Survey (1988–2010), based on data from Duffey and 
Popkin62 and Kit et al.69 The 2010 data were only analyzed for soda/cola and sweetened 
fruit drinks.
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Chart 5-3. 
Total US food expenditures away from home and at home, 1977 and 2007. Data derived 
from Davis and Saltos.66
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Chart 6-1. 
Prevalence of overweight and obesity among students in grades 9 through 12 by sex and 
race/ethnicity. NH indicates non-Hispanic. Data derived from Eaton et al (Table 101).72
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Chart 6-2. 
Age-adjusted prevalence of obesity in adults 20 to 74 years of age by sex and survey year 
(National Health Examination Survey: 1960–1962; National Health and Nutrition 
Examination Survey: 1971–1974, 1976–1980, 1988–1994, 1999–2002, and 2007–2010). 
Obesity is defined as body mass index of 30.0 kg/m2. Data derived from Health, United 
States, 2011 (National Center for Health Statistics).73
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Chart 6-3. 
Trends in the prevalence of obesity among US children and adolescents by age and survey 
year (National Health and Nutrition Examination Survey: 1971–1974, 1976–1980, 1988–
1994, 1999–2002, 2003–2006, and 2007–2010). Data derived from Health, United States, 
2011 (National Center for Health Statistics).73
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Chart 8-1. 
Trends in mean serum total cholesterol among adolescents 12 to 17 years of age by race, 
sex, and survey year (National Health and Nutrition Examination Survey: 1976–1980,* 
1988–1994,* 1999–2004, and 2005–2010). Values are in mg/dL. Mex. Am. indicates 
Mexican American; and NH, non-Hispanic. *Data for Mexican Americans not available. 
Source: National Center for Health Statistics and National Heart, Lung, and Blood Institute.
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Chart 8-2. 
Trends in mean serum total cholesterol among adults aged ≥20 years by race and survey year 
(National Health and Nutrition Examination Survey: 1988–1994, 1999–2002, 2003–2006, 
and 2007–2010). Values are in mg/dL. NH indicates non-Hispanic. Source: National Center 
for Health Statistics and National Heart, Lung, and Blood Institute.
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Chart 8-3. 
Age-adjusted trends in the prevalence of serum total cholesterol ≥200 mg/dL in adults ≥20 
years of age by sex, race/ethnicity, and survey year (National Health and Nutrition 
Examination Survey 2005–2006, 2007–2008, and 2009–2010). Mex. Am. indicates Mexican 
American; and NH, non-Hispanic.
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Chart 9-1. 
Prevalence of high blood pressure in adults ≥20 years of age by age and sex (National Health 
and Nutrition Examination Survey: 2007–2010). Hypertension is defined as systolic blood 
pressure ≥140 mm Hg or diastolic blood pressure ≥90 mm Hg, if the subject said “yes” to 
taking antihypertensive medication, or if the subject was told on 2 occasions that he or she 
had hypertension. Source: National Center for Health Statistics and National Heart, Lung, 
and Blood Institute.
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Chart 9-2. 
Age-adjusted prevalence trends for high blood pressure in adults ≥20 years of age by race/
ethnicity, sex, and survey (National Health and Nutrition Examination Survey: 1988–1994, 
1999–2004, and 2005–2010). NH indicates non-Hispanic. Source: National Center for 
Health Statics and National Heart, Lung and Blood Institute.
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Chart 9-3. 
Extent of awareness, treatment, and control of high blood pressure by race/ethnicity 
(National Health and Nutrition Examination Survey: 2007–2010). NH indicates non-
Hispanic. Source: National Center for Health Statistics and National Heart, Lung, and Blood 
Institute.
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Chart 9-4. 
Extent of awareness, treatment, and control of high blood pressure by age (National Health 
and Nutrition Examination Survey: 2007–2010). Source: National Center for Health 
Statistics and National Heart, Lung, and Blood Institute.
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Chart 9-5. 
Extent of awareness, treatment, and control of high blood pressure by race/ethnicity and sex 
(National Health and Nutrition Examination Survey: 2007–2010). NH indicates non-
Hispanic. Source: National Center for Health Statistics and National Heart, Lung, and Blood 
Institute.
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Chart 10-1. 
Age-adjusted prevalence of physician-diagnosed diabetes mellitus in adults ≥20 years of age 
by race/ethnicity and sex (National Health and Nutrition Examination Survey: 2007–2010). 
NH indicates non-Hispanic. Source: National Center for Health Statistics and National 
Heart, Lung, and Blood Institute.
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Chart 10-2. 
Age-adjusted prevalence of physician-diagnosed type 2 diabetes mellitus in adults ≥20 years 
of age by race/ethnicity and years of education (National Health and Nutrition Examination 
Survey: 2007–2010). NH indicates non-Hispanic. Source: National Center for Health 
Statistics and National Heart, Lung, and Blood Institute.
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Chart 10-3. 
Trends in diabetes mellitus prevalence in adults ≥20 years of age by sex (National Health 
and Nutrition Examination Survey: 1988–1994 and 2007–2010). Source: National Center for 
Health Statistics, National Heart, Lung, and Blood Institute.
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Chart 10-4. 
Diabetes mellitus awareness, treatment, and control in adults ≥20 years of age (National 
Health and Nutrition Examination Survey: 2007–2010). Source: National Heart, Lung, and 
Blood Institute.
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Chart 13-1. 
Prevalence of cardiovascular disease in adults ≥20 years of age by age and sex (National 
Health and Nutrition Examination Survey: 2007–2010). These data include coronary heart 
disease, heart failure, stroke, and hypertension. Source: National Center for Health Statistics 
and National Heart, Lung, and Blood Institute.
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Chart 13-2. 
Incidence of cardiovascular disease (coronary heart disease, heart failure, stroke, or 
intermittent claudication; does not include hypertension alone) by age and sex (Framingham 
Heart Study, 1980–2003). Source: National Heart, Lung, and Blood Institute.4
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Chart 13-3. 
Deaths attributable to diseases of the heart (United States: 1900–2010). See Glossary 
(Chapter 26) for an explanation of “diseases of the heart.” Note: In the years 1900 to 1920, 
the International Classification of Diseases codes were 77 to 80; for 1925, 87 to 90; for 1930 
to 1945, 90 to 95; for 1950 to 1960, 402 to 404 and 410 to 443; for 1965, 402 to 404 and 410 
to 443; for 1970 to 1975, 390 to 398 and 404 to 429; for 1980 to 1995, 390 to 398, 402, and 
404 to 429; and for 2000 to 2009, I00 to I09, I11, I13, and I20 to I51. Before 1933, data are 
for a death registration area and not the entire United States. In 1900, only 10 states were in 
the death registration area, and this increased over the years, so part of the increase in 
numbers of deaths is attributable to an increase in the number of states. Source: National 
Center for Health Statistics.
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Chart 13-4. 
Deaths attributable to cardiovascular disease (United States: 1900–2010). Cardiovascular 
disease (International Classification of Diseases, 10th Revision codes I00–I99) does not 
include congenital. Before 1933, data are for a death registration area and not the entire 
United States. Source: National Center for Health Statistics.
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Chart 13-5. 
Percentage breakdown of deaths attributable to cardiovascular disease (United States: 2010). 
Total may not add to 100 because of rounding. Coronary heart disease includes International 
Classification of Diseases, 10th Revision (ICD-10) codes I20 to I25; stroke, I60 to I69; heart 
failure, I50; high blood pressure, I10 to I15; diseases of the arteries, I70 to I78; and other, all 
remaining ICD-I0 I categories. *Not a true underlying cause. With any-mention deaths, heart 
failure accounts for 35% of cardiovascular disease deaths. Source: National Heart, Lung, and 
Blood Institute from National Center for Health Statistics reports and data sets.
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Chart 13-6. 
Cardiovascular disease (CVD) deaths vs cancer deaths by age (United States: 2010). CVD 
includes International Classification of Diseases, 10th Revision codes I00 to I99 and Q20 to 
Q28; cancer, C00 to C97. Source: National Center for Health Statistics.
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Chart 13-7. 
Cardiovascular disease (CVD) and other major causes of death: total, <85 years of age, and 
≥85 years of age. Deaths among both sexes, United States, 2010. Heart disease includes 
International Classification of Diseases, 10th Revision codes I00 to I09, I11, I13, and I20 to 
I51; stroke, I60 to I69; all other CVD, I10, I12, I15, and I70 to I99; cancer, C00 to C97; 
chronic lower respiratory disease (CLRD), J40 to J47; Alzheimer disease, G30; and 
accidents, V01 to X59 and Y85 to Y86. Source: National Center for Health Statistics and 
National Heart, Lung, and Blood Institute.
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Chart 13-8. 
Cardiovascular disease (CVD) and other major causes of death in males: total, <85 years of 
age, and ≥85 years of age. Deaths among males, United States, 2010. Heart disease includes 
International Classification of Diseases, 10th Revision codes I00 to I09, I11, I13, and I20 to 
I51; stroke, I60 to I69; all other CVD, I10, I12, I15, and I70 to I99; cancer, C00 to C97; 
chronic lower respiratory disease (CLRD), J40 to J47; and accidents, V01 to X59 and Y85 
to Y86. Source: National Center for Health Statistics and National Heart, Lung, and Blood 
Institute.
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Chart 13-9. 
Cardiovascular disease (CVD) and other major causes of death in females: total, <85 years 
of age, and ≥85 years of age. Deaths among females, United States, 2010. Heart disease 
includes International Classification of Diseases, 10th Revision codes I00 to I09, I11, I13, 
and I20 to I51; stroke, I60 to I69; all other CVD, I10, I12, I15, and I70 to I99; cancer, C00 to 
C97; chronic lower respiratory disease (CLRD), J40 to J47; and Alzheimer disease, G30. 
Source: National Center for Health Statistics and National Heart, Lung, and Blood Institute.
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Chart 13-10. 
Cardiovascular disease and other major causes of death for all males and females (United 
States: 2010). A indicates cardiovascular disease plus congenital cardiovascular disease 
(International Classification of Diseases, 10th Revision codes I00–I99 and Q20–Q28); B, 
cancer (C00–C97); C, accidents (V01–X59 and Y85–Y86); D, chronic lower respiratory 
disease (J40–J47); E, diabetes mellitus (E10–E14); and F, Alzheimer disease (G30). Source: 
National Center for Health Statistics and National Heart, Lung, and Blood Institute.
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Chart 13-11. 
Cardiovascular disease and other major causes of death for white males and females (United 
States: 2010). A indicates cardiovascular disease plus congenital cardiovascular disease 
(International Classification of Diseases, 10th Revision codes I00–I99 and Q20–Q28); B, 
cancer (C00–C97); C, accidents (V01–X59 and Y85–Y86); D, chronic lower respiratory 
disease (J40–J47); E, diabetes mellitus (E10–E14); and F, Alzheimer disease (G30). Source: 
National Center for Health Statistics and National Heart, Lung, and Blood Institute.
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Chart 13-12. 
Cardiovascular disease and other major causes of death for black males and females (United 
States: 2010). A indicates cardiovascular disease plus congenital cardiovascular disease 
(International Classification of Diseases, 10th Revision codes I00–I99 and Q20–Q28); B, 
cancer (C00–C97); C, accidents (V01–X59 and Y85–Y86); D, diabetes mellitus (E10–E14); 
E, chronic lower respiratory disease (J40–J47); F, nephritis (N00–N07, N17–N19, and N25–
N27). Source: National Center for Health Statistics and National Heart, Lung, and Blood 
Institute.
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Chart 13-13. 
Cardiovascular disease and other major causes of death for Hispanic or Latino males and 
females (United States: 2010). A indicates cardiovascular disease plus congenital 
cardiovascular disease (International Classification of Diseases, 10th Revision codes I00–I99 
and Q20–Q28); B, cancer (C00–C97); C, accidents (V01–X59 and Y85–Y86); D, diabetes 
mellitus (E10–E14); E, chronic lower respiratory disease (J40–J47); and F, nephritis (N00–
N07, N17–N19, and N25–N27). Number of deaths shown may be lower than actual because 
of underreporting in this population. Source: National Center for Health Statistics and 
National Heart, Lung, and Blood Institute.
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Chart 13-14. 
Cardiovascular disease and other major causes of death for Asian or Pacific Islander males 
and females (United States: 2010). “Asian or Pacific Islander” is a heterogeneous category 
that includes people at high cardiovascular disease risk (eg, South Asian) and people at low 
cardiovascular disease risk (eg, Japanese). More specific data on these groups are not 
available. A indicates cardiovascular disease plus congenital cardiovascular disease 
(International Classification of Diseases, 10th Revision codes I00–I99 and Q20–Q28); B, 
cancer (C00–C97); C, accidents (V01–X59 and Y85–Y86); D, diabetes mellitus (E10–E14); 
E, chronic lower respiratory disease (J40–J47); and F, influenza and pneumonia (J09–J18). 
Number of deaths shown may be lower than actual because of underreporting in this 
population. Source: National Center for Health Statistics and National Heart, Lung, and 
Blood Institute.
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Chart 13-15. 
Cardiovascular disease and other major causes of death for American Indian or Alaska 
Native males and females (United States: 2010). A indicates cardiovascular disease plus 
congenital cardiovascular disease (International Classification of Diseases, 10th Revision 
codes I00–I99 and Q20–Q28); B, cancer (C00–C97); C, accidents (V01–X59 and Y85–
Y86); D, diabetes mellitus (E10–E14); E, chronic liver disease (K70 and K73–K74); and F, 
chronic lower respiratory disease (J40–J47). Number of deaths shown may be lower than 
actual because of underreporting in this population. Source: National Center for Health 
Statistics and National Heart, Lung, and Blood Institute.
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Chart 13-16. 
Age-adjusted death rates for coronary heart disease (CHD), stroke, and lung and breast 
cancer for white and black females (United States: 2010). CHD includes International 
Classification of Diseases, 10th Revision codes I20 to I25; stroke, I60 to I69; lung cancer, 
C33 to C34; and breast cancer, C50. Source: National Center for Health Statistics and 
National Heart, Lung, and Blood Institute.
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Chart 13-17. 
Cardiovascular disease mortality trends for males and females (United States: 1979–2010). 
Cardiovascular disease excludes congenital cardiovascular defects (International 
Classification of Diseases [ICD], 10th Revision codes I00–I99). The overall comparability 
for cardiovascular disease between the ICD, 9th Revision codes (1979–1998) and ICD, 10th 
Revision codes (1999–2010) is 0.9962. No comparability ratios were applied. Source: 
National Center for Health Statistics and National Heart, Lung, and Blood Institute.
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Chart 13-18. 
US maps corresponding to state death rates (including the District of Columbia), 2010.
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Chart 13-19. 
Estimated average 10-year cardiovascular disease risk in adults 50 to 54 years of age 
according to levels of various risk factors (Framingham Heart Study). BP indicates blood 
pressure; and HDL, high-density lipoprotein. Data derived from D’Agostino et al.64
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Chart 13-20. 
Hospital discharges for cardiovascular disease (United States: 1970–2010). Hospital 
discharges include people discharged alive, dead, and “status unknown.” Source: National 
Center for Health Statistics and National Heart, Lung, and Blood Institute.
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Chart 13-21. 
Hospital discharges for the 10 leading diagnostic groups (United States: 2010). Source: 
National Hospital Discharge Survey/National Center for Health Statistics and National 
Heart, Lung, and Blood Institute.
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Chart 14-1. 
Prevalence of stroke by age and sex (National Health and Nutrition Examination Survey: 
2007–2010). Source: National Center for Health Statistics and National Heart, Lung, and 
Blood Institute.
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Chart 14-2. 
Annual age-adjusted incidence of first-ever stroke by race. Hospital plus out-of-hospital 
ascertainment, 1993 to 1994, 1999, and 2005. ICH indicates intracerebral hemorrhage; and 
SAH, subarachnoid hemorrhage. Data derived from Kleindorfer et al.11
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Chart 14-3. 
Annual rate of first cerebral infarction by age, sex, and race (Greater Cincinnati/Northern 
Kentucky Stroke Study: 1999). Rates for black men and women 45 to 54 years of age and 
for black men ≥75 years of age are considered unreliable. Source: unpublished data from the 
Greater Cincinnati/Northern Kentucky Stroke Study.
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Chart 14-4. 
Annual rate of all first-ever strokes by age, sex, and race (Greater Cincinnati/Northern 
Kentucky Stroke Study: 1999). Rates for black men and women 45 to 54 years of age and 
for black men ≥75 years of age are considered unreliable.
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Chart 14-5. 
Age-adjusted incidence of stroke/transient ischemic attack by race and sex, ages 45 to 74, 
Atherosclerosis Risk in Communities study cohort, 1987 to 2001. Data derived from the 
National Heart, Lung, and Blood Institute, Incidence and Prevalence: 2006 Chart Book.220
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Chart 14-6. 
Age-adjusted death rates for stroke by sex and race/ethnicity, 2010. Death rates for the 
American Indian/Alaska Native and Asian or Pacific Islander populations are known to be 
underestimated. Stroke includes International Classification of Diseases, 10th Revision 
codes I60 to I69 (cerebrovascular disease). Source: National Center for Health Statistics and 
National Heart, Lung, and Blood Institute.
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Chart 14-7. 
Stroke death rates, 2008 through 2010. Adults ≥35 years of age, by county. Rates are 
spatially smoothed to enhance the stability of rates in counties with small populations. 
International Classification of Diseases, 10th Revision codes for stroke: I60 to I69. Data 
source: National Vital Statistics System and the US Census Bureau.
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Chart 14-8. 
Estimated 10-year stroke risk in adults 55 years of age according to levels of various risk 
factors (Framingham Heart Study). AF indicates atrial fibrillation; and CVD, cardiovascular 
disease. Data derived from Wolf et al.221
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Chart 14-9. 
Proportion of patients dead 1 year after first stroke. Source: pooled data from the 
Framingham Heart Study, Atherosclerosis Risk in Communities study, and Cardiovascular 
Health Study of the National Heart, Lung, and Blood Institute.
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Chart 14-10. 
Proportion of patients dead within 5 years after first stroke. Source: pooled data from the 
Framingham Heart Study, Atherosclerosis Risk in Communities study, and Cardiovascular 
Health Study of the National Heart, Lung, and Blood Institute.
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Chart 14-11. 
Proportion of patients with recurrent stroke within 5 years after first stroke. Source: pooled 
data from the Framingham Heart Study, Atherosclerosis Risk in Communities study, and 
Cardiovascular Health Study of the National Heart, Lung, and Blood Institute.
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Chart 14-12. 
Trends in carotid endarterectomy and carotid stenting procedures (United States: 1980–
2010). Source: Nationwide Inpatient Sample, Healthcare Cost and Utilization Project, 
Agency for Healthcare Research and Quality.
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Chart 17-1. 
Prevalence (%) of coronary calcium: US adults 33 to 45 years of age. P<0.0001 across race-
sex groups. Data derived from Loria et al.5
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Chart 17-2. 
Prevalence (%) of coronary calcium: US adults 45 to 84 years of age. P<0.0001 across 
ethnic groups in both men and women. Data derived from Bild et al.6
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Chart 17-3. 
Hazard ratios (HR) for coronary heart disease (CHD) events associated with coronary 
calcium scores: US adults 45 to 84 years of age (reference group, coronary artery 
calcification [CAC]=0). All HRs P<0.0001. Major CHD events included myocardial 
infarction and death attributable to CHD; any CHD events included major CHD events plus 
definite angina or definite or probable angina followed by revascularization. Data derived 
from Detrano et al.9
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Chart 17-4. 
Hazard ratios (HR) for coronary heart disease events associated with coronary calcium 
scores: US adults (reference group, coronary artery calcification [CAC]=0 and Framingham 
Risk Score <10%). Coronary heart disease events included nonfatal myocardial infarction 
and death attributable to coronary heart disease. Data derived from Greenland et al.10
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Chart 17-5. 
Mean values of carotid intima-media thickness (IMT) for different carotid artery segments in 
younger adults by race and sex (Bogalusa Heart Study). Data derived from Urbina et al.25
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Chart 17-6. 
Mean values of carotid intima-media thickness (IMT) for different carotid artery segments in 
older adults, by race. Data derived from Manolio et al.32
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Chart 18-1. 
Prevalence of coronary heart disease by age and sex (National Health and Nutrition 
Examination Survey: 2007–2010). Source: National Center for Health Statistics and 
National Heart, Lung, and Blood Institute.
et al. Page 425
Circulation. Author manuscript; available in PMC 2017 April 28.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Chart 18-2. 
Prevalence of myocardial infarction by age and sex (National Health and Nutrition 
Examination Survey: 2007–2010). Myocardial infarction includes people who answered 
“yes” to the question of ever having had a heart attack or myocardial infarction. Source: 
National Center for Health Statistics and National Heart, Lung, and Blood Institute.
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Chart 18-3. 
Annual number of adults per 1000 having diagnosed heart attack or fatal coronary heart 
disease (CHD) by age and sex (Atherosclerosis Risk in Communities Surveillance: 2005–
2010 and Cardiovascular Health Study). These data include myocardial infarction (MI) and 
fatal CHD but not silent MI. Source: National Heart, Lung, and Blood Institute.
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Chart 18-4. 
Incidence of heart attack or fatal coronary heart disease by age, sex, and race 
(Atherosclerosis Risk in Communities Surveillance: 2005–2010). Source: National Heart, 
Lung, and Blood Institute.
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Chart 18-5. 
Incidence of myocardial infarction by age, sex, and race (Atherosclerosis Risk in 
Communities Surveillance: 2005-2010). Source: Unpublished data from Atherosclerosis 
Risk in Communities study, National Heart, Lung, and Blood Institute.
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Chart 18-6. 
Estimated 10-year coronary heart disease risk in adults 55 years of age according to levels of 
various risk factors (Framingham Heart Study). HDL-C indicates high-density lipoprotein-
cholesterol. Data derived from Wilson et al.59
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Chart 18-7. 
Prevalence of low coronary heart disease risk, overall and by sex (National Health and 
Nutrition Examination Survey: 1971–2006). Low risk is defined as systolic blood pressure 
<120 mm Hg and diastolic blood pressure <80 mm Hg; cholesterol <200 mg/dL; body mass 
index <25 kg/m2; currently not smoking cigarettes; and no prior myocardial infarction or 
diabetes mellitus. Source: Personal communication with the National Heart, Lung, and 
Blood Institute, June 28, 2007.
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Chart 18-8. 
Hospital discharges for coronary heart disease by sex (United States: 1970–2010). Hospital 
discharges include people discharged alive, dead, and “status unknown.” Source: National 
Hospital Discharge Survey/National Center for Health Statistics and National Heart, Lung, 
and Blood Institute.
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Chart 18-9. 
Prevalence of angina pectoris by age and sex (National Health and Nutrition Examination 
Survey: 2007–2010). Angina pectoris includes people who either answered “yes” to the 
question of ever having angina or angina pectoris or were diagnosed with Rose Angina. 
Source: National Center for Health Statistics and National Heart, Lung, and Blood Institute.
et al. Page 433
Circulation. Author manuscript; available in PMC 2017 April 28.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Chart 18-10. 
Incidence of angina pectoris (deemed uncomplicated on the basis of physician interview of 
patient) by age and sex (Framingham Heart Study 1986–2009). Data derived from National 
Heart, Lung, and Blood Institute.
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Chart 19-1. 
Prevalence of heart failure by sex and age (National Health and Nutrition Examination 
Survey: 2007–2010). Source: National Center for Health Statistics and National Heart, 
Lung, and Blood Institute.
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Chart 19-2. 
First acute decompensated heart failure annual event rates per 1000 (from ARIC Community 
Surveillance 2005–2010). Source: National Heart, Lung, and Blood Institute.
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Chart 19-3. 
Hospital discharges for heart failure by sex (United States: 1980–2010). Note: Hospital 
discharges include people discharged alive, dead, and status unknown. Source: National 
Hospital Discharge Survey/National Center for Health Statistics and National Heart, Lung, 
and Blood Institute.
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Chart 20-1. 
Rheumatic heart disease prevalence trends per 1000 people for each World Health 
Organization region: A, The Americas; B, Europe; C, Africa; D, Eastern Mediterranean; E, 
Western Pacific; and F, Southeast Asia. Reprinted from Seckeler and Hoke14 with 
permission of Dove Medical Press; permission conveyed through Copyright Clearance 
Center, Inc. Copyright © 2011, Seckeler and Hoke,
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Chart 21-1. 
Prevalence estimates for peripheral arterial disease in males by age and ethnicity. Amer. 
indicates American; and NH, non-Hispanic. Source: Reprinted from Allison et al1 with 
permission from Elsevier. Copyright © 2007, American Journal of Preventive Medicine.
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Chart 21-2. 
Prevalence estimates for peripheral arterial disease in females by age and ethnicity. Amer. 
indicates American; and NH, non-Hispanic. Source: Reprinted from Allison et al1 with 
permission from Elsevier. Copyright © 2007, American Journal of Preventive Medicine.
et al. Page 440
Circulation. Author manuscript; available in PMC 2017 April 28.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Chart 23-1. 
Trends in cardiovascular procedures, United States: 1979 to 2010. Note: Inpatient 
procedures only. PCI indicates percutaneous coronary intervention. Source: National 
Hospital Discharge Survey, National Center for Health Statistics, and National Heart, Lung, 
and Blood Institute.
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Chart 23-2. 
Number of surgical procedures in the 10 leading diagnostic groups, United States: 2010. 
Source: National Hospital Discharge Survey/National Center for Health Statistics and 
National Heart, Lung, and Blood Institute.
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Chart 23-3. 
Trends in heart transplantations (United Network for Organ Sharing: 1975–2012). Source: 
United Network for Organ Sharing, scientific registry data.
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Chart 23-4. 
Heart transplantations in the United States by recipient age, 2012. Source: Organ 
Procurement and Transplantation Network data as of April 11, 2013.
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Chart 24-1. 
Direct and indirect costs of cardiovascular disease (CVD) and stroke (in billions of dollars), 
United States, 2010. Source: Prepared by the National Heart, Lung, and Blood Institute.1,3
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Chart 24-2. 
The 22 leading diagnoses for direct health expenditures, United States, 2010 (in billions of 
dollars). COPD indicates chronic obstructive pulmonary disease; and GI, gastrointestinal 
tract. Source: National Heart, Lung, and Blood Institute; estimates are from the Medical 
Expenditure Panel Survey, Agency for Healthcare Research and Quality, and exclude 
nursing home costs.
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Chart 24-3. 
Projected total costs of cardiovascular disease (CVD), 2015 to 2030 (2012 $ in billions) in 
the United States. CHD indicates coronary heart disease; CHF, congestive heart failure; and 
HBP, high blood pressure. Unpublished data tabulated by the American Heart Association 
using methods described by Heidenreich et al.8
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Chart 24-4. 
Projected total (direct and indirect) costs of total cardiovascular disease by age (2012 $ in 
billions). Unpublished data tabulated by the American Heart Association using methods 
described by Heidenreich et al.8
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Chart 24-5. 
Projected direct costs of total cardiovascular disease by type of cost (2012 $ in billions). 
Unpublished data tabulated by the American Heart Association using methods described by 
Heidenreich et al.8
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Table 2-1
Definitions of Poor, Intermediate, and Ideal Cardiovascular Health for Each Metric in the AHA 2020 Goals
Level of Cardiovascular Health for Each Metric
Poor Intermediate Ideal
Current smoking
 Adults ≥20 y of age Yes Former ≥12 mo Never or quit >12 mo
 Children 12–19 y of age Tried during the prior 30 d … Never tried; never smoked whole 
cigarette
BMI*
 Adults ≥20 y of age ≥30 kg/m2 25–29.9 kg/m2 <25 kg/m2
 Children 2–19 y of age >95th percentile 85th–95th percentile <85th percentile
PA
 Adults ≥20 y of age None 1–149 min/wk moderate or 1–74 min/wk 
vigorous or 1–149 min/wk moderate 
+ 2×vigorous
≥150 min/wk moderate or ≥75 
min/wk vigorous or ≥150 min/wk 
moderate + 2×vigorous
 Children 12–19 y of age None >0 and <60 min of moderate or vigorous 
every day
≥60 min of moderate or vigorous 
every day
Healthy diet pattern, No. of components†
 Adults ≥20 y of age 0–1 2–3 4–5
 Children 5–19 y of age 0–1 2–3 4–5
Total cholesterol, mg/dL
 Adults ≥20 y of age ≥240 200–239 or treated to goal <200
 Children 6–19 y of age ≥200 170–199 <170
Blood pressure
 Adults ≥20 y of age SBP ≥140 mm Hg or DBP 
≥90 mm Hg
SBP 120–139 mm Hg or DBP 80–89 mm 
Hg or treated to goal
<120 mm Hg/<80 mm Hg
 Children 8–19 y of age >95th percentile 90th–95th percentile or SBP ≥120 mm Hg 
or DBP ≥80 mm Hg
<90th percentile
Fasting plasma glucose, mg/dL
 Adults ≥20 y of age ≥126 100–125 or treated to goal <100
 Children 12–19 y of age ≥126 100–125 <100
AHA indicates American Heart Association; BMI, body mass index; DBP, diastolic blood pressure; ellipses (. . .), data not available; PA, physical 
activity; and SBP, systolic blood pressure.
*
Represents appropriate energy balance, that is, appropriate dietary quantity and PA to maintain normal body weight.
†
In the context of a healthy dietary pattern that is consistent with a Dietary Approaches to Stop Hypertension [DASH]–type eating pattern, to 
consume ≥4.5 cups/d of fruits and vegetables, ≥2 servings/wk of fish, and ≥3 servings/d of whole grains and no more than 36 oz/wk of sugar-
sweetened beverages and 1500 mg/d of sodium.
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Table 2-3
Selected Secondary Metrics for Monitoring CVD, NHANES 2009 to 2010
In the Presence of CVD In the Absence of CVD
No.* % (SE)† No.* % (SE)†
Total 16 209 474 7.2 (0.4) 199 590 596 92.8 (0.4)
 CHD 6 916 012 3.2 (0.3)
 Stroke 5 717 759 2.7 (0.2)
 CHF 4 320 227 2.0 (0.3)
 Acute MI 6 929 905 3.2 (0.3)
Health behaviors
 Smoking
  Current smoker or smokers who quit <12 mo ago 3 127 273 37.2 (4.9) 40 760 066 20.1 (0.9)
 PA
  PA: intermediate or poor‡ 11 813 011 74.1 (5.1) 115 561 988 58.4 (1.5)
  PA: none 10 598 908 64.5 (5.5) 93 459 556 47.3 (1.2)
 Diet, No. of metrics
  Total diet score 0–3 of 5 12 665 860 100.0 (0.00) 161 370 154 99.7 (0.11)
  Total diet score 0–1 of 5 9 540 532 70.1 (4.69) 127 156 293 78.8 (1.42)
 Overweight/obesity
  Overweight or obese (BMI ≥25.0 kg/m2) 12 621 701 69.4 (4.1) 134 879 713 68.1 (1.3)
  Obese (BMI ≥30.0 kg/m2) 7 763 611 49.0 (5.2) 68 655 702 34.7 (1.0)
Health factors
 Hypertension
  Prevalence of BP ≥140/90 mm Hg or taking medications 10 591 170 51.0 (5.0) 53 523 895 28.5 (0.9)
  Awareness among those with hypertension 10 071 343 98.6 (0.3) 42 436 782 70.6 (3.2)
  Treatment those with hypertension 9 819 244 97.4 (0.4) 39 194 948 61.4 (2.9)
  BP control to <140/<90 mm Hg among treated 6 886 176 64.2 (9.5) 27 323 649 72.4 (2.4)
  BP control to <140/<90 mm Hg among hypertensive 6 886 176 62.3 (9.4) 27 323 649 43.3 (2.8)
 Hypercholesterolemia
  Prevalence of total cholesterol ≥240 mg/dL or taking medications 8 201 829 37.1 (4.2) 48 701 198 25.7 (0.7)
  Awareness among those with hypercholesterolemia 7 742 127 84.6 (8.0) 35 174 931 59.9 (2.6)
  Treatment among those with hypercholesterolemia 7 219 078 79.3 (8.5) 25 405 334 38.7 (2.4)
  Cholesterol control to <200 mg/dL among treated 6 659 732 95.0 (1.4) 22 804 724 90.4 (1.2)
  Cholesterol control to <200 mg/dL among hypercholesterolemia 6 659 732 75.0 (8.9) 22 804 724 34.7 (2.4)
 Diabetes mellitus
  Prevalence of fasting glucose ≥125 mg/dL or taking medications 4 769 759 15.2 (2.2) 21 078 443 10.3 (1.1)
  Awareness among diabetics 4 006 153 90.4 (2.3) 14 242 760 64.3 (4.6)
  Treatment among diabetics 3 935 446 87.1 (3.2) 13 391 291 58.4 (5.3)
  Blood glucose control among treated 1 527 151 32.6 (9.9) 5 878 676 45.0 (8.0)
  Blood glucose control among diabetics 1 527 151 27.2 (8.7) 5 878 676 25.5 (5.9)
BMI indicates body mass index; BP, blood pressure; CHD, coronary heart disease; CHF, congestive heart failure; CVD, cardiovascular disease; MI, 
myocardial infarction; NHANES, National Health and Nutrition Examination Survey; PA, physical activity; and SE, standard error.
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*Weighted sample size.
†Standardized to the age distribution of the 2000 US Standard population.
‡
Moderate <150 min/wk AND Vigorous <75 min/wk AND Combined <150 min/wk.
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Table 2-4
Evidence-Based Individual Approaches for Improving Health Behaviors and Health Factors in the Clinic 
Setting
• Set specific goals (Class IA). Set specific, proximal goals with the patient, including a personalized plan to achieve the goals (eg, 
over the next 3 mo, increase fish by 1 serving/wk, reduce smoking by half a pack per day, or walk 30 min 3 times per week).
• Establish self-monitoring (Class IA). Develop a strategy for self-monitoring, such as a dietary or physical activity diary or Web-
based or mobile applications.
• Schedule follow-up (Class IA). Schedule regular follow-up (in-person, telephone, written, and/or electronic), with clear frequency 
and duration of contacts, to assess success, reinforce progress, and set new goals as necessary.
• Provide feedback (Class IA). Provide feedback on progress toward goals, including using in-person, telephone, and/or electronic 
feedback.
• Increase self-efficacy (Class IA). Increase the patient’s perception that they can successfully change their behavior.*
• Use motivational interviewing† (Class IA). Use motivational interviewing when patients are resistant or ambivalent about 
behavior change.
• Provide long-term support (Class IB). Arrange long-term support from family, friends, or peers for behavior change, such as in 
other workplace, school, or community-based programs.
• Use a multicomponent approach (Class IA). Combine 2 or more of the above strategies into the behavior change efforts.
*
Examples of approaches include mastery experiences (set a reasonable, proximal goal that the person can successfully achieve); vicarious 
experiences (have the person see someone with similar capabilities performing the behavior, such as walking on a treadmill or preparing a healthy 
meal); physiological feedback (explain to the patient when a change in their symptoms is related to worse or improved behaviors); and verbal 
persuasion (persuade the person that you believe in their capability to perform the behavior).
†
Motivational interviewing represents use of individual counseling to explore and resolve ambivalence toward changing behavior. Major principles 
include fostering the person’s own awareness and resolution of their ambivalence, as well as their own self-motivation to change, in a partnership 
with the counselor or provider.
Modified from Artinian et al16 with permission. Copyright © 2010, American Heart Association, Inc.
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Table 2-5
Evidence-Based Healthcare Systems Approaches to Support and Facilitate Improvements in Health Behaviors 
and Health Factors17–21
• Electronic systems for scheduling and tracking initial visits and regular follow-up contacts for behavior change and treatments.
• Electronic medical records systems to help assess, track, and report on specific health behaviors (diet, PA, tobacco, body weight) 
and health factors (BP, cholesterol, glucose), as well as to provide feedback and the latest guidelines to providers.
• Practical paper or electronic toolkits for assessment of key health behaviors and health factors, including during, before, and after 
provider visits.
• Electronic systems to facilitate provision of feedback to patients on their progress during behavior change and other treatment 
efforts.
• Education and ongoing training for providers on evidence-based behavior change strategies, as well as the most relevant 
behavioral targets, including training on relevant ethnic and cultural issues.
• Integrated systems to provide coordinated care by multidisciplinary teams of providers, including physicians, nurse practitioners, 
dietitians, PA specialists, and social workers.
• Reimbursement guidelines and incentives that reward efforts to change health behaviors and health factors. Restructuring of 
practice goals and quality benchmarks to incorporate health behavior (diet, PA, tobacco, body weight) and health factor (BP, 
cholesterol, glucose) interventions and targets for both primary and secondary prevention.
BP indicates blood pressure; and PA, physical activity.
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Table 2-6
Summary of Evidence-Based Population Approaches for Improving Diet, Increasing Physical Activity, and 
Reducing Tobacco Use*
Diet
 Media and education Sustained, focused media and educational campaigns, using multiple modes, for increasing consumption of 
specific healthful foods or reducing consumption of specific less healthful foods or beverages, either alone (IIa 
B) or as part of multicomponent strategies (I B)†‡§
On-site supermarket and grocery store educational programs to support the purchase of healthier foods (IIa B)†
 Labeling and information Mandated nutrition facts panels or front-of-pack labels/icons as a means to influence industry behavior and 
product formulations (IIa B)†
 Economic incentives Subsidy strategies to lower prices of more healthful foods and beverages (I A)†
Tax strategies to increase prices of less healthful foods and beverages (IIa B)†
Changes in both agricultural subsidies and other related policies to create an infrastructure that facilitates 
production, transportation, and marketing of healthier foods, sustained over several decades (IIa B)†
 Schools Multicomponent interventions focused on improving both diet and physical activity, including specialized 
educational curricula, trained teachers, supportive school policies, a formal PE program, healthy food and 
beverage options, and a parental/family component (I A)†
School garden programs, including nutrition and gardening education and hands-on gardening experiences (IIa 
A)†
Fresh fruit and vegetable programs that provide free fruits and vegetables to students during the school day (IIa 
A)†
 Workplaces Comprehensive worksite wellness programs with nutrition, physical activity, and tobacco cessation/prevention 
components (IIa A)†
Increased availability of healthier food/beverage options and/or strong nutrition standards for foods and 
beverages served, in combination with vending machine prompts, labels, or icons to make healthier choices (IIa 
B)†
 Local environment Increased availability of supermarkets near homes (IIa B)†‡||
 Restrictions and mandates Restrictions on television advertisements for less healthful foods or beverages advertised to children (I B)†
Restrictions on advertising and marketing of less healthful foods or beverages near schools and public places 
frequented by youths (IIa B)†
General nutrition standards for foods and beverages marketed and advertised to children in any fashion, 
including on-package promotion (IIa B)†
Regulatory policies to reduce specific nutrients in foods (eg, trans fats, salt, certain fats) (I B)†§
Physical activity
 Labeling and information Point-of-decision prompts to encourage use of stairs (IIa A)†
 Economic incentives Increased gasoline taxes to increase active transport/commuting (IIa B)†
 Schools Multicomponent interventions focused on improving both diet and physical activity, including specialized 
educational curricula, trained teachers, supportive school policies, a formal PE program, serving of healthy food 
and beverage options, and a parental/family component (IIa A)†
Increased availability and types of school playground spaces and equipment (I B)†
Increased number of PE classes, revised PE curricula to increase time in at least moderate activity, and trained 
PE teachers at schools (IIa A/IIb A¶)†
Regular classroom physical activity breaks during academic lessons (IIa A)†§
 Workplaces Comprehensive worksite wellness programs with nutrition, physical activity, and tobacco cessation/prevention 
components (IIa A)†
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Structured worksite programs that encourage activity and also provide a set time for physical activity during 
work hours (IIa B)†
Improving stairway access and appeal, potentially in combination with “skip-stop” elevators that skip some 
floors (IIa B)†
Adding new or updating worksite fitness centers (IIa B)†
 Local environment Improved accessibility of recreation and exercise spaces and facilities (eg, building of parks and playgrounds, 
increasing operating hours, use of school facilities during nonschool hours) (IIa B)†
Improved land-use design (eg, integration and interrelationships of residential, school, work, retail, and public 
spaces) (IIa B)†
Improved sidewalk and street design to increase active commuting (walking or bicycling) to school by children 
(IIa B)†
Improved traffic safety (IIa B)†
Improved neighborhood aesthetics (to increase activity in adults) (IIa B)†
Improved walkability, a composite indicator that incorporates aspects of land-use mix, street connectivity, 
pedestrian infrastructure, aesthetics, traffic safety, and/or crime safety (IIa B)†
Smoking
 Media and education Sustained, focused media and educational campaigns to reduce smoking, either alone (IIa B) or as part of larger 
multicomponent population-level strategies (I A)†
 Labeling and information Cigarette package warnings, especially those that are graphic and health related (I B)†‡§
 Economic incentives Higher taxes on tobacco products to reduce use and fund tobacco control programs (I A)†‡§
 Schools and workplaces Comprehensive worksite wellness programs with nutrition, physical activity, and tobacco cessation/prevention 
components (IIa A)†
 Local environment Reduced density of retail tobacco outlets around homes and schools (I B)†
Development of community telephone lines for cessation counseling and support services (I A)†
 Restrictions and mandates Community (city, state, or federal) restrictions on smoking in public places (I A)†
Local workplace-specific restrictions on smoking (I A)†‡§
Stronger enforcement of local school-specific restrictions on smoking (IIa B)†
Local residence-specific restrictions on smoking (IIa B)†§
Partial or complete restrictions on advertising and promotion of tobacco products (I B)†
PE indicates physical education.
*
The specific population interventions listed here are either a Class I or IIa recommendation with an evidence grade of either A or B. The American 
Heart Association evidence grading system for class of recommendation and level of evidence is summarized in Table 2. Because implementation 
of population-level strategies does not require perfect evidence but rather consideration of risks versus benefits, associated costs, and alternate 
approaches, the absence of any specific strategy herein does not mean it should not also be considered for implementation. See the more detailed 
tables and text below for further information on the evidence for each of these interventions, as well as other strategies that were reviewed.
†At least some evidence from studies conducted in high-income Western regions and countries (eg, North America, Europe, Australia, New 
Zealand).
‡At least some evidence from studies conducted in high-income non-Western regions and countries (eg, Japan, Hong Kong, South Korea, 
Singapore).
§At least some evidence from studies conducted in low- or middle-income regions and countries (eg, Africa, China, Pakistan, India).
||
Based on cross-sectional studies only; only 2 longitudinal studies have been performed, with no significant relations seen.
¶
Evidence IIa A for improving physical activity; evidence IIb B for reducing adiposity.
Circulation. Author manuscript; available in PMC 2017 April 28.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
et al. Page 459
Reprinted from Mozaffarian et al17 with permission. Copyright © 2012, American Heart Association, Inc.
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Table 2-7
Reduction in BP Required to Increase Prevalence of Ideal BP Among Adults ≥20 Years of Age; NHANES 
2009 to 2010
%
Percent BP ideal among adults, 2009–2010 44.26
20% Relative increase 53.11
Percent of US adults whose BP would be ideal if population mean BP were lowered by*
 2 mm Hg 56.13
 3 mm Hg 59.49
 4 mm Hg 61.59
 5 mm Hg 65.31
Standardized to the age distribution of the 2000 US standard population.
BP indicates blood pressure; and NHANES, National Health and Nutrition Examination Survey.
*
Reduction in BP=(observed average systolic-X mm Hg) AND (observed average diastolic-X mm Hg).
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Table 2-8
AHA Advocacy and Policy Strategies Related to the 2020 Impact Goals for Ideal Cardiovascular Health
Measure of Cardiovascular Health Advocacy/Policy Solutions
Smoking status
 Ideal for cardiovascular health:
 Adults: Never smoked or quit more than a year ago
 Children: Never tried or never smoked a whole cigarette
Federal
• Support the full, authorized funding level for the FDA’s Center 
for Tobacco Products and advocate for comprehensive 
implementation of FDA regulation of tobacco.
• Implement clinical guidance and monitor health claims 
concerning smokeless tobacco and other “harm reduction” 
products.
• Support the Tobacco Tax Equity Act that closes tax loopholes to 
ensure that all tobacco products are taxed at levels similar to the 
current tax rate for cigarettes.
• Continue to advocate for ratification of WHO’s Framework 
Convention on Tobacco Control as part of the UN Political 
Declaration on Non-Communicable Diseases for implementation 
by all countries who are a party to the treaty.
State
• Establish, strengthen, and protect smoke-free air laws in 
compliance with the Fundamentals of Smokefree Workplace Laws 
guidelines.
• Support tobacco-free secondary school, college, university, and 
hospital campuses.
• Support significant increases in tobacco excise taxes on all 
tobacco products.
• Establish and protect sustainable funding for tobacco prevention 
and cessation programs to levels that meet or exceed the CDC 
recommendations.
• Provide comprehensive tobacco cessation benefits in Medicaid, 
Medicare, and private health insurance plans.
• Eliminate tobacco sales in pharmacies and other health-related 
institutions.
Physical activity
 Ideal for cardiovascular health:
 Adults: At least 150 min of moderate or 75 min of 
vigorous
 PA each week
 Children: >60 min of moderate to vigorous PA per day
Federal
• Preserve funding for Safe Routes to School and Complete Streets 
in transportation reauthorization.
• Include PA in nutrition education funding for the Farm Bill 
Supplemental Nutrition Assistance Program.
• Incorporate PA into electronic medical records.
• Support implementation of the National Physical Activity Plan.
• Increase the quality of physical education in schools and advocate 
for Physical Education for Progress grants to increase funding to 
schools to improve their PE programs.
• Advocate for regular revision and update of the Physical Activity 
Guidelines for Americans.
State
• Implement shared use of school facilities within the community 
and support the construction of school fitness facilities.
• Increase sports, recreational opportunities, parks, and green 
spaces in the community.
• Support efforts to design workplaces, communities, and schools 
around active living and integrate PA opportunities throughout the 
day.
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Measure of Cardiovascular Health Advocacy/Policy Solutions
• Provide safe routes to schools and school sites that offer walking/
biking options for more students.
• Support the creation of complete streets.
• Support the use of zoning policy to increase access to safe places 
for recreation.
• Create and maintain comprehensive worksite wellness programs.
• Support the creation and implementation, through legislation and 
regulation (including licensing), of PA standards for preschool, 
day care, and other out-of-school care programs.
• Require quality, more frequent PE in schools.
• Promote efforts within the school environment that will lead to 
increased PA.
BMI
 Ideal for cardiovascular health:
 Adults: between 18.5 and 25 kg/m2
 Children: between the 15th and 85th percentile
 Go to http://www.americanheart.org/obesitypolicy for 
additional policy resources
Federal
• Provide obesity counseling and treatment coverage in the 
healthcare environment.
• Provide robust surveillance and monitoring of obesity, diet, PA, 
and tobacco use.
State
• Provide robust coverage for guidelines-based prevention, 
diagnosis, and treatment of overweight and obesity in the 
healthcare environment.
• Implement and monitor strong local wellness policies in all 
schools.
• Ensure adequate funding and implementation of coordinated 
school health programs.
• Establish comprehensive obesity prevention strategies in early 
childhood and day care programs.
• Advocate for continued funding for obesity prevention research 
and work to ensure a strong evaluation component is a part of 
implementation of new laws and programs.
Healthy diet
 Ideal for cardiovascular health:
 In the context of a DASH-type dietary pattern, adults and 
children should achieve at least 4 of the 5 following key 
components of a healthy diet:
• Fruits and vegetables: >4.5 cups/d
• Fish: More than two 3.5-oz servings/wk 
(preferably oily fish)
• Fiber-rich whole grains (>1.1 g of fiber per 
10 g of carbohydrates): three 1-oz-equivalent 
servings per day
• Sodium: <1500 mg/d
• Sugar-sweetened beverages: <450 kcal (36 
oz) per week. Go to http://
www.americanheart.org/obesitypolicy for 
more specific policy resources
Federal
• Work to eliminate food deserts and improve access and 
affordability of healthy foods.
• Strengthen nutrition standards in schools for meals and 
competitive foods and in all government nutrition assistance or 
feeding programs.
• Improve food labeling to make the labels easier to read and 
convey more accurately the content of added sugars, trans fats, 
sodium, and whole grains in foods.
• Implement menu labeling in restaurants.
• Continue to support and monitor the removal of industrially 
produced trans fats from the food supply and ensure the use of 
healthy replacement oils.
• Restrict the marketing and advertising of unhealthy food to 
children.
• Support robust implementation of nutrition education and 
promotion in schools.
• Reduce added sugar and sodium in the food supply.
• Support the implementation and dissemination of procurement 
standards across federal agencies.
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Measure of Cardiovascular Health Advocacy/Policy Solutions
• Ensure that diet counseling is a covered benefit in Medicare.
State
• Support the implementation of the reauthorization of the Federal 
Childhood Nutrition Act and new regulations concerning 
competitive foods and beverages and use all available techniques, 
including legislation, to encourage schools to take advantage of 
opportunities to provide even healthier options for children.
• Support improvements in the school food environment just 
outside of school property, including corner stores and food 
trucks.
• Support the creation and implementation of nutrition standards, 
through legislation and regulation (including licensing), for 
preschool and day care and other out-of-school care program 
meals.
• Support opportunities for greater nutrition education in schools. 
Support opportunities to expand the availability of fruits, 
vegetables, and water, including policies that support expansion of 
school gardens and farm-to-school programs.
• Support strategies that reduce sodium in the food supply.
• Reduce trans fats in packaged foods, baked goods, restaurant 
meals, and school meal programs.
• Support the elimination of food deserts through policies such as 
Healthy Food Financing that increase the availability of fruits, 
vegetables, and water in underserved neighborhoods.
• Support the establishment of food procurement policies that meet 
the AHA or federal guidelines for government offices.
• Support policies identified to reduce children’s exposure to 
marketing and advertising for unhealthy food.
• Support policies that change relative prices of healthy versus 
unhealthy food items.
• Support on a pilot basis the taxation of sugar-sweetened beverages 
to assess impact on health and consumer behavior, including 6 
minimum criteria (at least a portion of the money is dedicated for 
HD and stroke prevention and/or obesity prevention; the tax is 
structured so as to result in an increase in price for sugar-
sweetened beverages; tax is at least 1 cent/ oz; there is money 
dedicated for evaluation with guidance that ensures rigorous 
evaluation, including health outcomes; there is a standard 
definition of “sugar-sweetened beverage”; and there is no sunset).
• Support policies designed to encourage retailers to increase access 
to healthy foods while decreasing access to unhealthy foods.
• Expand state participation in the Department of Defense Fresh 
Fruit and Vegetable program.
Total cholesterol
 Ideal for cardiovascular health:
 Adults: Total cholesterol <200 mg/dL
 Children: <170 mg/dL
Federal and state
• Partner with Department of Health and Human Services to 
promote the Million Hearts Campaign through increased public 
awareness and partnership engagement, science and evaluation, 
clinical care improvement, patient outreach, and public policy.
• Ensure adequate healthcare coverage for prevention and treatment 
of dyslipidemia.
• Secure and protect dedicated state appropriations aligned with HD 
and stroke priorities, and work to support appropriate program 
implementation. Support other public health initiatives and 
evaluation targeted at HD, stroke, and related risk factors, as well 
as the disparities that exist in these areas.
Blood pressure
 Ideal for cardiovascular health:
Federal
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Measure of Cardiovascular Health Advocacy/Policy Solutions
 Adults: <120/80 mm Hg
 Children: <90th percentile
• Partner with the Department of Health and Human Services to 
promote the Million Hearts Campaign, as above.
• Implement the Institute of Medicine’s recommendations to reduce 
sodium in the food supply.
• Improve food labeling to increase consumer understanding of 
sodium levels in packaged foods.
• Advocate for robust sodium limits in procurement standards, 
nutrition standards in schools, and other government feeding 
programs.
State
• Promote public funding for heart disease and stroke prevention 
programs.
• Ensure the availability of essential CVD preventive benefits in 
private insurance and public health programs.
Fasting plasma glucose
 Ideal for cardiovascular health:
 Children and adults: Fasting blood glucose <100 mg/dL
Federal and state
• Ensure adequate healthcare coverage for early treatment and 
prevention of diabetes mellitus.
For AHA advocacy resources, including fact sheets, policy briefs, published papers, and position statements, go to http://www.heart.org/
HEARTORG/Advocate/PolicyResources/Policy-Resources_UCM_001135_SubHomePage.jsp. At the time of press of this document, the AHA was 
in the process of updating its strategic policy agenda for 2014–2017.
AHA indicates American Heart Association; BMI, body mass index; CDC, Centers for Disease Control and Prevention; CVD, cardiovascular 
disease; DASH, Dietary Approaches to Stop Hypertension; FDA, US Food and Drug Administration; HD, heart disease; PA, physical activity; PE, 
physical education; UN, United Nations; and WHO, World Health Organization.
Circulation. Author manuscript; available in PMC 2017 April 28.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
et al. Page 465
Table 3-1
Cigarette Smoking
Population Group Prevalence, 2012 Age ≥18 y*6 Cost18
Both sexes 42 098 000 (18.1%) $193 Billion per year
Males 22 983 000 (20.5%) …
Females 19 115 000 (15.9%) …
NH white males 22.0% …
NH white females 19.2% …
NH black males 21.6% …
NH black females 14.2% …
Hispanic or Latino males 16.6% …
Hispanic or Latino females 7.5% …
Asian only (both sexes) 10.4% …
American Indian/Alaska Native only (both sexes) 18.8% …
Percentages are age adjusted. Estimates for Asian only and American Indian/Alaska Native only include non-Hispanic and Hispanic persons.
Ellipses (…) indicate data not available; and NH, non-Hispanic.
*
Rounded to the nearest thousand.
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Table 4-1
Met 2008 Federal PA Guidelines for Adults
Population Group Prevalence, 2012 (Age ≥18 y), %
Both sexes 20.7
Males 24.6
Females 17.1
NH white only 22.9
NH black only 16.6
Hispanic or Latino 15.7
American Indian/Alaska Native only 18.7
Asian only 17.1
“Met 2008 federal PA guidelines for adults” is defined as engaging in ≥150 min of moderate or 75 min of vigorous aerobic leisure-time physical 
activity per wk (or an equivalent combination) and engaging in leisure-time strengthening physical activity at least twice a wk.
Data are age adjusted for adults ≥18 y of age.
PA indicates physical activity; NH, non-Hispanic.
Source: National Health Interview Survey 2012 (National Center for Health sStatistics).7
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Table 7-1
OR for Combinations of Parental Heart Attack History
OR (95% CI)
No family history 1.00
One parent with heart attack ≥50 y of age 1.67 (1.55–1.81)
One parent with heart attack <50 y of age 2.36 (1.89–2.95)
Both parents with heart attack ≥50 y of age 2.90 (2.30–3.66)
Both parents with heart attack, one <50 y of age 3.26 (1.72–6.18)
Both parents with heart attack, both <50 y of age 6.56 (1.39–30.95)
CI indicates confidence interval; OR, odds ratio.
Data derived from Chow et al.4
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Table 7-2
Validated SNPs for CAD, the Nearest Gene, and the OR From the CARDIoGRAMplusC4D Consortium
SNP Chromosome Gene Effect Size (OR) Effect Allele Frequency
rs602633 1 SORT1 1.12 0.77
rs17464857 1 MIA3 1.05 0.87
rs17114036 1 PPAP2B 1.11 0.91
rs11206510 1 PCSK9 1.06 0.84
rs4845625 1 IL6R 1.04 0.47
rs6725887 2 WDR12 1.12 0.11
rs515135 2 APOB 1.08 0.82
rs2252641 2 ZEB2-AC074093.1 1.04 0.46
rs1561198 2 VAMP5-VAMP8-GGCX 1.05 0.45
rs6544713 2 ABCG5-ABCG8 1.06 0.30
rs9818870 3 MRAS 1.07 0.14
rs7692387 4 GUCY1A3 1.06 0.81
rs1878406 4 EDNRA 1.06 0.15
rs273909 5 SLC22A4-SLC22A5 1.09 0.14
rs12205331 6 ANKS1A 1.04 0.81
rs9369640 6 PHACTR1 1.09 0.65
rs12190287 6 TCF21 1.07 0.59
rs3798220 6 LPA 1.28 0.01
rs10947789 6 KCNK5 1.06 0.76
rs4252120 6 PLG 1.06 0.73
rs11556924 7 ZC3HC1 1.08 0.65
rs12539895 7 - 1.08 0.19
rs2023938 7 HDAC9 1.07 0.10
rs264 8 LPL 1.05 0.86
rs2954029 8 TRIB1 1.04 0.55
rs1333049 9 CDKN2A, CDKN2B 1.23 0.47
rs579459 9 ABO 1.07 0.21
rs2505083 10 KIAA1462 1.06 0.42
rs501120 10 CXCL12 1.07 0.83
rs12413409 10 CYP17A1-CNNM2-NT5C2 1.10 0.89
rs2246833 10 LIPA 1.06 0.38
rs9326246 11 ZNF259-APOA5-A4-C3-A1 1.09 0.10
rs974819 11 PDGFD 1.07 0.29
rs3184504 12 SH2B3 1.07 0.40
rs4773144 13 COL4A1-COL4A2 1.07 0.42
rs9319428 13 FLT1 1.05 0.32
rs2895811 14 HHIPL1 1.06 0.43
rs7173743 15 ADAMTS7 1.07 0.58
rs17514846 15 FURIN-FES 1.05 0.44
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SNP Chromosome Gene Effect Size (OR) Effect Allele Frequency
rs2281727 17 SMG6-SRR 1.05 0.36
rs12936587 17 RASD1-SMCR3-PEMT 1.06 0.59
rs15563 17 UBE2Z-GIP-ATP5G1-SNF8 1.04 0.52
rs1122608 19 LDLR 1.10 0.76
rs2075650 19 ApoE-ApoC1 1.11 0.14
rs9982601 21 KCNE2 1.13 0.13
CAD indicates coronary artery disease; CARDIoGRAMplusC4D, Coronary Artery Disease Genome-wide Replication and Meta-analysis 
(CARDIOGRAM) plus the Coronary Artery Disease (C4D) Genetics Consortium; OR, odds ratio; and SNP, single-nucleotide polymorphism.
Data derived from Deloukas et al.9
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Table 7-3
Heritability of CVD Risk Factors From the FHS
Trait Heritability
ABI 0.2124
SBP 0.4225
DBP 0.3925
Left ventricular mass 0.24 to 0.3226
BMI 0.37 (mean age 40 y) to 0.52 (mean age 60 y)27
Waist circumference 0.4128
Visceral abdominal fat 0.3629
Subcutaneous abdominal fat 0.5729
Fasting glucose 0.3430
HbA1c 0.2730
Triglycerides 0.4831
HDL cholesterol 0.5231
Total cholesterol 0.5731
LDL cholesterol 0.5931
Estimated GFR 0.3332
ABI indicates ankle-brachial index; BMI, body mass index; CVD, cardiovascular disease; DBP, diastolic blood pressure; FHS, Framingham Heart 
Study; GFR, glomerular filtration rate; HbA1c, glycosylated hemoglobin; HDL, high-density lipoprotein; LDL, low-density lipoprotein; and SBP, 
systolic blood pressure.
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Table 8-1
High Total and LDL Cholesterol and Low HDL Cholesterol
Population Group
Prevalence of Total 
Cholesterol ≥200 
mg/dL, 2010 Age ≥20 y
Prevalence of Total 
Cholesterol ≥240 
mg/dL, 2010 Age ≥20 y
Prevalence of LDL 
Cholesterol ≥130 
mg/dL, 2010 Age ≥20 y
Prevalence of HDL 
Cholesterol <40 
mg/dL, 2010 Age ≥20 y
Both sexes, n (%)* 98 900 000 (43.4) 31 900 000 (13.8) 71 000 000 (31.1) 48 700 000 (21.8)
Males, n (%)* 45 300 000 (41.3) 14 000 000 (12.7) 35 200 000 (31.9) 34 600 000 (31.8)
Females, n (%)* 53 600 000 (44.9) 17 900 000 (14.7) 35 800 000 (30.0) 14 100 000 (12.3)
NH white males, % 40.5 12.3 30.1 33.1
NH white females, % 45.8 15.6 29.3 12.4
NH black males, % 38.6 10.8 33.1 20.3
NH black females, % 40.7 11.7 31.2 10.2
Mexican-American males, % 48.1 15.2 39.9 34.2
Mexican-American females, % 44.7 13.5 30.4 15.1
Prevalence of total cholesterol ≥200 mg/dL includes people with total cholesterol ≥240 mg/dL. In adults, levels of 200 to 239 mg/dL are considered 
borderline high. Levels of ≥240 mg/dL are considered high.
HDL indicates high-density lipoprotein; LDL, low-density lipoprotein; and NH, non-Hispanic.
*
Total data for total cholesterol are for Americans ≥20 y of age. Data for LDL cholesterol, HDL cholesterol, and all racial/ethnic groups are age 
adjusted for age ≥20 y.
Source for total cholesterol ≥200 mg/dL, ≥240 mg/dL, LDL, and HDL: National Health and Nutrition Examination Survey (2007–2010), National 
Center for Health Statistics, and National Heart, Lung, and Blood Institute. Estimates from National Health and Nutrition Examination Survey 
2007 to 2010 (National Center for Health Statistics) were applied to 2010 population estimates.
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Table 9-1
High Blood Pressure
Population Group
Prevalence, 2010, Age 
≥20 y
Mortality,* 2010, All 
Ages
Hospital 
Discharges, 2010, 
All Ages Estimated Cost, 2010
Both sexes 77 895 000 (33.0%) 63 119 488 000 $46.4 Billion
Males 37 195 000 (33.6%) 28 373 (45.0%)† 216 000 …
Females 40 700 000 (32.2%) 34 746 (55.0%)† 272 000 …
NH white males 33.4% 20 819 … …
NH white females 30.7% 26 798 … …
NH black males 42.6% 6670 … …
NH black females 47.0% 6923 … …
Mexican American males 30.1% … … …
Mexican American females 28.8% … … …
Asian 21.2%‡ 1578§ … …
American Indian or Alaska Native 24.8%‡ 331 … …
Hypertension is defined in terms of National Health and Nutrition Examination Survey blood pressure measurements and health interviews. A 
subject was considered hypertensive if systolic blood pressure was ≥140 mm Hg or diastolic blood pressure was ≥90 mm Hg, if the subject said 
“yes” to taking antihypertensive medication, or if the subject was told on 2 occasions that he or she had hypertension.
Ellipses (…) indicate data not available; NH, non-Hispanic.
*
Mortality data for the white, black, Asian or Pacific Islander, and American Indian or Alaska Native populations include deaths among people of 
Hispanic and non-Hispanic origin. Numbers of deaths for the American Indian or Alaska Native and Asian or Pacific Islander populations are 
known to be underestimated.
†
These percentages represent the portion of total high blood pressure mortality that is for males vs females.
‡National Health Interview Survey (2010), National Center for Health Statistics; data are weighted percentages for Americans ≥18 y of age. 
Source: Blackwell et al.22
§
Includes Chinese, Filipino, Hawaiian, Japanese, and other Asian or Pacific Islander.
Sources: Prevalence: National Health and Nutrition Examination Survey (2007–2010), National Center for Health Statistics, and National Heart, 
Lung, and Blood Institute. Percentages for racial/ethnic groups are age adjusted for Americans ≥20 y of age. Age-specific percentages are 
extrapolated to the 2010 US population estimates. Mortality: Centers for Disease Control and Prevention/National Center for Health Statistics, 
2010 Mortality Multiple Cause-of-Death–United States, version dated May 28, 2013. These data represent underlying cause of death only. Hospital 
discharges: National Hospital Discharge Survey, National Center for Health Statistics; data include those discharged alive, dead, or status unknown. 
Cost: Medical Expenditure Panel Survey data include estimated direct costs for 2010; indirect costs calculated by National Heart, Lung, and Blood 
Institute for 2010.
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Table 12-1
BP and the Adjusted Risk of ESRD Among 316 675 Adults Without Evidence of Baseline Kidney Disease
JNC V BP Category Adjusted RR (95% CI)
Optimal 1.00 (Reference)
Normal, not optimal 1.62 (1.27–2.07)
High normal 1.98 (1.55–2.52)
Hypertension
 Stage 1 2.59 (2.07–3.25)
 Stage 2 3.86 (3.00–4.96)
 Stage 3 3.88 (2.82–5.34)
 Stage 4 4.25 (2.63–6.86)
BP indicates blood pressure; CI, confidence interval; ESRD, end-stage renal disease; JNC V, fifth report of the Joint National Committee on 
Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; and RR, relative risk.
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Table 12-2
Multivariable Association Between BMI and Risk of ESRD Among 320 252 Adults
BMI, kg/m2 Adjusted RR (95% CI)
18.5–24.9 (Normal weight) 1.00 (Reference)
25.0–29.9 (Overweight) 1.87 (1.64–2.14)
30.0–34.9 (Class I obesity) 3.57 (3.05–4.18)
35.0–39.9 (Class II obesity) 6.12 (4.97–7.54)
≥40.0 (Extreme obesity) 7.07 (5.37–9.31)
BMI indicates body mass index; CI, confidence interval; ESRD, end-stage renal disease; and RR, relative risk.
Circulation. Author manuscript; available in PMC 2017 April 28.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
et al. Page 482
Table 12-3
Adjusted HR for Death of Any Cause, Cardiovascular Events, and Hospitalization Among 1 120 295 
Ambulatory Adults, According to eGFR*
eGFR, mL·min−1·1.73 m−2
Adjusted HR (95% CI)
Death of Any Cause Any Cardiovascular Event Any Hospitalization
≥60† 1.00 1.00 1.00
45–59 1.2 (1.1–1.2) 1.4 (1.4–1.5) 1.1 (1.1–1.1)
30–44 1.8 (1.7–1.9) 2.0 (1.9–2.1) 1.5 (1.5–1.5)
15–29 3.2 (3.1–3.4) 2.8 (2.6–2.9) 2.1 (2.0–2.2)
<15 5.9 (5.4–6.5) 3.4 (3.1–3.8) 3.1 (3.0–3.3)
CI indicates confidence interval; eGFR, estimated glomerular filtration rate; and HR, hazard ratio.
*
The analyses were adjusted for age, sex, income, education, use or nonuse of dialysis, and presence or absence of prior coronary heart disease, 
prior chronic heart failure, prior ischemic stroke or transient ischemic attack, prior peripheral arterial disease, diabetes mellitus, hypertension, 
dyslipidemia, a serum albumin level of ≤3.5 g/dL, dementia, cirrhosis or chronic liver disease, chronic lung disease, documented proteinuria, and 
prior hospitalizations.
†
This group served as the reference group.
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Table 13-1
Cardiovascular Diseases
Population Group Prevalence, 2010: Age ≥20 y Mortality, 2010: All Ages*
Hospital Discharges, 
2010: All Ages Cost, 2010
Both sexes 83 600 000 (35.3%) 787 650 5 802 000 $315.4 Billion
 Males 40 700 000 (36.7%) 387 318 (49.2%)† 3 021 000 …
 Females 42 900 000 (34.0%) 400 332 (50.8%)† 2 781 000 …
NH white males 36.6% 330 330 … …
NH white females 32.4% 342 581 … …
NH black males 44.4% 46 266 … …
NH black females 48.9% 49 977 … …
Mexican American males 33.4% … … …
Mexican American females 30.7% … … …
Asian or Pacific Islander … 16 829‡ … …
American Indian or Alaska Native … 3667 … …
Ellipses (…) indicate data not available; NH, non-Hispanic.
*
Mortality data for the white, black, Asian or Pacific Islander, and American Indian or Alaska Native populations include deaths among people of 
Hispanic and non-Hispanic origin. Numbers of deaths for the American Indian or Alaska Native and Asian or Pacific Islander populations are 
known to be underestimated.
†
These percentages represent the portion of total cardiovascular disease mortality that is attributable to males vs females.
‡
Includes Chinese, Filipino, Hawaiian, Japanese, and other Asian or Pacific Islander.
Sources: Prevalence: National Health and Nutrition Examination Survey 2007 to 2010, National Center for Health Statistics (NCHS) and National 
Heart, Lung, and Blood Institute (NHLBI). Percentages for racial/ethnic groups are age adjusted for Americans ≥20 y of age. Age-specific 
percentages are extrapolated to the 2010 US population estimates. Mortality: Centers for Disease Control and Prevention/NCHS, 2010 Mortality 
Multiple Cause-of-Death–United States, version dated May 21, 2013. These data represent underlying cause of death only for International 
Classification of Diseases, 10th Revision codes I00 to I99 (diseases of the circulatory system) and Q20 to Q28 (congenital malformations of the 
circulatory system). Hospital discharges: National Hospital Discharge Survey, NCHS. Data include those inpatients discharged alive, dead, or of 
unknown status. Cost: NHLBI. Data include estimated direct and indirect costs for 2010.
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Table 13-4
Remaining Lifetime Risks for CVD and Other Diseases Among Men and Women Free of Disease at 40 and 70 
Years of Age
Diseases
Remaining Lifetime Risk at Age 40 y Remaining Lifetime Risk at Age 70 y
Men Women Men Women
Any CVD5a 2 in 3* 1 in 2* 2 in 3† 1 in 2
CHD6 1 in 2 1 in 3 1 in 3 1 in 4
AF56 1 in 4 1 in 4 1 in 4 1 in 4
CHF57 1 in 5 1 in 5 1 in 5 1 in 5
Stroke58 1 in 6‡ 1 in 5‡ 1 in 6 1 in 5
Dementia58 … … 1 in 7 1 in 5
Hip fracture59 1 in 20 1 in 6 … …
Breast cancer60 … 1 in 8 … 1 in 15
Prostate cancer60 1 in 6 … 1 in 9 …
Lung cancer60 1 in 13 1 in 16 1 in 15 1 in 20
Colon cancer60 1 in 19 1 in 21 1 in 25 1 in 27
DM61 1 in 3 1 in 3 1 in 9 1 in 7
Hypertension62 9 in 10‡ 9 in 10‡ 9 in 10† 9 in 10†
Obesity63 1 in 3 1 in 3 … …
AF indicates atrial fibrillation; CHD, coronary heart disease; CHF, congestive heart failure; CVD, cardiovascular disease; DM, diabetes mellitus; 
ellipses (…), not estimated.
*Age 45 y.
†Age 65 y.
‡Age 55 y.
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Table 14-2
Modifiable Stroke Risk Factors
Factor Prevalence, % PAR, %* RR
Cigarette smoking
 Overall 19.8 12–14† 1.9
  Men 22.3
  Women 17.4
Hypertension ‡ 8
 Ages 20–34 y
  Men 13.4 99
  Women 6.2 98
 Ages 35–44 y
  Men 23.2 99
  Women 16.5 106
 Ages 45–54 y
  Men 36.2 100
  Women 35.9 103
 Ages 55–64 y
  Men 53.7 100
  Women 55.8 102
 Ages 65–74 y
  Men 64.7 100
  Women 69.6 101
 Ages ≥75 y
  Men 64.1 100
  Women 76.4 101
Diabetes 7.3 5–27 1.8–6.0
High total cholesterol Data calculated for highest quintile (20%) vs 
lowest quintile
9.1 (5.7–13.8) 1.5 (95% CI, 1.3–1.8)
Continuous risk for ischemic stroke … 1.25 per 1-mmol/L (38.7 mg/dL) 
increase
Low HDL cholesterol
 <40 mg/dL
  Men 35
  Women 15
Data calculated for highest quintile (20%) vs 
lowest quintile
23.7 0.4
 <35 mg/dL 26 20.6 (10.1–30.7) 2.00 (95% CI, 1.43–2.70)
Continuous risk for ischemic stroke ≈0.5–0.6 for each 1-mmol/L increase
AF (nonvalvular)
 Overall age, y
  50–59 0.5 1.5 4.0
  60–69 1.8 2.8 2.6
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Factor Prevalence, % PAR, %* RR
  70–79 4.8 9.9 3.3
  80–89 8.8 23.5 4.5
Asymptomatic carotid stenosis 2–8 2–7§ 2.0
Sickle cell disease 0.25 (of blacks) … 200–400||
Postmenopausal hormone therapy 25 (Women 50–74 y of age) 9 1.4
Oral contraceptive use 13 (women 25–44 y) 9.4 2.3
Dietary factors
 Na intake >2300 mg 75–90 Unknown Unknown
 K intake <4700 mg 90–99 Unknown Unknown
Physical inactivity 25 30 2.7
Obesity 1.39 Stroke death per increase of 5 
kg/m2
 Men 33.3
 Women 35.3
CHD
 Men 8.4 5.8 1.73 (1.68–1.78)
 Women 5.6 3.9¶ 1.55 (1.17–2.07)
Heart failure
 Men 2.6 1.4
 Women 2.1 1.1¶
Peripheral arterial disease 4.9 3.0¶
AF indicates atrial fibrillation; CHD, coronary heart disease; CI, confidence interval; HDL, high-density lipoprotein; PAR, population attributable 
risk; and RR, relative risk.
*
PAR is the proportion of ischemic stroke in the population that can be attributed to a particular risk factor (see Goldstein et al96 for formula).
†
PAR is for stroke deaths, not ischemic stroke incidence.
‡
PAR percent=100×{[prevalence (RR-1)/prevalence (RR-1)+1]}.
§Calculated on the basis of referenced data provided in the table or text.
||
Relative to stroke risk in children without sickle cell disease.
¶Calculated on the basis of point estimates of referenced data provided in the table. For peripheral arterial disease, calculation was based on average 
RR for men and women.
Adapted from Goldstein et al96 with permission. Copyright © 2011, American Heart Association, Inc.
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Table 15-1
Congenital Cardiovascular Defects
Population Group
Estimated Prevalence, 2002, All 
Ages Mortality, 2010, All Ages*
Hospital Discharges, 2010, All 
Ages
Both sexes 650 000 to 1.3 million16 3196 62 000
Males … 1718 (53.8%)† 38 000
Females … 1478 (46.2%)† 24 000
NH white males … 1333 …
NH white females … 1120 …
NH black males … 311 …
NH black females … 271 …
Asian or Pacific Islander … 120 …
American Indian or Alaska Native … 41 …
Ellipses (…) indicate data not available; and NH, non-Hispanic.
*
Mortality data for the white, black, Asian or Pacific Islander, and American Indian or Alaska Native populations include deaths among people of 
Hispanic and non- Hispanic origin. Numbers of deaths for the American Indian or Alaska Native and Asian or Pacific Islander populations are 
known to be underestimated.
†
These percentages represent the portion of total congenital cardiovascular mortality that is for males vs females.
Sources: Mortality: Centers for Disease Control and Prevention/National Center for Health Statistics, 2010 Mortality Multiple Cause-of-Death—
United States, version dated May 23, 2013. These data represent underlying cause of death only; data include Hispanics. Hospital discharges: 
National Hospital Discharge Survey, National Center for Health Statistics; data include those inpatients discharged alive, dead, or status unknown.
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Table 15-4
Surgery for Congenital Heart Disease
Sample Population, Weighted
Surgery for congenital heart disease, n 14 888 25 831
 Deaths, n 736 1253
 Mortality rate, % 4.9 4.8
By sex (81 missing in sample)
 Male, n 8127 14 109
  Deaths, n 420 714
  Mortality rate, % 5.2 5.1
 Female, n 6680 11 592
  Deaths, n 315 539
  Mortality rate, % 4.7 4.6
By type of surgery
 ASD secundum surgery, n 834 1448
  Deaths, n 3 6
  Mortality rate, % 0.4 0.4
 Norwood procedure for HPLHS, n 161 286
  Deaths, n 42 72
  Mortality rate, % 26.1 25.2
In 2003, 25 000 cardiovascular operations for congenital cardiovascular defects were performed on children <20 y of age. Inpatient mortality rate 
after all types of cardiac surgery was 4.8%. Nevertheless, mortality risk varies substantially for different defect types, from 0.4% for ASD repair to 
25.2% for first-stage palliation for HPLHS. Fifty-five percent of operations were performed in males. In unadjusted analysis, mortality after cardiac 
surgery was somewhat higher for males than for females (5.1% vs 4.6%).
ASD indicates atrial septal defect; and HPLHS, hypoplastic left heart syndrome.
Source: Reprinted from Ma et al65 with permission from Elsevier. Copyright © 2007, The Society of Thoracic Surgeons.
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Table 16-1
Incidence and Outcome of Out-of-Hospital Cardiac Arrest in the United States, 2011
Incidence per 100 
000, Point Estimate 
(95% CI)
Annual Number of 
Cases in United States, 
Point Estimate (Quasi 
CI)
Annual Number of 
Fatalities in United 
States, Point Estimate 
(Quasi CI)
Survival, Point 
Estimate (95% 
CI), %
EMS assessed
 Overall 134.1 (131.7–136.6) 424 000 (417 000–432 
000)
401 000 (392 000–410 
000)
5.2 (4.8–5.6)
 Adults 135.8 (133.0–138.7) 322 000 (315 000–328 
000)
299 000 (291 000–307 
000)
6.7 (6.2–7.2)
 Children 11.9 (10.5–13.4) 9500 (8400–10 700) 8800 (7500–10 200) 4.4 (2.0–6.9)
EMS treated
 Overall 66.7 (64.9–68.4) 211 000 (205 000–216 
000)
187 000 (181 000–194 
000)
10.4 (9.7–11.2)
 Adults 84.8 (82.5–87.0) 201 000 (195 000–206 
000)
178 000 (172 000–184 
000)
10.7 (9.9–11.5)
 Children 9.7 (8.4–11.1) 7700 (6700–8800) 7000 (5800–8400) 5.4 (2.4–8.4)
Shockable rhythm
 Overall 13.4 (12.6–14.2) 42 000 (40 000–45 000) 30 000 (27 000–33 000) 28.3 (25.7–30.8)
 Adults 17.4 (16.4–18.5) 41 000 (39 000–44 000) 29 000 (26 000–32 000) 28.4 (25.9–30.9)
 Children 0.7 (0.3–1.0) 560 (240–800) 370 (100–720) 26.7 (4.3–49.1)
Bystander-witnessed shockable rhythm
 Overall 7.7 (7.1–8.3) 24 000 (22 000–26 000) 16 000 (14 000–18 000) 31.7 (28.3–35.2)
 Adults 10.1 (9.3–10.9) 24 000 (22 000–26 000) 16 000 (14 000–18 000) 31.7 (28.2–35.1)
 Children 0.3 (0.1–0.5) 240 (80–400) 160 (30–360) 26.7 (4.3–49.0)
US sites only; 2011 cases.
CI indicates confidence interval; and EMS, emergency medical services.
Source: Resuscitation Outcomes Consortium Investigators, unpublished data, July 23, 2013.
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Table 16-2
Outcome of In-Hospital Cardiac Arrest in United States, 2011
Survival, % Point Estimate (95% CI)
Treated IHCA
 Adults 22.7 22.0–23.4
 Children 36.8 32.6–41
Shockable rhythm
 Adults 41.5 39.3–43.7
 Children 33.3 15.5–51.1
CI indicates confidence interval; and IHCA, in-hospital cardiac arrest.
Source: Get With The Guidelines–Resuscitation Investigators, unpublished data, July 27, 2013.
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Table 17-1
CAC Scores for the 75th Percentile of Men and Women of Different Race/Ethnic Groups, at Specified Ages
Age, y
75th Percentile CAC Scores*
Black Chinese Hispanic White
Women
 45 0 0 0 0
 55 0 2 0 1
 65 26 45 19 54
 75 138 103 116 237
Men
 45 0 3 0 0
 55 15 34 27 68
 65 95 121 141 307
 75 331 229 358 820
CAC indicates coronary artery calcification.
*
The 75th percentile CAC score is the score at which 75% of people of the same age, sex, and race have a score at or below this level and 25% of 
people of the same age, sex, and race have a higher score. (Source: MESA CAC Tools Web site.42)
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Table 18-2
Angina Pectoris
Population Group Prevalence, 2010, Age ≥20 y Incidence of Stable AP, Age ≥45 y Hospital Discharges, 2010, All Ages*
Both sexes 7 800 000 (3.2%) 565 000 22 000
Males 3 700 000 (3.3%) 370 000 12 000
Females 4 100 000 (3.2%) 195 000 10 000
NH white males 3.3% … …
NH white females 2.8% … …
NH black males 2.4% … …
NH black females 5.4% … …
Mexican American males 3.4% … …
Mexican American females 3.3% … …
AP is chest pain or discomfort that results from insufficient blood flow to the heart muscle. Stable AP is predictable chest pain on exertion or under 
mental or emotional stress. The incidence estimate is for AP without myocardial infarction.
AP indicates angina pectoris; ellipses, data not available; and NH, non-Hispanic.
*
There were 56 000 days of care for discharges of patients with AP from short-stay hospitals in 2010.
Sources: Prevalence: National Health and Nutrition Examination Survey 2007 to 2010 (National Center for Health Statistics) and National Heart, 
Lung, and Blood Institute; percentages for racial/ethnic groups are age adjusted for US adults ≥20 y of age. AP includes people who either 
answered “yes” to the question of ever having angina or AP or who were diagnosed with Rose angina (the Rose questionnaire is only administered 
to survey participants >40 y of age). Estimates from National Health and Nutrition Examination Survey 2007 to 2010 (National Center for Health 
Statistics) were applied to 2010 population estimates (≥20 y of age). Incidence: AP uncomplicated by a myocardial infarction or with no 
myocardial infarction (Framingham Heart Study [the original cohort and the Offspring Cohort 1986–2009], National Heart, Lung, and Blood 
Institute). Hospital discharges: National Hospital Discharge Survey, National Center for Health Statistics; data include those inpatients discharged 
alive, dead, or status unknown.
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Table 20-2
Rheumatic Fever/Rheumatic Heart Disease
Population Group Mortality, 2010: All Ages* Hospital Discharges, 2010: All Ages
Both sexes 2987 20 000
Males 996 (33.3%)† 5000
Females 1991 (66.7%)† 15 000
NH white males 885 …
NH white females 1759 …
NH black males 79 …
NH black females 153 …
Asian or Pacific Islander‡ 97 …
American Indian or Alaska Native‡ 14 …
Ellipses (…) indicate data not available; and NH, non-Hispanic.
*
Mortality data include Hispanics.
†
These percentages represent the portion of total mortality that is for males vs females.
‡Number of deaths shown may be lower than actual because of underreporting in this population.
Sources: Mortality: Centers for Disease Control and Prevention/National Center for Health Statistics, 2010 Mortality Multiple Cause-of-Death–
United States, version dated May 29, 2013; data represent underlying cause of death only. Hospital discharges: National Hospital Discharge Survey, 
National Center for Health Statistics, and National Heart, Lung, and Blood Institute; data include those inpatients discharged alive, dead, or of 
unknown status.
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Table 21-1
Peripheral Artery Disease Table 21-1. Peripheral Artery Disease
Population Group Prevalence, Age ≥40 y Mortality, 2010, All Ages* Hospital Discharges, 2010, All Ages
Both sexes ≥6.8 Million 13 854 146 000
Males … 5826 (42.1%)† 84 000
Females … 8028 (57.9%)† 62 000
NH white males … 5074 …
NH white females … 7045 …
NH black males … 648 …
NH black females … 868 …
Asian or Pacific Islander … 172 …
American Indian/Alaska Native … 47 …
Ellipses (…) indicate data not available; and NH, non-Hispanic.
*
Mortality data for the white, black, Asian or Pacific Islander, and American Indian or Alaska Native populations include deaths among people of 
Hispanic and non-Hispanic origin. Numbers of deaths for the American Indian or Alaska Native and Asian or Pacific Islander populations are 
known to be underestimated.
†
These percentages represent the portion of total mortality attributable to heart failure that is for males vs females.
Sources: Prevalence: Allison et al.1 Prevalence of peripheral arterial disease is based on an ankle-brachial index <0.9 or a previous 
revascularization for peripheral arterial disease. Mortality: Centers for Disease Control and Prevention/National Center for Health Statistics, 2010 
Mortality Multiple Cause-of-Death–United States, version dated May 21, 2013.
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Table 22-1
ACS Quality-of-Care Measures, 2012
Quality-of-Care Measure VHA*
National Data 
From HIQR 
Program† ACTION-GWTG STEMI‡ ACTION-GWTG NSTEMI‡
Aspirin within 24 h of admission 99 99.2 98.3 97.5
Aspirin at discharge 99 99.1 98.9 98.1
β-Blockers at discharge 99 98.9 97.8 96.7
Lipid-lowering medication at discharge§ 99 97.7 99.1 98.5
ARB/ACEI at discharge for patients with 
LVEF <40%
97 97.5 91.4 88.3
ACEI at discharge for AMI patients NM NM 71.6 59.6
ARB at discharge for AMI patients NM NM 9.2 13.3
Adult smoking cessation advice/counseling Retired 99.7|| 98.6 98.2
Cardiac rehabilitation referral for AMI patients NM NM 82.5 73.7
Values are percentages.
ACEI indicates angiotensin-converting enzyme inhibitor; ACS, acute coronary syndrome; ACTION-GWTG, Acute Coronary Treatment and 
Intervention Outcomes Network Registry–Get With The Guidelines; AMI, acute myocardial infarction; ARB, angiotensin receptor blocker; HIQR, 
Hospital Inpatient Quality Reporting; LVEF, left ventricular ejection fraction; NM, not measured; NSTEMI, non–ST-segment–elevation myocardial 
infarction; STEMI, ST-segment–elevation myocardial infarction; and VHA, Veterans Health Administration.
*VHA: AMI patients. Data reported include data from October 1, 2011, to September 30, 2012.
†
HIQR Program includes data from all payers, including Medicare and Medicaid. Data reported include data from the third quarter of 2011 to the 
second quarter of 2012.
‡ACTION Registry: STEMI and NSTEMI patients are reported separately. Patients must be admitted with acute ischemic symptoms within the 
previous 24 h, typically reflected by a primary diagnosis of STEMI or NSTEMI. Patients who are admitted for any other clinical condition are not 
eligible. Data reported include data from the second quarter of 2012 to the first quarter of 2013.
§
Denotes statin use at discharge. Use of nonstatin lipid-lowering agent was 8.1% for STEMI patients and 11.7% for NSTEMI patients in the 
ACTION registry.
||
Measure was retired in January 2012.
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Table 22-2
HF Quality-of-Care Measures, 2012
Quality-of-Care Measure
National Data From HIQR 
Program* AHA GWTG-HF VHA
LVEF assessment 98.7 96.5 100
ARB/ACEI at discharge for patients with LVSD 96.4 95.4 97
Complete discharge instructions 92.9 93.4 97
Adult smoking cessation advice/counseling 99† 97.3 99
β-Blockers at discharge for patients with LVSD, no contraindications NM 97.2 NM
Anticoagulation for AF or atrial flutter, no contraindications NM 78.7 Retired
Values are percentages.
In the GWTG registry, mechanical ventilation was required in 0.9% of patients. In-hospital mortality was 2.5%, and mean length of hospital stay 
was 5.0 d (median 4.0 d).
AF indicates atrial fibrillation; AHA GWTG-HF, American Heart Association’s Get With The Guidelines–Heart Failure; ARB/ACEI, angiotensin 
receptor blocker/angiotensin-converting enzyme inhibitor; HF, heart failure; HIQR, Hospital Inpatient Quality Reporting; LVEF, left ventricular 
ejection fraction; LVSD, left ventricular systolic dysfunction; NM, not measured; and VHA, Veterans Health Administration.
*
HIQR Program includes data from all payers, including Medicare and Medicaid. Data reported include data from the third quarter of 2011 to the 
second quarter of 2012.
†
Measure was retired in January 2012.
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Table 22-6
Additional ACTION-GWTG Quality-of-Care Metrics for ACS Care, 2012*
Quality Metrics Overall STEMI NSTEMI
ECG within 10 min of arrival 64.5 75.0 59.8
Aspirin within 24 h of arrival 97.8 98.3 97.5
Any anticoagulant use† 93.4 95.9 91.7
Dosing error
 UFH dose 47.0 47.3 47.0
 Enoxaparin dose 11.0 11.2 11.0
 Glycoprotein IIb/IIIa inhibitor dose 6.7 7.1 6.0
Aspirin at discharge 98.4 98.9 98.1
Prescribed statins on discharge 98.8 99.1 98.5
Adult smoking cessation advice/counseling 98.4 98.6 98.2
Cardiac rehabilitation referral 77.3 82.5 73.7
In-hospital mortality‡ (95% CI) 4.8 (4.6–4.9) 6.5 (6.3–6.7) 3.6 (3.5–3.7)
Values are percentages.
ACS indicates acute coronary syndrome; ACTION-GWTG, Acute Coronary Treatment and Intervention Outcomes Network Registry–Get With 
The Guidelines; CI, confidence interval; ECG, electrocardiogram; NSTEMI, non–ST-segment–elevation myocardial infarction; STEMI, ST-
segment–elevation myocardial infarction; and UFH, unfractionated heparin.
*2012 data reported include data from second quarter of 2012 to first quarter of 2013.
†
Includes UFH, low-molecular-weight heparin, or direct thrombin inhibitor use.
‡
Excludes transfer-out patients.
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Table 22-7
National Committee for Quality Assurance Health Plan Employer Data and Information Set Measures of Care, 
2011
Commercial Medicare Medicaid
AMI
 β-Blocker persistence* 81.3 87.3 80.5
Cholesterol management for patients with CVD
 Cholesterol screening 88.1 88.8 82.0
 LDL cholesterol control (<100 mg/dL) 59.8 56.5 42.1
Hypertension
 BP <140/90 mm Hg 65.4 64.0 56.8
DM
 HbA1c testing 90.0 91 82.5
 HbA1c >9.0% 28.3 26.5 43.0
 Eye examination performed 56.9 66.0 53.3
 LDL cholesterol screening 85.3 88.3 75.0
 LDL cholesterol <100 mg/dL 48.1 52.5 35.2
 Monitoring nephropathy 83.8 89.9 77.8
 BP <140/90 mm Hg 65.8 63.1 60.9
Advising smokers and tobacco users to quit 77.6 81.5 74.6
BMI percentile assessment in children and adolescents 44.7 N/A 46
Nutrition counseling (children and adolescents) 46.4 N/A 50.1
Counseling for physical activity (children and adolescents) 43.0 N/A 40.6
BMI assessment for adults 55.4 68.2 52.6
Physical activity discussion in older adults (≥65 y of age) N/A 53.0 N/A
Physical activity advice in older adults (≥65 y of age) N/A 48.7 N/A
Values are percentages.
AMI indicates acute myocardial infarction; BMI, body mass index; BP, blood pressure; CVD, cardiovascular disease; DM, diabetes mellitus; 
HbA1c, hemoglobin A1c; LDL, low-density lipoprotein; and N/A, not available or not applicable.
*β-Blocker persistence: Received persistent β-blocker treatment for 6 mo after AMI hospital discharge.
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Table 22-8
Quality of Care for EMS-Treated Out-of-Hospital Cardiac Arrest
Overall Adults Children
Bystander CPR, %* 40.8 (39.6–42.0) 40.4 (39.1–41.7) 53.9 (47.3–60.4)
Shocked by AED before EMS, %* 2.1 (1.7–2.4) 2.1 (1.8–2.5) 0 (0–0)
Time from dispatch to first EMS defibrillator applied, min* 8.9 (4.7) 8.9 (4.7) 9.0 (3.7)
Chest compression fraction, %*† 0.75 (0.16) 0.75 (0.16) 0.80 (0.15)
Compression depth, mm*‡ 39.5 (14.9) 39.6 (14.9) 35.9 (16.5)
Preshock pause duration, s§ 18.5 (8.6) 18.5 (8.6) N/A
Values are mean (95% confidence interval) or mean (standard deviation).
US sites only; 2011 cases.
AED indicates automated external defibrillator; CPR, cardiopulmonary resuscitation; EMS indicates emergency medical services; and N/A, not 
available.
*
Denominator is EMS-treated cardiac arrest.
†
During first 5 min of resuscitation.
‡
During first 10 min of resuscitation.
§Up to and including first 6 shocks.
Source: Unpublished data, Resuscitation Outcomes Consortium Investigators, July 23, 2013.
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Table 22-9
Quality of Postresuscitation Hospital Care for Out-of-Hospital Cardiac Arrests
Overall Adults Children
Hypothermia induced* 55.7 (50.5–61.0) 55.8 (50.6–61.1) 66.7 (13.3–100)
Care not withdrawn during hospitalization† 44.8 (41.7–47.9) 44.7 (41.5–47.8) 51.5 (34.5–68.6)
Assessed for implantable defibrillator‡ 31.3 (23.7–38.8) 31.2 (23.6–38.9) 50.0 (0–100)
Values are mean percentages (95% confidence interval).
US sites only; 2011 cases.
*
Denominator is admitted to hospital after cardiac arrest with first rhythm of ventricular tachycardia/ventricular fibrillation.
†
Denominator is all cases admitted to hospital.
‡
Denominator is all cases admitted to hospital with first rhythm of ventricular tachycardia/ventricular fibrillation and no acute myocardial injury.
Source: Unpublished data, Resuscitation Outcomes Consortium Investigators, July 23, 2013.
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Table 22-10
Quality of Care for In-Hospital Cardiac Arrest, 2012
Adults Children
Monitored before arrest, % 86.6 (86.0–87.2) 90.0 (87.8–92.8)
ETCO2 used during arrest, % 4.5 (4.1–4.9) 9.1 (6.8–11.8)
Induced hypothermia after resuscitation from shockable rhythm, % 7.6 (6.2–9.1) 17.7 (3.8–43.4)
Achieved temperature between 32°C and 34°C if cooled, % 54.2 (43.5–64.9) N/A
Values are mean percentages (95% confidence interval).
ETCO2 indicates end-tidal carbon dioxide; N/A, not applicable.
Source: Unpublished data, Get With the Guidelines–Resuscitation Investigators, July 27, 2013.
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Table 22-11
Timely Reperfusion for ACS and Stroke, 2012
Quality-of-Care Measure
VHA (for STEMI) 
or GWTG-Stroke 
(for Stroke)
National Data 
From HIQR 
Program* ACTION-GWTG STEMI†
STEMI
 tPA within 30 min 50‡ 60.1 44.6‡
 PCI within 90 min 69 94.5 95.3
Stroke
 IV tPA in patients who arrived <2 h after symptom onset, 
treated ≤3 h
82.0 N/A N/A
 IV tPA in patients who arrived <3.5 h after symptom onset, 
treated ≤4.5 h
60.4 N/A N/A
 IV tPA door-to-needle time ≤60 min 39.9 N/A N/A
Values are percentages.
ACS indicates acute coronary syndrome; ACTION-GWTG, Acute Coronary Treatment and Intervention Outcomes Network Registry–Get With 
The Guidelines; GWTG-Stroke, Get With The Guidelines–Stroke; HIQR, Hospital Inpatient Quality Reporting; IV, intravenous; N/A, not 
applicable; PCI, percutaneous coronary intervention; STEMI, ST-segment–elevation myocardial infarction; tPA, tissue-type plasminogen activator; 
and VHA, Veterans Health Administration.
*
HIQR Program includes data from all payers, including Medicare and Medicaid. Data reported include data from third quarter of 2011 to second 
quarter of 2012.
†ACTION Registry: Data reported include data from second quarter of 2012 to first quarter of 2013.
‡
Indicates low number.
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Table 23-1
2011 National HCUP Statistics: Mean Hospital Charges, In-Hospital Death Rates, and Mean Length of Stay 
for Various Cardiovascular Procedures
Procedure
Mean Hospital 
Charges, $
In-Hospital 
Death Rate, %
Mean Length 
of Stay, d ICD-9-CM Procedure Codes
Total vascular and cardiac surgery and 
procedures
75 746 2.88 6.1 35–39, 00.50–00.51, 00.53–00.55, 
00.61–00.66
Cardiac revascularization (bypass) 147 435 1.63 9.2 36.1–36.3
PCI 70 176 1.13 3.2 00.66
Cardiac catheterization 42 337 0.93 3.7 37.21–37.23
Pacemakers 69 205 1.21 5.0 37.7–37.8, 00.50, 00.53
Implantable defibrillators 146 210 0.61 5.3 37.94–37.99, 00.51, 00.54
Endarterectomy 38 500 0.34 2.5 38.12
Valves 203 009 3.63 11.0 35.1–35.2, 35.99
Heart transplantation 706 199 5.28 41.0 37.51
HCUP indicates Healthcare Cost and Utilization Project; ICD-9-CM, International Classification of Diseases, Clinical Modification, 9th Revision; 
and PCI, percutaneous coronary intervention.
Data derived from the Agency for Healthcare Research and Quality, HCUP Nationwide Inpatient Sample, 2011.
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